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Abstract 
Cases of a novel form of liver disease, localised to a cluster of villages in the Tigray region of 
Northern Ethiopia, were first reported in 2001. Up to January 2010, 591 cases were recorded, 
including 228 deaths. Symptoms include epigastric and abdominal swelling. Children are particularly 
susceptible, with some children having died within three months of the onset of symptoms, whereas 
some adults report living with the disease for many years. The pattern of spread suggested an 
environmental toxin was the causative agent, with investigations implicating the plant toxins, 
pyrrolizidine alkaloids. The ultimate aim of the research presented in this thesis was to determine 
the aetiology of the disease and a multi-disciplinary approach, involving clinical research, 
ethnography, biochemical and metabonomic analysis and toxicology, has been employed to achieve 
this. 
The disease was first characterised clinically: The disease presents with epigastric pain, initial bloody 
diarrhoea and progressive ascites with either hepatomegaly or splenomegaly or both. Histology of 
liver biopsy specimens revealed centrilobular necrosis in acute cases and bile ductular proliferation 
and fibrosis in chronic cases. Biochemical analysis identified γ-glutamyl transferase as a sensitive 
indicator of the disease. Ethnographic investigation of the lifestyle of the residents of the affected 
villages revealed a monotonous diet, the presence of a similar disease among livestock and 
suggested millet and animal products as potential sources of exposure to the aetiological agent(s). 
The pesticide DDT was identified as a further potential risk factor for the disease. A global 
metabonomic analysis of patient urine samples using 1H NMR spectroscopy was conducted and 
several metabolites associated with the disease were identified. Targeted LC-MS assays were then 
developed to detect pyrrolizidine alkaloid exposure among patients, either through detection of the 
parent alkaloid, acetyllycopsamine (AL), in urine samples or extraction and detection of pyrrolic 
metabolite adducts from whole blood.  Relative AL urinary concentrations were found to be 
significantly higher among cases. 
AL was shown to be hepatotoxic in the mouse model, and at high doses induced centrilobular 
hepatic necrosis and metabolic changes similar to that observed in the human disease. Finally, DDT 
was detected at high levels in patient urine and serum samples.  DDT was shown to substantially 
enhance the toxic effects of AL in the mouse model, through induction of the CYP3A11 enzyme, and 
in combination with AL induced liver pathology closely resembling the human disease. In conclusion, 
the available evidence suggests that the disease arises from co-exposure to DDT and pyrrolizidine 
alkaloids, including AL.  
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Structure of Thesis 
This thesis is about an outbreak of several hundred cases of an unknown liver disease localised to a 
cluster of villages in the Tigray region of Northern Ethiopia. The disease, which is referred to in this 
thesis as ‘Hirmi Valley Liver Disease (HVLD)’, has a high fatality rate and presents with symptoms 
characteristic of portal hypertension.  The central aim of the thesis is to determine the aetiology of 
HVLD. Early investigations indicated that the disease is caused by hepatotoxin exposure and the 
plant toxins, pyrrolizidine alkaloids (PAs) were implicated. To orientate the reader an outline of the 
thesis in given below: 
Chapter 1: General introduction: I provide a general review of the state of knowledge that is 
relevant to the investigation of HVLD. I start with a discussion of liver disease with focus on the 
causes of portal hypertension. Then I discuss hepatotoxicity, human occurrence of hepatotoxin 
exposure and factors which can affect the toxic potential of hepatotoxins. Finally I review the 
current knowledge regarding PAs specifically. 
Chapter 2: Hirmi Valley Liver Disease: I introduce HVLD, describing its extent and the area and the 
people it affects. I review the available evidence regarding the disease including investigations 
undertaken by other research groups and data available from local clinics. I describe results from a 
census directed by the US Centres for Disease Control (CDC) to which I contributed and present a 
spatial analysis of some of the census data. I then review the evidence regarding Ageratum 
conyzoides, a PA-producing plant identified in the area, and specific PAs, including acetyllycopsamine 
(AL), identified in grain analysis.  
Finally I draw together the evidence and state the central hypothesis that has guided the research in 
this thesis and outline the specific objectives of the subsequent chapters.  
Chapter 3: Clinical Characterisation: I fully describe the spread of clinical signs and symptoms in a 
well defined group of HVLD patients, along with associated clinical chemistry changes and present a 
histopathological analysis of liver biopsy specimens from both acute and chronic stages of the 
disease.  
Chapter 4: Ethnographic Study of Residents of the Affected Villages:  I present an ethnographic 
study of the life style of the residents of the affected villages using a small number of detailed case 
studies. I determine whether lifestyle practices are consistent with PA contamination, and identify 
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some potential novel risk factors such as alcohol and use of the pesticide dichloro-
diphenyltrichloroethane (DDT).  
Chapter 5: 1H NMR Metabonomic Profiling of Patient Urine Samples:  I present a global 
metabonomic nuclear magnetic resonance (NMR) analysis of case and control urine samples. This 
was initiated to identify potential toxin metabolites without an a priori hypothesis regarding disease 
aetiology. Metabolic changes and potential biomarkers of HVLD are described.  
Chapter 6: Detection of Pyrrolizidine Alkaloid Exposure in Biofluids: A targeted approach to 
demonstrating PA exposure among HVLD cases is pursued through a two-pronged approach, using 
the more sensitive platform of liquid chromatography coupled to mass spectrometry (LC-MS). 
Attempts are made to both detect pyrrole-protein adducts in whole blood and AL itself in urine 
samples.  
Chapter 7: Toxicology of Acetyllycopsamine: The effects of AL are tested in the mouse model using 
a range of doses. Its ability to induce liver injury similar to that observed in HVLD is judged through 
biochemical, histopathological and metabonomic analysis.  
Chapter 8: DDT as a Modulator of PA Toxicity: The potential of the pesticide DDT as an additional 
risk factor for HVLD is explored. Levels of DDT and its metabolites are measured in HVLD case and 
control biosamples and in the mouse model, the effects of DDT exposure on cyp3A11 expression is 
measured and the effects on acetyllycopsamine metabolism and toxicity is analysed.  
Chapter 9: General Discussion: I draw together the evidence presented in the thesis and make 
overall conclusions. I then make specific public health recommendations to reduce the burden of 
HVLD. I outline potential future areas of research for both HVLD, and PAs and the use of DDT in a 
wider context. 
  
29 
 
1. General Introduction 
1.1 Diseases of the Liver 
 
he liver is the largest solid organ of the body, comprising approximately 2% of the adult 
body weight. It performs numerous roles, essential for the well-being and proper 
functioning of the human organism. A single liver cell houses around 500 separate 
biochemical processes and the liver itself is responsible for 70 partial functions within 12 
major metabolic areas. These include regulatory metabolic mechanisms such as maintaining the 
acid-base and trace element balance of the body, production of substances such as bilirubin, bile 
acids, porphyrins, and hormones, metabolism of macromolecules such as proteins, lipids and 
carbohydrates and detoxification and biotransformation of superfluous or harmful substances. 
Therefore many systemic or localised disorders arise if the functional and morphological integrity of 
the organ is not maintained 1. 
Liver disease is now the fifth most common cause of death from disease in England and Wales and 
the number of cases is increasing with twice as many deaths as in 19912. The main causes of liver 
disease in the UK and the developed world are alcohol abuse, hepatitis C virus (HCV) infection and 
obesity. Worldwide, Hepatitis viruses contribute substantially to chronic morbidity with hepatitis B 
(HBV) affecting 2 billion people worldwide 3 while approximately 3% of the world’s population are 
infected with HCV. 170 million people are chronically infected with HCV and 3-4 million are newly 
infected each year 4. Hepatocellular carcinoma (HCC) is a major source of liver morbidity and 
mortality in many parts of the world including Africa with over 600,000 new cases a year. 
Contributory factors are HBV and toxins such as aflatoxins5. Parasitic diseases such as 
schistosomiasis 6 and visceral leishmaniasis, particularly in East Africa7, are also considerable 
contributors to liver related morbidity in developing countries. The most frequent cause of acute 
liver failure in humans around the world is toxin or drug-induced liver injury, and exceeds all other 
causes combined8.  
Diagnosis of liver diseases can be challenging due to the many roles the liver plays.  Similar clinical 
features may result from impairment of different liver functions, which can have a number of 
different pathogeneses.  For instance hepatomegaly, a common sign of liver disease, can be caused 
by cell replication, enlargement of cellular structures or augmentation of extracellular space, or 
localised lesions such as parasites.  It can result from many forms of liver disease such as 
T 
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inflammatory, cirrhotic, choleostatic, and vascular or even a combination of these9. Therefore 
successful diagnoses must take account of the whole spectrum of signs and symptoms presented 
and patient lifestyles and histories to identify potential causes. Liver function tests (LFTs) can aid in 
determining the type of liver dysfunction while invasive techniques such as liver biopsy may be 
ultimately necessary to confirm the underlying pathology. 
1.1.1 Portal hypertension 
The classic clinical triad of ascites, splenomegaly and sometimes hepatomegaly is consistent with 
portal hypertension, defined as a persistent elevation in pressure of >12 mmHg in the portal vein 
circulation, dilation of portal vein to >13mm or an increase in portal pressure gradient (portal vein 
pressure – inferior vena cava) of >7mmHg 1. It usually is a result of obstruction to portal blood 
circulation anywhere along its route and can be classified as extrahepatic or intrahepatic depending 
on the site of the blockage. The presence of hepatomegaly indicates that portal hypertension results 
from an intrahepatic block, which may in turn be pre-sinusoidal, sinusoidal or post-sinusoidal in 
origin. 
Presinusoidal forms include those caused by portal tract lesions such as with schistosomiasis where 
the ova of the parasite cause a reaction in the minute portal-venous radicles, early primary biliary 
cirrhosis and sarcoidosis which are thought to cause sinusoidal narrowing due to cellular infiltration, 
and congenital hepatic fibrosis which is likely to block flow due to deficiency in the terminal 
branches of the portal veins in the fibrotic portal zones. Presinusoidal blockages may also have toxic 
origins, where the toxin is taken up by the endothelial cells in Disse’s space and are fibrogenic 
causing the minute portal-venous radicles to be obstructed9. 
The most common cause of sinusoidal portal hypertension (and indeed all forms of portal 
hypertension) is cirrhosis9.  The primary event is obstruction to portal flow due to the nodules 
compressing the hepatic venous radicles and portal inflow vessels. In addition narrowing of the 
sinusoids follows changes, such as collagenisation in particular, in Disse’s space. Cirrhosis itself, 
defined as widespread fibrosis and nodule formation, results from the liver responses to hepato-
cellular necrosis. The hepatic lobules collapse, diffuse fibrous septa form and there is nodular 
regrowth of the liver cells. These responses are similar irrespective of the many different possible 
aetiologies of the necrosis, which include viral hepatitis, alcohol abuse, metabolic disorders, 
choleostasis, hepatic venous outflow block and many different toxins and drugs. Cytotoxic drug 
therapy may also lead to sinusoidal fibrosis and portal hypertension without cirrhosis 10. 
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1.1.2 Veno-occlusive disease 
Veno – occlusive disease (VOD) is classed as a post-sinusoidal form of portal hypertension9. It can 
occur following chemotherapy and nowadays it most often occurs as a serious complication of bone 
marrow transplants 11, but it was first described in Jamaica, following consumption of ‘bush teas’, 
infusions made from local plants including Senecio and Crolataria species which produce 
pyrrolizidine alkaloids (PAs) 12. Indeed, it is considered pathognomic of PA poisoning 13. It is a 
disorder caused by thrombotic occlusion of the small zone 3 hepatic veins, due to toxic damage 
resulting in subendothelial oedema and subsequent collagenisation. The disease carries a high 
mortality rate with children the most vulnerable, and if survived it can lead to cirrhosis. Stuart and 
Bras 12 provide a detailed summary of VOD in Jamaica and divide it into three ‘often ill-defined and 
overlapping stages’ (Figure 1-1). 
Acute VOD
(Sudden hepatomegaly 
and ascites)
Subacute VOD
(Persistent firm 
hepatomegaly)
Chronic VOD
(Cirrhosis of 
liver)
Complete 
recovery (48%)
Clinical 
recovery (20%)
Latent period 
of years
13%
Rapid death (19%) 
(increasing jaundice, 
cholaemia)
Complete recovery
Clinical 
improvement
 
Figure 1-1: Clinical natural history of veno-occlusive disease of the liver. Subacute and Chronic stages may be present 
with no clinical history of preceding illness. From Stuart and Bras
12
 
Through serial biopsies and follow-up of 73 patients, Stuart and Bras12 define an acute stage 
characterised by sudden development of hepatomegaly and ascites, usually in children between one 
year and six years, a sub-acute stage with persistent, often symptomless, hepatomegaly and a 
chronic stage that may be clinically identical to cirrhoses of other causes. They describe the typical 
primary lesion in acute and sub-acute patients as widespread occlusion of the smaller and medium-
sized branches of the hepatic veins, with varying degrees of sinusoidal congestion and what is 
described as ‘pressure-necrosis’ of the centrilobular hepatocytes. The veno-occlusion was reversible 
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and linked to the acute symptoms of ascites and hepatomegaly, which disappeared following 
recovery. In some cases, there was development of non-portal cirrhosis, which frequently progresses 
more rapidly than cirrhosis of other causes. 
Budd-Chiari syndrome 9 has a similar clinical picture but is differentiated from VOD by occlusion in 
the larger hepatic veins as well as thrombi formation and is more commonly seen in adults. The first 
reported human cases of PA poisoning, in South Africa following wheat contamination by Senecio 
seeds14, presented as Budd-Chiari syndrome.  
1.2 The Liver as a target of toxicity 
Due primarily to the substantial role of the liver in the metabolism of foreign compounds 
(xenobiotics); the liver is especially vulnerable to toxic damage, particularly when the toxin is 
ingested orally. The liver is positioned as an entry point of xenobiotics to the tissues of the body 
since it first receives blood arriving from the intestines. The compound must be lipid soluble to pass 
the intestinal cell membrane, after which it is presented to the liver for conversion to a more water-
soluble compound for excretion via urine or bile. This biotransformation role may have unfortunate 
consequences leading to the conversion of xenobiotics to a reactive toxic product, causing localised 
injury. All cell types of the liver may be affected and possible cell injury or responses include 
necrosis, steatosis, infiltration and pigmentation, cholestasis, cirrhosis, hepatitis, vascular injury and 
neoplasia15. The effects of toxic compounds may mimic almost every naturally occurring liver disease 
in man9. The biochemical mechanisms that drive these cytotoxic responses are now understood for 
many hepatotoxins and include depletion of cellular ATP16 and UTP17, physiochemical changes in cell 
membranes15 and the covalent binding to tissue macro molecules such as DNA or proteins 18.  
The enzyme systems concerned with the metabolism of xenobiotics are highly concentrated in the 
liver, presumably an adaptive response to the strategic position of the liver permitting a defensive 
role against ingested toxins. Enzyme systems able to metabolize xenobiotics are also found in tissues 
at sites where xenobiotics may enter the body, but at much lower levels than in the liver19. Other 
factors that contribute to the vulnerability of the liver are the higher accumulation of xenobiotics in 
the liver compared to other organs (likely related to its metabolic role) and the role of enterohepatic 
circulation whereby compounds may by excreted from the liver in the bile and then reabsorbed from 
the intestines, thereby potentially prolonging the hepatic exposure to xenobiotics15.   
1.2.1 Hepatic metabolism of xenobiotics 
To understand the hepatotoxicity of many compounds it is important to understand the role of the 
liver in their metabolism. The stages involved in the biotransformation of xenobiotics were clarified 
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by their classification into two phases of metabolism by Williams20. Phase I metabolism provides a 
polar group on the compound, in preparation for phase II metabolism, which conjugates the 
compound with a further group. Phase I reactions are primarily oxidative and are particularly likely 
to result in a transient species that may damage the liver and is therefore often referred to as the 
toxifying phase. Conversely, phase II is considered the detoxifying phase and involves a synthetic 
biotransforming reaction that destroys the biologic properties of the xenobiotic and its product 
allowing excretion as a conjugate with groups such as glucuronide, glutathione and sulphate. The 
reactions of the two phases are normally tightly coordinated15. 
The main phase I enzyme systems, the mixed function oxidases (MFO) and the flavoprotein 
monooxygenases (FMO), are integral parts of the smooth endoplasmic reticulum of the hepatocyte 
and are attached to the lipid layers of membrane. The enzyme machinery of the MFO system are the 
haemoproteins cytochromes P450 and the two terms are used interchangeably. The MFO system 
uses equivalent amounts of the xenobiotic, molecular oxygen and NADPH (the reductant). Both the 
xenobiotic and the oxygen molecule are bound to the cytochrome P450 whereby one atom of the 
oxygen molecule is reduced to water and the xenobiotic is oxidized, which in some cases can 
produce an active intermediary that can react with vital macromolecules of the hepatocyte and 
cause liver injury15. More than 500 isoforms of cytochrome P450 have been identified in various 
organisms and 28 isoforms have been described in humans of which 15 are present in the liver21. The 
individual cytochrome isoforms are referred to as CYP, followed by an Arabic number denoting its 
gene family and a letter for its subfamily. The various isoforms have differing levels of substrate 
specificity, with some able to metabolize a wide variety of substrate and others having more specific 
roles. The CYP1, CYP2 and CYP3 gene families are most commonly involved in xenobiotic 
metabolism, with CYP3A metabolising the widest variety of drugs and playing a pivotal role in 
xenobiotic metabolism. Isoform CYP3A4 is the most common isoform in the human liver, making up 
28% of total CYP content22. The FMO system has received less attention that the CYP enzymes but so 
far three separate FMO genes have been identified in humans22. It is independent of the MFO and 
plays a role in the N-oxidation of amines and may also activate the toxicity of certain compounds23. 
The phase II enzymes are for the most part situated in the cytosol although glucuronyl transferase is 
situated in the smooth endoplasmic reticulum. Like for the cytochrome P450, there are multiple 
forms of the phase II enzymes. Although the phase II reactions conjugate the polar groups of 
molecules following phase I reactions, some molecules already have a polar group and may enter 
phase II reactions without prior phase I transformation. Glucuronidation, in particular, generally 
protects by withdrawing the xenobiotic from the activating pathways. Glutathione (GSH) is a 
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particularly important conjugate, as it detoxifies the active metabolites of many different 
hepatotoxins under the control of glutathione-S-transferase, allowing the compound to be excreted 
as a mercapturic acid15. 
1.2.2 Liver Structure and its relationship to toxicity 
The structure of the liver can be described by its basic architecture, the hepatic lobule. The repeating 
lobule is broadly pyramidal in shape and consists of the hepatic vein in its centre and at the 
periphery are the portal triads, which are made up of the bile ducts, the portal veins and the hepatic 
arteries. In between these two systems are the columns of liver cells and the blood carrying 
sinusoids. Blood enters the liver from the portal triads and flows through the lobule to the central 
vein where it is drained. Conversely, bile produced in the hepatocytes flows outwards from the 
lobule where it is excreted through the bile duct9.  
An alternative functional description of the liver divides into units defined by the acinus, of which 
there are three zones based on the quality of the blood supply. Zone 1 is centred on the portal tract 
and radiates outwards. Cells in this region receive blood first, which has the greatest nutrient and 
oxygen content.  Zone 2 cells lie in the region between the central vein and portal triads and receive 
blood next. Cells in the zone 3 region, surrounding the central veins, are on the periphery of the 
microcirculatory systems of adjacent acinars and receive blood after the cells of zones 1 and 2, and 
as such has a depleted oxygen and nutrient content9.  
The effects of various hepatotoxins may be distinguished by the type of necrosis they induce. 
Necrosis, if induced by the particular toxin, may be non-zonal and appear as either randomly 
distributed ‘spotty’ patches of necrotic cells or massive necrosis across large regions of the liver lobe. 
If the necrosis induced is zonal it may occur as well-defined patches restricted to cells in the any of 
the zones of the acinus15. Zone 3 necrosis is a characteristic lesion of toxins such as pyrrolizidine 
alkaloids24, carbon tetrachloride25, bromobenzene26 and acetaminophen27 while Zone 1 necrosis may 
be induced by agents such as ferrous sulphate, allyl alcohol and cocaine15, 28. Zone 2 necrosis is 
relatively uncommon except when induced as an extension of zone 1 or 3 necrosis. The zonal 
patterns of necrosis are a consequence of the uneven distribution of metabolizing enzymes and 
oxygen availability across the lobule. The cytochrome P450 enzymes are found in higher 
concentrations in the zone 3 region and therefore compounds whose toxicity is activated by these 
enzymes cause cell necrosis principally in this zone9. Conversely, agents such as allyl compounds are 
preferentially converted to toxic metabolites when there are higher levels of oxygen and therefore 
induce zone 1 necrosis28. 
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1.2.3 Human Exposure to Hepatotoxins 
Toxins are referred to as true, predictable or intrinsic hepatotoxins when they consistently induce 
damage to the liver of a variety of species15. Agents that may occasionally induce liver injury due to 
an unusual susceptibility of the host are not referred to as hepatotoxins and instead the injury is 
deemed to result from host idiosyncrasy.  White phosphorus at one extreme consistently injures the 
liver of both vertebrate and invertebrate species, whereas penicillin may on very rare occasions 
cause liver damage despite millions of patients being regularly exposed to it15. However in reality 
most agents are positioned on a spectrum of hepatotoxic potential with their effects modified by a 
number of different mechanisms based on an interaction between their intrinsic toxicity and the 
vulnerability of the host. 
Humans may be exposed to chemicals that induce hepatic injury in a range of circumstances. The 
environment can pose a number of hazards in the form of natural toxins that may be ingested by 
people unaware of their toxicity, through contamination of the food supply or taken as an herbal or 
traditional medicine. These include fungal toxins such as the very potent peptides produced by the 
mushroom Amanita phalloides that are sometime mistaken for edible varieties29, or mycotoxins, 
produced by microscopic fungi and are considered to be among the most serious contaminants of 
the food supply. Known hepatotoxic mycotoxins include aflatoxins and fumonisins and have caused 
serious human disease worldwide and can contaminate crops if improperly dried before storage30. 
Most recently in 2004, an outbreak of aflatoxicosis, caused by the Aspergillus fungus growing on 
maize, resulted in 317 cases and 125 deaths in eastern Kenya, and produced classic symptoms of 
portal hypertension31. Aflatoxins cause pathological changes in the liver including necrosis, 
cytomegaly and the development of cirrhosis32. The development of protein and DNA aflatoxin 
adducts to accurately measure aflatoxin exposure has revealed it to be an important risk-factor for 
HCC, and is often cited as a shining example of the utility of molecular exposure assessment in 
epidemiology33. Of the hepatotoxins produced by plants, pyrrolizidine alkaloids (PAs) are among the 
most potent and have caused the greatest degree of morbidity and mortality34. These will be 
discussed separately in section 1.3. A number of other hepatoxicants are known to be produced by 
plants that may be ingested. These are summarised in Table 1-1. 
Other natural hepatotoxins may be bacterial in origin.  Some exotoxins produced by bacteria can 
cause severe liver injury and have been responsible for large outbreaks of human disease. The 
alkaloidal toxins produced by cyanobacteria, may contaminate bodies of water, and have been 
implicated as the causes of liver disease following heavy algal blooms. High levels of cyanobacterial 
toxins have sometimes been detected in municipal water supplies and have been associated with 
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liver disease in America and Australia, while people have also been poisoned following recreational 
use of lakes and rivers35. Mass poisoning by the cyanobacterial toxin microcystin was confirmed in a 
dialysis centre in Brazil, following the use of trucked-in contaminated water, and resulted in 100 
cases of acute liver failure, including 76 deaths36. Symptoms included massive hepatomegaly, 
jaundice and bleeding abnormalities and histopathology showed mixed choleostatic and 
hepatocellular liver injury. Bacteria may also contaminate food, if improperly prepared or stored, 
and some species may produce potent hepatotoxins. Bacillus cereus, for example, was responsible 
for fatal liver failure in a family who had consumed pasta prepared four days previously37.  
Table 1-1: Known hepatoxic plants. From 
15, 38
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Plant Active agent Liver pathology 
Germander (Teucrium 
chamaedrys) 
diterpenoids Mixed hepatocellular and choleostatic or 
acute choleostatic hepatitis 
Pennyroryal pulegone zonal necrosis 
Skullcap diterpenoids Mixed hepatocellular and choleostatic or 
acute choleostatic hepatitis 
Teucrium polium  acute liver failure 
Chaparral leaf (Larrea 
tridentate) 
 mixed choleostatic hepatitis, acute liver 
failure, cirrhosis 
Kava (Piper methysticum)  acute hepatitis, occasional choleostasis 
Senna fruit extracts rhein anthrane 
metabolite 
 
Cycad tree fruit cycasin very potent hepatoxin 
Camphor  hepatitis 
Glue thistle (Atractylis 
gummifera) 
 hepatic necrosis 
Impila (Callilepsis laureola) carboxy-atractyloside centrizonal necrosis (acute renal and liver 
failure with profound hypoglycaemia) 
Cascara sagrada  choleostatic hepatitis 
Isabgol  Giant cell hepatitis 
Venencapsan (horse 
chestnut leaf) 
 Steatosis 
Prostata  hepatic fibrosis 
Ma Huang (Ephedra spp.)  severe acute hepatitis 
Jin Bu Huan Levotetra-hydro-
palmatine 
acute and chronic hepatitis 
Greater celandine 
(Chelidonium majus) 
20 alkaloids isolated 
from extracts 
reversible mixed choleostasis-hepatitis 
Sassafras safrole  
Ackee fruit Hypoglycin Microvesicular steatosis 
Tea. Terminalia oblongata, 
Cidema hirta 
tannic acid hepatic necrosis 
Breynia officinalis  Hepatocellular liver injury 
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People may be exposed domestically to man-made hepatotoxins when the food supply is 
contaminated due to accident or even fraudulent activity. Examples includes the epidemic of 84 
cases of “Epping jaundice” in 1965 caused by accidental contamination of a large wheat supply with 
4,4-methylenedianiline40 and the large outbreak of fatal hepatotoxicity and associated porphyria in 
Turkey in the 1950’s that resulted in 500 deaths, following the consumption of wheat grain intended 
for agricultural use that had been treated with the fungistatic agent hexachlorobenzene41. In Spain in 
1981, an epidemic of almost 20,000 cases of ‘toxic oil syndrome’ was caused by consumption of olive 
oil adulterated with aniline sold on the black market 42. Approximately a quarter of cases showed 
signs of choleostatic liver injury 43. 
The risks of subacute and acute hepatic injury due to occupational exposure to chemicals is now 
much lower than in the past due to greater awareness and regulation. The use of halogenated 
hydrocarbons, which have been widely used as industrial solvents and reagents, has previously been 
a prominent cause of liver disease15. The most well-known of these, carbon tetrachloride, is now also 
commonly used to induce experimental models of liver disease44. Occasional outbreaks of acute 
poisoning do still occur although generally through accident, such as the case of nine factory workers 
exposed to hydrochlorofluorocarbons leaking from the air-conditioning unit connected to the cabin 
they shared 45. There is still concern regarding the more subtle effects of long term low exposure to 
industrial chemicals which may contribute to the development of chronic liver diseases. A number of 
studies of occupational cohorts exposed to polychlorinated biphenyls have indicated some 
alterations to liver function46. Farm workers may also be exposed to high levels of pesticides, and 
poisonings through this route still occur relatively frequently in developing countries47 and may 
result in liver dysfunction48. 
Exposure to toxins through pollution of the environment is also a potential hazard. Acute mass 
poisoning events have occurred following industrial catastrophes such as the Union Carbide disaster 
in Bhopal49 and Minamata Bay mercury poisoning in Japan50, although in these instances the liver 
was not the principal target organ, and pollution in general is an unlikely cause of acute and 
subacute liver disease. However, pesticides such as organochlorines, which may persist in the 
environment for many years and also bioaccumulate in human tissues, have long been suspected of 
contributing to chronic liver disease. Recently a positively associated dose-dependent trend was 
shown for serum levels of both p,p’-dichlorodiphenyltrichloroethane (DDT) and β-
hexachlorocyclohexane with HCC in a Chinese case-control study51. Arsenic pollution has a more 
established link to liver disease and is found at high levels in water from community wells in many 
countries and has caused widespread disease in countries such as Bangladesh52. There is good 
38 
 
evidence linking it to non-cirrhotic portal hypertension53. Other heavy metals such as cadmium also 
have the potential to cause liver disease54.  
One of the most important sources of chemical induced liver disease among humans is 
pharmaceutical drugs. Approximately 20 % of acute liver failure cases among children (and a greater 
proportion among adults) are drug-induced55. Most patients however will experience milder 
hepatotoxic reactions such as hepatitis, cholestasis or asymptomatic enzyme elevations. Almost 
1,000 different drugs have been identified as possible causes of liver injury15 and most are not 
predictable hepatotoxins and cause adverse liver-related reactions on rare occasions. Drugs 
associated with hepatic injury include the anaesthetic halothane, antimicrobial therapies such as 
isonazid and rifampicin, antifungal agents such as ketoconazole and antiepileptic drugs such as 
phenobarbital55.  Ketoconazole has a relatively high risk of hepatotoxicity and a cohort study found 
asymptomatic elevation of serum transaminases is 18% of users and overt hepatitis in 3%56. The 
incidence of symptomatic hepatotoxicity for patients receiving antimicrobials for tuberculosis ranges 
from 6-18% depending on other risk factors such as age, drug and alcohol use and co-morbidities57.  
Acetaminophen is by far the most common cause of drug induced liver injury accounting for 14% of 
cases of acute liver failure among children55. In the USA it is estimated that there are more than 
26000 hospitalizations and 450 deaths per year due to acetaminophen overdose58. Despite fewer 
than 10% of patients with acetaminophen overdose developing serious liver disease, its widespread 
use and availability, makes it the most common cause of acute liver failure in the UK and USA27. It is 
a predictable hepatotoxin that causes hepatotoxicity at doses above 125-150 mg/kg and induces 
dose-related zone 3 necrosis. Overdose of the drug overwhelms the sulphation and glucuronidation 
conjugation pathways, allowing more to be metabolised by the MFO system (mainly CYP2E1159) to 
its toxic metabolite, N-acetyl-p-benzoquinoneimine60. If insufficient glutathione is available to 
conjugate and remove this metabolite, it may accumulate within the hepatocyte and form harmful 
covalent bonds with macromolecules resulting ultimately in cell death. Mitochondrial dysfunction16 
and inappropriate activation of the innate immune system61 are also thought to contribute to 
acetaminophen induced hepatic injury. Clinical features of acetaminophen toxicity include initial 
nausea and vomiting, tender hepatomegaly appearing on the second day after overdose, and 
jaundice and encephalopathy may appear from the third day.  Diagnosis is made through clinical 
history and measurement of acetaminophen levels and adducts27. 
No discussion of human exposure to hepatotoxins would be complete without reference to ethanol 
that as the major aetiological factor of cirrhosis it is one of the most important causes of death in the 
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Western world and a growing problem in the UK, with over 800 000 hospital admissions directly 
attributable to alcohol each year2. Ethanol may ‘be ranked as the most important hepatotoxins to 
which humans are exposed’15. Furthermore it also plays an important role in potentiating the effects 
of other hepatotoxins, such as acetaminophen62.  
1.2.4 Factors effecting toxicity 
The balance between the toxification and detoxification metabolic pathways of potential 
hepatotoxins will determine the extent of their toxic effects. These pathways may be modified to a 
remarkable degree by exposure to other agents. It was shown over 50 years ago that administration 
of agents such as phenobarbital enhances the ability of the liver to metabolise a variety of 
compounds, accompanied by increases of liver weight, amount of smooth endoplasmic reticulum 
and the hepatic content of drug-metabolising enzymes63. This phenomenon, referred to as 
induction, is an adaptive process that provides increased metabolic capacity and occurs in all species 
from bacteria to mammals15. Some compounds may induce only specific enzymes while others may 
induce several enzymes simultaneously. Compounds known to induce CYP3A include rifampin64, 
corticosteroids65, alcohol66, DDT67, midazolam68 and St. John’s Wort69. 
Induction of cytochrome P450 enzymes by xenobiotics occurs at the transcriptional level through 
regulation by a number of ligand-activated transcription factors19. The intracellular receptors most 
commonly involved include aryl hydrocarbon receptor (AhR) and the nuclear receptors pregnane X 
receptor (PXR) and constitutive androstane receptor (CAR).  AhR is widely distributed in tissues 
throughout the body70 and typically accepts both endogenous and foreign hydrophobic, planar 
compounds as ligands71. It primarily regulates expression of genes in the CYP1 family.  PXR is thought 
to be the main environmental ‘xenosensor’ since it is mainly expressed within the liver and small 
intestine and its main target gene is CYP3A4. It has a large and flexible binding pocket, allowing 
activation by a range of different sized ligands72 and its own expression is regulated by microRNA73. 
Upon activation, ligand bound PXR forms a heterodimer with another nuclear receptor retinoid X 
receptor (RXR), which together can bind to several distinct DNA elements in the target genes74. It is 
known to induce CYP subfamilies 2A, 2B, 2C and 3A, with its role in the induction of CYP3A4 the most 
studied75. Several promoter elements have been identified within CYP3A4 such as the ER6 motif in 
the proximal promoter region 76and the ‘Xenobiotic-response enhancer module’ in the distal region77 
that enable PXR binding and up-regulation of transcription. Numerous other cofactors are thought to 
be involved in this complex process.  CAR is closely related to PXR and is only found in mammals, 
suggesting a recent gene duplication event from the PXR ancestor78. It is expressed mainly in the 
liver and kidneys, also suggesting a ‘xenosensor’ role. It has been shown that some inducing agents 
40 
 
may also activate this receptor through a ligand-independent mechanism79. Upon activation it also 
dimerises with RXR and binds to many DNA-binding elements, many of which are common to PXR80. 
Its main targets are members of the CYP2B subfamily, but it is also involved in CYP3A and CYP2C 
regulation. 
Cytochrome P450 activity may also be inhibited by a number of agents. This is a particularly 
important consideration in clinical practice where harmful drug-drug interactions can be caused by 
the increased bioavailability of a drug that is normally eliminated by cytochrome P450 enzymes19. 
Inhibition may be irreversible or reversible depending on whether the inhibitor must first be 
metabolised by the cytochrome P450 enzyme19. Reversible inhibition is most common and results 
from competition for the active site of the enzyme. Bonds are quickly formed but easily broken so 
inhibition is rapid but does not permanently damage the enzyme. Irreversible inhibition can occur 
when the metabolised intermediary form strong covalent bonds to the protein or the heme of the 
enzyme and may inactivate it completely. Known CYP3A inhibitors include macrolide antibiotics81, 
ketoconazole82 and ritonavir83. 
Diet can also affect compound metabolism and toxicity84. Fasting can deplete stores of glycogen, 
reducing availability for the detoxifying glucuronidation pathway, while a low protein diet can 
decrease the amount and activity of cytochrome P450 expression, reducing the toxicity of 
compounds activated by these enzymes25. Alcohol can increase toxicity by both inducing cytochrome 
P450 expression66 and depleting available stores of glutathione62.  
Genetic factors play a fundamental part in host susceptibility which is illustrated in the first instance 
by the great differences observed in the metabolism and toxicity of compounds when given to 
different strains and species of laboratory animals85, 86. Genetic polymorphisms in Man have been 
identified within all the major drug-metabolising genes22 and these may translate to differences in 
phenotype. For some enzymes such as CYP2D6, expression levels varies between individuals by as 
much as 1000 fold22, due to several missense mutations reducing the function of certain alleles or 
making them not function completely. In addition some individuals may have more than two 
functional alleles due to gene duplication events. This is reflected in enzyme activity as illustrated 
with studies of the drug debrisoquine which showed a multimodal distribution of metabolic activity 
among participants which corresponded to the number of functional alleles they possessed87. 
However enzymes that play a more general role in xenobiotic metabolism are far more 
evolutionarily conserved. CYP3A4 expression levels vary by only 20-fold between individuals with 
only moderate, but significant, differences in enzyme activity22. Studies of the clearance of CYP3A4 
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substrates reveal a unimodal distribution, indicating the influence of many different genes on 
CYP3A4 activity88, 89. Polymorphisms among the genes for phase II metabolising enzymes will also 
play an important role the potential toxicity of a compound. Of these the UDP-
glucuronysltransferases (UGT) are the most relevant to drug toxicity after the cytochrome P450 
enzymes. Polymorphisms of the isozyme UGT1A1, required for bilirubin glucuronidation, can lead to 
hyperbilirubinemia, which in most cases is manifested by mild sporadic jaundice called Gilbert’s 
syndrome90. Mutations in this gene also increases the risk of severe side effects following treatment 
with the drug irinotecan, since reduced conjugation of its active metabolite in the intestine may lead 
to life-threatening diarrhoea91.  
Age and gender also affects toxin susceptibility. Although clear differences are observed in the 
expression patterns of drug-metabolising enzymes among rats and mice, no genetic differences in 
these enzymes between the sexes are observed in humans22. However sex hormones are involved in 
the regulation of some drug-metabolising enzymes92. Females do appear to be more likely to 
develop adverse reactions to some drugs, such as tetracycline-induced hepatic injury, particularly 
when pregnant9.  On some of the rare occasions when men experienced an adverse reaction to this 
drug, they had also been receiving estrogens15. Children and infants appear to be more susceptible 
to hepatic injury with some drugs such as valproate93 and aspirin15. 
The important role of the gut microflora in the metabolism of drugs is increasingly recognised94. The 
gut microflora consists of more than 400 species of bacteria that increase in density from the 
duodenum to the colon95. They play a key role in first-pass metabolism and contain many drug-
metabolising enzymes. The slower a compound is absorbed by the intestinal mucosa, the more likely 
it will be biotransformed by the gut bacteria. Since they are mostly anaerobes, hydrolysis and 
reduction reactions are favoured96. These may provide alternative metabolic pathways to the often 
toxifying mammalian oxidation reactions97 or may produce toxic metabolites themselves22. 
Hydrolysis may deconjugate glucuronides, sulfates, and cysteine conjugates which may be excreted 
in the bile. Through extrahepatic circulation, this may present toxic intermediaries back to the liver. 
Gut microflora have also been shown to interact with mammalian drug-metabolising systems. 
Antibiotic treatment suppressed CYP3A11 expression in the mouse98, mediated through lithocholic 
acid-producing gut bacteria, while re-colonisation of germ-free mice had an inducing effect of both 
CYP3A11 and CYP2C2999. Among human volunteers, the ratio of sulfate to glucuronide 
acetaminophen conjugates in the urine was predicted by urinary levels of p-cresol sulphate, a 
bacteria-originated metabolite, prior to acetaminophen dosing100. Metabonomics, a systems-biology 
approach that profiles all detectable metabolites in a biofluid in single analytical sweep, has helped 
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to show the size of the contribution of the gut biota to metabolism. Studies have revealed 
unexpected drug metabolites produced by the gut bacteria97, while a typical analysis of mammalian 
urine by nuclear magnetic resonance (NMR) spectroscopy reveals a large proportion of detectable 
metabolites to be microbial in origin101. 
1.3 Pyrrolizidine alkaloids 
1.3.1 Structure and Toxicity 
PAs are plant toxins of which more than 350 are known, which play a protective role in plant defence 
against herbivores102. Besides causing human illness through ingestion of herbal medicine and teas, 
PAs has been implicated in mass poisoning events worldwide due to contamination of the food 
supply. PA contamination of staple grain has caused outbreaks of human poisoning in South Africa 
103, the former soviet republics of Central Asia 104, India 105, Afganistan106, 107, Tajikistan108 and Iraq109. 
PA poisoning is also a widely recognized disease of livestock from grazing on contaminated 
pastures110. PAs are the most common plant hepatotoxins, estimated to be found in 3% of the 
world’s flowering plants 111 and are globally distributed in many plant species from unrelated genera. 
Most human poisoning cases have been caused by plants of the Senecio, Crotalaria, Heliotrope and 
Sympytum species.  
 
 
 CH3OH
CH3
H
O
CH3
OH
O
O
H
O
N
Monocrotaline 
O
CH3
CH3H
OH
OH
O
O
H
O
N
Senecionine 
Lasiocarpine 
CH3
H
CH3
CH3
CH3
CH3
O
H
O
O
N
O
CH3
OH
OH
O
H
O
OH
N
O
CH3
CH3
OH
CH3
OH
Lycopsamine 
CH3
CH3 O H
OH
CH3
CH3 O
O
H
OH
N
Heliotrine 
Figure 1-2: Representative PA structures 
43 
 
They share a basic structure derived from esterification of one of four necine bases (platynecine, 
retronecine, heliotridine and otonecine) with an acid moiety, which are termed necic acids. The 
necine base is composed of a pyrrolizidine ring system consisting of two five-membered rings fused 
together and attached on either side to a nitrogen atom. PAs can exist as monoesters, open diesters 
or as closed macrocyclic diesters, depending on the type of necic acid present, which may be doubly 
esterified to opposing carbons of the necine base to form a macrocyclic structure. The PAs 
lycopsamine and heliotrine are examples of monoester type. Examples of open diesters include 
lasiocarpine while examples of macrocyclic diesters include senecionine and monocrotaline (Figure 
1-2). Heliotrine and lasiocarpine are derived from the necine base, heliotridine, while lycopsamine, 
senecionine and monocrotaline are derived from the necine base retronecine. Not all PAs are 
hepatotoxic and a number of structural features determine whether the PA is capable of being 
metabolized to hepatotoxic intermediaries. The minimum structural requirements for a PA to be 
hepatotoxic  (Figure 1-3), as described by Mattocks112, are as follows: 
1. They must be esters of unsaturated necines that have a 1,2-double bond. 
2. There must be at least one hydroxyl group attached to the pyrroline ring via the carbon. 
3. At least one of these hydroxyl groups must be esterified. 
4. The acid moiety of the ester linkage must contain a branched chain. 
 
Figure 1-3: The generic structure required for PAs to cause toxicity. 
From Table 1-2, that lists known acute toxicity work carried out in male rats with isolated PAs, 
administered intraperitoneally, it is apparent that macrocyclic diester PAs are more toxic than non-
cyclic diester PAs, which are in turn more toxic than monoester PAs. It also appears that PAs 
composed of the necine heliotridine are more toxic than those composed of the necine retronecine, 
which differs in the stereoconfiguration at the C7 position.  The structure of the acid moiety provides 
steric hindrance restricting the hydrolysis, and detoxification, of the ester groups113. The complex 
branching structure of the acid moieties may therefore have been driven by the ‘evolutionary arms 
race’ between plant and animal. The lipophilicity of the PA is also important, since more water 
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soluble PAs such as indicine (a stereoisomer of lycopsamine), tend to be more easily excreted and 
have lower toxicity since less is available for hepatic activation114. 
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Table 1-2: LD50 (dose which causes death in 50% of group) and median lethal dose (MLD) values for PAs administered 
intraperitoneally to male rats. 
alkaloid type necine necic 
acid(s) 
LD50/ 
MLD  
mg/kg 
95% 
CI 
time 
range 
(days) 
reference 
retrosine macrocyclic 
diester 
retronecine isatinecic 34 30-39 4 or 7 115 
senecionine macrocyclic 
diester 
retronecine senecic 50 44-58 4 or 7 115 
heliosupine diester heliotridine angelic; 
echi-
midinic 
60 MLD 3 110 
lasiocarpine diester heliotridine angelic; 
lasiocarpic 
72 66-79 3 110 
seneciphylline macrocyclic 
diester 
retronecine senephyllic 77 71-86 3 110 
senecionine macrocyclic 
diester 
retronecine senecic 85 MLD 3 110 
monocrotaline macrocyclic 
diester 
retronecine mono-
crotalic 
95 79-114 7 115 
monocrotaline macrocyclic 
diester 
retronecine mono-
crotalic 
109 93-127 4 115 
latifoline diester retronecine angelic; 
latifolic 
125 MLD 3 110 
symphytine diester retronecine tiglic; (-) 
viridofloric 
130 MLD NR 112 
heleurine monoester (-) supinidine heliotric 140 MLD 3 110 
monocrotaline macrocyclic 
diester 
retronecine mono-
crotalic 
175 160-
195 
3 110 
echimidine diester retronecine angelic; 
echi-
midinic 
200 MLD 3 110 
senkirkine macrocyclic 
diester 
otonecine senecic 200 MLD NR 112 
spectabiline macrocyclic 
diester 
retronecine acetyl 
mono-
crotalic 
220 MLD 3 110 
cynaustine monoester (+) supinidine (-) 
viridofloric 
260 MLD 3 110 
heliotrine monoester heliotridine heliotric 300 270-
330 
3 110 
echinatine monoester heliotridine (-) 
viridofloric 
350 MLD 3 110 
supinine monoester (-) supinidine (+)trache-
lanthic 
450 410-
490 
<1 110 
riderine monoester heliotridine (+)trache-
lanthic 
550 MLD 3 110 
heliotridine monoester heliotridine none 1200 MLD 3 110 
europine monoester heliotridine lasiocarpic >1000 MLD 3 110 
indicine monoester retronecine (-) trache-
lanthic 
>1000 MLD NR 116 
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1.3.2 Metabolism 
PAs are stable chemically and require metabolic activation to exert toxicity85. There are generally 
three main phase I pathways for the metabolism of PAs of the heliotridine/retronecine type 111, 112, 
117.  These are hydrolysis, N-oxidation and a two step oxidation process (Figure 1-4).  Hydrolysis is 
considered the major detoxification pathway and involves cleavage of the ester functional groups at 
the C7 (if present) and C9 positions, to produce the necine base and necic acid, neither of which is 
toxic or undergoes further biotransformation. The second detoxification pathway is N-oxidation of 
the necine base to the corresponding PA N-oxide. The final oxidation pathway is the principal 
toxification pathway, which produces a highly reactive pyrrolic ester, responsible for hepatotoxicity. 
Further hydrolyisis of the pyrrolic esters produces a pyrrolic alcohol, dehydropyrrolizidine (DHP) 
which is a secondary toxic metabolite of lower toxicity but longer lifespan.  
 
Figure 1-4: Phase 1 metabolism of riddelliine. Reproduced from 
117
. 
The cytochrome P450 enzymes have a role in both toxification and detoxification, since they are 
responsible both for the oxidation to pyrrolic ester metabolites and for the N-oxidation to the PA N-
oxides117, 118. Senecionine metabolism in human liver microsomes was shown to be primarily 
mediated by the CYP3A4 isoform119. CYP2B and CYP2C have also been shown to contribute to PA 
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metabolism in animal studies117, 118, and may also have a role in human PA metabolism. Flavin-
containing monooxygenases also contribute to N-oxidation with the relative contribution of the 
different enzymes differing among species120. The carboxylesterases catalyze the hydrolysis 
pathways involving ester cleavage and are extremely substrate specific. In guinea pigs, isozyme 
GPH1 was able to metabolize a variety of PAs while GPL1 showed no activity. The substrate 
specificity may explain the resistance of guinea pigs to PA toxicity121 
Phase II metabolism of the toxic pyrrolic metabolites by binding with one or two molecules of GSH, is 
catalysed by the glutathione S-transferases and may also occur non-enzymatically 122. The products 
formed are 7-GSH-DHP and 9-diGSH-DHP123.  Glucuronidation has also been shown in vitro for a 
variety of macrocyclic PAs, with the glucuronysl group conjugating on the nitrogen atom of the 
untransformed PA124. This would prevent the PA entering the oxidation pathways to toxic pyrrolic 
metabolites in a similar way to acetaminophen metabolism. This reaction has been shown in human 
microsomes to be exclusively catalysed by isozyme UGT1A4125.   
1.3.3 Mechanisms of Toxicity 
The highly electrophilic nature of the pyrrolic metabolites is responsible for the adverse effects of PA 
since they can bind to nucleophilic molecules such as DNA and proteins111 and cause immediate 
damage to the hepatocyte. It has been demonstrated that pyrroles alkylate the sulfhydryl groups of 
cysteine and GSH122, the extra-cyclic amino group of deoxyguanosine126, 127 and the N7 position of 
guanines in a sequence selective fashion128. In addition the pyrrolic ester rapidly polymerises and 
forms a structure capable of crosslinking several fragments of DNA128 and forming DNA-protein 
crosslinks. The ability of various PAs to forms crosslinks corresponds to their known toxicity129 
suggesting their probable role in PA-induced injury. This property has also been suggested as the 
reason for the progressive hepatopathy observed following single doses of PA130, since reversible 
thiol-pyrrole bonds may store a proportion of the toxic metabolite in the hepatocyte which may over 
time be released as pyrrolic alcohols causing further cell damage 111. If the primary toxic metabolites 
of the PA are sufficiently persistent they may pass from the hepatocyte into Disse’s space and the 
sinusoidal lumen131 where they may attack the endothelial cells lining the sinusoid and induce VOD. 
Pyrroles from some PAs such as monocrotaline may also attach to the red blood cells and be carried 
to other organs, which can lead to damage to the lungs and heart111. 
One of the most characteristic aspects of PA poisoning in animals is the development of enlarged 
cells, or megalocytosis. It appears to result from the combined effect of stimulus to regenerate 
following parenchymal cell injury and the antimitotic activity of the pyrrolic metabolites111. It has 
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been observed in post-mortem in many species of grazing animal and induced in many different 
experimental animals but has never been previously reported in Man111. It is thought that damage to 
key genes in the control of the cell cycle disrupt cell division leading to mitotic bypass, while allowing 
continued production of proteins and DNA132. Mutations in the p53 tumour suppressor gene have 
been observed following PA administration in a number of studies111, 133, 134 and this gene has a role 
in controlling the cell cycle at the G1/S  phase and possibly also the G2/M phase. 
Approximately half of identified PAs have been shown to be mutagenic in variety of systems135 
including Drosophila melanogaster102, in the Salmonella mammalian-microsome mutagenicity test102, 
135, 136 and in transgenic rodents137. Primary liver tumours have also been induced in rodents 
following administration of several PAs116, 134. While PAs are likely therefore to be hepatocellular 
carcinogens, no cancer has been reported in association with human PA exposure.  
1.3.4 Effects in laboratory animals 
The different hepatoxic PAs have similar effects in small animal species. Death normally occurs 1-4 
days after administration of a lethal dose, the liver is firm and congested and hemorrhagic ascitic 
fluid is often present.  Histologically, the characteristic effect of acute PA exposure in laboratory 
animals is zonal hemorrhagic necrosis112 and the zone may vary according to species and PA used. 
Retrosine24 and heliotrine138 both cause centrilobular necrosis in the rat at acute doses, while 
laisocarpine caused midzonal necrosis138. In addition, the sinusoids may become dilated with blood 
and the lumen may become narrowed as in human VOD 24, 112. 
The ability to induce VOD in rats depends on the type of PA used; macrocyclic diesters such as 
monocrotaline and fulvine often produce this lesion while open PAs such as laisiocarpine and 
heliotrine rarely do34. The dosage is also important; McLean34 reports that a single large dose  of 
Crotalaria fulva (near to the LD50), is effective in inducing VOD in rats, while repeated small doses 
produce a different pathological picture leading to cirrhosis in rats, but never VOD. The sequence of 
events following a single large dose of C. fulva shows that the occlusive lesions (appearing after 7-10 
days) are secondary to centrilobular necrosis (present at 1 day) and the signs of portal hypertension 
(present after 2-5 days). 
The ability of PAs to induce chronic liver lesions (following repeated or single small doses) is 
associated with their ability to induce acute toxicity130, 139. The histological hallmark of chronic PA 
hepatotoxicity is the progressive enlargement of the parenchymal cells and nuclei often referred to 
as megalocytosis or cytomegaly. Other features reported include bile duct proliferation, necrosis, 
fatty change, fibrosis, cirrhosis and vascular lesions34. An early study in rats of the chronic effects of 
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heliotrine139, following an episode of sheep poisoning in Australia, is typical. Following death after 
i.p. injection of 0.1 x LD50 thrice weekly, the liver had become atrophic and appeared to be the only 
organ affected. Histologically, swollen hepatocytes were present, sometimes present just around the 
central vein and sometimes more widely distributed, and there was also extensive bile duct 
proliferation in the portal tract. Furthermore they demonstrated that small doses of the alkaloid 
over an extended period produced a rise in liver copper values well above normal. The study by 
American National Toxicology Programme (NTP) on the effects of riddelliine in rodents represents 
the most robust study of chronic PA toxicity140. Riddelliine was administered by gavage 5 days per 
week for 105 weeks to groups of 50 male and 50 female rats and mice. In rats, no observable 
adverse effect followed 0.01 mg/kg/day, 0.033 mg/kg/day caused hepatocyte cytomegaly and at 
0.33 mg/kg/day regenerative hepatocyte hyperplasia was observed. In mice, focal necrosis of the 
liver was observed at 0.1 mg/kg/day (lowest dose given) and hepatocyte cytomegaly and 
karyomegaly was observed at 0.3 mg/kg. 3 male rats dosed 1 mg/kg/day survived the test period 
while 38 of the male mice survived on the same dose. Other liver lesions noted include focal 
necrosis, bile duct proliferation, haemorrhage and mixed cellular infiltration. 
1.3.5 Exposure in humans 
The World health Organisation (WHO) appointed taskforce on PAs102 list 32 separate known human 
PA poisoning events from all regions of the world (up to 1988), ranging from poisoning of single 
individuals to outbreaks of over 1000 cases. The two main routes through which humans have been 
exposed to PAs, is through consumption of herbals medicines or teas, or through contamination of 
the staple food by the seeds of PA-producing plants. Sporadic cases of poisoning by herbal medical 
concoctions are still occasionally reported around the world, including in developed countries where 
the popularity of alternative medicines has been increasing 13.  PA poisoning in the West Indies 
through consumption of ‘bush teas’, is now effectively controlled by public education programmes, 
since the epidemic of the 1950’s that resulted in several hundred cases12. Epidemics of PA poisoning 
now more frequently occur through grain contamination in countries where the agricultural systems 
are less developed or compromised through political instability.  
In all reported cases of exposure, patients present as classical cases of VOD, as described by Stuart 
and Bras12 where the most prominent liver lesion is occlusion of the central and sub-lobular veins. It 
is therefore conventionally accepted that the presence of this lesion is required for the diagnosis of 
PA poisoning13. However this may be a rather circular argument since the presence of VOD may be 
needed to encourage doctors to search for possible sources of PA in diet, as they may not take into 
account the possibility of plant poisoning when examining patients with liver disease. McLean 34 also 
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makes the point that most reported cases in humans fall into the category of acute, rather than 
chronic, poisoning in the sense of exposure to a large dose or doses. Chronic lesions of 
megalocytosis and gradual liver failure are seen in grazing animals but have not been previously 
observed in Man. This is not to say they do not occur but would be more likely to occur in regions 
where medical services are rudimentary (since herbal remedies would be more popular and 
agricultural systems less developed) and so less likely to be recorded. 
Among poisonings by herbal teas and medicines, cases of comfrey (Symphytum) poisoning has 
attracted the most attention in the West, as this is a widely used herbal medicine. It contains at least 
8 PAs including echimidine, symphytine, lycopsamine, intermedine and acetyllycopsamine 141. In the 
USA, a 49 year-old woman, was admitted to hospital with progressive swelling of the abdomen and 
extremities and was diagnosed as suffering from VOD. Biopsy showed centrilobular necrosis and 
congestion. While no demonstrable obstruction of outflow was observed, balloon distension of an 
intrahepatic venous tributary showed near obliteration of the smaller hepatic venules and 
extravasation of the dye into the hepatic parenchyma. She admitted consuming a herbal tea and 
comfrey pepsin pills on a daily basis for 6 and 4 months which were analysed for PA content giving 
an estimated minimum daily PA intake of 15 μg/kg b.w142. This would appear to be a rare example of 
a chronic level of intoxication as it is a minute fraction of the pre-acute lethal dose in rats 143, 
although the authors admit she may have had other sources of PA exposure. This calculated dose is 
also a fraction of doses estimated to have caused other episodes of human toxicity102.  Rasenack 144 
reports VOD in a male infant in Germany, who was delivered by emergency caesarean section during 
week 32 of gestation but died 12 hours later. An herbal mixture of which 2 g was used for cooking 
daily by the mother during pregnancy was believed to be the cause. Analysis showed that it 
contained 12.5 mg/kg of PAs and the dehydro- derivatives of lycopsamine and integerrimine were 
found in the fetal liver tissue. There is also growing recognition in China about the risk posed by PA-
containing plants when used, sometimes in error, in traditional medicine145, 146. Resultant research 
had led to important recent developments in our understanding of PA metabolism124 and in 
analytical techniques146, 147 
Epidemics of PA poisoning that has been linked to contamination of grain have been reported in five 
different areas of the world (Table 1-4). The first reported cases of occurred in South Africa in the 
1920’s, due to contamination of wheat by seeds of the Senecio ilicifolus and S. burchelli plants 103. 
The disease had existed for at least 10 years, causing some 80 cases, prior to it being reported by the 
authors. The disease affected whole families who suffered mainly from abdominal pain and vomiting 
with ascites. Blood was sometimes present in the stools or vomit. Investigations found that in wheat 
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bought from mills of ‘the old-fashioned type where winnowing is not efficient’, senecio seeds had 
been ground into the grain. The plants also caused similar disease in livestock (which was shown 
with feeding experiments) known locally as Moltedo disease. Wilmot reports an autopsy of one case, 
with cirrhosis described as the most marked change in the liver and the central venule is only 
described as dilated. Interestingly, hepatocytes are marked with a brown pigment. The walls of the 
stomach contained tiny ulcers which may explain the bleeding abnormalities. In a later and more 
extensive report the disease is described as presenting as Budd-Chiari syndrome 14. Experiments 
where the plants were fed to rats and guinea pigs reproduced the human disease. The disease 
appeared to disproportionately affect ‘poor whites’ which is speculated by Selzer as being due to 
lower protein intake, although Wilmot points out that the poorer the family the greater the 
proportion of diet will be made up by bread. Black families, who staple was maize, were not 
affected. 
An outbreak of disease, described in the Soviet literature as ‘dystrophy of the liver’ and later as ‘toxic 
hepatitis with ascites’, occurred in the Central Asian republics of the USSR from 1931-1946102. The 
disease was known locally as ‘camel-belly disease’ and was associated with bread with a bitter taste. 
Two waves of cases occurred, in 1931-35 affecting 1000-1500 people, and in 1945-46 where 60-70% 
of the population in agricultural areas were estimated to have been affected. Domestic animals were 
also affected and grazing animals did not appear to be affected, just those fed contaminated grain or 
grain offal 139. The disease was found to be caused by the seeds of Heliotropium lasiocarpum 
contaminating wheat (and linseed, according to a paper cited by McClean34) during the second wave 
and this aetiology was confirmed on a variety of experimental animals 148. A description of 28 
patients is available, translated into English 104. The disease presents as VOD with veins narrowed or 
obstructed by silver-staining fibres. Haemorrhages are reported in many organs but not the brain. 
Again brown pigment is present in the liver and bile ductular proliferation is reported but only in 
cases of prolonged illness in a state of cirrhosis. Agricultural measures and controls had largely 
eradicated the disease in the region until fighting in Tajikistan caused an outbreak in the winter of 
1992-93108. 3906 cases or 4% of the local population were affected. A blockade of the region led to 
famine and a delay in the wheat harvest of 2 months, causing Heliotrope seeds (containing 
lasiocarpine and heliotrine) to be collected with wheat and ground into bread. The first cases of liver 
toxicity occurred six weeks after consumption of the contaminated bread. Effects by age are shown 
below (Table 1-3):  
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Table 1-3: Fatality and attack rate by age in the 1992-1993 Tajikistan outbreak 
Age <1 1-14 15-30 31-50 >50 
Attack rate % 0.4 5.4 4.0 2.8 1.5 
Fatality % 0 0.8 1.3 2.3 5.9 
 
They defined four stages of disease: abdominal pain, nausea or vomiting, and weakness (55.5% 
cases); hepatomegaly (29.9% cases); ascites (13.7% cases); and alteration of consciousness (0.9%). 
The population continued to eat the contaminated flour, despite warnings until a flour-exchange 
program was put in place.  
A similar outbreak occurred in NW Afghanistan following a severe drought 1970-1972106. The 
affected district of Gulran consists of a landscape of undulating hills with scanty vegetation serving 
as pasture lands. Inhabitants are principally farmers whose diet is wheat bread and occasionally 
meat. Water is scarce, in some places salty and taken from shallow wells and springs. 
Communications were very poor and village was totally isolated during winter. Goat and sheep 
flocks were destroyed (apparently due to starvation) and there was serious food shortage. By the 
middle of 1974, cases of massive abdominal distension started to appear that soon turned into an 
epidemic. The poorest families were disproportionately affected. In many instances, several 
members of family were affected within weeks of each other and all had died. Typical symptoms are 
reported and the authors noted prominent veins over skin and occasional spider naevi. The disease 
was usually fatal, with death occurring 3-9 months after onset. A census of 7200 villagers showed 
evidence of liver damage in 22.6% and in 15%, the damage was advanced. There were 1034 affected 
males and 598 females and 45% were aged below 14. Biopsies findings were characteristic of VOD. 
H. popovii (known locally as “charmac”) were found to be growing abundantly in wheat fields and 
wheat samples were found to contain on average 40 seeds (weighing 300 mg) /kg wheat. PAs were 
identified as heliotrine and PAs similar to lasiocarpine. Seeds showed alkaloid content by weight of 
0.72-1.49% and the alkaloid content in wheat flour samples varied from 0.5-1.86%. Their estimate 
based on 700g of flour minimum per adult daily would contain about 2mg of toxic alkaloids. 
Conservatively over two years (since end of drought) this would amount to 1.46g. 
Further outbreaks have subsequently been reported in the Gulran district in 1999 - 2001 with an 
estimated 400 cases, including over 100 deaths, and most recently in 2008107. The most recent 
outbreak occurred in a year when levels of rainfall were normal. It was reported that many farmers 
did not believe the disease could be caused by wheat contamination by the charmac weed, since it is 
present throughout the district every year but the disease occurred in only five of the 230 villages 
and in large households only a few family members had the disease despite all of the household 
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consuming the same bread. However a case-control investigation revealed odds ratios (OR) for 
having the disease among those who reported high bread consumption (versus low consumption) of 
35.8 (95% Confidence interval (CI): 7.6–168.2). Furthermore toxic quantities of PAs including 
heliotrine, laisiocarpine and heliotrine N-oxide were detected in flour samples, with  median PA 
concentration of samples from case houses found to be 5.6mg/kg (95%CI: 0.4–38.4) whereas among 
control samples it was found to be 2.7 mg/kg (95%CI: 0.4–4.0). The PA concentrations were 
significantly higher among households who reported charmac growing on their land or among their 
wheat. PAs were also detected in samples of yoghurt made from goat’s milk (median 0.09 mg/kg), 
including trichodesmine, a PA not found in the charmac or wheat samples. The study also showed 
significantly different patterns of bread consumption between cases and controls from the same 
household. 
Tandon also reports a VOD epidemic in four villages in India in 1975, which followed a previous small 
epidemic in 1973105. Nutrition is inadequate in the area and the staple diet is a type of millet called 
gondli. The community was consuming grain that was heavily contaminated with the seeds of a local 
plant of Crotalaria species. The plant was found to contain PAs similar to monocrotalline or fulvine.  
Of a population of 486, there were 67 reported cases, 28 (42%) of which died. The disease occurred 
at all ages and in both sexes. More than one family member had the disease in 80% of cases. Biopsy 
of 8 patients and 3 necropsies confirmed VOD. 
An outbreak occurred recently in Northern Iraq in 1994, among three families of Bedouin nomads 
109. The families had buried their harvest of wheat according to their traditional method and 
inadvertently mixed it with the seeds of Senecio vulgaris. The presence of PA in the wheat and flour 
was confirmed by Ehrlich’s reaction, a colorimetric test. 
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Table 1-4: Previous epidemics of PA poisoning due to contamination of the staple food supply 
Date of 
outbreak 
Location Source Plant # 
Cases 
Fatal-
ity 
rate 
epidemiological 
features 
Symptoms described Autopsy/biopsy ref 
1910 - 
1920. 
Further 
deaths 
reported 
1930-1940 
South Africa Wheat senico 
ilicifolius,  
senico 
burchelli 
80 High -Family clustering 
-affects poor 
white people 
-Disease in 
animals 
First nausea, then vomiting, then acute stomach 
pain. Symptoms more severe and frequent as 
disease progresses. Diarrhoea sometimes present. 
Blood sometimes present in vomit and stools. 
Hepatomegaly, ascites develops rapidly in all 
severe cases. No dropsy. Abdominal distension 
considerable 
1 autopsy. Liver: increased in size, edges 
rounded, raised area of deeper colour noted 
(engorged with blood). Histology: capillaries 
between hepatic cells distended with blood, 
central venule dilated, liver cells reduced in size, 
some brown pigment, some fatty cells. Round-
celled infiltration, fibrosis. Stomach: tiny ulcers 
extending through mucous coat. Congested 
kidney 
14, 
103
 
1931-1949 
(first 
wave1931-
35 and the 
second 
between 
1945 - 46) 
Central Asia 
(Former 
USSR) 
especially 
Uzbekistan, 
Tajikistan 
Wheat, 
linseed? 
helio-
tropium 
lasio-
carpum 
First 
wave: 
1000-
1500.  
First 
wave 
13-15% 
-Affects young 
and middle aged  
-Not known in 
infants 
-Disease in 
animals 
General debility, lassitude, Headaches, hot 
sensations, pain in abdomen vomiting, 
constipation but more often diarrhoea, ascites, 
subcutaneous mesh of venous vessels observed on 
abdomen. Icterus in only 5 cases, blood in vomit 
and stools before death. More severe in children 
and death rapid. Oedema of lower legs 
Liver: Necrosis of wall of capillaries and central 
veins and of centrilobular hepatic cells, fibrosis, 
fibres close lumen of vessels and run alongside 
central veins. No fatty stain, no cellular infiltrate, 
pycnotic cells. Brown pigment. Bile ductular 
proliferation only observed in cases of prolonged 
illness in state of cirrhosis. Haemorrhages also 
observed in spleen, tonsils, oesophagus, 
pancreas, suprarenals, gastric mucosa, large 
intestine and renal tissues. 
104, 
149
 
1970-1972 North-
Western 
Afghanistan 
wheat 
(mean 40 
seeds /kg 
wheat) 
heliotrop
ium 
popovii 
1632 often 
fatal 
-Poorer families 
more affected. 
 -2:1 male to 
female, -46% <14 
years old 
-Disease in 
animals 
Begins with anorexia, lassitude, dull heaviness in 
upper abdomen, jaundice and fever rare. After 
several weeks, abdominal distension develops with 
wasting. Prominent veins over skin. Oedema of 
lower extremities. Jaundice and spider naevi 
observed occasionally. Hepatomegaly with hard 
consistency and sharp margins. Splenomegaly. 
10% liver not palpable in cases with advanced 
ascites and emancipation. No significant bleeding 
abnormalities. 
5 necropsies, 16 liver biopsies. Duration 1-9 
months. Liver finely granular and nutmegged. 
Striking centrilobular congestion. Extreme 
hemorrhagic congestion of parenchymal cells. No 
inflammation. Central veins often 
unrecognisable. Those present showed 
subendothelial oedema with partial or complete 
occlusion. Varying degrees of fibrosis observed 
around central vein areas, extending towards 
portal regions. Occasional bile stasis observed. 
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1973, Nov-
Dec 1975 
North India millet Crolatari
a spp. 
67 42% -All ages and 
sexes, >80% had 
family history 
-Disease in 
animals 
Epigastric pain, abdominal distension, fever and 
jaundice rare, 18 cases had distended veins over 
abdomen, 13 had oedema of feet, hepatomegaly 
(2-5cm) in 13 cases (39%), splenomegaly in 7 cases 
(21%), icterus in 7 cases (21%), encephalopathy in 
6 cases. No bleeding from gastrointestinal tract. 
All autopsy (3) and biopsy specimens (8) had 
identical changes. Large areas of centrilobular 
haemorrhagic necrosis. When central vein 
recognisable, it was dilated and empty but 
surrounded by sinusoids distended with blood. In 
all necropsies, central and sublobular veins had 
varying occlusion. Collagenisation of sinusoids 
even in early stages. No cirrhosis. 
105
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Date of 
outbreak 
Location Source Plant # 
Cases 
Fatal-
ity 
rate 
epidemiological 
features 
Symptoms described Autopsy/biopsy ref 
1992 Tajikistan wheat helio-
tropium, 
lasio-
carpum 
3906 1% Attack rates 
highest in 1-14 
year olds 
Four stages of disease were defined:1: abdominal 
pain, nausea or vomiting, and weakness (55.5% 
cases).2: hepatomegaly (29.9% cases).3: ascites 
(13.7% cases).4: alteration of consciousness (0.9%) 
None reported although disease referred to as 
VOD 
108
 
1994 Iraq wheat senecio 
vulgaris 
16 25% 57% male, 50%  
<15 yrs. 
Abdominal pain and ascites in all patients. 
Vomiting and hepatomegaly observed 
14 biopsies showed typical pathology of veno-
occlusive disease. 
109
 
1999-2001, 
2008- 
North-
Western 
Afghanistan 
wheat, 
possibly 
yoghurt 
helio- 
tropium 
popovii 
First 
wave: 
400 
25%  Massive ascites, no oedema of face or arms. None reported although disease referred to as 
VOD 
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1.3.6 Effects in domestic animals 
PA poisoning affects most species of domestic livestock and is endemic in many regions of the world. 
It has many different names, either popular in origin or resulting from the name of the region. 
Stockowners in Britain are reported to have first suspected the poisonous nature of S. jacobaea as 
far back as 1787, while a Crolataria species was suspected of causing ‘Missouri River Bottom 
Disease’ of horses in the USA in 1884 or earlier 110. In other instances such as for Pictou disease of 
cattle in Canada, Winton disease of cattle and horses in New Zealand and Schweinsberger disease of 
horses in Germany, the disease was recognised as cirrhosis of the liver before being linked to 
poisonous plants. The suspicion that Senecio species were causing Molteno disease of cattle and 
horses in South Africa led to the plants being shipped to the Scientific and Technical Department of 
the Imperial Institute (which has now become Imperial College London), where the poisonous 
alkaloids were identified by Watt 150, in one of the first experiments to isolate PAs. 
The susceptibility and effects vary by species. Cattle151 and horses152 succumb very quickly to S. 
jacobaea with an intake of 5% of the body weight proving lethal, while for goats153 and sheep152 
cumulative lethal doses several times their body weight are required. Sheep are affected slowly by 
grazing on Heliotrope infested pastures and most survive one season’s grazing. The next year three 
groups of affects are observed: in the first group sheep die very quickly; another group die more 
slowly with haemoglobinuria and high levels of copper in their liver while a third group dies much 
later with small livers with enlarged hepatocytes110. Sheep fed Crolataria die within three weeks with 
fluid in the thoracic cavity 34. Cattle are quickly affected by grazing on infested pastures and common 
signs include ascites, violent diarrhoea, wasting, inability to stand a straddled gait and death34. In 
horses the signs are neurological including compulsive walking in a straight line and butting any 
obstacle 110. Dogs poisoned with heliotrope alkaloids develop liver failure with ascites 148. The organs 
affected also vary by species: the WHO taskforce reports that in goats and cattle only the liver and 
lungs are affected while in sheep, chickens and horses the liver, lungs and kidneys are affected; only 
the liver is thought to be affected in dogs and man102. 
1.3.7 Routes of exposure 
In addition to their presence in grain and medicinal preparations, PAs have been in detected in milk, 
honey and eggs, although there are no confirmed cases of human illness following exposure to PA 
through these potential sources.  
PAs has been detected in the milk of goats and cattle following feeding experiments 111. The milk of 
goats fed a diet of 25% Senecio jacobaea (containing 0.33 to 0.81 ppm of Senecio PAs) was fed to 
rats over a period of six months to give a calculated dose of 0.96 mg/rat. At the end of the 
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experiment, liver injury including swollen centrilobular hepatocytes and bile ductular proliferation 
was present in the rats, indicating mild PA poisoning. Similar effects were observed in rats fed a diet 
of 0.01% S. jacobaea directly153. Feeding experiments in lactating mice and rats with labelled senecio 
PA found that around 0.1% of the original dose is excreted in the milk, with most in the form of 
water-soluble metabolites such as N-oxides152.  One may expect to recover a greater proportion the 
original dose of more water soluble PAs than Senecio PAs (i.e. senecionine) in milk. Reports by UK 
and Australian government organisations 149, 154 found that the risk of PA exposure due to milk 
consumption in their respective countries was low due to the practice of milk bulking from different 
sources. However Cheeke believes that the only human health hazard would be in circumstances 
where a family goat was grazed on PA-containing plants 152. 
N-oxide forms of PAs gives cause for concern in relation to both animal and human breast milk, 
because they are more readily excreted due to their increased water solubility.  N-oxide forms of 
PAs have similar toxicity to the alkaloid base when ingested orally since most are converted back 
into the base alkaloid in the alimentary tract 112. Plants may contain as much as 90% of their 
alkaloids in the N-oxide form 155 and the greater the proportion of PA in N-oxide form the greater 
the risk posed by the milk of animals feeding on those plants. In addition PAs have apparently been 
detected in human milk during previous PA poisoning epidemics 149 and it is possible that PAs 
detoxified by oxidation in the mother’s liver may contribute further N-oxides for excretion in the 
milk. 
Recent reviews of the PA content of honey concluded that honey posed a potential human health 
risk 156, 157. Dübecke et al156 surveyed 3197 honey samples and found PAs present in 66% of raw 
honeys. In all reported cases honey produced from a single species of PA-containing plant contained 
the PAs known to be produced by that plant. Honey attributed to S. jacobaea was found to contain 
3.9 µg PA per gram of honey while honey from Echium plantagineum contained 0.95 µg/g of various 
PAs, consisting mainly of echimidine. Since the extraction efficiency in these studies was considered 
to be only around 50%, ‘single-species’ honeys from PA-containing species can be expected to 
contain several µg of PA per gram of honey.  
It has been reported that chickens fed wheat contaminated with 26 mg/kg of PAs laid eggs that 
contained up to 0.168mg/kg of PA 154. However a study where chickens were fed a diet of up to 4% 
Senecio vernalis, did not detect any PA in the eggs although it was suggested that the PA might have 
been irreversibly bound to the egg proteins and so not detected158. 
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There are no records of PA being detected in meat following ingestion of PAs by livestock. Meat is 
not considered a potential source of PA exposure by Mattocks112, unless the animal had been killed 
immediately after  a massive intake of PA, since in laboratory animals the levels of PA in tissue falls 
rapidly after intake. However offal may be a potential source since levels of PA between <0.010 to 
0.073 mg/kg have been detected in the livers and kidneys of domestic animals 149. 
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2. Hirmi Valley Liver Disease 
2.1 Background 
ases of a new, often fatal, liver disease were first reported in Tseada Amba in April 2001. 
Tseada Amba is a remote village of around 1500 people, inaccessible by road, in the Tigray 
region in Northern Ethiopia. The disease is characterised by acute presentation with upper 
abdominal (epigastric) pain and vomiting sometimes accompanied by fever and jaundice. After a 
variable period, during which the vomiting, jaundice and fever may subside, abdominal swelling 
develops, which is linked to signs of ascites with either hepatomegaly or splenomegaly or both. 
Some adults report having been unwell for as long as six years whereas children have reportedly 
died within three months of the onset of symptoms.  
Cases were initially confined to Tseada Amba but were then reported in the adjacent village of Jek 
Amba in 2006 and in villages to the south in the kebelle (administrative district) of Kiburto in 2005. 
These villages are all located within the Hirmi Valley, whose name can be roughly translated as 
‘forbidden valley’.  For this reason the disease will be referred to in this thesis as Hirmi Valley Liver 
Disease (HVLD). A similar outbreak was reported in November 2008 in Mekeyho village in the 
Mayhanse area, which is around 40 miles from Tseada Amba (Figure 2-1). 
591 cases, including 228 deaths, were reported to local health authorities up to January 2010, from 
21 different kebelles. Although the disease has spread from its original location, the kebelle of Kelakil 
(which includes the villages of Tseada Amba and Jek Amba) is still considered the epicentre of the 
outbreak, with 141 (62 % of total) deaths due to the disease coming from this district, despite having 
254 (43 % of total) cases. Interviews with local informants suggest that the actual number of cases 
may be higher as many patients did not bother to attend hospital due to the distance and 
inadequacy of treatment 
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Figure 2-1: Map of affected villages. Bottom left: Ethiopia. Middle left: Tigray. Top Left: Western Tigray Zone. Main map: 
Affected villages. From FAO report February 2009 
2.2 The area and its people 
Tigray is the North most region of Ethiopia. The majority of its inhabitants are Orthodox Christians, 
who speak Tigrinya, one of the oldest Semitic languages in Africa 159. It has a highly variable 
landscape with diverse topography and altitudes creating many different agro-ecological niches. The 
region has highly variable seasonal rainfall and frequent droughts; the coefficient of variation in 
annual rainfall for Tigray is 28% compared to 8% for Ethiopia as a whole 160 
The affected villages are in a hilly area of Tigray at an average altitude of 1500m, where many 
villages are inaccessible by road (Figure 2-2). The region is classified as ‘weyna dega’ zone, according 
to the Ethiopian system of natural zone classification, which describes a medium altitude area with 
sufficient rainfall and moderate temperatures, and forested vegetation with patches of grassland 159. 
The local climate is characterised by daily temperature ranges of 25 to 29°C with very low humidity 
during the prolonged dry season and a wet season of heavy rains between June and September 
(reaching a maximum of 222mm in total for the month of July). 
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Figure 2-2: Typical undulating landscape of the Hirmi Valley 
Farming is the most important activity in Tigray, where 65% of land is under cultivation and 95% of 
this land is farmed by smallholders161. Almost all residents in the affected villages are subsistence 
farmers who operate a mixed crop/livestock farming system. Farming practices have changed little 
over the centuries. Holdings are traditionally small (averaging 1.2 hectares per household in 1994162) 
and managed and worked by all members of the farmer’s family. Title to land is inherited and a 
symbol of status, evolved from the past when land was granted in return for service to religion or 
state and it is said that a ‘Tigrai cannot be without land unless he is a Muslim or a tradesman’159. 
Homes are generally built on the highest point of this land, with crops grown in the surrounding 
area. The ownership of livestock too, connotes wealth and status. Animals may be given to sons or 
daughters as wedding gifts or on reaching adulthood, and inherited after the death of parents.  
Medical services in this region are rudimentary with 1 doctor for every 100,000 people in Tigray. 
Health care is therefore mainly provided through health posts manned by nurses (1: 5000 people) 
and health extension workers (1:3,500 people)163. In Tahtay Koraro (population: 121,059 people), 
the woreda (administrative district) encompassing Kelakil, the leading causes of outpatient disease 
cases in 2002 was malaria (5648 cases), then acute upper respiratory infection related illness (4044 
cases) and then helminth infections (4.004 cases). The leading causes of death were pneumonia (20) 
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TB-respiratory (13) and malaria (13). This was the only woreda in Tigray where cirrhosis was in the 
top 10 causes of death with 3 recorded deaths163. 
2.3 History of investigations up to November 2008 
The disease outbreak has been investigated by a number of different organisations. A rapid 
assessment was initially conducted by the Faculty of Medicine at the University of Addis Ababa, who 
reported their findings to the Ethiopian Health and Nutrition Research Institute (EHNRI) in December 
2005. ENHRI then proceeded with laboratory and epidemiological investigations into the causes of 
the disease. Their report concluded that contamination of a water source used by most inhabitants 
was responsible for the outbreak. This was based on a number of findings; the relatively high levels 
of nitrates, nitrites and phosphates measured may have allowed the proliferation of cyanogenic 
bacteria; the free access of the water to animals may have given rise to zoonotic disease and the 
plant Ageratum conyzoides was noted to be growing abundantly around the spring. The plant 
subsequently tested strongly positive for the presence of PAs and despite water from the source 
meeting WHO drinking quality standards and testing negative for the presence of PAs, the toxins 
were believed to have leached into the water. When this water was administered to mice, mild 
hepatic necrosis was observed and the liver tested slightly positive for PA metabolites. Additionally, 
Interviews with 30 households from Tseada Amba and 30 households from neighbouring Jek Amba, 
which at the time had no disease cases, did not expose any lifestyle and dietary differences between 
the villages except in the water source used. 
PA toxicity was further supported by the similar clinical presentation of HVLD to VOD, which is the 
typical effect of PA exposure.  VOD was also reported in an autopsy conducted by Addis Ababa 
University, of a 12-year old boy who died while being transported form Tseada Amba. No PAs were 
detected in any food or grain samples collected by the investigatory team; however a distilled 
sample of a home-brewed beer caused hepatic necrosis in mice whose livers also tested positive for 
PA metabolites. No effect was observed when a non-distilled portion of the same beer sample was 
used. 
As a result of this report, and the desire of the inhabitants of Tseada Amba to move from the village, 
the water supply in Tseada Amba was filled in and the people internally displaced into a 
resettlement area within the same kebelle of Kelakil, around seven miles away.  However, new cases 
with acute symptoms have continued to appear 2-3 years after the population was re-housed, 
including very young children born since the resettlement. The displaced villagers continue to get 
food from Tseada Amba and the indigenous residents of resettled area in Kelakil, who grow their 
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food locally, have remained free of the disease.  In August 2007 the United States Centres for 
Disease Control (CDC) conducted a census of the resettled area in Kelakil and a small case control 
study and took serum samples164, 165. The case control study found no evidence that the water supply 
in Tseada Amba was to blame, as all people in the village had used the same source. Serum analyses 
were used to exclude HBV, HCV, malaria, metal poisoning and visceral leishmaniasis as potential 
causes of end stage liver disease. Their report concluded that due to positive antibody tests for 
schistosomiasis, mass treatment for the disease should be implemented. 
 After a stasis in investigations, The Oasis Foundation, a charitable organisation that works in the 
area, asked the Schistosomiasis Control Initiative (SCI) of Imperial College London to evaluate the 
active schistosomiasis prevalence and its relationship to HVLD. Analysis of stool and urine samples 
revealed that the active schistosomiasis prevalence was low and therefore not the causative agent 
of HVLD.  
After being contacted by the SCI, Professor Thursz, consultant hepatologist at Imperial College, 
visited the area in June 2008 to obtain liver biopsies to determine the underlying pathology. He 
concluded that the disease was a toxic liver injury that shows a full range of severity from mild 
fibrosis to cirrhosis and none of the four biopsy specimens examined showed the pathological 
features of VOD. Findings from these biopsies along with further specimens will be presented in 
chapter three. Interviews with local residents and health professionals suggested that males and 
females are equally affected and children aged between 7 and 15 appear to be most susceptible. 
The disease is clustered within households, with whole families of affected individuals living next 
door to unaffected households, and most deaths have occurred between May and November each 
year.  
2.4 The weekly Oasis foundation clinics 
The Oasis Foundation ran weekly clinics from June 2008 until March 2009 in three affected woredas, 
manned by health extension workers and nurses. They report treating 369 patients, of whom 55% 
were male and 56% were under 18 years old. During this time 184 patients were discharged and 8 
deaths were recorded. The following signs and symptoms were reported: ascites (27% of patients), 
splenomegaly (51%), hepatomegaly (23%), epigastric pain (45%), abdominal distension (82%), 
jaundice (1.5%), epistaxis (6%) and spontaneous bacterial peritonitis (2%). The majority of their 
patients report an onset of symptoms in 2nd and 3rd quarters of year. The following treatment 
protocol, introduced by Prof. Thursz, was used:  
 Ascites is treated with spironolactone and conservative paracentesis.  
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 Spontaneous bacterial peritonitis is treated with oral amoxicillin or ciprofloxacin.  
 Nutritional supplements of soya flour and sugar for each affected family  
 Vitamins C and B complex and methionine, in the form of barley flour, to supplement the 
anti-oxidants in their diet. 
The Oasis Foundation reported that treatment was effective at ameliorating the symptoms of the 
disease. From April 2009, clinics have been ran by the Tigray Health Bureau (THB) although funds 
were unfortunately no longer available for nutritional and barley supplements. 
2.5 Detection of pyrrolizidine alkaloids in grain samples 
During the visit to Tseada Amba by Prof. Thursz and colleagues in June 2008, samples of millet and 
teff, a local grain, were collected opportunistically from grain stores in six vacated houses belonging 
to affected villagers. Grain samples were transported to the Pharmaceutical Institute of the 
University of Bonn, Germany for analysis of levels of PAs using a validated gas chromatography-mass 
spectrometry (GC-MS) method for plant material sources (Table 2-1) and reported in February 2009. 
In teff samples from houses 1 and 3, no PAs were detectable; in a mixed millet and teff sample from 
house 5, traces of those compounds could be found but quantification was not possible as it was 
under the detection limit. 0.007 µg/g of toxic PA was detected in a millet sample from house 2 and 
0.015 µg/g of toxic PA were detected in a teff sample from house 4. In the largest millet sample from 
house 6, 0.477 µg/g of PA was detected. The PAs were identified as a mixture of acetyllycopsamine, 
lycopsamine and its isomer, intermedine (Figure 2-3). Acetyllycopsamine made up the majority of 
the PA detected. These results have been published previously166. The largest concentration found is 
at a level that is considered to be potentially toxic154 and it is notable that this sample was the 
largest quantity sampled, indicating that the method of sampling may contribute to the amounts of 
PA detected. 
Table 2-1: Pyrrolizidine alkaloid content of grain samples analysed 
House Number Samples Pyrrolizidine alkaloid content 
Crop seed Weight (g) μg μg/g 
1 Teff 42.93 Negative - 
2 Millet 47.77 0.34 0.007 
3 Teff 71.42 Negative - 
4 Teff 24.04 0.36 0.015 
5 Millet & Teff 11.35 Trace quantity - 
6 Millet 182.7 87.06 0.477 
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21 samples from 19 affected and 2 unaffected households in Kiburto were also collected during the 
CDC directed census of December 2008 (see section below). These samples (mainly millet and teff) 
were sent to the Poisonous Plant Research Laboratory of the USDA for PA analysis167. Samples were 
tested for levels of lycopsamine (extracted from Hawaiian specimens of A. conyzoides) and this PA 
was detected at low levels in samples of millet (6/9 samples), teff (6/8 samples), maize (1/2 samples, 
trace quantity only) and sesame (1/1 sample) from both the 2007 and 2008 harvests. The highest 
concentration of lycopsamine found was 0.068 µg/g. No lycopsamine was found in one sample of 
soy. Ten out of 19 (53%) of samples from affected households had measurable levels of lycopsamine 
(>0.005 µg/g) and four samples had trace quantities. No lycopsamine could be detected in the two 
samples (maize and millet) from unaffected households. 
2.6 Parallel Disease in Domestic Animals 
Following reports (See Chapter four) that there was parallel liver related morbidity and mortality 
among domestic animals, field investigations by the Food & Agriculture Organization Ethiopia and 
Dr. Mike Hauser of the SCI, were made in November 2008 and January 2009. The liver appeared to 
be the most affected organ among the sheep, goats and cows sampled. The most common signs in 
animals were a distended abdomen and ascites in the body cavities. Anaemia and an enlarged 
haemopietic system were sometimes also observed, particularly among goats. Many animals had 
elevated levels of serum enzymes alanine transaminase (ALT), aspartate transaminase (AST) and 
alkaline phosphatase (ALP). Some of the animals had received antibiotics and antihelminths but had 
not shown any improvement. Histological analysis of organ samples was conducted by three 
different pathologists. The most significant lesions were liver atrophy with associated centrilobular 
and portal fibrosis and a notable variation in nuclear size (karyomegaly) of hepatocytes. There were 
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Figure 2-3: PAs detected in grain samples collected in Tseada Amba. Left: Acetyllycopsamine, Middle: Lycopsamine, 
Right: Intermedine. 
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some subtle changes that were suggestive of chronic PA exposure such as the karyomegaly, mild bile 
ductular proliferation (noted by one pathologist only) and some megalocytosis (also noted by one 
pathologist only) although this was not conclusive. 
 The investigators also reported that A. conyzoides grows more abundantly on hilly areas and 
increases in density as one moves down into valleys. The plant was observed to be abundant on crop 
land and grazing areas. 
2.7 The December 2008 Census of Kiburto 
During December 2008, I supported the work of CDC and ENHRI in conducting a census of Kiburto to 
enumerate the population and disease prevalence.  During this investigation, teams of local health 
workers visited households to determine the size and number ill at each household. A limited 
number of small household lifestyle questionnaires were completed and blood and grain samples 
were taken. Global positioning system (GPS) coordinates were taken from each household visited. 
Disease cases were identified using the following multilevel case definition developed by the CDC 
along with the WHO: 
 Suspect –– individual with abdominal distension and either abdominal pain/cramps for at 
least two weeks or another household member with similar symptoms.  
 Possible – individual meeting the suspect case definition with hepatomegaly and/or 
splenomegaly upon physical examination  
A third level, ‘Probable’, was to be introduced for use in a routine surveillance system, following 
evaluation of the most suitable serum enzyme biomarkers to use. 
2.7.1 Prevalence estimates 
A total of 568 households were visited during the census and data on 2832 individuals was collected. 
112 people (4% of surveyed population) met the suspect or possible case definition. 68 (12%) of all 
households had at least one suspect/possible case, while 44 (65%) of these households at least 2 
suspect/possible cases. There were 27 deaths reportedly due to the disease. 84/1445 (5.8 %) males 
and 55/1,400 (4.0%) females were reportedly affected by the disease. The mean age of non-cases 
was 22.5, the mean age of suspect/possible cases was 23, and the mean age of deaths reportedly 
due to disease was 10. 
2.7.2 GIS analysis 
Using data compiled during the visit, which included the house locations, number of residents and 
number of suspect and possible cases at each household, I produced a map of houses visited during 
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the census. Maps were produced using ArcGIS software ver. 9 by overlaying collected GPS 
coordinates upon either a base map (map 1338 A2) obtained from the Ethiopian Mapping Authority 
in Addis Ababa, or a map of the region produced by the FAO.  Shown in Figure 2-4 are the all the 
affected houses (with at least one suspect or possible case) and unaffected houses, surveyed during 
the census.  
Areas that had a higher than expected number of affected households were detected using a log-
likelihood ratio test using the SatScan programme 168. The software scans a window that is allowed 
to vary in size across space and decides on which window is most likely based on the ratio of 
observed to expected number of affected houses. A Bernoulli process was used to model expected 
number of affected houses, using a binary variable. Figure 2-5 zooms in on the bulk of the houses 
surveyed and shows the boundary of the significant spatial cluster located by the likelihood 
clustering routine. Results of the analysis are presented in Table 2-2. 
Table 2-2: Characteristics of top-ranked (Monte Carlo) spatial cluster of households that has a 
higher than expected disease prevalence. 
Coordinates / radius of spatial cluster (13.907390 N, 38.372100 E) /  0.45 km 
Number of houses in window 14 
Number of affected houses 10 
Expected number of affected houses 1.95 
Observed / expected 5.127 
Relative risk 5.920 
Log likelihood ratio 12.586 
Monte Carlo rank 1/1000 
P-value 0.001 
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Figure 2-4: Map of all houses visited during census. Green dots show unaffected households and red dots affected 
households. The central blue H is Kiburto Health post while the blue H in the top right area is Zana health post. 
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Figure 2-5: Zoomed in Map of Kiburto area showing bulk of houses visited during census. The circle shows boundary of 
significant spatial cluster. Blue lines are streams during wet season and red lines are paths. Double black line shows 
drivable road. The river in the top-left corner marks the boundary between Kiburto and Kelakil (the kebelle which 
incorporates both Tseada Amba and the displaced village). 
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While this is a relatively simple analysis it does show that there is an uneven distribution of affected 
households and that some areas have significantly higher disease prevalence than other areas, 
suggesting a geographical component to the disease.  The maps also display some limitations of the 
census investigation. Workers would arrive each day by road at the Kiburto heath post and fan out 
to survey the surrounding households. Within the timescale of the investigation (and the difficult 
conditions of the area) it was therefore only possible to visit those households located around the 
health post. This may therefore bias the prevalence estimates from the census due to the non-
random nature of sampling, particularly as sampling excludes houses closest to Tseada Amba where 
the disease was first identified. 
2.7.3 Lifestyle Risk factors 
Questionnaires regarding farming and dietary practices were administered to 160 households during 
the census. 33 (21%) of these were affected households, with at least one suspect/possible cases 
and 127 (79%) were unaffected households. I contributed to the development of the questionnaire 
at joint meetings with the other investigators, drawing from the information obtained in previous 
open-ended individual interviews presented in chapter 4. The questionnaire consisted of 13 
questions with simple yes/no answers (see appendix). Selected odds ratios, which were calculated 
comparing the odds of a specific lifestyle practice occurring in an affected household compared to 
an unaffected household, were presented in the CDC final report (Table 2-3) 
Of the grains grown millet had the most elevated odds ratio (2.5, 95% CI = 0.9-6.5) but was not 
statistically significant. The odds ratio for drinking tela (sua) was not reported, presumably because 
it was not elevated or significantly reduced. However drinking tej, an alcoholic mead-like drink 
brewed from honey was identified as a risk factor (OR=2.6, 95% CI = 1.0-6.9) although conversely, 
eating honey was found to have a protective effect (OR= 0.3, 95% CI = 0.1-0.7). Eating food not 
grown by the household also was protective (OR=0.4, 95% CI = 0.2-0.9) which supports food 
contamination (or may indicate higher socio-economic status). The most striking elevated odds ratio 
was for having sick animals (OR= 5.0, 95% CI = 2.1-11.7) strongly suggesting the involvement of 
animals in the casual pathway or that they are exposed to the same toxin as their owners. In 
addition drinking goat’s milk was also identified as a statistically significant risk factor (OR= 2.5, 95% 
CI = 1.0-6.0), but not cow’s milk. This could be a social artefact or a real effect arising from different 
animal metabolism or behaviour (goats are browsers that feed on leaves while cows mainly graze on 
grass). These lifestyle risk factors will be discussed further in chapter 4. 
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Table 2-3: Selected risk factors from household questionnaires collected during December census of Kiburto. 
Reproduced from
169
 
Risk Factor OR (95% CI)* 
Sick animals  5.0 (2.1-11.7)  
Grains grown by HH  
Millet 2.5 (0.9-6.5)  
Teff 1.1 (0.2-5.4)
† 
 
Sorghum 0.4 (0.1-1.4)
† 
 
Maize Undefined
† 
 
Farming Practices  
Used herbicides 2.0 (0.6-7.0)
† 
 
Used pesticides 1.8 (0.8-3.9)  
Noticed more weeds 1.3 (0.6-2.9)  
Consumption habits  
Drank tej 2.6 (1.0-6.9)  
Drank goat’s milk 2.5 (1.0-6.0)  
Ate earth (geophagia) 2.2 (0.7-7.0)  
Ate goat butter 2.2 (0.5-9.5)
† 
 
Ate sheep 1.4 (0.6-3.3)  
Ate food not grown by HH 0.4 (0.2-0.9)  
Ate honey 0.3 (0.1-0.7)  
Water source  
Unprotected well 1.1 (0.2-5.6)
† 
 
Protected well 1.0 (0.3, 2.8)  
River/spring/stream 1.0 (0.3, 3.1)  
* Bold represents statistically significant odds ratios.  
† 
At least one cell in the 2x2 table contained fewer than 5 observations. Caution should be used 
when interpreting the results due to small sample  
2.7.4 Serum Analysis 
Blood samples were collected from all those willing (1160 individuals) during the household visits. 
Possible and suspect cases had higher median serum levels of γ-glutamyltransferase (GGT), ALP, AST, 
and ALT than non-cases. 10 out of 32 possible cases whose serum was analysed had elevated GGT 
(above the upper normal limit) while 8 had elevated ALP.  LFTs were also raised among some 
members of the non-symptom displaying population indicating a level of sub-clinical disease. 
Serum copper levels were measured in 189 samples and were in the normal reference range 
indicating that there was no abnormal exposure to copper. Concentrations of aflatoxin B1-lysine 
adducts in 178 samples were too low to support aflatoxicosis.  
2.7.5 Grain Analysis 
67 samples of grain from both unaffected and affected households were analysed for levels of 
aflatoxins, cyclopiazionic acid (another mycotoxin) or mycotoxigenic species at the CDC laboratories.  
Levels of these mycotoxins were either non-detectable or at a very low levels below US regulatory 
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limits. Furthermore, a thin layer chromatography analysis of grain and tela extracts by ENHRI found 
detected no aflatoxin. 
ENHRI reported that teff, sesame and millet samples they collected during the census contained 2 to 
6 Ageratum seeds per gram (Figure 2-6). The remaining grain samples (maize, sorghum, lekwa) did 
not contain any seeds. Trace quantities of PA were detected by thin layer chromatography in teff, 
sesame, millet & tela samples but not in maize, sorghum, lekwa samples suggesting that Ageratum is 
responsible for the detected PAs. 
 
Figure 2-6: Ageratum seeds in Teff, Millet and Sesame. From ENHRI report May 2009 
2.8 Ageratum conyzoides 
Ageratum conyzoides belongs to the family Asteraceae tribe Eupatoriae. The centre of origin is in 
Central America and the Caribbean and the traditional range of Ageratum species is from South-
eastern North America to Central America. While most taxa are found in Central America, A. 
conyzoides is rapidly invasive plant and is now is found in several countries in tropical and sub-
tropical regions, including Brazil170. It has become very common in West Africa and some parts of 
Asia and South America171. It was recorded as present in Java, Indonesia prior to 1870172. Records in 
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the East African Herbarium at the National Museums of Kenya first show the plant in 1917. Analysis 
of the herbarium record indicates that the plant was originally restricted to high altitudes in Kenya 
but spread regionally to lower altitudes. The authors ascribe the spread to an increase in agricultural 
activities such as irrigation in arid areas 173.  
It is an annual branching herb and grows to approximately 1 m in height (Figure 2-7). The plant 
grows commonly near habitation, thrives in any garden soil and is very common in wastelands and 
on ruined sites. The essential oil of the plant is reported to have a powerful nauseating odour and in 
Australia its smell is likened to that of a male goat and is duly referred to as ‘goatweed’ or ‘billy goat 
weed’171. In some countries the species is considered a weed, and control is often difficult170. 
 
Figure 2-7: Ageratum conyzoides. From FAO report February 2009 
This plant is widely used in ethno-medicine around the world and in parts of Ethiopia it is sometimes 
used for wound dressing174. It is known to contain a number of pharmacologically active 
compounds175, including hepatotoxic PAs. The PA content of specimens collected in Kenya was 520 
ppm (0.052%) and contained the PAs lycopsamine, and its isomer echinatine176. Indonesian 
specimens were found to have an alkaloid of content of 0.014% which is also relatively low.  The 
essential oil of this plant has been widely studied and the oil content has been found to vary 
throughout the year from 0.11 to 0.58% for leaves and from 0.03 to 0.18% for the roots 171.  GC-MS 
analysis of the essential oil of A. conyzoides has identified many different constituents; the most 
reported being a total of 51 constituents from sample of the plant collected from a university 
campus in Nigeria. The most common component of the oil are precocene I, found in ranges of 30 -
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93%, and precocene II, detect in ranges from 0.7 – 55% 171.  Compounds such as coumarins, 
saponins, tannins and flavonoids have also been detected177. 
Besides PAs, coumarins and perocenes have been shown to be hepatotoxic. A NTP two year study 
with 120 rats where 100 and 200 mg/kg coumarin in corn oil was administered by oral gavage 5x per 
week found significantly higher levels of serum ALT, AST and GGT in dosed groups than in controls 
and a range of lesions in the liver and kidneys including hepatocellular necrosis, fibrosis, cytologic 
alteration, and bile duct hyperplasia 178. One study found that a single i.p. dose of precocene I (300 
mg/kg) administered to groups of 5 rats resulted in severe centrilobular necrosis and significantly 
raised serum ALT activity 179. However, a recent paper tested the hepatotoxicity of precocene II 
(similar structurally to precocene I) which had been extracted from Chinese specimens of A. 
conyzoides. No liver damage could be detected following doses of up to 50 mg/kg/day over 11 days 
by gastric tube in rats, although hypoglycaemic properties were shown180. 
A. conyzoides is listed as poisonous to rabbits and the active components listed as ‘HCN, coumarin 
and alkaloid’ in Useful Plants of Ghana 181. Interestingly, rabbits (like goats) are known to be resistant 
to PAs182.  It has been suspected of poisoning cattle in Australia172 and Indonesia183. The related 
species Ageratum houstonianum is known to poison cattle with photodynamic dermatitis being the 
most prominent sign. An outbreak of poisoning in Zebu cattle in Brazil did not show characteristic 
toxic dermatitis but post mortem examination revealed bloody serous fluid in coccyx-femoral joints 
and haemorrhages in the large muscle tissues, liver, kidney and heart184. 
Findings from toxicological studies with A. conyzoides are mixed with two concluding the plant was 
safe for use in ethno-medicine177, 185 while another found it caused substantial liver injury. The 
studies where rats were administered extracts of the A. conyzoides plants collected in Brazil177 and 
Nigeria185 found no apparent hepatotoxicity (measured by LFTs) and the LD50 was determined to be 
over 10,000 mg/kg.  However, a 6-week study where rats were fed a diet containing 10 and 20% 
powered leaves of A. conyzoides collected in Indonesia (following suspicion that the plant was 
responsible for poisoning of cattle) showed extensive liver injury, including bile ductular 
proliferation in the portal tract (appearing in the second week of the study), hepatocyte 
enlargement appearing by the third week and focal necrosis appearing by the fourth week 186.  
This difference may be due to specimens from different localities containing different compounds. 
Different chemotypes of the plant (plants which contain different profiles of type and quantity of PA) 
are present in different geographic locations, as has been shown for Senecio species 187. Analysis of 
Kenyan specimens of A. conyzoides found it to contain the PAs lycopsamine and echinatine176, while 
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specimens collected in Hawaii contained lycopsamine and a new acetyl derivative of lycopsamine 
with the acetyl group positioned within the necic acid branched chain167. It is therefore likely that 
Hirmi Valley varieties of A. conyzoides are capable of producing the PAs lycopsamine, intermedine 
and acetyllycopsamine (with the acetyl group at the C7 position) detected in grain samples. 
The PA content may also vary over time and within the plant. The PA content of S. Riddellii collected 
at different times of the year and in different locations in the USA ranged from 0.18% to as much as 
17.99% by dry weight155. There was a definite seasonal pattern with the total alkaloid content 
reaching a maximum at the preflower or early bud stage in the summer months.  A limited analysis 
of the PA content of different parts of three Senecio plants was conducted which found the flowers 
to have the most PA and the stem to have the least. 
Attention has been drawn since the start of the investigation to A. conyzoides by the original work of 
ENHRI, and this plant is obviously widespread on the farm and pasture lands of Hirmi Valley. 
However other potential sources of PAs may be present. At least ten plants (Crotalaria laburnifolia 
L., Crotalaria recta, Cynoglossum caeruleum, Cynoglossum geometricum, Heliotropium cinerascens, 
Heliotropium supinum L., Senecio gigas, Senecio myriocephalus, Senecio Schirnperi , and  Senecio 
Schultzii.) have been collected in Ethiopia that have proved hepatoxic to rats116. 
2.9 Toxicity of Lycopsamine and its derivatives 
Lycopsamine and intermedine are all monoesters composed of the necine retronecine, suggesting 
that they will have low toxicities. Intermedine contains the necic acid (+) trachelanthic and its 
stereoisomer lycopsamine, contains the necic acid (-) viridofloric. Acetyllycopsamine is a diester 
derivative of lycopsamine and contains an additional acetyl group at the C7 position of 
retronecine141. 
While no complete toxicological work has been conducted with these PAs individually, Culvenor et 
al188 conducted a comparative structure-toxicity study of PAs using a limited amount of lycopsamine 
and intermedine. Selected results from the study, where increasing doses of PA were administered 
intraperitoneally (i.p.) to groups of mixed sex 14-day old rats, are shown in Table 2-4. 
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Table 2-4: Reproduced from Culvenor
188
, Dose levels start at level 1 (0.025 mmoles/kg bodyweight) and double at each 
subsequent dose level. 
alkaloid Dose 
levels 
tested 
Dose level 
causing 
acute 
toxicity  
(death 1-
7 days)  
Dose level 
causing 
preacute 
toxicity 
(death 
<1day) 
Dose level 
causing 
acute liver 
lesions 
(necrosis) 
Dose level causing 
chronic liver lesion 
(megalocytosis) 
lasiocarpine 1 to 5 2 - 3 1 
seneciphylline 1 to 6 2 - 2 1 
heliosupine 1 to 7 3 5 - 3 
retrosine 1 to 6 3 - 3 1 
senecionine 1 to 5 3 - 1 1 
crispatine 1 to 6 3 4 1 2 
usaramine 2 to 6 3 - 4 2 
heliotrine 1 to 7 5 - 5 3 
monocrotaline 1 to 5 5 - 3.5 4 
acetylheliotrine 2 to7 5 7 4 3 
lycopsamine 4 - - - - 
intermedine 4 to 5 - - - - 
supinine 4 to 7 - - - - 
cynaustine 3 to 6 - 6 - - 
heleurine 6 to 8 - 7 - - 
 
The study suggests that lycopsamine and intermedine will have a relatively low acute toxicity, as no 
effects were observed at levels 4 (59.8 mg/kg) and 5 (120 mg/kg) respectively. Indeed indicine, 
another stereoisomer of lycopsamine, did not induce significant liver lesions at 1000mg/kg116. A 
single oral dosage of rats with an alkaloidal fraction from Amsinckia intermedia, consisting mainly of 
lycopsamine and intermedine plus two other PAs, caused acute death at a dose rate of 1500 mg/kg, 
acute CNS effects at 1000 mg/kg and chronic liver damage, at 500 mg/kg189. 
Table 2-4 shows little difference in toxicity between heliotrine and acetylheliotrine, suggesting that 
acetyllycopsamine will show toxicities close to those of lycopsamine188, although this may be 
misleading due to the different stereoconfigurations of the necines of heliotrine and lycopsamine at 
the C7 position. While no previous toxicological work has been done with isolated 
acetyllycopsamine, rats were administered the alkaloid fraction of Symphytum uplandicum which 
contained acetyllycopsamine (32%), along with lycopsamine (12%) and intermedine (3%) and four 
other PAs, including the more toxic echimidine (24%). Preacute (non-hepatic) deaths occurred with a 
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dose of 284 mg/kg i.p. and rats given repeated doses at the rate of 71 mg/kg i.p., thrice weekly, died 
within 3-4 weeks with severely impaired liver function143.  
2.10 Aims and objectives of thesis 
The central aim of this project is to determine the aetiology of Hirmi Valley Liver Disease. The central 
hypothesis driving this thesis is that PA poisoning, through food contamination by the plant 
Ageratum conyzoides is the cause of HVLD. The evidence to support this hypothesis is summarised 
as follows: 
 PAs have been detected in grain collected from households affected by the disease. 
 The PAs are of the type produced by A. conyzoides. 
 A. conyzoides grows abundantly on farmland and its seeds contaminate grain. 
 The clinical presentation is similar to previous outbreaks of PA poisoning. 
 Parallel disease in domestic animals is similar to previous outbreaks of PA poisoning. 
 Other causes of similar outbreaks in rural communities such as aflatoxin poisoning have 
been excluded 
However some aspects of HVLD do not appear consistent with this hypothesis. Initial biopsy 
specimens did not show any evidence of VOD, pathology widely considered as necessary to confirm 
PA poisoning in Man. Furthermore, the levels of PA detected in grain were at an order of magnitude 
lower that detected in grain samples from the recent Gulan outbreak of PA poisoning. It is also not 
clear why the disease is restricted to only some villages, when A. conyzoides is common throughout 
the region.  
To address these questions and other aspects of the disease a variety of approaches, including 
clinical research, ethnography, biochemical and metabonomic analysis and toxicology have been 
used. The specific objectives for each subsequent chapter of the thesis are as follows: 
Chapter 3: Clinical Characterisation of HVLD: 
- Fully describe the clinical features of the disease in a well defined group of patients.  
- Describe the biochemical changes associated with the disease, using a panel of standard 
clinical chemistry tests. 
- Describe the histopathological features of the disease, in a wider range of biopsy specimens. 
Chapter 4: Ethnography Study of Residents of the Affected Villages: 
- Describe and understand the way of life of residents of the affected villages. 
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- Identify possible risk factors for HVLD and routes of toxin exposure. 
Chapter 5: 1H NMR Metabonomic Profiling of Patient Urine Samples: 
- Determine whether HVLD patients and controls may be distinguished by their metabolic 
profiles.  
- Identify any metabolites of toxins that may cause HVLD.  
- Gain insight into any metabolic changes among HVLD patients.   
- Identify specific urinary biomarkers for HVLD. 
Chapter 6: Detection of Acetyllycopsamine Exposure in Patient biosamples: 
- Develop an LC-MS assay to show previous exposure to PAs though the extraction and 
detection of pyrrolic-protein adducts in whole blood. 
- Detect acetyllycopsamine in HVLD case and control urine samples using UPLC-MS. 
- Determine whether there is any difference in urinary acetyllycopsamine levels between 
HVLD cases and controls. 
Chapter 7: Toxicology of Acetyllycopsamine: 
- Determine the dose levels required to cause liver injury. 
- Test the effects of both chronic and acute dosing, using both biochemical and 
histopathological analysis. 
- Describe the metabolic changes in the mouse urine following acetyllycopsamine exposure, 
through 1H NMR analysis. 
Chapter 8: DDT as a Modulator of PA toxicity: 
- Measure levels of DDT and its metabolites in biofluids of HVLD cases and controls using 
ELISA. 
- Determine whether there is a difference in DDT levels between HVLD cases and controls. 
- Determine the effects of DDT exposure on cyp3A11 expression in the mouse model using 
rtPCR (real time – polymerase chain reaction). 
- Test whether DDT exposure increases susceptibility to the PA, acetyllycopsamine, in the 
mouse model, judged by biochemical and histopathological analysis. 
- Characterise the effects of DDT exposure on PA metabolism and associated endogenous 
metabolic changes, through 1H NMR analysis. 
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Chapter 9: Discussion: 
- Draw together the available evidence and make specific conclusions regarding the causes of 
HVLD. 
- Make specific public health recommendations 
- Outline further areas of research regarding HVLD. 
- Outline further areas of research regarding PA and DDT exposure more generally. 
- Discuss the wider implications of HVLD on the hazards posed by PAs and the use of DDT. 
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3. Clinical characterisation 
3.1 Aims and Objectives 
he ultimate aim of the study described in this chapter is to characterize HVLD as a clinical 
entity. This is of upmost importance for a number of reasons. Firstly, in order to help 
identify the causes of the disease, one needs a thorough account of its clinical features so 
comparisons can be made with previous incidents of liver disease and also with animal models 
where potential aetiological agents can be tested. A complete description needs a histological 
account of the primary damage to the liver, from a spread of patients at different stages of disease, 
to determine the pathogenesis of the signs and symptoms observed. This is particularly important 
for cases of suspected PA poisoning, since the histological evidence of VOD has been diagnostic in 
previous occurrences 105-109.  
Secondly, HVLD occurs in a region where the features of portal hypertension, such as “gua kua” 
(swollen belly in Tigrinya) may be produced, even in early stage disease, by diseases such as malaria, 
schistosomiasis infection or visceral leishmaniasis. It is therefore important both for appropriate 
treatment and surveillance efforts, to have a specific case definition that is suitably discriminatory. 
Patients were diagnosed in this study by a Professor of Hepatology, whereas previous reports of the 
range of signs and symptoms associated with HVLD (such as the data released by the Oasis 
Foundation clinics) may have been subject to a greater degree of misclassification bias due to a 
relative lack of hepatology training by health workers.  Efforts have already been made in developing 
a multi-level case definition that incorporates suspect, possible and probable case definitions. The 
work presented here identifies the most sensitive clinical chemistry indicators to incorporate into a 
‘probable case’ definition. 
Finally, as a new clinical entity, it is important that HVLD is accurately and fully described and 
incorporated into the scientific record to aid future diagnoses of disease outbreaks. Therefore the 
specific objectives are: 
 To describe the spread of signs and symptoms of HVLD in a well-defined cohort of patients. 
 To describe the changes in routinely used clinical chemistry tests among HVLD patients and 
identify the most sensitive indicators. 
 To provide a histopathological analysis of liver biopsy specimens from a larger sample of 
patients at different stages of the disease. 
T 
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3.2 Methods 
A visit was made to the region in November 2008. Clinics were held at Kiburto and Kelakil health 
posts and at Grace Village in Shire town, which is an orphanage run by the Oasis Foundation. 
Patients seen in Shire had been transported from the kebelle of Mayhanse, which then had been 
newly identified as affected. All patients were carefully interviewed and examined by a consultant 
hepatologist, Prof. Mark Thursz and medical histories were taken. Patients suspected to be suffering 
from other diseases, such as visceral leishmaniasis, were excluded from the analysis. 
 Blood samples were taken both from cases (meeting the criteria of the possible case definition) and 
from controls (not meeting the suspect/possible case definition criteria). Case definitions had been 
developed following the original investigation of the CDC, in conjunction with the THB and WHO. 
They were as follows: 1) Suspect case – individual with abdominal distension and either abdominal 
pain/cramps for at least two weeks or another household member with similar symptoms, 2) 
Possible case – individual meeting the suspect case definition with hepatomegaly and/or 
splenomegaly upon physical examination. All samples were stored on ice packs on collection. Serum 
was extracted following centrifuging at local hospital laboratories. Samples were then stored at -
20°C before transport on ice packs to London. 
Collected serum samples were analysed by a standard panel of LFTs including creatinine, urea, total 
bilirubin, AST, ALT, ALP, GGT, total protein, albumin and globulin. Five serum samples, taken from 
clinically confirmed possible cases, were analysed for bile acids. All tests were performed following 
routine clinical chemistry procedures at Imperial College Healthcare, St. Mary’s Hospital, London. 
11 patients were selected for liver biopsy and transported to St Mary’s Hospital in Axum, Tigray. 
Liver function tests for these patients were performed at Shire Hospital (the nearest hospital to the 
affected villages). Bleeding and prothrombin time tests and biopsies were performed in Axum. Liver 
biopsies were performed by Prof. Thursz using the menghini technique with ultrasound guidance. In 
two patients who were under the age of 12 biopsies were performed under general anaesthetic and 
in the others local anaesthetic was used.  
Biopsy specimens were stored in 10% formaldehyde and transported to Imperial College Healthcare, 
St. Mary’s Hospital, London for histological examination, by pathologist Prof. Rob Goldin.   
Specimens were processed to paraffin wax and 5 m sections cut and stained with haematoxylin and 
eosin and a range of other special stains by Ms. Hiromi Kudo. 
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Ethical permission was provided by the Minister of Health for Ethiopia and by the Tigray Health 
Bureau as part of an outbreak investigation. Informed consent was obtained from patients or their 
parents by local health workers. 
3.3 Results 
3.3.1 Clinical description 
Of the patients examined, six were female (18%) and 27 (82%) were male. 15 patients (45%) were 
younger than 18 years old and the median age was 18 years old.  The reported duration of illness 
ranged from 1 week to 6 years with a median duration of 1 year. 74% of patients report that other 
family members are also affected by the disease.  
The majority of patients with the disease reported epigastric pain as their initial symptom. In some 
patients this was accompanied by abdominal swelling, epistaxis or bloody diarrhoea. In most 
patients abdominal swelling was reported to occur either simultaneously with the epigastric pain or 
within a few days or a few months of the initial symptoms. Patients lacked stigmata of chronic liver 
disease such as spider naevae, palmar erythema and gynaecomastia. Clinical examination of 32 
patients, revealed hepatomegaly of up to 5cm in 66% of cases and splenomegaly of up to 15cm in 
66% of cases. Ascites was present in 38% of cases and 13% had gross ascites (Figure 3-2) which 
impaired their ability to conduct their daily activities (Table 3-1). 
Patients presenting with ascites had mean disease duration (time since report onset of symptoms) of 
34 months while those without ascites had mean disease duration of 19.5 months. The period 
between initial presentation and progression to ascites was highly variable but was generally shorter 
in children than in adult cases.  All patients presenting with ascites and who had been ill for less than 
four months were aged 7 years or younger while patients presenting with ascites and who had been 
ill for a year or longer were aged 14 years or over. One boy aged 5, suffered from gross ascites 
having been ill for only one month. 
Of the patients we examined, there was a clear difference in the duration of disease in patients from 
Kiburto and the newly identified area of Mekeyho. The mean duration of disease in Kiburto was 15 
months while in Mekeyho it was 52 months. Only one patient (the boy mentioned above) in 
Mekeyho was ill for less than a year and they reported an onset of illness in October. In Kiburto 
there were 12 patients who had been ill for less than a year and they generally reported an onset in 
the summer months, with August the most frequent month. (Figure 3-1) 
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Table 3-1: Summary of patient characteristics, symptoms & signs.  
Number of patients examined 32 
Median age in years (range) 18 (4-64) 
Number of males (%) 26 (81) 
Median duration of illness (range) 1 year (1 week – 6 years) 
Patients reporting family history of disease (%) 20* (74) 
Patient reported symptoms (%): 
  Epigastric pain  30 (94) 
  Abdominal swelling 28 (88) 
  History of bloody diarrhoea  12 (38) 
Patient clinical signs (%): 
  Hepatomegaly 21 (66) 
  Splenomegaly 21 (66) 
  Hepato- or splenomegaly 29 (91) 
  Ascites 13 (41) 
  Gross ascites 5 (16) 
  Jaundice 3 (1) 
  Cachexia / malnourished 6 (2) 
* Family history known only for 27 patients. 
 
Figure 3-1: Reported month of onset of disease in patients examined in Kiburto who were ill for less than 1 year. 
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Figure 3-2: Patient presenting with gross ascites 
3.3.2 Biochemical Analysis 
42 serum samples were analysed. 27 samples were taken from patients who met the criteria for a 
possible case and 15 were taken from controls 
The median serum levels of liver enzymes AST, ALT, ALP and GGT were all higher among possible 
cases than among controls (Figure 3-3). 
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Figure 3-3: Comparison of distribution of serum levels of liver enzymes between cases and controls. Heavy black bar = 
median, box= interquartile range, dots= outliers 
22 (81%) cases had elevated levels of AST and 7 (26%) cases had elevated levels of ALT above the 
upper limit of normal (ULN) of the laboratory reference range. The highest level of AST was 2.5 times 
the ULN (mean 1.70 times the ULN) while no ALT levels were more than two times the ULN (mean 
0.83 times the ULN). The mean AST/ALT ratio was 2.29 among cases and 1.82 in controls. Of the 15 
cases for whom disease duration (time since reported initial symptoms) was known, AST and ALT 
activity appeared to decline with increasing duration, while the AST/ALT ratio remained constant. 
Eight out of nine (89%) patients who reported a disease duration of one year or less had AST values 
above the ULN, while two out of six (33%) patients who reported a disease duration of more than 
one year had AST values above the ULN (Figure 3-4). 
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Figure 3-4: Serum levels of AST plotted against disease duration (months). Horizontal dotted line = ULN 
22 (81%) cases had elevated levels of ALP (mean 1.95 times the ULN) and 25 (93%) had levels of GGT 
above the ULN (mean 3.39 times the ULN, range 0.33-10.60 times ULN). However, many of the cases 
were children who may be expected to have elevated levels of ALP (up to  400 U/L) compared to 
adult ranges as a normal part of growth, and all children in the control group had elevated ALP. The 
highest level of ALP among adult cases was approximately 3 times the ULN. Of the 15 cases for 
whom disease duration (time since reported initial symptoms) was known, ALP and GGT activity did 
not appear to decline with increasing duration (Figure 3-5). All nine patients who reported a disease 
duration of one year or less had GGT values above the ULN, while five out of six patients (83%) who 
reported a disease duration of more than one year had GGT values above the ULN. 
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Figure 3-5: Serum levels of ALP and GGT plotted against disease duration (months). Horizontal dotted blue line = UNL for 
ALP. Horizontal dotted pink line = UNL for GGT 
22 (81%) cases had both elevated ALP and GGT, 19 (70%) cases had elevated GGT, ALP and AST and 
7 (26%) cases had elevated levels of all four liver enzymes. 
The median serum level of creatinine among cases was lower than among controls while the median 
serum level of urea was similar between cases and controls (Figure 3-6). 17 (63%) cases had lowered 
levels of creatinine while one case (4%) had elevated creatinine.  
 
Figure 3-6: Comparison of distribution of serum levels of creatinine and urea between cases and controls. Heavy black 
bar = median, box= interquartile range, dots= outliers 
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Median serum bilirubin was higher among cases than among controls (Figure 3-7) with eight cases 
having levels above the ULN. Median serum total protein and albumin were lower among cases than 
among controls while median globulin levels were similar. 16 (59%) cases had levels of albumin 
below the lower reference limit. Several cases and controls had elevated globulin levels. 
Five serum samples from possible cases were analysed for bile acids. 4 of the cases had elevated 
levels of bile acids, ranging from 1.3 to 2.2 times the ULN.  
  
 
Figure 3-7: Comparison of distribution of serum levels of proteins between cases and controls. Heavy black bar = 
median, box= interquartile range, dots= outliers 
3.3.3 Histology 
Limited ultrasonography was performed on a subset of patients transported for biopsy procedure, 
which showed increased echogenicity of the liver and no evidence of biliary dilation nor liver lesions. 
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Following clinical examination at Axum, eight patients were selected for biopsy. Two patients 
withdrew their consent and liver tissue was successfully removed from five of the six patients who 
underwent the biopsy procedure, conducted by Prof. Mark Thursz.  There were no complications 
and the patients were observed over night. For completeness, these biopsies are described below 
alongside four further specimens previously collected by Prof. Thursz in June 2008. 
Nine liver biopsy specimens in total were collected. These showed varying degrees of fibrosis from 
none in one specimen, through generalised fibrous portal expansion (Ishak stage 2/6) in two cases 
(Figure 3-8 a.), to developing cirrhosis with focal nodule formation (Ishak 5/6) in four cases (Figure 
3-8 b) and finally to cirrhosis with widespread nodule formation (Ishak 6/6) in one case. Three of the 
biopsies showed bridging fibrosis.  
Marked inflammatory changes are seen in the biopsies of the two patients with most recent onset of 
symptoms but in patients with more prolonged durations of disease inflammatory changes were not 
conspicuous. The most striking histological abnormalities are seen in the youngest patient, who had 
been ill for only four months. His biopsy shows extensive zone 3 drop out of the perivencular 
hepatocytes surrounded by an inflammatory infiltrate (Figure 3-8c).   
The clinical differential diagnosis had included veno-occlusive disease but all central veins were 
patent in every specimen. In addition there was no evidence of venous outflow obstruction (Figure 
3-8h). All the biopsies show mild portal and lobular inflammation. Five specimens also contained 
schistosome eggs associated with granuloma formation and an eosiniophil rich inflammatory 
infiltrate (Figure 3-8i). Brown pigmentation was present in the portal tract in three of these 
specimens (Figure 3-8j). However, the pattern of fibrosis, where present, is not that typically seen in 
schistosomiasis.  There was no significant fatty change and special stains for iron and alpha-1-
antitrypsin bodies were negative.   
Three of the biopsies contained foci of swollen hepatocytes in the perivencular region and in one of 
these this was associated with prominent lipofuschin accumulation (Figure 3-8d).  No Mallory-Denk 
bodies were seen and there is no ballooning of hepatocytes. No dysplasia was present.  
Aside from the fibrosis, the most striking changes were seen in the bile ducts. Although there was no 
bile duct loss there was widespread bile ductular proliferation at the parenchymal interface (Figure 
3-8e) and this was confirmed on cytokeratin 7 staining (Figure 3-8f).  This was associated with 
marked copper associated protein accumulation (a surrogate marker for copper retention) in 
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periportal hepatocytes in all of the cases (Figure 3-8g) even in those with normal bile ducts or only 
mild architectural distortion (Figure 3-8j).  
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Figure 3-8: Histology A) Generalised fibrous portal expansion (Ishak stage 2/6). B) Cirrhosis with focal nodule formation 
(Ishak 5/6). C) Zone 3 drop out and central vein. D) Foci of swollen hepatocytes (arrowed) associated with prominent 
lipofuschin accumulation. E) Widespread bile ductular proliferation at the parenchymal interface (white arrows) but no 
bile duct loss (black arrows). F) Confirmation of bile ductular proliferation with cytokeratin 7 staining. G) Marked copper 
associated protein accumulation in periportal hepatocytes (arrowed). H) Patent central vein. I) Schistosome eggs 
associated with granuloma formation and an eosiniophil rich inflammatory infiltrate. J) Marked pigmentation and a 
normal bile duct. 
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3.4 Discussion 
3.4.1 Natural History 
This is the first description of Hirmi Valley liver disease, which has a unique constellation of 
symptoms, signs and histological findings. At this stage the natural history of this disease can only be 
pieced together from the testimony of patients and their families and from the small number of 
cases who have been observed from initial onset of symptoms to death. The progression of disease 
appears to be more rapid in children under the age of 12 than in adults. There have been several 
cases of children who died with typical features of this disease within a few weeks or months of their 
initial symptoms. The histological features in patients with recent onset symptoms are characterised 
by zone 3 necrosis. This could be associated, in severe cases, with the development of a sub-acute 
liver failure. Coma, jaundice and fever have been reported in patients approaching death, which 
would be consistent with this diagnosis. 
In some adults the disease appears to have persisted for several years from the onset of symptoms. 
In these cases the histological pattern is characterised by liver fibrosis and bile ductular proliferation. 
Bile ductular proliferation is a characteristic finding in diseases that cause biliary obstruction or 
cholestasis but no clinical or histological evidence of biliary obstruction is present in Hirmi Valley 
liver disease.  Bile ductular proliferation is an expansion of oval cells, liver stem cells that are capable 
of differentiating into either hepatocytes or cholangiocytes. Oval cell expansion occurs in situations 
where hepatocyte loss is not compensated by appropriate hepatocyte regeneration. One can 
postulate that in Hirmi Valley liver disease, toxic liver damage results in a substantial loss of 
hepatocytes and an impaired ability of the remaining hepatocytes to regenerate leading to oval cell 
proliferation.   
3.4.2 Biochemical parameters 
Elevated activity of ALT and AST reflect hepato-cellular damage while changes of aminotransferase 
activity are usually only moderate in chronic liver disease as hepato-cellular injury is less extensive. 
The higher levels for patients who had recently become ill are likely to reflect the zone 3 necrosis 
seen in the liver biopsies while the lower levels seen for patients ill for a longer length of time reflect 
inactive cirrhosis. Permanently elevated levels indicate active disease. 
The ratios of AST/ALT are more similar to those seen in metabolic liver diseases such as non-
alcoholic fatty liver disease and alcoholic hepatitis than in cirrhosis (characteristically around 1.44)9 
but the individual aminotransferase levels are much lower than seen in alcoholic hepatitis. 
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The elevated ALP and GGT reflect the choleostatic component of the disease. However the mean 
elevations of ALP and GGT are lower than normally seen in other choleostatic diseases. ALP and GGT 
often rise in situations where there is bile ductular proliferation as seen on the liver biopsies of 
patients with this disease. Bilirubin and bile acids rise substantially when there is marked cholestasis. 
However, the modest rise seen in these two parameters, probably reflect liver dysfunction rather 
than true cholestasis.  
Albumin levels are significantly decreased in the majority of cases. This reflects a reduction in the 
liver synthetic function and probably a component of malnutrition. Interestingly creatinine levels are 
lower than laboratory reference ranges in many cases which are likely to reflect a low muscle mass 
consistent with malnutrition. In contrast globulin levels were increased in some cases. This is a 
common finding in patients with advanced liver disease. The normal levels for urea suggest that no 
renal dysfunction is present. 
3.4.3 Histology 
Zone 3 necrosis is typically seen as dose-dependent hepatic reaction to drugs such as paracetamol, 
halothane or carbon tetrachloride, which may result in multi-organ failure. The hepato-cellular injury 
is usually due a toxic metabolite of the drug and is greatest in zone 3 where concentrations of drug 
metabolizing-enzymes are highest. Enzymes, such as members of the cytochrome P450 family of 
haemoproteins, activate chemically stable drugs to produce electrophilic metabolites, which bind 
covalently to essential liver molecules leading to necrosis of the hepatocyte 9. In addition free 
radicals are produced, which subject the cell membranes to oxidative stress resulting in lipid 
peroxidation and membrane damage. One would expect to see depletion of intra-cellular substances 
such glutathione which bind preferentially to the toxic metabolites. Fatty changes often accompany 
drug-induced necrosis but none are seen in the biopsies. 
While it is highly unlikely that any of the pharmaceutical drugs known to cause zone 3 necrosis are 
responsible for the outbreak, the biopsies suggest that the acute stages of the disease, as in the 
youngest patient, result from a large dose of toxin which causes massive oxidative stress. The 
oxidative defences of patients who are nutritionally depleted are already challenged and therefore 
may be more susceptible to the toxin. One may speculate that the advanced fibrosis seen in chronic 
patients develops following repeated challenges by the toxin that cause repeated periods of acute 
liver damage and then recovery. The damage indicates that there may be distinct metabolic 
consequences within patients.  
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Copper accumulation was observed in all biopsies. The commonest cause for copper retention is 
cirrhosis because of the associated impairment of copper excretion in the bile due to the distorted 
architecture. However, the degree of copper retention, especially in the cases with only mild or no 
fibrosis, excludes the non-specific accumulation of copper. The causes of specific copper 
accumulation are primary disorders of copper metabolism (Wilson’s disease and Indian childhood 
cirrhosis) or secondary to chronic diseases of bile ducts such as Primary biliary cirrhosis. The biopsies 
show none of the inflammatory or other changes (such as ballooning degeneration) typical of the 
Wilson’s disease and serum analysis by the CDC found copper levels to be within the normal range. 
The distribution of the copper and the presence of associated biliary changes in some cases make 
secondary copper accumulation the more likely cause. Although there is bile ductular proliferation 
there is, somewhat surprisingly, no loss of interlobular bile ducts that is the usual finding in chronic 
choleostatic diseases. 
3.4.4 Case Definition 
Clinical diagnosis of the disease was made in patients from Kiburto, Kelakil and Mayhanse based on 
the case definitions. Liver biopsies performed on ‘possible cases’ from all three areas showed the 
same pattern of histological injury confirming that the same disease is present in all areas, and 
supporting the utility of the case definitions. A proposed case definition for a ‘probable case’ 
included ALP > 1.5 x ULN as a criteria. 19% of possible cases had ALP within the normal range and 1 
control had a raised ALP (and other LFTs). The abnormality in the control patient does not give cause 
for concern as it had already been anticipated that there would be sub-clinical cases of the disease 
with abnormalities of liver biochemistry. However, ALP does not appear to be a sensitive indicator of 
disease. 
 In contrast the GGT was raised in over 93% of cases. The problem with GGT is lack of specificity in 
normal hepatological practice. However when combined with specific symptoms and signs, that 
meet the definition of a possible case, a raised GGT (> 65 U/L or 1.3x ULN) would be a pragmatic 
definition of a probable case, particularly in the context of the Hirmi Valley. 
3.4.5 Pyrrolizidine Alkaloid Hypothesis 
The central veins were patent in all specimens sampled and there was no other evidence of venous 
outflow obstruction, such as sinusoidal congestion. Therefore the histological analysis cannot 
confirm PA poisoning. The specimens were collected from patients with both chronic and early-stage 
disease and are therefore well-representative of the range of pathologies present. Furthermore in 
previous accounts VOD is observable at all stages of the disease12. However these results are at odds 
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with the reported presence of VOD in an autopsy of a 12 year old boy with HVLD (although I have 
not personally seen the autopsy report). It may be that in this case, the boy was exposed to a greater 
quantity of PA, necessary for the development of VOD, since it has been shown in animal models 
that VOD-like pathology is induced at only the highest doses34. However the two biopsies from 
acute, child cases showed massive centrilobular necrosis, which could only be induced following 
exposure to a very high dose of toxin. Also, in previous accounts centrilobular necrosis was present 
alongside VOD and originally considered secondary to the VOD12.  
The pattern of pathological changes, is however similar to that observed following PA exposure in 
experimental and domestic animals. Enlarged hepatocytes (megalocytosis) as observed in three of 
the biopsy specimens is considered a diagnostic feature of PA poisoning among livestock149 but has 
never previously been observed in Man following PA exposure. Extensive toxicological work has 
been conducted with heliotrine, and open monoester PA similar in structure to lycopsamine, that 
induces zone 3 necrosis following single large doses (but not VOD)138, and megalocytosis, bile 
ductular proliferation, copper accumulation and fibrosis in the liver following repeated small 
doses139. More recent studies has described the ability of the PA retrorsine to induce both 
megalocytosis and the proliferation of small hepatocyte-like progenitor cells, morphologically 
indistinct from oval cell expansion, in the injured rat liver190.   Bile ductular proliferation and 
megalocytosis was also reported following a 6-week feeding trial of Indonesian specimens of A. 
conyzoides to rats186. 
Furthermore some of the features described here were reported in previous account of PA 
poisoning in Man. These include the bile ductular proliferation, the presence of brown pigmentation, 
the centrilobular necrosis and the rapidly developing fibrosis14, 103, 104. Bleeding abnormalities have 
also been reported (in the early South African and Soviet outbreaks) and may be related to 
ulceration and haemorrhage observed on autopsy in the gastric mucosa14, 103, 104.  It may be that the 
open monoester type PAs detected in grain samples from the Hirmi Valley are less capable of 
inducing VOD in Man than the more complex diester and macrocyclic PAs involved in previous 
epidemics of PA poisoning, as is the cases in rats34.  
3.4.6 Strengths and Limitations 
This study was limited to some extent by what is achievable in a clinical study of patients in remote 
and inaccessible area with only basic medical facilities.  In an ideal world, advanced techniques such 
as the use of venograms for example, may have better characterised the source of hepatic blockage 
to the portal blood flow. Repeated examination of patients (and serial biopsies) would have allowed 
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a more detailed picture of the clinical course of the disease. It would also have been useful to have 
linked all the serum samples to full clinical histories and all the biopsy samples to a full panel of LFTs. 
This was not always possible due to time constraints and the need to perform limited blood tests at 
the local hospital prior to the biopsy procedure. 
However, especially considering the conditions, this study has provided a full picture of the clinical 
presentation of HVLD, demonstrated the most sensitive biochemical indicators of the disease and 
provided a histopathological picture of the disease, to which animal studies, such as those presented 
in chapters 7 and 8, may be compared.   
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4. Ethnographic Study of Residents of 
the Affected Villages 
4.1 Introduction 
 refer to the work presented in this chapter as an ‘ethnographic study’ in the narrow sense of a 
written account of the lives of a people. I prefer the term ‘ethnography’ commonly used in the 
field of socio-cultural anthropology, to the synonymous term ‘case-study’ that is commonly used 
in biomedical research, as it emphasises that this account is written by an outsider observing an 
alien culture. I will however use both terms interchangeably, since I am also providing a background 
account of ‘disease cases’ in the medical sense. I make no pretence that this work helps us 
understand the knowledge and systems of meaning that guide the people of the Hirmi Valley. 
Instead I focus on the material aspects of their lives since this is where the reasons for the outbreak 
of poisoning will lie. 
Using in-depth and semi-structured interviews I have been able to build up a study on the farming, 
dietary practices and attitudes of a small number of disease cases. The case study, ‘…the detailed 
examination of single example of a class of phenomena…’191, is an invaluable research tool for 
providing concrete, context-dependent knowledge. Research into the aetiology of Hirmi Valley Liver 
Disease, which is a localised outbreak of poisoning enabled by particular lifestyle practices in a 
relatively culturally homogenous area, is particularly suitable for the ethnographic approach as we 
need to gain an intimate understanding of resident’s lives in the context of their particular 
environment.   
In epidemiological research, the case study is often considered most important during the 
preliminary stages of the research process as a way to generate hypotheses that can then be tested 
using systematic, larger surveys and their associated quantitative analyses.  It is viewed by many 
researchers, particularly those who adhere to the natural science ideal of hypothetico-deductive 
explanation, as having less worth than other social science methodologies since they ‘…cannot 
provide reliable information about the broader class’ 191.  This view has been challenged by 
Flyvbjerg192 who argues that while the case study is certainly valuable at the primary stages of 
investigation, it should be seen as being equally important to more quantitative methodologies and 
may also be used as a means of hypothesis testing and theory-building. He believes that it is wholly 
possible to generalise from even a single case, depending on how the case is chosen. He cites the 
example of the natural sciences where single well-designed experiments are essential for theoretical 
I 
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development. Galileo’s rejection of Aristotle’s law of gravity was not based on observations across a 
large and wide range of contexts but based upon a single conceptual experiment and later a 
practical one.  The practical experiment made possible by the invention of the vacuum tube, saw a 
coin and a feather fall with the same speed, thereby rejecting the view that the heaviest object 
should fall quickest. The clever choice of extremes of metal and feather provided a critical case: if 
Galileo’s thesis held for these objects it could be expected to be true for all or a large range of 
objects.  
This type of test was termed ‘falsification’ by Karl Popper and is one of the most demanding tests to 
which a scientific proposition can be subjected since if just one observation does not fit with the 
proposition it must not be valid generally and must be rejected or revised. Popper famously gave the 
example of how the proposition that ‘all swans are white’, would be falsified if a single black swan is 
observed, thereby stimulating further theory-building on the colour of swans. The case study 
provides an ideal means of identifying black swans, especially since under in-depth examination, 
white swans may in fact turn out to be black. The key then to allowing broader generalisations to be 
made from case studies are the particular characteristics of the case in question. In comparative 
studies, random selection is desired to remove systematic biases and generalisation is possible due 
to a large sample size.  In single case or small sample research, information obtained is maximised by 
selection of cases chosen for their validity and the information they are expected to contain. A case 
may be a critical case, if it is strategically important and allows logical deductions of the type ‘if this 
is (not) valid for this case, then it applies to all or many (none or few) cases’. These could be ‘most 
likely’ or ‘least likely’ cases. A ‘most likely’ case, such as Galileo’s coin and feather, is most suitable 
for falsification while a least ‘likely case’ is more suitable for verification. Another strategy is to study 
an extreme case, which is unusual in some way but then may activate more mechanisms or actors in 
the situation being studied.  
Case studies have also been criticised by researchers such as Diamond192 as containing a bias 
towards verification, since researchers ‘may stamp one’s pre-existing interpretations on data as they 
accumulate’. However, Flyvberg points out that it is instead falsification that is characteristic of case 
study research. Case studies allow the researcher to focus in on real-life situations and test directly 
whether ideas related to certain events can be sustained as the events occur. Those under study are 
more able to ‘talk back’ and correct researchers, than with methods where the researcher is more 
removed. 
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Therefore the case study or ethnography can provide an important tool in the hypothetico-
deductive model of explanation, and they also have value in and of themselves, without being linked 
to hypotheses. The concrete, practical context-dependent knowledge of the kind provided by the 
case study is as important as the broader and more theoretical knowledge that many see as the 
ideal of social science research. This may be particularly true for Hirmi Valley Liver Disease where all 
patients are likely to share exposure to an as yet unknown xenobiotic. The first step to 
understanding its causal factors, must be to gain as much experience and knowledge of patient’s 
lifestyles as possible. As Eysenck 193says:  
‘… sometimes we simply have to keep our eyes open and look carefully at individual cases-not in the 
hope of proving anything but rather in the hope of learning something!’  
The thick narrative provided by a good ethnography allows this as it should hopefully capture the 
rich ambiguity and complexity of human lives. 
4.2 Aims and objectives 
Over three visits to the region I conducted interviews with residents of the affected villages and 
individuals affected by the new liver disease. The ultimate aim was to learn more about their 
lifestyles with the specific objectives of generating and, if possible, testing hypotheses about the 
causal pathways of Hirmi Valley Liver Disease.  
4.3 Methods 
Interviews were conducted in November 2008, with patients who were attending specially held 
clinics in Kiburto health post and Grace Village in Shire. Additionally visits were made to households 
in Kiburto and Mekeyho. Health professionals from organisations including THB, EHNRI, CDC and 
WHO attended the interviews and questions relating to aspects of farming, diet, the environment 
and the disease were asked by myself and others in a semi-structured format. Questions were 
translated into Tigrinya by Dr. Abidara, the WHO National Consultant for the outbreak. 
During a visit in December 2008 as part of wider investigations to survey Kiburto, focus group 
discussions (FGDs) organised by ENHRI were held at the Health Post, with groups of women and men 
from the village interviewed separately. Again open-ended questions were asked by different health 
professionals and myself, and translated by Dr. Abidara. Mixed FGDs were also held in Kelakil, with 
displaced and indigenous residents interviewed separately. Additional information was also 
obtained through observation of farming and dietary practices while walking and visiting houses 
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within the kebelle of Kiburto, while contributing to census efforts. Conversations with local health 
workers also helped reveal more about the lives of local people.  
I had the opportunity to interview the father of young girl from Tseada Amba with HVLD being 
treated at the local Shire hospital in December 2009, translated by health officer Yohannes G’ 
Haweria. I also referred to the excellent ethnography ‘The Tigrinya Speaking Christians of the Tigre’ 
by Anant Potnis159, which used questionnaires collected by Tigrai college students, for confirmation 
of certain descriptions that were unclear.   
In the following sections, I first give a detailed description of the diet, farming and their perceptions 
of the disease of the residents of the affected villages. I then focus on individual households and 
draw out information on the disease origin from their accounts and test some hypotheses.  
4.4 Thick description 
4.4.1 Diet 
The diet eaten is rather monotonous, and for many families consists almost entirely of a small 
number of crops that they grow themselves. The staple of their diet is injera, a flat spongy pancake-
like bread, which is eaten at every meal several times a day. It is made from the flour of maize, 
sorghum (in Tigrinya, silete) and occasionally teff, a grain much prized in Ethiopia. After being sieved, 
the grains are pounded on a wooden mortar (mukocha) and ground on a millstone (mouthan) within 
each household by the women of the house. The flour is made into a paste and cooked upon a 
mogogo, a wood-burning earthenware cooker with a concave pan. Sesame (setit) or linseed (nug) oil 
is used for cooking oil (water is used if no oil is available). Sesame is more commonly used in Kiburto 
while linseed is more often used in Mekeyho. Villagers take their seeds to a central place for 
processing into oil. 
Injera is flavoured with wot, a hot powder/paste made from chilli peppers, sometimes thickened 
with lekwa (a type of millet unknown to ENHRI and reported only in the Kiburto discussions). Salt is 
also added, bought from the market. 
The most common drink is sua (tella in Amharic), a beer brewed from millet (degusa) and sometimes 
with lekwa millet added in Kiburto. It is drunk at all meals (if it is not available water is drunk 
instead) and when relaxing, and by all ages including infants. Indeed a Mekeyho father reported in 
good humour that their children pester them to make more when they have run out. It was also 
reported that they drink more in the rainy season, presumably because the workload is less. Only 
men drink hot drinks such coffee (bunna, bought from market) and tea made from root powder of 
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mekmeko (Rumex abyssinicus). Women collect the household’s water mainly from local rivers and 
ponds. 
Cow and goat’s milk (tsaba) are an important part of the diet. It is consumed as a drink, and made 
into yoghurt, cheese and butter. The butter is clarified so it can be stored. Milk is more plentiful in 
rainy season (May – September) when abundant grass is available for grazing and is consumed by all 
families during this period. In other times of the year milk is only available to those with enough 
livestock to supply it. Women may only drink milk if it has been boiled first and they are prohibited 
from eating the yoghurt that they make.  The reason given for this was that the yoghurt is so 
delicious that if the women were to taste it they would eat it all up and deprive the rest of the 
family! Dairy products are generally not consumed by adults on Mondays and Wednesday, as these 
are the fasting days of their faith. 
Meat (normally raw or dried, although sometimes cooked) and eggs are a luxury and are eaten 
occasionally, especially on holidays. When an animal is slaughtered the meat is often shared with 
neighbours. The testicles are reserved for the children while the jaws and tongue may only be eaten 
by men. Many, but not all, villagers eat honey. It is either bought from the markets or produced 
themselves (mear) and is consumed in greatest quantities when in season in October and 
November, following the ends of the rain.  Wild honey (nehbii) is eaten in Mekeyho and, according 
to the Kiburto FGD, in Tseada Amba but not Kiburto. Meass (tej in Amharic) is an alcoholic drink that 
is brewed from the honey and is freely consumed until the supply runs out around December.  One 
man from Tseada Amba reported that of the honey he farms, the white honey is eaten or sold, while 
the red honey is used to make meass. He also prefers to use wild honey for the production of meass. 
During the rainy season vegetables including pumpkins, green salad leaves (hamelea) and tomatoes 
are eaten.  They are grown in small kitchen gardens along with herbs and spices. When in season 
from April to August, villagers collect and eat wild plants such as aye (Diospyros mespiliformis), gaba, 
comel, awhi and gutamayle (Vangueria edulis) berries. In Mekeyho some villagers said that they like 
to chew gum from trees. 
Those who can afford to do so supplement their diet with food bought from the market. There they 
can also buy foods grown further afield such as coffee, kidney beans and flavourings such as garlic 
and fenugreek.   
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4.4.2 Farming the Land 
Farming is the mainstay of Tigray and it appears that all inhabitants are involved in farming- even 
priests have their own plots of farmland. The villages operate a mixed crop/ livestock system. Most 
farmland is situated around the household to which the farmland belongs. Here high value crops can 
be protected and tended to in the evenings.  Many interviewees in Kiburto have extra farmland that 
can be up to around an hour and a half walk away from their homestead. 
 
Figure 4-1: Typical terraced millet field (top left) in Kiburto 
The main crops include sorghum, maize, millet (Figure 4-1) and teff. Teff is mainly grown as a cash 
crop and most households also grow chilli peppers and oil seeds. The type of crop grown on a parcel 
of land is rotated with generally a different crop grown each year. After several years the land is left 
fallow for a year. 
The land is prepared for sowing by ploughing several times, using a mostly home constructed plough 
(mesrie) pulled by oxen, This work is done by the men over a long ploughing season from the end of 
January up to May. Stubble and weeds on the field are burnt and the ash is spread over the field. 
Manure may be added and some farmers also use a government-provided fertiliser. 
Sowing begins with the first rains, which can come in May, or if late in early July. Seeds are sieved 
before being sowed by hand. Seeds are buried by further ploughing, brushing or trampling the land 
with animals. 
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The growing season, generally until around October is accompanied by weeding, which is done by 
women aided by their children and is their busiest time of year. The weeds they find problematic are 
shown in Table 4-1. Weeds are generally absent from the harvests of maize and sorghum since these 
crops grow to a taller height than the weeds.  However, hareq is a problem for sorghum as it can 
wind around the stem. The grain of millet and teff are also smaller, so the seeds of weeds may pass 
through when sieved. Only three plants (gumgumo, akquaqume and metselem) were reported as 
having newly appeared on farmland in Kiburto. In Mekeyho, they see many new plants but this is 
because they moved into the area recently, following government land allocation. It used to be 
forest and so all the villagers carry axes with them to deforest the area.  
Table 4-1: Problematic weeds 
Name (Tigrinya) Most commonly 
affected crop 
Time since first 
appearance 
Mereret   
quaquito/aquaquomo   
agliti   
gumgumo millet 5 years 
tirgita teff  
Anchekile Teff and millet  
gelgelemeshel   
tingita millet  
akquaqume teff 7 years 
Metselem ( English; 
striaga) 
Millet and sesame 20 years 
hareq sorghum  
 
The villagers were also questioned specifically about the presence of Ageratum conyzoides on their 
fields. Most reported that Ageratum grows widely in their fields. Some respondents said they 
separated the weed from crops at harvest while others did not. At the FGD in Kiburto, they knew 
Ageratum as hagafeto and reported that its seeds could not be combined with other grains since it 
seeds after the harvest. They did state however that all the animals eat it. Ageratum is also reported 
in Kelakil by the indigenous residents who knew the plant only by its scientific name. 
Harvesting is done by the whole family and crops are cut by hand. Depending on the crop, 
harvesting may continue right into December. The crops are bundled into heaps and then dried out 
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raised off the ground. They are transported to the threshing ground to make one large heap. The 
threshing ground (awudi) is a circular area near the field that has been cleared from weeds and 
stones and plastered flat and smooth by spreading mud and sometimes straw around with an ox. 
The men then thresh the crops with oxen to separate the grain from the chaff. They then toss the 
threshed crops into the air with forks, where the heavier grain falls straight to the ground while the 
stalks are blown a little way away. The grain is then sieved from the husks and put into a sack for 
transport home. The stalks and husks are also collected and dried out raised up in trees. They are 
used for animal feed and building materials. 
If the grain is mouldy they clean it by throwing it in the wind and then use it. If the grain is not clean 
after this air washing it is sold at market. Normally grain is stored dry but occasionally it is stored wet 
or damp because it may be collected early if there is a fear of rain. If grain is discoloured (which is 
rarely observed) it is usually separated and fed to animals such as donkeys. 
The grain is stored in a traditional container (koffo), which is constructed from mud, dung and straw 
over a wooden frame, and is over two metres high. The stores are kept in a specially built small hut 
(hidamo), which is cool and dry with a strong door. Some households also store larger grains such as 
maize in outside containers (shirfa), woven together from strips of pliable plant. Many families use 
DDT on stored grain, particularly on large harvests, to prevent insect infestation. Men at the FGD 
report using one tablet of an unspecified chemical per quintal of grain. Ash is also added to protect 
the grain. It takes a household one year to eat a container of stored maize and sorghum. Containers 
of teff and millet are consumed over four or five years. If container space is scarce, such as following 
a particularly good harvest, grains such as millet and teff may be stored in the same container, 
separated from each other using a plastic sheet. They make holes in the bottom of the container to 
remove food as needed.  
The only other occupation widely practiced in the area is small scale mining for gold. The area is 
experiencing a mini-gold rush and many residents pan for gold in the traditional manner in their 
spare time. I came across one woman in Kiburto panning for gold in a small stream who proudly 
showed me the small grains of gold she had collected that day. 
4.4.3 Livestock 
All residents of the villages keep a range of animals, which represents fixed wealth and connotes 
status in the communities. Cattle and goats provide the dairy products that are essential to their 
diet, and hides that are used for a variety of purposes such as providing a comfortable place to sit 
when guests are visiting. Oxen and donkeys provide the farm power and are used for transporting 
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goods (Figure 4-2). Some cattle are of the local zebu variety (with a characteristic hump) while 
others are interbred with foreign breeds to boost the stock quality. Chickens are kept around the 
homestead to provide eggs, which provide a useful extra income at market or are eaten on special 
occasions. In addition to the farm animals, guard dogs are kept to deter unwanted visitors (as I can 
personally attest to!), while cats keep rodents at bay but may be semi-stray and flit to different 
households. 
 
Figure 4-2: Farmers driving oxen in Kiburto 
The animals are tended to by the children of the households during the day, particularly the boys. 
They drive the herds around the hills and valleys to fresh pasturelands while skilfully keeping the 
animals away from crops. They may make a round trip of up to six hours per day, visiting common 
grazing lands, which for some villages in Kiburto is shared with Tseada Amba. Some villagers take 
their animals far to graze (near to their second farms) while others keep their animals near to their 
homes.  At night animals are kept in pens, either in their homesteads on their second farm plots, 
fenced in by stone walls with thorny bushes for protection against wild animals. During the rainy 
season, lush green leaves are available which is superior grazing to the pastures available in the rest 
of the year. When food is scarce, prior to the coming of the rains, the animals are fed from the 
stores of straw from the previous harvest. 
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The villagers report that their animals are also being affected by a new disease. The men of the 
Kiburto FGD report that their cows, oxen and goats started dying around two years ago and that the 
goats are the most susceptible, though one female Kiburto interviewee believed she first saw signs 
of the disease in her animals 15 years ago. She also reports that her chickens are also ill. In Mekeyho, 
they report that their goats, cattle, oxen and chickens are diseased. The majority of their accounts 
also suggest a greater susceptibility of the goats, although in one household, their cows became ill 
before their goats. One respondent believed the disease in animals has been around for 10 years in 
Mekeyho.  
Cattle become depressed and emaciated, their skin becomes discoloured and they may lose their 
hair. Goats may become epileptic, their skin and meat becomes fragile and their abdomens 
distended. On slaughter, the gall bladders are found to be full of bile. The villagers generally believe 
the disease in animals to be linked to the disease in humans and belong to the same class of 
misfortune.  
The disease is supposed to have appeared in animals at a similar time to the appearance of disease 
in humans although some report their family members becoming ill after their animals while others 
report the opposite. 
4.4.4 Perception of Disease and treatment 
In Kiburto the disease is generally believed it to be new, appearing in the last couple of years. They 
refer to it as ‘Tseada Amba disease’ and differentiate it from other ‘swollen belly (gua qua)’ diseases 
such as chronic malaria and visceral leishmaniasis, which they view as treatable.  In Mekeyho the 
disease is believed to have been around for about 15 years but recently there have been more cases. 
Most villagers originally posited a supernatural origin either as punishment from God for some 
previous sin or a curse performed by an evil magician in Tseada Amba. They are generally quite 
sceptical of a dietary origin of the disease but the continued questioning and investigations by 
outsiders may be changing their views. The men of the Kiburto FGD now do not believe the disease 
is a punishment from God since the disease is distributed all around the villages and say that the 
cause is unknown. It is also maintained by Tseada Amba residents that the wanza tree (Cordia 
africana) stopped bearing fruit ever since the disease appeared in 2001. 
Following questioning about meat eating habits, one woman suggested that the eating of livestock 
might be the cause. According to the women of the Kiburto FGD, the meat of diseased animals is 
sometimes eaten but only if they have recently become ill and not if the animal has been ill for a 
long time. The unaffected indigenous residents of Kelakil said at their FGD that if they had sick 
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animals they too would eat them, but only if cooked. However, in individual interviews, the 
respondents claimed that they never ate sick animals. One of the women at the Kiburto FGD said 
that she has never eaten sick animals yet still has two affected children. She does however drink milk 
and may have drunk the milk from sick animals. The villagers generally have not noticed any changes 
in the climate or environment in the last 10 years, apart from the two new weeds described in the 
previous section. One Mekeyho resident suggested that perhaps there had been less rain recently. 
In the villages of Kiburto they travel to the central health post for treatment. They report that it does 
not help and most expect to eventually die from the disease. Some families travel to the hospitals in 
the larger urban centres such as the town of Shire for treatment. In the FGD at Kelakil of displaced 
residents from Tseada Amba, they say there is a good health service at Kelakil Health Post but the 
government food supplies are inadequate so they have to still get food from Tseada Amba. They still 
maintain their farms and keep their animals there. There are still deaths occurring due to chronic 
cases and new cases have been reported. One resident said the only solution would be to leave 
Tseada Amba completely and continue to study the area. They feel the soil should be investigated. 
The original residents of Kelakil, who live and farm around the displaced village, reported no health 
problems. They knew of one Kelakil resident that had died from the disease and they had a relative 
in Tseada Amba. 
The villagers own treatment for the new liver disease is the root of the solum plant (similar to a 
potato), which is chewed to alleviate abdominal pains. Other traditional medicines include Holy 
water, the root of hafta plant and the root of hafflo taken as medicine for malaria. They do not use 
Ageratum for any medicinal purposes.  
4.5 Household focus 
We interviewed five people (from four affected households and one unaffected household) during a 
clinic held at Kiburto health post. One affected house was visited on the same day as the clinic. Two 
interviews were conducted during visits to affected households in Mekeyho. Five further patients 
from Mekeyho were interviewed at Grace Village, Shire. 
The Hirmi Valley Liver Disease cases that were interviewed all had similar ways of life in that they all 
make their living through farming their own land and keeping animals. However, a degree of 
heterogeneity existed between households that allow us to draw some conclusions. Questions were 
asked with the prior assumption that the disease is caused by the ingestion of a toxin, giving much 
information about their diet and how it is produced. The absence of a particular item of the diet 
within a selected critical case may falsify the hypothesis that that item is a pathway of exposure. 
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However, while the shared clinical and histological presentation of patients indicates exposure to 
the same toxin, patients may be exposed through a number of pathways, making this type of logical 
deduction problematic. Critical cases can however, be used to reject more general hypotheses. 
For instance, as can be seen from Table 4-2, different affected households give different priorities to 
different crops and only millet was grown by all households that we interviewed. We can therefore 
reject the hypothesis that maize, sorghum and teff are the sole sources of exposure, but we cannot 
reject the hypothesis that millet is the sole or principle source of exposure.  
In this section I present descriptions of the lives of individual cases selected for information they 
contain relevant to the aetiology of the disease and to illustrate the impact of the disease on 
individual lives. Three cases are chosen, representative of the three affected areas, Tseada Amba, 
Kiburto and Mekeyho. 
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Table 4-2: Farming practices of the households of 11 disease cases interviewed individually. Question marks indicate that aspect is not known 
Household 
location 
Animals ill 
Crops grown 
Consumes 
honey 
Grows all 
own food 
Uses DDT on 
grain Maize Sorghum Teff Millet Sesame Linseed 
Kiburto one animal yes yes yes yes no yes ? yes ? 
Kiburto 
cattle, goats 
chickens 
yes yes yes yes ? ? yes ? ? 
Tseada Amba cattle yes no no yes ? ? yes no ? 
Kiburto ? yes yes yes yes ? ? ? ? ? 
Mekeyho none no yes no yes yes no no no yes 
Mekeyho cattle, goats yes yes no yes yes no wild no no 
Mekeyho 
cattle, goats 
chickens 
no yes no yes yes no ? ? yes 
Mekeyho goats no yes no yes yes no no ? yes 
Mekeyho all dead yes yes no yes ? ? yes ? yes 
Mekeyho 
cattle and 
goats dead 
yes yes no yes ? ? yes ? yes 
Mekeyho 
cattle, goats 
chickens 
no yes no yes yes no yes ? no 
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4.5.1 Sisters from Kiburto 
We interviewed Yirg Gessesew and her younger sister Zenebech separately at Kiburto Health Post. 
They were healthy themselves but had bought their ill children to be examined at the concurrent 
clinic. They live in neighbouring households in the village (kushet) of Myworki, one of the four 
villages that make up the kebelle of Kiburto. Their households are among a group of seven close 
neighbouring households, which all share food with each other. Of these, three have been affected 
by the new disease. They have another sister who lives elsewhere whose household is unaffected. 
Yirg is a widow (her husband died a death unrelated to the new disease many years ago) and has lost 
one of her sons to the disease. He was aged ten years old when he died, having become ill three 
months previously.  She has eight surviving children. Her four oldest, all aged over 21 are healthy 
while her youngest children, aged 21, 18, 13 and eight, are ill from the disease. Their symptoms 
started with chest pains, before developing abdominal cramps and vomiting, with traces of blood. 
Zenebech has nine children. Four of her children are married and the remaining five live at home 
with her and her husband. Of these five children, she has a 22 year old who is healthy, a 16 year old 
girl and a 14 year old boy who have been suffering with the disease for three years, and a 12 year 
old daughter and nine year old son that have both been ill for five years. Their initial symptoms were 
abdominal distension, wasting and constipation. Despite these symptoms, her children retained 
healthy appetites. Her family have been treated in a hospital and her nine year old is making a 
recovery at Axum Hospital.  
One of Yirg’s animals is ill, while Zenebech has lost cattle, goats and all her chickens. She now only 
has one goat and two oxen left. She reports that the skin colour of her cattle changed before they 
died and her animals became sick before her children. She thinks that the first of her animals started 
showing symptoms of the disease about 15 years ago. 
They eat the daily diet of injera, seasoned with salt and red pepper. Teff and meat are reserved for 
special occasions. Milk is occasionally consumed and Zenebech makes cheese from the curds. Yirg 
says that all the food they consume is grown by themselves. They do not eat wild animals and do not 
fish. Yirg says she has never eaten any of the meat from her sick animals. During the rainy season 
they eat vegetables, such as green leaves and pumpkins, and consume honey and wild berries when 
they are in season. Zenebech says that the whole family eats the same food. However, her 14-year-
old son who is suffering from the disease does occasionally eat earth. 
Their main crops are maize and sorghum, but they also grow a small amount of millet and teff. 
Zenebech grow maize on her home plot of land and millet and teff on a second plot, some way 
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away. Yirg could not think of any changes in their lifestyle, the climate or the environment in the last 
ten years or previously. They have noticed a new plant, akwakame, that has appeared in the last 6 
years but it does not grow on their home plots of land. Zenebech also reports that Ageratum is more 
common in her teff and millet fields. Yirg says that their food is always well dried before being 
stored. 
Their families may be viewed as critical cases, as each has many affected members and affected 
animals. The pattern of disease within each household, where the youngest members are ill while 
the parents and older siblings remain unaffected, is typical. The fact that they consume all home-
grown food and use no market-bought or food aid grain, along with the localised nature of the 
disease verifies the hypothesis that the toxin exposure pathway is within the food they grow 
themselves.  
Geophagy is practiced in many African countries 194, particularly among children and pregnant 
women. This practice is not widespread among cases and in these households was practiced by just 
one of the affected family members, indicating that it is unlikely to be linked to the disease origin. Of 
importance too, is that their households apparently always store their grain dry, as the storage of 
damp grain is a risk factor for growth of toxigenic fungi 31.  
4.5.2 Monk from Tseada Amba Monastery 
Aba G’hiwot Mulaw is a 25-year-old monk who lives in a monastery which is high up in the hills in 
Tseada Amba and has been affected by the disease since the earliest reports. We interviewed him 
when he came to the Kiburto clinic. He was very unwell and appeared to be suffering from 
encephalopathy. He said he had been ill for one year, and was suffering from a swollen abdomen 
and legs for which he was being treated with diuretics. He used to live in the capital in Addis Ababa 
and moved to the monastery two years ago.  
The Monastery keeps 150 cattle. These cattle get ill during the dry season and for the past seven to 
eight years the majority of deaths amongst them have occurred in June and July. While they are ill, 
the cattle show symptoms of depression and wasting.  
This monk’s diet consists mainly of maize and millet, which is made into sua. He occasionally eats 
honey and eats wild berries, which he says is a religious rule. When asked if he had ever eaten soil, 
he reported that some red pepper that was bought from the market had been cut with red earth by 
the merchants. The Monastery believed this was the cause of their illness and stopped using this 
pepper three years ago.  
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The monastery can be viewed as a larger, but unusual household unit. It makes a useful extreme 
case since the rules and ways of life unique to the monks can provide additional information.  For 
instance, only men are allowed to live and work in the monastery and so the causal pathway of the 
disease within the monastery will be confined to the male (and monastic) sphere of life. Dietary 
rules may also further reduce the possible pathways.  
He gives important information about the disease in animals since he reports that the disease also 
has a seasonal pattern (although the monastery cattle appear to become ill before the disease 
season starts among people) and that the disease in animals has first occurred around the same 
time that it first occurred in humans. Another informative aspect of the monastery is that the monks 
are not all local to the area but may come from all over Ethiopia, such in Aba G’hiwot’s case, Addis 
Ababa. This indicates that the localised nature of this disease is unlikely to be due to genetic 
isolation of the population. 
4.5.3 Visit to Mekeyho homestead 
We visited the homestead of Toddesse in the kushet of Mekeyho. She is apparently aged 19 
(although this seems likely to be a translation error). Her husband is healthy and she has three 
children: an eight-year old boy, a five-year old boy and a three-year old girl. They have lived in the 
house for 14 years. 
Her five-year old boy, Benihu Girmay, has been unwell with the new disease for one month. They 
visited three different health facilities to treat him. At the first one, he was given red pills and the 
symptoms became worse. At the second he was given diuretics, and he got better. The third facility 
was Shire hospital. He was confirmed as a case at our clinic at Grace Village and he was transported 
to Axum hospital for biopsy. However he was too frightened to proceed with the operation. 
The family owns 10 goats, 3 cows, 2 oxen, 3 calves, 2 chickens and 1 donkey. None of the animals 
had been ill or had any skin discolouration. Their 8 year old tends the animals the most.  
She has enough cows to drink milk throughout the year and her children drink the most. The milk is 
boiled first and comes from the cows only. Up until they were around two and a half years old, her 
children were breastfed. 
She says that none of her neighbours have a similar illness and she does not share food and milk 
with them. She grows sorghum, millet and sesame and does not eat honey. She says the seeds of 
weeds may be mixed with the crops at harvest. The crops are stored in both inside and outside 
containers and if kept for a long time the harvest is mixed with DDT. Crops may sometimes be stored 
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slightly wet but were completely dry this year. The sick child and her youngest will occasionally eat 
soil. 
This year, their harvest ran out in July so bought millet from the market in Mayhanse (This is the 
kebelle that encompasses Mekeyho). The first time they bought grain was it was discoloured and 
smelt and lasted until September. The second time it was normal and lasted until October. The child 
became ill after the second lot was bought. 
This household is interesting for a number of reasons. Firstly when we were taken to her homestead 
we were informed by the local health extension workers that she was relatively wealthy for the area. 
Reports from other Ethiopian professionals working with the disease had suggested that the disease 
disproportionately affected the poorer households, but here was an example of the disease affecting 
the better off. While it was hard to distinguish what made her wealthier than other households I 
visited, she did own a total of 21 animals. This compares favourably with another household I visited 
close-by, which was headed by a much older man who owned only 10 animals. Additionally she was 
able to buy extra food as needed and to drink milk all year round, unlike many other households. 
She also only drank milk from cows, which since she owns many goats, may be a preference on her 
part. Many families I visited drank goat’s milk and this may be because it is a cheaper protein source 
than cow’s milk (In fact Pontis159 makes no mention of goat’s milk being drunk in Tigray, so this could 
be a practice fairly unique to the affected areas). If the drinking of goat’s milk is linked to lower 
economic status, this could confound associative investigations. 
Furthermore, we can now exclude goat’s milk as the sole exposure pathway (although it may be 
important in other households). Likewise, honey may also be excluded as a sole exposure pathway. 
Letebirham’s household was the only affected household we came across whose animals did not 
show any signs of being unwell. We can conclude therefore that having animals with outward clinical 
signs of illness is not a prerequisite for illness in humans. 
4.6 Discussion 
4.6.1 Routes of exposure 
This study has improved our knowledge of the way of life of the residents of the affected villages. It 
has provided a baseline of understanding from which hypotheses can be generated and has also 
allowed some specific hypotheses to be tested. The information obtained here is broadly in line with 
the subsequent findings from the household questionnaires distributed during the census of Kiburto 
in 2008 and reported by the CDC. 
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It was found that the disease occurs among people who only eat the food they grow themselves, 
indicating that the source of exposure lies within the homegrown food supply. Eating food not 
grown by the household was also found to have a significant protective effect in the CDC analysis 
(although no attempts were made to adjust for socio-economic status). The monotony of their 
homegrown diet therefore narrows down the possible sources of exposure. The ubiquitous use of 
millet suggests this grain may be important in the causal pathway of the disease and indeed this 
grain had the most elevated risk of the four grains included in the questionnaire (OR = 2.5, 95% CI = 
0.9-6.5) in the CDC analysis. However due to ubiquitous nature of millet consumption, any significant 
association with the disease is unlikely to be teased out unless attempts are made to differentiate 
levels of consumption in a quantitative analysis. 
Most affected households also reported that their animals were also ill, and it was generally 
considered that the animals were suffering from the same disease as humans. The presence of ill 
animals in a household was also the most elevated risk factor reported by the CDC (OR= 5.0, 95% CI 
=2.1-11.7). This points to a role for animals in HVLD either through common exposure or as an actor 
in the exposure pathway. Although the findings of this study suggest that goat’s milk consumption is 
unlikely to be the sole exposure pathway and may be confounded by socio-economic aspects, it was 
notable that the drinking of goat’s milk had an elevated odds ratio (2.5, 95% CI =1.0-6.0).  It is also of 
interest that the consumption of yoghurt was confined to men, since PAs were detected in yoghurt 
during the Gulran outbreak (although at much lower levels than detected in grain) and this dietary 
difference may contribute to the disease among men. Although the available surveillance data are 
not at present sufficient to determine whether there is a difference in the disease rate between men 
and women, the majority of patients attending our clinics (27/32) were male, suggesting greater 
disease prevalence among males. 
The seasonality of the disease may be due to some seasonal aspect of the diet. Grain is stored and 
eaten throughout the year, so we might not expect to see a seasonal peak in exposure through this 
route if contaminated at harvest, however sua (made from millet) is reported to be drunk more 
during the rainy season (prior to the busy working period of the harvest) and widely drunk, even by 
children. Alcohol would also potentiate the effect of the putative toxin due to glutathione depletion, 
as is often seen with cases of paracetamol overdose62. Milk was widely reported to be more plentiful 
during the peak disease season and could provide a direct link for the disease between animal and 
human.  
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Honey was widely consumed and is a potential source of exposure to plant toxins such as PAs, and 
the flowers of A. conyzoides are attractive to honeybees with a Taiwanese study finding that 18.95% 
of pollen collected by honeybees was from A. conyzoides 195. Honey collected mainly from A. 
conyzoides may be expected to contain several g/g of PA.  However the census questionnaire data 
showed the consumption of honey to have a significantly protective effect, suggesting that plant 
toxin exposure through the eating of unprocessed honey is negligible. The protective (OR=0.3, 95% 
CI =0.1-0.7) effect may indicate a richer and more varied diet or may be directly protective as honey 
consumption would increase available glucose, allowing more glucuronidation and detoxification of 
toxins. The lower consumption of honey during the rainy season may therefore also contribute to 
greater onset of disease cases during that time. An apparent contradictory finding of the CDC data 
was the borderline significant elevated risk from drinking tej, an alcoholic drink brewed from honey 
(OR =2.6, 95% CI =1.0-6.9). This may be explained by the practice of using the darker ‘red’ honey, 
more often collected from wild honeybees in Tseada Amba and Mekeyho, for brewing tej, with the 
preferred white honey reserved for consumption raw. One can speculate that the red honey is 
derived from a greater proportion of A. conyzoides nectar and has a greater PA content. Tej is also 
highly alcoholic, and high alcohol consumption could contribute to the development of HVLD. 
4.6.2 Pyrrolizidine alkaloid contamination 
Although some residents reported that grain could not be mixed with Ageratum seeds due to the 
times of seeding (in contradiction of the observed grain contamination), the findings of this study 
are otherwise consistent with Ageratum contamination. Millet and teff were the grains most likely to 
be contaminated by the seeds of weed species, due to the height of these crops and the small size of 
their grains and Ageratum was also reported to grow more abundantly in millet and teff fields. Millet 
was the only grain grown by all the affected households we interviewed, while teff is widely grown 
but more often grown as a cash crop. Animals are also said to eat the plant and their milk may 
consequently provide another pathway for the toxins of the plant to enter the human diet. The 
name of the plant was not widely known by residents and the fact that it is not used for medicinal 
purposes as it is in other parts of Ethiopia 174, indicates that the plant is fairly insignificant to the 
villagers, suggesting it may be a recent arrival.  
If the hypothesis of contamination of millet by PA-containing Ageratum seed is correct then a 
worrying interpretation can be made of the case of Benihu Girmay, the recently ill, five year old boy 
from Mekeyho. His case was unusual as he had become ill only a month previously in October, unlike 
all other Mekeyho cases we saw who had been ill for longer than a year and the acute cases from 
Kiburto who mainly became ill in the summer months. His household too was unusual in that they 
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had been consuming millet bought from the market and the house was also the only affected 
household we were aware of that did not have any sick animals, which could indicate that their own 
farmland was not contaminated. Benihu became ill after buying this millet suggesting that the grain 
was contaminated. The wider implications are worrying if contaminated grain is being sold at 
market. 
4.6.3 DDT use 
A worrying aspect of residents’ reported methods of grain storage is the widespread addition of DDT 
to the stored grain. DDT has been shown to induce zone 3 necrosis in animal models 196 and the fact 
it is added directly to grain means it will be orally ingested which is likely to increase its 
hepatotoxicity. However the doses required are very large and despite the widespread use of DDT, 
acute human liver injury as a result of occupational or environmental exposure has only very rarely 
been reported. DDT is not universally used by affected residents and also widely used by unaffected 
households, so is unlikely to be the sole aetiological agent. However, it is known to increase 
expression of the cytochrome P450 enzymes 197 that activate the toxicity of a number of compounds 
including PAs and may therefore have a potentiating role in HVLD. The potential of DDT as risk factor 
for HVLD is explored in chapter 8. 
4.6.4 Strengths and limitations 
Although an ethnography by its very nature is presented as a complete and authoritative account of 
the cultural practices of the subjects, it should be remembered that all the descriptions presented 
are my interpretation and blending together of translated answers given at interviews and may 
therefore be subject to some unintentional observer bias. Interviews were often conducted in an 
unnatural environment with a number of outsiders present, which may have affected the types of 
answers given. Although I was able to observe some practices, such as the harvesting of crops, a 
greater component of other information gathering techniques such as participant observation may 
have provided more revealing and accurate information.  More time in the field, after I had gained a 
basic knowledge of the cultural practices of the region, may have allowed the uncovering of 
potentially more important, smaller details. 
This study has however revealed many important aspects of the lives of Hirmi Valley residents that 
are relevant to HVLD. The account given here has proven extensive enough its own right for 
important conclusions to be drawn. For instance the critical case of the Gessesew sisters from 
Kiburto has indicated the importance of the homegrown food supply as the source of exposure for 
many cases, while the extreme case of the Tseada Amba monastery indicated that genetic isolation 
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is not the reason for the uneven distribution of the disease. Furthermore the detailed information 
given here has proven complimentary to the quantitative lifestyle analysis generated during the 
Kiburto census and aided in its interpretation. 
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5. 1H NMR Metabonomic Profiling of 
Patient Urine Samples 
5.1 Introduction 
he term ‘metabonomics’ is used to describe studies which provide a ‘comprehensive and 
simultaneous systematic profiling of multiple metabolite concentrations and their cellular and 
systematic fluctuations in response to drugs, diet, lifestyle, environment, stimuli, and genetic 
modulations, in order to characterise the beneficial and adverse effects of such 
interactions’198. Advances in the sensitivity of analytical techniques such as NMR spectroscopy 
and mass-spectrometry (MS), coupled with new pattern recognition statistical methods have 
facilitated the development of a top-down systems biology approach, comparable with other ‘-
omics’ sciences such as genomics. Metabonomics is used to generate ‘fingerprints’ of metabolites 
detected in biological tissues or fluids that can then be used to characterise certain pathological or 
physiological states. 
The use of metabonomic analysis has been increasing in recent years and can be used for a number 
of different applications including toxicology199 200, drug development201, clinical studies202, 203 and 
biomarker discovery204, eco-toxicology205, 206 and epidemiological population studies207, 208. 
Metabonomic analysis has also been successfully used in the clinical setting to distinguish patients 
with different disease states. It has been applied to patient serum samples as a means of simplifying 
diagnosis of complicating nephropathy among diabetics203 and applied to cerebrospinal fluid to 
distinguish bacterial from viral meningitis209, and has enabled the development of a new diagnostic 
marker for coronary heart disease204. It has also recently been used to distinguish cohorts with 
different idiopathic forms of inflammatory bowel syndrome through analysis of the metabolic 
profiles of their urine202 and provided evidence supporting a microbial origin for the syndrome. 
Early toxicological studies using hepatotoxins in animal models found that elevated taurine, 
sometimes accompanied by changes in creatine concentrations, was a useful urinary marker of liver 
disease210.More recently, hepatotoxicants such as hydrazine211, thioacetamide212, galactosamine213 
and bromobenzene26 have been investigated, revealing important new markers of various liver 
injury and perturbed metabolite concentrations that have provided new insight into mechanisms of 
toxicity213. Metabonomic profiling has also been successfully used in clinical studies of liver disease. 
Yang et al214 used in vitro magic angle spinning NMR to compare hepatocellular carcinoma (HCC) 
tissue to adjacent normal tissue, finding elevations in glycine, leucine, lactate, glutamate, alanine, 
T 
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choline metabolites and phosphorylethanolamine, with reduced levels of glycogen, glucose and 
triglycerides. Cobbold et al.215 applied a similar approach to liver tissue from chronic hepatitis C 
patients, to correlate total lipid content with severity and virus genotype but were unable to 
translate their findings to in vivo NMR of patients. 1H NMR analysis of serum samples distinguished 
patients with liver cirrhosis and hepatic cellular carcinoma216, demonstrating elevations in acetate, 
glycerol, N-acetylglycoproteins, pyruvate, glutamine, -ketoglutarate, tyrosine, 1-methylhistidine 
and phenylalanine, and lower levels of low- density lipoprotein, creatine, valine, isoleucine, 
acetoacetate, choline and unsaturated lipids in liver disease patients relative to controls. Sharif et 
al.217 differentiated HCC and liver cirrhosis (LC) patients from each other and controls, through 
analysis of urine in a Nigerian population. Creatinine, carnitine, creatine and acetone were found to 
be discriminatory metabolites. 
5.2 Aims and objectives 
Metabonomic analysis of urinary samples provides an ideal analytical platform to study HVLD, a 
novel disease caused by undetermined environmental toxin exposure. The approach allows the 
assessment in one analytical sweep of the metabolic phenotype, to which diet, environment 
exposure and lifestyle factors all contribute, modulated by genomic and extra-genomic (the gut 
microflora) factors207. The approach is systematic and unbiased allowing global profiling without 
prior assumptions. 
The aims are of the study are three-fold:  
1. To identify toxins and urinary metabolites of toxins that may cause HVLD,  
2. To gain insight into any endogenous metabolic pathways which have been changed 
among HVLD patients thus gaining information about the mechanisms of this 
disease,  
3. To determine whether HVLD patients may be distinguished by their metabolic 
profiles, and whether specific urinary biomarkers can be developed, which would aid 
in diagnosis and epidemiological investigations. 
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5.3 Methods 
5.3.1 Collections 
During the visit to the Tigray region in November 2008, clinics were held where patients were 
examined by Prof. Mark Thursz, full clinical histories were recorded and biological samples were 
taken by local health workers. 21 urine samples were taken during a morning clinic held on 12 
November 2008, in Kiburto health post, one of the three districts known to be affected at the time. 
13 were collected from people likely to be HVLD cases (following pre-defined case definitions) and 8 
from controls (individuals with no signs of liver disease), selected from friends and family who had 
accompanied patients to the clinic. Samples were collected in sterile containers and stored on ice 
until being frozen at -20°C and then transported on ice packs to Imperial College London. 
Following promising results from an initial analysis of these samples, an additional visit was made to 
the Tigray region in December 2009. 65 samples of urine were collected during one morning from 
residents of the displaced village in Kelakil, who originate in Tseada Amba. Information about age, 
gender, residence and treatment received was obtained from each participant. Participants were 
defined as a HVLD case or a healthy control by health officer Ato Yohannes G’ Haweria, following the 
previously defined case definitions. Participants were also questioned about the health status of 
people sharing their household. In addition six urine samples were collected longitudinally over 
different time points from two HVLD patients staying overnight at the local Shire hospital. Samples 
were collected into containers pre-filled with the preservative boric acid, frozen at -20°C following 
collection and transported in an icebox back to Imperial College London. The study was assisted by 
staff from Shire Hospital. 
5.3.2 Sample preparation 
Samples were prepared following a standard protocol198. They were first centrifuged at 13,000 rpm 
and filtered through a 0.2 micron filter. 400 µL of each sample was then mixed with 200 µL of a 
phosphate buffer (pH 7.35) prepared with 100% D2O solvent (Cortecnet, France) and containing 3 
mM NaN3 preservative and 1 mM TSP (3-trimethylsilyl-(2,2,3,3,-
2H4)-1-propionate) (Sigma, UK) as the 
internal chemical reference standard. 550 µL of supernatant was then transferred to a 5 mm NMR 
tube (Cortecnet, France) for spectral acquisition. 
5.3.3 Spectral Acquisition  
One-dimensional (1D) 1H NMR spectra were acquired using a Bruker Avance II NMR spectrometer 
(Bruker Biospin, Rheinstetten, Germany) operating at a 1H frequency of 600 MHz. A standard water-
suppressed 1-dimensional pulse sequence (–RD-90° -t-90°- tm-90°-ACQ, where RD is the relaxation 
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delay, t is a short delay, 90° represents a 90° RF pulse, tm is the mixing time and ACQ is the data 
acquisition period) was used based on the nuclear Overhauser enhancement spectroscopy (NOESY) 
experiment198. The ACQ was 4.56 s and the t was 3 μs. Presaturation of the water signal was applied 
during the RD of 2 s and the tm of 0.1s. For each sample, 256 scans and 8 dummy scans were 
collected into 32k data-points with a spectral width of 12.2 ppm. An exponential line broadening 
function of 0.3 Hz and zero-fill was applied to each free induction decay (FID) prior to Fourier 
transformation (FT), to give a 64k Fourier domain data points. Spectra were manually phased and 
baseline corrected using TOPSPIN (version 2.1, Bruker BioSpin) and referenced to the TSP resonance 
(δ 1H ) 0.00). 
5.3.4 Spectral data processing 
Data were imported into the MATLAB computing environment (R2007a, The MathWorks, Inc., MA) 
to produce a matrix consisting of approximately 9,000 columns (spectral data points or variables) 
and 90 rows (each representing a different urine sample). The area between 4.7 and 4.9 ppm was 
excluded to remove any effect of variation from the suppression of the water resonance.  
To account for systematic differences in spectral intensities between samples (due to differences in 
concentration of urinary samples), the spectra were normalised using the probabilistic quotient 
method218 (using in-house MATLAB script written by Dr. J. Pearce). This method has been shown to 
be more robust than the more commonly used total area normalisation (where each variable value 
is divided by the total area of the spectrum), since it does not assume that the total integral of a 
spectrum is only a function of dilution, which may be invalid if samples contain extreme amounts of 
single metabolites218, 219. Instead, the most likely dilution factor for each spectrum was estimated by 
calculating the n-fold changes between each metabolite peak in the individual spectra and in a 
reference spectrum (in this case, the median of all sample spectra). The median of these n-fold 
changes was then used as the scaling factor for the whole spectrum. 
To account for variable peak position across spectra, arising from variations in pH, ionic strength, 
metal ion concentrations and osmolarity, the spectra were then aligned by the recursive segment 
peak alignment method (RSPA)220, using an in-house script written by Dr. K. Veselkov. Certain peaks 
particularly those produced by molecules such as citrate, whose ionization state is very sensitive to 
pH, may vary in peak position by around 0.05 ppm221, complicating information retrieval using 
multivariate statistical modelling of full-resolution NMR data.  The RSPA algorithm proceeds by first 
sub-dividing spectra into segments, each containing many peaks sufficient to include individual 
multiplets. The spectra in each segment are then shifted to match the corresponding reference 
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spectrum (either the median of all spectra or selected individual spectra) by calculating the 
maximum of the fast Fourier transformed derived cross-correlation to determine the optimal 
alignment. Each segment is then recursively subdivided into smaller segments that are aligned 
further as required. Finally the segments are rejoined to create the total aligned spectrum. 
5.3.5 Statistical analyses 
To enhance the interpretability of the multivariate models, mean centred (MC) scaling was applied 
prior to model construction, where the means of all variables are set to zero. In most models further 
unit variance (UV) scaling was applied which set the variances of each variable column to 1, by 
dividing each variable by its standard deviation (SD). This prevents models being dominated by 
variables with a large variation219 
The data set was initially analysed using principal component analysis (PCA)222,  either in the SIMCA 
P+ 11.5 programme or in MATLAB using an in-house script. PCA is a data reduction method allows 
the visualisation of any grouping among samples based on similar ‘metabonomic fingerprints’ 
without providing any a priori information about disease (or other sample information) status. Each 
principal component (tipi
T) consists of a score vector (ti) that provides a summary of the position of 
the cloud of points on the model plane, and a loading vector (pi) that defines the relationship 
between the spectral variables (the columns of the data matrix, X). The first principal component 
(t1p1
T) models the largest variation present in X, the second principal component (t2p2
T) describes the 
second largest and so on with each subsequent component describing a smaller amount of variation. 
Scatter plots of the score vectors of different components (e.g. t1 – t2) were drawn to visualise any 
groupings inherent in the samples, as the position of the different samples on the model plane 
displays the relatedness of their metabolic profiles. The Hotelling T2, a multivariate extension of the 
t-test, was used to exclude any outliers, whose presence would reduce model sensitivity. 
Partial least squares (PLS) and orthogonal-PLS (O-PLS)222 was applied to further discriminate samples 
and identify discriminatory metabolites. PLS is a supervised pattern recognition method that can be 
seen as the regression equivalent to PCA, since it reduces the many variables in the dataset to a 
small number of predictive components. However instead of finding the maximum variation in the 
dataset as in PCA, components are computed that explain the maximum co-variance between X and 
Y (the class membership or other sample information).  The analyses in this study are referred to as 
partial least squares discriminant analysis (PLS-DA) since the Y matrix consists only of class 
membership (e.g. case or control) rather than a continuous variable. O-PLS-DA incorporates an 
orthogonal signal correction filter, which models variation orthogonal to the predictive component 
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that is not related to Y, separately from data that are related. This is very useful in metabonomic 
studies of human data where there is large systemic noise due to inherent inter-individual variation.  
Back-scaled loadings plots were used to visualise those metabolites that contribute most to the 
predictive component221, and hence are discriminatory between classes. The loadings plot back-
scales the co-variance onto a pseudo-NMR spectrum, which represents the direction of the variation 
and is colour-coded by the correlation coefficient (r2). All scaling and modelling in MATLAB was 
conducted using an in-house script written by Dr. O. Cloarec. 
A number of validation steps were used to prevent over-fitting and generation of spurious 
correlations. All models were first subjected to an internal 7-fold cross validation, where a portion of 
the samples are sequentially left out of the model, and their class membership predicted using the 
remaining data. This is repeated 7 times to ensure an accurate spread of the data. From this the Q2 
parameter is calculated, which gives a measure of the predictive ability of the model. The numbers 
of components used in each model was optimised by finding the number that gave the highest Q2 
value. Other model parameters include the R2Y value, which shows the amount of variation in Y that 
is explained while the R2X value gives the amount of variation in X that is explained. 
A further external validation step was also applied using an in-house script provided by Dr. S. 
Richards. This involved the random permutation of the Y matrix 100 times to assess the probability 
of obtaining a model with similar predictive ability based on the Q2 parameter. If the Q2 score of the 
actual model was in the top 5% of possible scores, the model was accepted as valid. 
To assess the significance of metabolites identified as discriminatory in the O-PLS-DA models, a 
similar permutation validation was applied to the X matrix, which was randomly permuted 10,000 
times, to provide a p-value for each variable (metabolite). If the metabolite had at least as high 
correlation to the Y in 1% of permutations it was accepted as significant. The confidence level was 
relaxed to 5% in model 3 (comparing controls only based on disease status of residence) only if the 
metabolite had been identified in the previous models. An in-house script written by Drs. I. Yap and 
K. Veselkov was used. 
To test the univariate association with class membership of metabolites identified in the multivariate 
analysis, metabolite peaks were integrated and the integrals expressed as the percentage of the 
highest integral value found across all samples, to give a semi-quantitative measure of metabolite 
concentration. Wilcox Rank Sum tests were then applied to the resulting values. Box and whisker 
plots were drawn to visualise the metabolite distribution across sample classes. T-tests and 
proportion tests were used to assess gender and age differences between classes. Logistic regression 
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models were used to adjust for any potential confounding variables. This analysis was performed 
using the R software package. 
5.3.6 Metabolite Assignment 
Assignment of metabolites responsible for discriminatory peaks was assisted by first determining the 
intra-molecular peak connectivity, and was initially carried out by statistical correlation spectroscopy 
(STOCSY)223 using an in house routine in MATLAB (written by Dr. O. Cloarec). STOCSY identifies 
spectral peaks that are highly correlated to a chosen driver peak, and hence are often structurally 
related. A correlation matrix of variables across all samples is calculated and then plotted to display 
the correlation coefficients of different spectral regions to chosen peaks. Peaks belonging to the 
same molecule will have correlation coefficients approaching 1, giving information about peak 
connectivity, which was sufficient for most assignments. 
For further information and confirmation of STOCSY, a number of 2-dimensional NMR experiments 
were conducted on selected samples on a 600 MHz Avance II spectrometer. These experiments use 
two spin-echo pulses with a varying evolution period in-between to provide NMR spectra on a Y and 
X axis, creating a matrix contour plot from which additional information can be derived. J-resolved 
spectroscopy224 was used to elucidate the 1H NMR peak multiplicity of signals, which may be 
obscured by peak overlap. 64 scans were collected into 20k increments at a resolution of 16k with 
an acquisition time of 0.682 s. The sweep width in F1 was 0.8 ppm and water pre-saturation was 
employed during a relaxation delay of 2 s. Spectra were processed using a sine window function 
along the F1 and F2 axes with SSB=0 and a resolution of 16k (in F2) and 128 (F1).  
Homonuclear 1H-1H correlation experiments were used to provide connectivity information similar to 
that provided with STOCSY but not affected by peak overlap or alignment. Correlation spectroscopy 
(COSY)225 provides connectivity information about two protons in a molecule that are J-coupled to 
each other. The acquisition parameters were as follows: 4096 data points were collected for each of 
162 increments with 32 scans per increment over a spectral width of 10.2 ppm. The data were zero- 
filled to 1024 data points in the F1 domain, and a sine-bell apodization function was applied in both 
dimensions before double FT.  
Total correlation spectroscopy (TOCSY)226 gives connectivity information for an unbroken chain of 
coupled protons. The following acquisition parameters were used: 32 transients (16 dummy scans) 
were collected into 162 increments at a spectral width of 10.2ppm. Spectra were processed into a 
resolution of 4096 (F2) and 1024 (F1) using a shifted qsine function. 
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Heteronuclear 13C and 1H experiments such as Heteronuclear single quantum coherence (HSQC)227 
were employed to resolve the chemical shift for both protons and carbons atoms in each moiety of a 
molecule, by linking 13C and 1H spectra. This additional information can be especially useful for 
singlet peaks and final assignment confirmation. Acquisition parameters were as follows: 320 scans 
were collected into 398 increments at a spectral resolution of 4096 in F2 and 128 in F1 across a 
spectral width of 12 ppm and 170 ppm for the 1H and 13C axes respectively, with an acquisition time 
of 0.284 s and a relaxation delay of 1.2 s; Spectra were zero-filled in F2 by a factor of two to 8192 
and zero filling and linear prediction was applied in F1 to result in a resolution of 1024.  
The resultant peak information was then used to interrogate metabonomic databases such the 
Human Metabolome Database228 or relevant literature. 
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5.4 Results 
5.4.1 Comparison of 1H NMR spectral acquisition with traditional clinical chemistry 
Traditional clinical chemistry measures were obtained from serum samples of five patients who also 
gave urine samples for NMR analysis. Creatinine levels in urine as measured relatively by 1H NMR 
were found to be comparable to when measured absolutely in serum by traditional clinical 
chemistry (detailed in chapter 3 methods), with the highest value found by each method 
corresponding to the same individual (Figure 5-1).  
 
Figure 5-1: 1H NMR spectra showing creatinine peak from urine samples from five patients. Colour key shows creatinine 
measurements in serum for corresponding patient. 
5.4.2 Comparison of November 2008 and December 2009 collections 
A total of 90 1D NMR spectra were acquired from participant urine samples. A clear difference could 
be observed by PCA between samples collected in November 2008 and those collected in December 
2009 (Figure 5-2). The vast majority of this difference was caused by the addition of the preservative 
boric acid to only those samples collected in December 2009. The preservative formed complexes 
with urinary metabolites such as citrate and mannitol altering the spectral profile, as described by 
Smith et al229. For this reason it was decided to initially present separate analyses for each collection. 
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Figure 5-2: Scores Scatter plot of first two components of PCA of all 1D 1H NMR spectra acquired. Blue circles = 
November 2008 collection, red circles = December 2009 collection. Percentages on axes indicate % variance explained by 
that component. 
5.4.3 November 2008 Collection 
 Three urine samples from patients who did not meet the pre-defined ‘probable’ case definition and 
one sample from a ‘control’ individual who reported having recovered from disease with Hirmi 
Valley Liver Disease symptoms, were excluded from the analysis. Of the 10 included case samples, 
six had LFT or biopsy data available, which confirmed their status as HVLD patients. Cases were 
slightly younger and proportionally more male than controls (Table 5-1), reflecting differences seen 
in previous studies. Seven of the 10 cases had first presented with symptoms less than a year prior 
to collection and the mean duration of disease (time since presentation) among cases was 13 
months. 
Table 5-1: Demographics of participants in November 2008 collection, included in analysis. 
 
NMR spectra were successfully acquired from each sample. Representative NMR spectra are shown 
in Figure 5-3. 
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Figure 5-3: Mean Urinary 1H NMR Spectra on Cases (blue) overlaid on mean urinary spectra from controls (red). From November 2008 sample collection. Discriminatory metabolites (from 
OPLS_DA analysis) are annotated  
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5.4.3.1 PCA 
PCA was able to separate case and control urine samples. Analysis was performed on both data that 
had been mean-centred only and data that was mean-centred and with variances set to unity. PCA 
on MC data explained more of observed variance (57% on first component, 14% on second 
component and 7% on third component) than PCA on UV data (16% on first component, 13% on 
second component and 1% on third component), however PCA on UV data more clearly separated 
cases and controls, along the first component, as observed on the scores scatter plots (Figure 5-4). 
This indicates the importance to separation of metabolites with smaller variances (i.e. lower relative 
concentrations) as these give a greater contribution in UV PCA. This comes at the expense, however, 
of also giving greater weighting to noise in the PCA which results in the lower overall explained 
variance. No outliers were detected in UV PCA, as judged by location within the 95% limit of 
Hotelling’s T2 score, with one control just outside the limits in mc PCA due to high creatinine (3.05 δ, 
4.05 δ) concentration. UV scaled data was used for all subsequent analyses. 
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Figure 5-4: PCA scores scatter plots of cases (black points) versus controls (red points) showing: 1st and 2nd 
components of MC data (top left); 2nd and 3rd components of MC data (top right); all three components of MC data 
(middle left); all three components of UV data (middle right); 1st and 2nd components of UV data (bottom left); 2
nd
 and 
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 components of UV data (bottom right). Circles and spheres show 95% tolerable limits of Hotelling’s T2. 
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A cross-validated O-PLS-DA model constructed on UV data was able to differentiate between cases 
and controls as indicated by the model statistics. The model was well-fitted (R2Y=0.98) with good 
predictive ability (Q2Y = 0.48).  External validation of the model by class membership permutation 
indicated that the Q2Y score of the model lay in the top 5 % of possible scores (permutation 
validation p value < 0.05). Cases and controls clearly grouped together by cross-validated score, 
except for one case (the youngest case, a recently ill, four-year old boy) that grouped along with 
controls (Figure 5-5).  Interestingly this boy was the only case (for whom clinical chemistry data was 
available) that had normal transaminase values, despite showing the characteristic symptoms of 
HVLD and having high serum GGT levels. 
 
Figure 5-5: Scores plot of O-PLS-DA model of case versus control samples from November 2008 collection. Cross-
validated scores from predictive component plotted against case (black circle) or control status (red square). UV data. 
Metabolites responsible for this discrimination between cases and controls were identified through 
the O-PLS-DA loadings plot (Figure 5-6). The plot is representative of the NMR-spectrum since the 
metabolite chemical shift values are plotted along the x-axis, while the respective peak contribution 
to the O-PLS discriminatory variable on the y-axis. The plot is coloured according to correlation to 
the latent discriminatory variable (r2) with those metabolites in red being highly discriminating 
between cases and controls. Metabolite peaks in the upper half of the plot are increased among 
cases while those in the lower half are decreased, with the intensity of these peaks corresponding to 
the degree of change.  
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Concentrations of bile acids, pyruvate, tyrosine and formate were found to be elevated among cases 
while concentrations of p-cresol sulphate and hippurate were reduced. A number of metabolites 
that remained unidentified also had perturbed concentrations among disease cases (Table 5-2). 
Control 
Case 
Case 
Figure 5-6: Loadings plot of O-PLS-DA model of case versus control samples from November 2008 collection. Model 
constructed from one predictive and two orthogonal components (Q2Y: 0.48, R2Y: 0.98, R2X: 0.33). Class permutation 
validation p < 0.05. Back-scaled covariance loadings plot of regions 0.5-4.7 δ (top) and 6.5-9.5 δ (bottom). Annotated 
metabolites have spectral permutation p < 0.01.   
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Table 5-2: Most important discriminatory metabolites identified from O-PLS-DA of case versus control samples from 
November 2008 collection 
1H δ ppm 
(multiplicity) 
Metabolite Change 
among 
cases 
r p value 
permutation 
validation 
Reference 
used for 
identification 
0.68 (s), 0.72 (s) Bile acids ↑ 0.67 >0.005 230 
O.79 (s?) Unknown 1 ↓ -0.75 >0.005 212, 231 
1.8 (t), 2.22(d), 
2.24 (s), 3.75 (d) 
Unknown 2 ↑ 0.76 
 
>0.005  
2.35 (s), 7.21 (d), 
7.28 (d) 
P-cresol 
sulphate 
↓ -0.57 
 
>0.01 232 
2.37 (s) Pyruvate ↑ 0.62 >0.005 216, 231 
3.97 (d), 7.55 (t), 
7.64 (t), 7.84 (d) 
Hippurate ↓ -0.75 >0.005 233 
5.35 (d) Unknown 3 ↑ 0.75 >0.005  
6.75 (d), 6.82 (d), 
7.25 (d), 7.57 (d), 
8.1 (d) 
Unknown 4 ↓ -0.69 >0.005 3-hppa?234 
6.90 (d) Tyrosine ↑ 0.62 >0.005 216, 231 
8.46 (s) Formate ↑ 0.55 >0.01 231 
5.4.4 December 2009 Collection 
Urine samples were collected from 31 Hirmi Valley Liver Disease cases, from 18 control individuals 
who did not display any symptoms but shared a household with at least one disease case (household 
control) and from 18 control individuals who did not display any symptoms and lived in a household 
free from Hirmi Valley Liver Disease (village control). Again there were a greater proportion of men 
among cases than among controls but the age range was similar (Table 5-3). Only two of the cases 
reported having been ill for less than a year, and the mean duration of disease (time since 
presentation) among cases was 40 months. Two cases were hospitalised at the time of collection 
enabling overnight longitudinal sampling. From one of these patients, four samples were collected 
and a spectrum was successfully acquired from each sample and included in the analysis. From the 
other hospitalised patient, only two samples were collected but the spectral acquisition from one 
sample had a poor signal to noise ratio and was therefore excluded from the analysis. 
Table 5-3: Demographics of participants in December 2009 collection, included in analysis. 
 Number % 
Male 
Test for gender 
(vs. village 
controls) 
Mean age 
(SD) 
t-test for age 
(vs. village 
controls) 
Cases 35 60 p = 0.004 28.8 (18.6) p= 0.88 
Household 
Controls 
18 28 p= 0.21 23.7(16.9) p= 0.29 
Village 
Controls 
18 11 NA 31.2 (19.1) NA 
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5.4.4.1 PCA 
A PCA was performed for all December 2008 samples.  The first component explained 12% of 
variation; the second explained a further 10% while the third component explained a further 7%. 
There was little clear separation between cases, household controls and village controls, as 
visualised on the scores scatter plot (Figure 5-7). There appeared to be a small separation between 
cases and controls along the second component with cases more likely to have positive scores than 
controls. Longitudinal samples from the same hospitalised individual grouped together, although the 
variation between these longitudinal samples was quite large due to the administration of medicines 
at the hospital. 
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Figure 5-7: PCA scores scatter plots of samples collected in December 2009. Bright red squares = hospitalised 
cases and cases ill for less than 1 year, Dark red squares= cases ill for more than a year, blue diamonds = 
household controls, green diamonds = village controls. Circles and spheres show 95% tolerable limits of 
Hotelling’s T2. Yellow circle indicates samples from individual patient. Top figure shows 1
st
 and 2
nd
 
components, bottom figures shows 1
st
, 2
nd
 and 3
rd
 components. 
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5.4.4.2 O-PLS-DA Model 2: December 2009 Cases vs. Village Controls 
An O-PLS-DA model was constructed to discriminate between cases and village control samples 
collected in December 2009. The model had a good fit to the data (R2Y=0.85), a reasonable 
predictive ability (Q2Y=0.35), and was validated by permutation testing (p<0.05). Classes were 
separable by cross-validated score although there was also some overlap (Figure 5-8b). This model 
was preferred to models constructed comparing cases to both household and village controls 
combined due to its superior model statistics, which is likely to be driven by a smaller proportion of 
sub-clinical cases among the village controls. 
 
 
 
δ 1H 
δ 1H 
A 
B 
Case 
Control 
Figure 5-8: O-PLS-DA model of case versus village controls samples from December 2009 collection. Model constructed 
from one predictive and three orthogonal components (Q2Y: 0.35, R2Y: 0.85, R2X: 0.16). Class permutation validation p < 
0.05. A: Back-scaled covariance loadings plot of regions 0.5-4.7 δ (top) and 6-9.5 δ (bottom). Annotated metabolites have 
spectral permutation p < 0.01.  B: Cross-validated scores from predictive component plotted against case (black circle) or 
village control status (red square). 
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The concentration of bile acids, N-acetylglycoproteins and N-methylnicotinamide were found to be 
higher in samples from cases than in samples from village controls, while the concentration of p-
cresol sulphate, hippurate and p-hydroxybenzoate were relatively lower in case samples. The 
concentration of some unidentified metabolites was altered among case samples relative to village 
controls (Figure 5-8a, Table 5-4). 
Table 5-4: Most important discriminatory metabolites identified from O-PLS-DA model comparing case and village 
control samples collected in December 2009. 
δ ppm 
(multiplicity) 
Metabolite Change 
among 
cases 
r p value 
permutation 
validation 
Reference 
used for 
identification 
0.68 (s), 0.72 (s) Bile acids ↑ 0.50 >0.005 230 
1.24 (t), 3.6, 3.8, 
4.94 (d) 
Unknown 5  ↑ 0.40 >0.005  
2.35 (s), 7.21 (d), 
7.28 (d) 
p-cresol sulphate ↓ -0.39 >0.005 232 
3.97 (d), 7.55 (t), 
7.64 (t), 7.84 (d) 
Hippurate ↓ -0.33 >0.005 233 
2.02 (s) N-acetyl-
glycoprotein 1 
↑ 0.41 >0.005 235 
4.32 (t), 3.6 (m), 
4.0, 1.17 (d) 
Unknown 6  ↑ 0.42 >0.005  
6.99 (d), 7.77 (d) p-
hydroxybenzoate 
↓ -0.42 >0.005 101 
4.48 (s) 8.90 (d), 
8.97 (d), 9.28 (s) 
N-methyl-
nicotinamide 
↑ 0.30 >0.005  
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5.4.4.3 O-PLS-DA Model 3: December 2009 household controls vs. village Controls 
To explore the changes in urinary metabolic profile in those residents exposed to the putative 
toxin(s) relative to those residents unexposed, an O-PLS-DA model was constructed comparing 
samples collected from household controls (presumably exposed since they share food with disease 
cases) and samples from village controls (presumably unexposed since no member of their 
household is reported to be suffering from HVLD). One may expect this model to identify biomarkers 
of exposure rather than biomarkers of disease resulting from long-term metabolic changes induced 
by HVLD. The model was well fitted (R2Y=0.96) and although the Q2Y score (0.20) was lower than 
other presented models it could still be validated by permutation testing (p <0.05).  The fact that 
controls were separable indicates a level of sub-clinical disease among affected households (Figure 
5-9b). 
  
δ 1H 
δ 1H 
Household 
Control 
Village 
A B 
r2 
p-hydroxybenzoate 
Figure 5-9: O-PLS-DA model of household control versus village control samples from December 2009 collection. 
Model constructed from one predictive and two orthogonal components (Q2Y: 0.20, R2Y: 0.96, R2X: 0.22). Class 
permutation validation p < 0.05. A: Back-scaled covariance loadings plot of regions 0.5-3 δ (top) and 6.5-8.3 δ 
(bottom). Annotated metabolites have spectral permutation p < 0.01 (or p <0.05 if identified in previous model).  B: 
Cross-validated scores from predictive component plotted against household control (black circle) or village control 
status (red square). 
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An increase in the relative concentration of tyrosine and N-acetylglycoprotein (although a different 
glycoprotein than that identified in the case versus village control model) among household control 
samples and a relative decrease in the concentration of p-cresol sulphate and p-hydroxybenzoate 
was responsible for the discrimination between household and village controls (Figure 5-9, Table 
5-5). 
Table 5-5: Most important discriminatory metabolites identified from O-PLS-DA model comparing household and village 
control samples collected in December 2009. 
δ ppm 
(multiplicity) 
Metabolite Change 
among 
cases 
r p value 
permutation 
validation 
Reference 
used for 
identification 
2.04 (d) N-acetylglyco-
protein 2 
↑ 0.45 
 
>0.01 
 
235 
2.35 (s), 7.21 (d), 
7.28 (d) 
p-cresol sulphate ↓ -0.31 >0.05 232 
6.90 (d) Tyrosine ↑ 0.46 >0.005 216, 231 
6.99 (d), 7.77 (d) p-
hydroxybenzoate 
↓ -0.45 >0.05 101 
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5.4.5 Univariate Analysis 
Metabolites identified as being of potential relevance to Hirmi Valley Liver disease by the three 
separate multivariate O-PLS-DA models were then individually subjected to Wilcox Rank Sum tests to 
detect any univariate association with sample classes (Table 5-6).  A significant association with a 
particular sample class in separate analyses (for instance an association being found with both 
December 2009 collection cases and November 2008 collection cases) lends further support to that 
particular metabolite having a true association with HVLD. Bile acids (p < 0.005) and N-
methylnicotinamide (p<0.05) showed statistically significant increases in concentration in both 
December 2009 and November 2008 cases, while p-cresol sulphate (p<0.05) concentration was 
significantly lowered in both sets of case samples. Hippurate was significantly reduced in 
concentration among November 2008 cases (p<0.005) and showed a reduction in concentration 
among December 2009 cases that bordered on significance at the 95% confidence level (p=0.05). 
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Table 5-6: Univariate tests of difference in median concentration between samples classes for metabolites identified in 
O-PLS-DA analyses. Numbers displayed are p values computed from Wilcox Rank Sum tests. 
Metabolite November 2008 
Collection Cases vs. 
controls 
December 2009 
Collection Cases vs. 
village controls 
December 2009 
Collection 
household 
controls vs. village 
controls 
N-
methylnicotinamide 
0.014 0.018 0.46 
Bile acids 0.0020 0.0032 0.83 
Formate 0.0046 0.21 0.46 
Hippurate 0.0046 0.053 0.17 
N-acetyl-  
glycoprotein 1 
0.74 0.00019 0.33 
N-acetyl-  
glycoprotein 2 
0.42 0.43 0.03 
p-cresol sulphate 0.033 0.0030 0.26 
p-hydroxybenzoate  0.96 0.025 0.071 
Pyruvate 0.0068 0.16 0.96 
Tyrosine 0.0097 0.94 0.10 
Unknown 1  0.0031 0.021 1 
Unknown 2 0.00021 0.17 0.69 
Unknown 3 0.0097 0.36 0.76 
Unknown 4 0.00041 0.98 0.98 
Unknown 5 1 0.012 0.98 
Unknown 6 0.67 0.034 0.71 
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One may also examine the trends in the distribution of metabolite concentrations across the sample 
classes to assess the relevance of different metabolites.  Figure 5-10 shows the distributions of 
concentrations (expressed as the percentage concentration of the highest concentration found 
among all samples) for each sample class. Hippurate and p-cresol sulphate show similar trends with 
cases from both collections having lower median concentrations than their respective controls, with 
household controls forming an intermediate group between cases and village controls in the 
December 2009 collection. Another identified microbial metabolite p-hydroxybenzoate shows a 
similar trend among the December 2009 samples but with little difference observed between 
November 2008 cases and controls, which may be partially explained by the low concentrations 
found in all November 2008 samples (relative to December 2009 samples).  Bile acids show a large 
increase in concentration in case samples relative to control samples, with little difference observed 
between household and village controls. Formate and N-methylnicotinamide show a similar pattern 
with concentration increases in cases relative to control samples and slight increase in household 
controls relative to village controls. Tyrosine and pyruvate also follow a similar pattern to each 
other, albeit with larger concentration changes exhibited by tyrosine. There is a large concentration 
increase in these metabolites in the November 2008 cases relative to the November controls and 
smaller increases observed in December household controls relative to village controls. However no 
change was observed between December 2009 cases and controls. Finally two separate N-
acetylglycoproteins were identified as discriminatory. N-acetylglycoprotein 1 (2.02  ppm) had 
higher relative concentration in cases than in controls and area controls had a median concentration 
between that of the December 2009 Cases and village controls. Conversely, N-acetylglycoprotein 2 
only shows a relative increase between household and area controls. 
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Figure 5-10: Box and whisker plots showing the relative distributions of identified metabolites across sample classes. 
Thin black line = median, box= interquartile range, circles =outlier values. Class category key: D_case=December 2009 Case, 
D_hh=household control, D_village=village control, N_case= November 2008 case N_control= November 2008 control. 
Figure 5-11 shows the relative distribution of the metabolites that have not been assigned. Again, 
evidence of a consistent trend across separate analyses provides additional non-statistical validation 
of the relevance of these metabolites to HVLD. Unknowns 3, 4 and 6 all show consistent trends with 
Unknown 3 having a higher concentration among cases and Unknown 4 having a lower 
concentration. For both metabolites the changes are greater in the November 2008 collection than 
the December 2009 collection. Unknown 6 shows similar concentration increases between cases and 
controls in both collections, with the household controls having a median concentration between 
the cases and village controls No consistent trend can be observed for Unknowns 1 and 5.  
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Figure 5-11: Box and whisker plots showing the relative distributions of unassigned metabolites across sample classes. 
Thin black line = median, box= interquartile range, circles =outlier values. Class category key: D_case=December 2009 Case, 
D_hh=household control, D_village=village control, N_case= November 2008 case N_control= November 2008 control. 
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Unknown 2 appears to be of particular interest: There is a very large concentration increase among 
November cases relative to controls (p = 0.0002) and most of the highest concentrations found in 
the December 2009 collection are from case samples, however relative concentrations among the 
December collection is much lower than the November collection and in most samples Unknown 2 is 
not detected. This appears to be due to interactions between the preservative boric acid, used only 
in the December 2009 collection, and unknown 2. The concentration of boric acid used varied from 
tube to tube since the tubes were pre-filled with the same quantity of boric acid yet had varying 
volumes of urine, which in turn is likely to have led to differing levels of reaction with diols and other 
borate-reactive groups. This effect is suggested by the correlation shown between the concentration 
of Unknown 2 and the predictive component of a PLS-DA model (R2Y=0.82, R2X= 0.11, Q2Y=0.78) 
separating the November 2008 and December 2009 collections (Figure 5-12), since those December 
cases that have lower scores for the predictive component (which is dominated by the mannitol- and 
citrate-borate complex signals) tend to have higher concentrations of Unknown 2 (r2 = 0.33). 
 
Figure 5-12: Predictive component scores (cross-validated) of PLS-DA model separating the November 2008 collection 
samples from the December 2009 collection samples (where borate acid was used), plotted against Unknown 2 
concentration. Dotted line shows regression line of December 2009 samples only.  = December 2009 samples,  = 
November 2008 samples 
5.4.6 Metabolite correlations  
Correlations were found between hippurate and P-cresol sulphate, both of which are believed to be 
of microbial origin. These metabolites were also correlated with the concentration of Unknown 4, 
R
2
 = 0.33 
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which suggests, along with its chemical shift that is nestled in the aromatic spectral region alongside 
other microbial metabolites, that it too is a metabolite of microbial origin. Unknown 4 has been 
tentatively assigned as 3-hydroxypropionic acid (3-HPPA), based on the chemical shift data in the 
paper of Swann et al. 234, although different chemical shift data are given on the Human 
Metabolome Database228.  Little correlation was observed between these microbial metabolites and 
the other assigned microbial metabolite p-hydroxybenzoate (Figure 5-13).     
  
  
Figure 5-13: Correlation between microbial metabolites associated with HVLD. Concentration values are expressed a 
relative % index 
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5.4.7 Effects of Gender on metabolic profile 
In this study a higher proportion of cases than controls, were male. This difference was significant (p 
= 0.004) when December 2009 cases and village controls were compared. To determine whether 
there was any confounding effect on the O-PLS-DA models presented comparing disease class, an O-
PLS-DA (R2Y=0.85, R2X=0.19, Q2Y=0.24) model comparing gender was constructed (Figure 5-14).  The 
most important contributor to the predictive component was P-cresol sulphate (r = -0.15 with 
predictive component for maleness), which had been identified as contributing to the separation of 
disease class metabolic profiles (r for: model 1: - 0.57, model 2: -0.39, model 3: -0.31), suggesting 
that the association observed with HVLD may be confounded by an association with gender (if not 
completely since p-cresol sulphate is more strongly correlated with HVLD status than gender). No 
other metabolites were indentified in the O-PLS-DA model for gender that had been identified as 
discriminatory in the disease status O-PLS-DA models. 
 
Figure 5-14: O-PLS-DA back-scaled loading plot from O-PLS-DA model of males versus female samples from all 
collections (n=84). Model has one predictive component and two orthogonal components, R
2
Y=0.85, R
2
X=0.19, Q
2
Y=0.24, 
permutation validation p <0.05. Arrows highlight p-cresol sulphate peaks. 
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Although there were not a sufficient number of samples to construct valid O-PLS-DA models for 
disease status stratified by gender, the distribution of p-cresol sulfate concentrations across samples 
class, when stratified by gender, was broadly similar to previously found (Figure 5-15), with median 
concentrations in case samples lower than the median concentrations of their respective control 
samples. To adjust statistically for any gender bias in the association between p-cresol sulphate and 
HVLD, logistic models were constructed to determine the odds ratios for being a HVLD case with 
every percentage increase in the relative percentage index of p-cresol sulphate concentration, with 
gender used as an additional variable (Table 5-7). When all available case samples were regressed 
against all available control samples, a significant effect was still observed (p = 0.024) after adjusting 
for gender.  This indicates that while gender may have augmented the association observed 
between p-cresol sulphate and HVLD, it does not account entirely for it. 
 
Figure 5-15: Box and whisker plots showing the relative distributions of p-cresol sulfate across sample classes., for male 
and female samples.  Thin black line = median, box= interquartile range, circles =outlier values. Class category key: 
D_case=December 2009 Case, D_hh=household control, D_village=village control, N_case= November 2008 case 
N_control= November 2008 control. 
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Table 5-7: Logistic regression models determining the odds ratios of being a HVLD case, for every % increase in p-cresol 
sulphate (relative % index). 
Samples Compared N p-cresol sulphate only p-cresol sulphate (adjusted 
for gender) 
  Odds Ratio 
(confidence 
interval) 
p value Odds Ratio 
(confidence 
interval) 
p value 
November 2008  
cases vs. controls 
21 0.89 (0.77-1.01) 0.086 0.88 (0.75-1.04) 0.075 
December 2009 
Cases vs. village 
controls 
51 0.95 (0.92- 0.99) 0.012 0.96 (0.93-1.00) 0.057 
December 2009 
household vs. village 
controls 
33 0.97 (0.92-1.01) 0.165 0.97 (0.94-1.01) 0.157 
All cases vs. all 
controls 
90 0.97 (0.93-0.98) 0.002 0.97 (0.938-0.995) 0.024 
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5.5 Discussion 
5.5.1 Comparison of models presented 
I have been able to show that HVLD cases and controls can be discriminated on the basis of their 
urinary metabolic profiles, using O-PLS-DA modelling. The clearest separation was achieved through 
comparison of case and control samples collected first in November 2008 (model 1, Q2Y= 0.48).  This 
separation was again demonstrated with a comparison of case and village control (residents of 
households unaffected by HVLD) samples from a second collection in December 2009 (model 2, Q2Y= 
0.35). Furthermore, asymptomatic control samples from this collection could be separated based on 
whether they were from residents who shared a household with at least one HVLD case or a 
household free of the disease (model 3, Q2Y = 0.20), suggesting the presence of sub-clinical disease 
in the region. 
The clearer separation by cross-validated score and improved predictive ability of model 1 compared 
to model 2 can be explained by the difference is the health status of the HVLD patients themselves. 
70% of cases analysed in model 1, were ill for less than one year (time since onset of symptoms) 
with a mean duration of disease of 13 months, whereas only 6% of cases in model 2 were ill for less 
than a year and the mean duration of disease was 40 months. Patients in the early stages of the 
disease (i.e. ill for less than a year) are most likely to be suffering from the acute stage of the 
disease, characterised by sudden hepatomegaly and ascites, abdominal pain and bleeding 
abnormalities, raised serum amino transaminase levels and necrosis of the hepatocytes. Patients ill 
for longer than a year are most likely to have moved onto the chronic stage of the disease, which in 
many cases is indistinguishable from other forms of chronic liver disease such as compensated 
cirrhosis, characterised by a firm hepatomegaly, often normal amino transferase values, and 
histologically, there are varying states of fibrosis and bile ductular proliferation.  Therefore one 
would expect differences in urinary metabolic profiles between the cases from the two collections, 
with model 1 reflecting changes associated with the acute stage and model 2 reflecting longer term 
chronic changes. The smaller difference between cases and their controls in the second collection 
may also be expected since the patients from the first collection were generally more visibly unwell 
than those sampled in the second. 
Discriminatory metabolites identified as contributing to the separation of household (exposed) and 
village (unexposed) controls in model 3, that were also indentified as biomarkers of HVLD in the 
other models, can be considered biomarkers of exposure that may be perturbed without the 
development of clinically apparent disease. Metabolites perturbed in models 1 and 2 but not in 
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model 3 can be considered biomarkers of disease rather than exposure. Metabolites identified as 
being perturbed only in models 1 and 3 may indicate changes present only in the early sub-clinical 
and acute stages of the disease that become less apparent as the disease moves into the chronic 
stage. 
5.5.2 Identified metabolites 
As can be seen in Table 5-8, many of the discriminatory metabolites identified in this study have 
been identified as important in metabonomic studies of liver toxicity in rodent models and clinical 
studies of LC and HCC. Others such as gut microbial metabolites p-cresol sulphate and p-
hydroxybenzoate are unique, among metabonomic studies of toxic liver injury, to HVLD. I will now 
discuss each metabolite in turn. 
5.5.2.1 Tyrosine 
Tyrosine has long been recognised as clinical marker of liver disease236 and is raised in the serum of 
patients with HCC and LC216. The branched chain tyrosine ratio, which expresses the ratio of 
branched chain amino acids (principally metabolised in the skeletal muscle) to tyrosine (metabolised 
mainly in the liver) in blood plasma or serum, has been found to be a useful indicator of hepatic 
parenchymal damage in the clinical setting, being significantly reduced in patients with cirrhosis or 
hepatitis compared to controls237. Here, it is shown to be applicable as a urinary marker of early 
stage toxic hepatitis (identified in models 1 and 3) but not late stage chronic disease (model 2). This 
would support the findings of Shariff et al217, who did not report a rise in urinary tyrosine among 
HCC and LC patients. Among metabonomic studies of various liver toxins in rodent models, 
hypertyrosinemia is often26, 211, 233, but not always observed238, 239. Hypertyrosinuria is also reported 
for the hepatotoxin galactosamine230, for which the rise in plasma tyrosine following administration, 
is described as dramatic213.  Since we do not see any concomitant rises in the aromatic amino acid 
phenylalanine (also metabolised by the liver), the observed hypertyrosinuria does not appear to be 
the result of general liver insufficiency, and the lack of any changes in other amino acids does not 
suggest a general shift in metabolism towards transamination, indicating that the cause is toxin 
specific. Clayton et al239 attribute the hypertyrosinemia observed following hepatotoxin 
administration to a reduction in the tyrosine aminotransferase (TAT) activity that metabolises 
tyrosine to 4-hydroxyphenylpyruvate. TAT has a remarkably short half-life of around 2 hours, and it 
is the failure to resynthesise TAT, through a range of mechanisms such as impaired protein 
synthesis, that leads to the observed rises in tyrosine. 
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5.5.2.2 Pyruvate 
As with tyrosine, pyruvate was identified in model 1 and not model 2, and had a higher median 
concentration among household controls relative to village controls, although this was not 
significant. It was found to be raised in the serum of patients with HCC and LC216 and the authors 
suggest this is due to reduced utilisation in the tricarboxylic acid (TCA) cycle; however no 
perturbation to TCA cycle intermediaries are detected in this analysis suggesting the pathway is 
unaffected. Rather the rise in pyruvate may be linked to the excess tyrosine, since the amino acid 
may be interconverted to pyruvate240. 
5.5.2.3 N-methylnicotinamide 
N-methylnicotinamide was significantly raised in both models 1 and 2 and showed low variability 
amongst controls, making it a good candidate biomarker for HVLD.  N-methylnicotinamide is known 
to be raised in the urine of LC patients241, and the enhanced methylation pathway is postulated to 
protect against intracellular accumulation of nicotinamide resulting from the catabolic state of 
cirrhotic tissue. However, only a minority of liver biopsy specimens from HVLD patients were found 
to be cirrhotic, indicating the metabolite is a more general marker of liver injury. Furthermore, N-
methylnicotinamide was found to be raised in the urine of rats following bromobenzene26 and 
galactosamine213 administration, both of which cause hepatocellular necrosis.  This may be due to 
necrosis enhanced nucleotide catabolism leading to a substrate overload of the enzymes xanthine 
oxidase and aldehyde oxidase, responsible for N-methylnicotinamide catabolism26.  
5.5.2.4 Bile acids   
Bile acids were also consistently raised in both models 2 and 3, providing an indicator of both acute 
and chronic stages of HVLD. The rises may be linked to the bile ductular proliferation observed in 
biopsies from patients in both stages of the disease. Bile acids are produced in the liver from 
cholesterol and are excreted into the intestinal lumen as glycine or taurine conjugated forms. There 
they undergo further metabolism by gut microflora and may be reabsorbed into the liver through 
enterohepatic circulation where they undergo further metabolism242. Raised serum bile acids are 
specific for hepato-biliary disease, reflecting a failure to fully reabsorb bile acids from the intestine 
on first passage through the liver, while rises in the urine are associated with cholestasis9.  However, 
liver function tests and histology of HVLD patients indicated that the choleostatic component was 
less significant than the general liver dysfunction observed, with only modest rises in serum bile 
acids measured (Chapter 3). This suggests that the urinary rises are the result of reduced liver 
function. Toxin exposure has been shown to induce rises in urinary bile acids following 
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administration of galactosamine230 thioacetamide212 (inducers of hepatocellular necrosis and bile 
ductular proliferation) and 1-naphthylisothiocyanate238 (inducer of bile duct epithelial cell necrosis 
and cholestasis) in the rat model. 
Interestingly, C-18 methyl singlet signals were only detected at 0.68 and 0.72 ppm and not across 
the whole region of bile acid C-18 methyl signals (0.66-0.76). This indicates that there is not a 
general rise in all bile acids but rather a rise in specific bile acid species, which would account for the 
modest serum levels. The signals detected here are shown by Beckwith-Hall et al230, as arising from 
taurine-conjugated or unconjugated bile acids, but not glycine conjugated, although it is impossible 
to identify individual bile acids with certainty by NMR spectroscopic means. Taurine-conjugated bile 
acids have been shown recently to account for the majority of changes in serum following 
galactosamine exposure243, proving a good indicator of histopathological severity. This is in contrast 
to carbon tetrachloride (an inducer of centrilobular necrosis) exposure where the majority of 
changes were to glycine-conjugated bile acids244. These studies show that hepatotoxin exposure 
induces changes to the profile of bile acids detected in serum that may reflect the site and severity 
of damage rather than just general liver insufficiency.  
5.5.2.5 N-acetylglycoproteins  
Resonances from the N-acetyl groups of 1-acid glycoproteins
235 have been found to be indicative of 
the pathological state in many metabonomic studies, with elevated levels found in the serum26, 203, 
216, 233 and urine230, 233 and are thought to reflect the inflammatory response. ‘Acute phase’ proteins 
such as these are known to rise in concentration following a number of clinical disorders, including 
liver disease235, 245. Two separate metabolite signals from this region (2.0-2.05 ppm) were identified 
in this study. The first, N-acetylglycoprotein 1 (2.02 ppm) showed a consistent trend with median 
elevations among cases and household controls relative to village controls and controls from the 
November 2008 collection. The second, tentatively assigned N-acetylglycoprotein 2 (composite 
signals at 2.03 and 2.04 ppm) was significantly elevated only in household controls relative to village 
controls, with no changes observed in other pair-wise comparisons.  
5.5.2.6 Microbial associated metabolites 
A range of microbial-associated metabolites was found to be perturbed among HVLD patients. 
Formate was elevated among cases, while hippurate and p-cresol sulphate were reduced, and this 
trend was consistent across both collections. This pattern of metabolite differences distinguished 
patients with the inflammatory bowel disease Crohn’s Disease from controls202 and is associated 
with an altered composition of gut microflora. Raised urinary formate and reduced hippurate 
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concentration was also found to be associated with raised blood pressure by the INTERMAP 
epidemiological study207.  Reduced hippurate is associated with obesity246 and is consistently noted 
in studies of liver toxicity211, 230, 233, 238, including following partial hepatectomy without toxin 
exposure247, and so may be considered a general marker of ill health. 
Formate is produced endogenously as a product of the one-carbon metabolic pathway248, in addition 
to being a by-product of fermentation of dietary fibre principally by Enterobacteriaceae species249, 
so cannot be considered an exclusive indicator of changes to the gut microbiome. Indeed, urinary 
concentrations will rise in patients with folate deficiency250, itself a known consequence of chronic 
liver disease9, while elevations of formate in the liver, serum and urine were recorded following 
thioacetamide exposure in the rat212, supporting toxin specific changes to endogenous metabolism. 
Hippurate and p-cresol sulphate are both mammalian and microbial co-metabolites. Hippurate is the 
product of the microbial conversion of conversion of dietary aromatic compounds such as purines and 
amino acids such as tyrosine to benzoic acid, followed by glycine conjugation in the kidney or liver, 
while p-cresol sulphate is produced by bacterial metabolism of tyrosine to p-cresol, which is then 
sulphate conjugated (in humans) in the liver251. Clostridia species, among others, are known to 
contribute to these processes202. A reduction in these microbial metabolic pathways may therefore 
also contribute to the observed rise in tyrosine. Unlike hippurate, a reduction in p-cresol conjugates 
has not been previously associated with liver injury. However a rise in urinary p-cresol glucuronide (an 
alternative conjugate of p-cresol, produced in rodents) was observed in a mouse model of 
Schistosoma mansoni infection, suggesting a three-way interaction between host, parasite and 
microbial metabolism252. This may be of potential use in simplifying the differential diagnosis of HVLD 
as it shares many symptoms with schistosomiasis, and this disease is prevalent in the some of the 
same areas, which complicated initial investigations into HVLD. 
Two further metabolites of microbial origin were found to discriminate against cases and controls in 
the two collections. In model 1, Unknown 4 (tentatively assigned as 3-HPPA) concentration was 
significantly reduced among cases, with a small non-significant reduction among December 2009 
collection cases relative to village controls. P-hydroxybenzoic acid was identified in models 2 and 3 and 
showed a trend for higher concentration among village controls relative to household controls and 
cases, but no difference was observed between cases and controls in model 1. These are both 
products of bacterial decomposition of dietary polyphenols253 254 and are known antioxidants, so may 
contribute to the protection from toxin-induced oxidative stress. Unknown 4 / 3-HPPA is correlated 
with the concentration of other microbial metabolites so is likely to also be indicative of the general 
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gut microbiome alterations. P-hydroxybenzoate did not show a similar correlation and it is also 
possible that the differences observed are simply driven by the consumption of certain foods, rich in 
chemicals such as catechin253, among village controls. 
It is likely that damage to the mucosal lining is a feature of HVLD. Cytochrome P450 enzymes are 
responsible for the metabolism of xenobiotics such as pyrrolizidine alkaloids, to toxic intermediaries, 
and their distribution contributes to the observed zonal pattern of necrosis in the liver lobule.  
Cytochrome P450 enzymes are also active in the intestine and nasal and tracheal mucosa19, so one 
may expect the production of toxic intermediaries in these sites leading to localised cell necrosis. The 
bloody stools and epistaxis reported by HVLD patients may be a symptom of this. Damage to the gut 
mucosa would be expected to cause changes to the microbiome ecosystem with the observed 
associated changes in microbial metabolites. It is also possible that the xenobiotic metabolites are 
directly toxic to certain gut bacterial species. 
There is also growing evidence that the initial composition of gut microflora can modulate the toxic 
response in the host94 and the composition of the gut microbiome can vary for a number of reasons 
including diet, location and gender207, as was shown in this study by the higher levels of p-cresol 
sulphate among female participants. This may make individuals more or less likely to develop disease 
following toxin exposure and be reflected in the different urinary profiles of microbial metabolites 
between cases and controls. Xenobiotic metabolism is significantly affected by the gut microbiome, as 
demonstrated by an initial reduced expression and activity of cyp3a11 in germ-free mice (raised in an 
aseptic environment), and over-expression of CAR and PXR, receptors, which induce the expression of 
cyp3a11, following re-colonisation relative to conventional mice99. Furthermore, hydrazine toxicity is 
significantly enhanced in germ-free rats compared to conventional rats234. Clayton et al100 showed that 
among human volunteers,  the metabolism of acetaminophen (commonly known as paracetamol) is 
affected by pre-dose urinary levels of p-cresol sulphate; those participants with high levels produced 
lower levels of sulphate conjugates of acetaminophen relative to glucuronide conjugates post-dose, 
which is thought to reflect competition for hydroxyl-sulfonation capacity.  While this may not be 
directly relevant to HVLD, it illustrates the effects the gut microbiome can have on detoxification 
pathways. Were p-cresol sulphate urinary concentration to reflect a microbial mechanism that is 
protective against HVLD, it may be a factor in the reduced incidence of HVLD among women observed 
in this study. Determining causation is a problem inherent in cross-sectional association studies such 
as these, and while differences in microbial metabolites are likely to reflect the effects of HVLD, this 
does not preclude the possibility that these metabolites also reflect some of its causes.  
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5.5.3 Unassigned metabolites 
One of the great difficulties in metabonomic analysis of human populations is in assigning all detected 
metabolites. Humans are exposed to an extraordinary number of different compounds through diet, 
drugs and environmental exposure, which has been likened to living in a “chemical jungle”15. This 
creates a huge range of possible metabolites that are observable by NMR spectroscopy that makes 
identification extremely challenging, particularly with low concentrations and considerable peak 
overlap.  Despite extensive searching of the literature and databases and further 2D NMR 
experiments, five metabolites were identified in the individual models that have yet to be assigned. 
The trend in concentration changes in these metabolites was compared across all samples classes to 
determine their validity as potential biomarkers of HVLD. Three metabolites were identified that 
showed consistent changes. Unknown 3 (5.35 1H ppm, doublet multiplicity indicated by j-resolved 
NMR) was a signal of very low intensity and showed the greater changes in the November 2008 
samples. It is found in the region of the NMR spectrum known for the anomeric protons of glucuronide 
moieties, so could perhaps be a product of phase II conjugation of a xenobiotic. Unknown 6 (4.32 
triplet 1H ppm (69 13C ppm), 3.6 multiplet 1H ppm (63 or 75 13C ppm), 4.0 1H ppm, 1.17 doublet 1H ppm 
(19 13C ppm)) was consistently raised in cases and household controls in both collections and its 
ubiquity in all samples suggest it is an endogenous metabolite. However the high variability observed 
in its concentration would lessen its utility as a biomarker. Unknown 2 (1.8 triplet, 2.22 doublet, 2.24 
singlet, 3.75 doublet 1H ppm) showed great promise as a biomarker or even toxin metabolite 
associated with HVLD, when identified following the first collection since it had the highest correlation 
with HVLD of any metabolite (r = 0.76). In the majority of samples from the December 2009 collection 
it was not present, and when present it was most likely to be detected in samples from cases, 
suggesting a varying interaction with boric acid used as a preservative in that collection. These 
metabolites are of particular interest since as they were not assigned they are more likely to be 
biomarkers unique to HVLD or even associated with the putative aetiological agent(s). 
5.5.4 Pyrrolizidine Alkaloid exposure 
Although one of the advantages of metabonomic analysis is that one does not need an a priori 
hypothesis to direct the analysis, exposure to pyrrolizidine alkaloids (PAs), including acetyl-
lycopsamine (AL) is hypothesised to be responsible for HVLD. Therefore the urinary spectra of mice 
dosed with AL (see chapter 7 for details) were compared to the HVLD patient spectra. While no 
metabolites of AL could be conclusively identified in the HVLD spectra, this does not necessarily 
reject the hypothesis. 1H NMR can detect metabolites at micro- to millimolar concentrations and 
urinary concentrations of PA in recently exposed patients would generally be expected to be lower 
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than this. Furthermore if present, the metabolites may be obscured by overlapping endogenous 
metabolite signals and if the patient was exposed more than three days prior to sampling, all 
alkaloid would be expected to be completely excreted112. Alternative methods to detect PA exposure 
are presented in chapter 6. 
The suite of metabolic changes identified, are consistent with the known specific effects of PA 
exposure. Damage to the gut mucosa has been previously reported in cases of human poisoning.14, 
so one would expect microbial changes. Tyrosine levels, which are raised following exposure to 
certain hepatotoxins, has been found to be raised in the serum of horses exposed to PA255. 
Furthermore, a rat model of liver regeneration following exposure to the PA retrorsine was 
characterised by the rapid expansion of small hepatocyte-like progenitor cells, which share 
phenotypic characteristics with both oval cells and hepatocytes190. These cells showed significantly 
reduced expression of tyrosine aminotransferase, which would be expected to lead to greatly 
elevated tyrosine concentrations. Metabolic changes induced by exposure to AL in the mouse model 
are explored in chapter 7. 
5.5.5 Strengths and limitations of study 
One limitation of this study was the lack of traditional clinical chemistry measures, with which to 
anchor the NMR spectral data. While the majority of cases in the first collection of urine samples, 
were confirmed by LFTs of serum samples or biopsy, the confirmation by LFT in the second collection 
was not possible for logistical reasons. This may have led to misclassification of some cases (and 
controls) in the analysis of samples from the second collection and may be an alternative 
explanation for the lower predictive ability of model 2, despite a greater number of samples.  
However the health officer responsible for the diagnoses, knew the patients well having run weekly 
clinics over a period of a year. Furthermore, confounding diseases such as schistosomiasis and 
visceral leishmaniasis have low active prevalence in the sampled area. Serum clinical measures 
would have also been useful in assessing the severity of disease, providing, for instance, a 
continuous variable to compute PLS regression models. The relatively small number of samples used 
in model 1 was also not ideal, however the strict classification of the participants contributed to the 
robustness of this model. It was also not feasible to completely age and gender match cases and 
controls, although attempts have been made to adjust for this in the analysis. Specific information 
on diet was not obtained, and diet can significantly affect metabolic profiles. However the relative 
homogeneity of the participants’ diet, relative to Western populations can be considered a strength.  
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The use of borate acid in the second collection was also problematic. The preservative was used 
because it was not possible to maintain the cold chain as effectively in the second collection, which 
could have allowed bacterial contamination of samples and is less toxic than alternatives such as 
sodium azide. While the preservative has been used previously in clinical studies and has been 
shown to cause variation that is small in comparison to inter-individual variation229, it confounded 
global comparisons of samples between collections (although one would expect to see ‘batch 
effects’ nevertheless) and interfered with the detection of a potentially important metabolite. 
However the separate analysis of the two collections may also be considered a strength, since it 
provided an additional external validation, which often corroborated the veracity of identified 
metabolites. The differentiation of controls allowed the differentiation of biomarkers of exposure 
and disease, and the differing disease statuses of the cases in the two collections enabled the 
identification of early and long-term metabolic changes. The use of 600 MHz NMR spectroscopy 
allowed many metabolites to be simultaneously identified and distinguished. While offering less 
sensitivity than analytical platforms such as UPLC-MS, it provides a robust, inherently quantitative 
platform and much additional structural information facilitating metabolite assignment and 
multivariate analysis. Furthermore the use of recently developed statistical methods such as O-PLS-
DA, allowed a thorough, robust and systematic analysis, unbiased by any prior assumptions. The 
multivariate statistical approach also provides the required power to discriminate pathological states 
and identify potential biomarkers, above and beyond what would possible using a univariate analysis 
alone. 
5.5.6 Concluding remarks  
This is the first metabonomic analysis of hepatotoxin-induced disease in humans. 1H NMR 
spectroscopy has been used to distinguish HVLD patients from controls and has substantiated many 
of the changes previously observed in animal studies of hepatotoxin exposure. A number of 
metabolites associated with liver dysfunction have been identified alongside indicators of alterations 
to the gut microbiome. Tyrosine and p-cresol sulphate were found to be sensitive indicators of 
exposure and early stage disease, while changes to the concentrations of hippurate, formate, bile 
acids, N-acetylglycoproteins and N-methylnicotinamide, were found to indicative of both acute and 
chronic stages of HVLD. While no toxin-metabolite could be conclusively identified, a number of 
metabolites that may potentially be developed into biomarkers suitable for low-resource countries 
have been identified. 
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Table 5-8: Comparison of metabolites indentified in the three O-PLS-DA models with associated literature. Grid squares marked green show similar metabolite changes in those studies, in 
either liver, serum or urine compartments. 
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Pyruvate ↑                       
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p-cresol sulfate ↓                       
  N- acetyl- glycoproteins ↑                       
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6. Detection of Pyrrolizidine Alkaloid 
Exposure in Biofluids 
6.1 Introduction 
revious epidemics of human PA poisoning have generally been confirmed by the presence 
of the characteristic histology of VOD12, 104-106, 109, the identification of PAs and the plant 
source of the PAs in the staple food or herbal teas/medicines12, 103, 107, 148, 256 and a 
demonstration of the hepatotoxicity of these PAs in animal models103, 148, 256, 257. Only rarely has PA 
exposure been demonstrated through chemical means. While PAs and a plant source of PAs has 
been detected in the food supply of HVLD cases, the highly specific histology of VOD was not 
observed in any of the nine liver biopsy specimens presented in chapter 3. Therefore to confirm the 
diagnosis of PA poisoning among HVLD cases, it is necessary to demonstrate that they have been 
exposed to PAs and at a greater level than controls. 
PAs are rapidly converted by the liver to chemically reactive, toxic pyrrolic metabolites, and to 
readily excreted detoxification by-products such as through hydrolysis and N-oxidation112. Therefore 
these metabolites or the parent alkaloids may only be detected in the body for a day or so following 
ingestion. Only a couple of studies have reported the detection of the parent alkaloids or derivatives 
in human tissues or biofluids. During the 1976 Afghan outbreak it was reported that trace quantities 
of alkaloid were detected in urine samples from five patients256, although the type of alkaloid was 
not confirmed, while dehydro-PAs were detected by GC-MS  on autopsy, in the liver of a preterm 
neonate born with VOD resulting from consumption of a herbal food additive by the mother144. 
The strongly alkylating nature of the pyrrolic metabolites does however provide a means of 
demonstrating PA exposure many months previously. The dehydrogenated metabolites form strong 
covalently bonds to the thiol groups present in proteins and free GSH and also to DNA. The 
conjugates are long lasting and may be detected chemically. Fu et al.117 have shown that the same 
set of eight exogenous DNA adducts are formed by range of PAs of all types both in vivo and in vitro. 
These are two enantiomers of DHP-derived 7’-deoxyguanosin-N2-yl adducts, and six other adducts 
described as DHP- modified dinucleotides. Using a 32P-postlabelling/High performance liquid 
chromatography (HPLC) system, Yan et al.258 were able to detect these adducts in the pooled blood 
samples of groups of rats exposed to riddelliine, indicating that reactive metabolites bind to 
leukocyte DNA, providing a potential non-invasive biomarker of PA exposure. 
P 
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Mattocks and Jukes259, 260 have developed a technique for releasing the S-conjugated pyrroles in the 
form of ethyl ethers, which are relatively simple to extract and detect by chromatography and mass-
spectrometry. The technique has been applied to experimental rats260 and pigs261, and has 
successfully diagnosed PA poisoning in cattle262, horses262, and yaks263. Whole blood has been mainly 
assayed as the pyrrolic metabolites react with the red cells, binding to the thiol groups on 
haemoglobin. The thioester bond is broken by silver nitrate in the presence of ethanol, to form low 
molecular weight ethoxy-pyrroles which may be identified by thin-layer chromatography (TLC), GC-
MS and HPLC (Figure 6-1).  
 
Figure 6-1: Schematic of metabolism and reaction pathways of PAs, including the release of tissue bound pyrrolic 
metabolite as a detectable pyrrolic ether derivative (PDE). Reproduced from
261
. 
Efforts to develop the technique to give a quantitative measure of PA exposure have proved 
unsuccessful261 and the technique has proved fairly insensitive. Mattocks and Jukes260 were able to 
detect a pyrrolic diethyl ether (PDE, 7-Ethoxy-l-ethoxymethyl-6,7-dihydro-5H-pyrrolizine) by TLC in 
the 4 ml blood sample of rat a exposed to 500 mg/kg indicine (an isomer of lycopsamine) 24 hours 
earlier, but not in a rat exposed to only 150 mg/kg. The studies that detected previous PA exposure 
in horses and yaks used samples of blood in excess of 10 ml. Recently, however Lin et al.146 
demonstrated previous PA exposure in a patient suffering from VOD, following mistaken ingestion of 
a PA-containing herb as a medicine. They used a new extension of the technique that extracted and 
detected in serum samples, a derivative of the PDE that had been reacted with Ehrlich’s reagent (4-
(Dimethylamino)benzaldehyde, DMBA) to improve ultra-violet detection. Their use of ultra-
performance liquid chromatography (UPLC) coupled to a quadrupole-equipped time of flight (QToF) 
mass spectrometer (MS) was able to considerably increase the sensitivity of the technique. 
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Experiments in rats showed that PA exposure was detectable by these means up to four weeks from 
exposure. 
6.2 Aims and objectives 
The ultimate aim of the work presented here was to detect PA exposure among HVLD patients. To 
achieve this I adopted a two pronged approach: To try both to detect unchanged acetyllycopsamine 
(AL) in urine samples and detect the extracted pyrrole metabolites from whole blood samples. 
Since I had collected a large number of urine samples (from 45 cases and 44 controls) I reasoned that 
AL itself might be detectable in some of the samples using a sufficiently sensitive UPLC-MS 
spectrometer.  As this PA was detected in samples of the staple food supply from Tseada Amba, 
residents were likely to be exposed daily to small quantities and so a fraction of AL that was not 
metabolized to other compounds may still have been present in the urine. A UPLC system coupled to 
a LCT (Liquid Chromatography Time of Flight) Mass spectrometer was available at the Department of 
Biomolecular Medicine (BMM) at Imperial College. This set-up has high sensitivity (analytes 
detectable at pico- to nanomolar concentrations) and enables accurate mass measurement, while 
also allowing high through-put analysis of many samples and is therefore generally used in the 
department for metabonomic profiling. 
Since there was a long queue to get time on this machine, I first proceeded with the development of 
the assay introduced by Mattocks and Jukes260 to extract and detect PDE from whole blood samples. 
This approach has the advantage of potentially being able to detect cumulative PA exposure many 
weeks previously by detecting metabolically activated PA. The method of detecting S-conjugated 
adducts was also preferred to attempting to detect DNA adducts since the quantity of haemoglobin 
in whole blood (approximately 150 mg/ml) was greater that the available DNA (approximately 5 
µg/ml). I had previously collected whole blood samples from HVLD cases (16 samples) and controls 
(8 samples) and planned to first develop a reliable assay using mouse blood samples (exposed to AL 
during the toxicology study presented in chapter 7) and then apply it to the human samples.  
After initiating the development of the assay to release and detect PDE, the paper of Lin et al.146 was 
published outlining the successful use of a related method to detect PA exposure in a Chinese VOD 
patient. The UPLC-QToF MS set up used in that study was also available at BMM and since the 
method of Mattocks and Jukes had proved rather unreliable and insensitive in my hands, I decided 
to develop this method on the more readily available LC-MS machine at the Chemovation 
laboratories in Horsham where I undertook the work, while waiting for either of the more sensitive 
UPLC-MS machines at BMM to become available for my use. 
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The specific objectives were therefore: 
Approach 1: Detect pyrrole-protein adducts in whole blood of HVLD cases, by either pursuing the 
method of Mattocks and Jukes: 
 Synthesise a PDE reference standard 
 Determine the detection limit and standards curve for PDE 
 Extract and detect PDE in blood samples from mice exposed to AL 
 Apply the developed assay to HVLD case and control samples. 
Or subsequently by pursuing the related method of Lin et al: 
 Synthesise a PDE-DMBA reference standard 
 Develop an assay to extract and detect PDE-DMBA in whole blood 
 Apply the developed assay to HVLD case and control samples. 
Approach 2: Detect AL in the urine samples of HVLD cases and controls by: 
 Detect an AL standard on the UPLC-MS setup and record its retention time (RT) 
 Detect  an  ion with the characteristics of the AL produced ion in HVLD case (and control) 
urine samples 
 Perform a spike-in experiment in a single patient urine sample to confirm that the detected 
ion is produced by AL 
 Determine if there is a statistically significant difference in the relative ion intensity of the 
AL-associated ion between cases and controls. 
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6.3 Methods 
6.3.1 Pyrrolic Adduct Extraction Assays 
All reagents used in this assay were acquired from Sigma-Aldrich (UK). Two slightly different 
methods were pursued to detect the formation of S-conjugated pyrroles in the blood. The first relied 
on the detection of released pyrroles as the pyrrolic diethyl diester (PDE), while the second 
introduced an additional derivatization step by reacting PDE with Ehrlich’s reagent (4-
(Dimethylamino)benzaldehyde, DMBA) to produce the more easily detectable product PDE-DMBA. 
6.3.1.1 Synthesis of pyrrolic diethyl ether (PDE) reference standard 
A reference standard of the PDE (7-Ethoxy-l-ethoxymethyl-6,7-dihydro-5H-pyrrolizine) which is 
released following cleavage of the thiol bond, was prepared first by preparation of 
dehydromonocrotaline (DHM), essentially following the method of Mattocks et al.264, that was then 
converted to PDE using a method adapted from Culvenor et al.265. The quinone o-chloranil is used to 
oxidize the starting material monocrotaline and has several properties that make it useful for this 
purpose; it readily dissolves in organic solvents, reacts rapidly and its breakdown products are easy 
to remove. Furthermore it produces a strong colour that enables the reaction to be tracked as it 
proceeds. The unreacted o-chloranil is then removed using a cooled KOH (70%) and sodium 
borohydride (2%) solution. The DHM in then stirred in ethanol for five hours, by which time the 
macrocyclic  structure attached to the pyrrolic ring system is replaced by two ether groups (Figure 
6-2). 
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Figure 6-2: Reactions involved in the production of the pyrrolic diethyl ether (PDE) reference standard. 
The steps in the synthesis were as follows: 
1. 2.8g of KOH was dissolved in 4 ml water and kept on ice until use. 
2. 80 mg of monocrotaline was dissolved in 20 ml of chloroform. 
3. 100 mg of o-chloranil was dissolved in 20 ml of chloroform, giving a deep red solution. 
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4. The monocrotaline and o-chloranil solutions were added together and mixed well in a 
separating flask. A flash of orange colour could be seen with careful observation on mixing. 
5. 80 mg of NaBH4 was added to the cooled KOH solution. 
6. The KOH/ NaBH4 solution was then added to the reaction mixture in the separating flask and 
shaken for 10-15 seconds, turning the mixture a blue/green colour. 
7. The green aqueous phase was removed and the bluish organic phase washed three times 
with water until all colour was removed. 
8. The organic phase was dried with Na2SO4, filtered and the solvent removed under reduced 
pressure using a rotary evaporator. 
9.  8 ml of absolute ethanol was then added to the residue and then stirred in the dark for 5 
hours.  
10. An excess of water was added and the solution extracted with chloroform. The organic 
phase was then dried with Na2SO4 and the solvent then removed under reduced pressure, 
giving a few mg of brown product. 
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6.3.1.2 Synthesis of pyrrolic diethyl ether coupled to Ehrlich’s reagent (PDE-DMBA) reference 
standard 
The method that successfully detected PA exposure in a Chinese patient146 also converts DHM to the 
PDE, but introduces an additional step where Ehrlich’s reagent (4-(Dimethylamino)benzaldehyde, 
DMBA) is attached to the pyrrole ring catalysed by the presence of boron trifluoride etherate. DMBA 
is a strong chromophore, allowing clear ultraviolet detection of the product, which should increase 
sensitivity and reduce the need for extensive product clean-up (Figure 6-3). 
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Figure 6-3: Reactions involved in the synthesis of PDE-DMBA reference standard. 
The steps in the synthesis, following the method of Zhang et al.147 are as follows: 
1. 20 mg of monocrotaline was dissolved in 10 ml of chloroform. 
2. 50 mg of o-chloranil was dissolved in 5 ml of chloroform. 
3. The solutions were mixed together for 5 minutes, giving a blue colour. 
4. A solution of 100 mg of DMBA in 50 ml of absolute ethanol was prepared, to which 1 ml of 
BF3·O(Et)2 was added. 
5. The solutions were added together and left at room temperature for four hours to give a 
final purple colour. 
6.3.1.3 Detection of PDE 
TLC was initially used to detect PDE, which could be visualized using Ehrlich’s reagent to give 
distinctive purple spots on reaction with the pyrrole ring. No reaction occurs with the pyrrolizidine 
ring system of the starting material. The TLC was run on silica-coated aluminium sheets of around 65 
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mm in length using a solvent system of 4:1 hexane: acetone. The spots were visualized by spraying 
with pre-prepared Ehrlich’s Solution (DMBA in HCl solution, Fluka) followed by gentle heating. 
The product was analyzed using the following LC-MS system: LC conditions: 10μl of sample was 
injected into a Genesis, C18 50 x 4.6 mm (4.0μm) column and eluted for 10 minutes, at 1.00 ml/min 
using the mobile phase; A% 0.1% formic acid in H2O; B% 0.1% formic acid in acetonitrile, with a 
gradient of T 0 mins- B% 95; T 7 mins- B% 5%; T 10 mins- B% 5%. The diode array detected at 
ultraviolet wavelength of 210nm-400nm.The autosampler was at ambient temperature and the 
column temperature was 25°C. MS conditions: A single quad Micromass ZMD was run in positive 
mode at pressure <1.0x10-4 mBar. The source block temperature was 80 °C and the desolvation 
temperature was 250 °C. The LM Res and HM res were both set to 12.5 and the ion energy was set 
to 0.5. 
Confirmation of the identity of the product was made using 1H NMR spectroscopy on a Bruker 
Avance II NMR spectrometer (Bruker Biospin, Rheinstetten, Germany) operating at a 1H frequency of 
400 MHz. The standard nuclear 1D NOESY pulse sequence was used with an acquisition time of 
2.04s. 64 scans and 4 dummy scans were collected into 32k data-points with a spectral width of 20 
ppm. An exponential line broadening function of 0.3 Hz was applied to each FID prior to FT. 
6.3.1.4 Construction of PDE Standard curve 
To determine the detection limit of the LC-MS system, a stock solution of 200 µg/ml of PDE in 
chloroform, was serially diluted 1:1 with chloroform and the diluted solutions analyzed on the LC-MS 
machine, until PDE could be longer be detected. A standard curve was constructed using the known 
concentrations and the PDE chromatographic peak intensities, detected using the ion channel of the 
MS machine.  
6.3.1.5 Detection of PDE-DMBA 
The PDE-DMBA reference standard was analysed using the same LC-MS system outline above, 
except the diode array was set to detect at 480-560 nm and the run time was 5 mins. 
6.3.1.6 PDE Extraction from blood of mice exposed to AL 
Male C57BL/6J strain mice were exposed to various dosing regimens of acetyllycopsamine (AL) as 
part of the toxicology study that is presented in chapter 7. On sacrifice, whole blood was removed by 
cardiac puncture under general anaesthetic (Isoflurane-vet 100% w/w inhalation vapour).  Blood was 
collected into lithium-heparin tubes (Microvette CB300, Sarstedt, Germany), and the blood cells 
were separated from plasma by centrifuging at 5000 rpm for 10 minutes on a benchtop micro-
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centrifuge. The red blood cells (RBCs) and any plasma not required for LFTs were reserved for the 
purposes of this assay and kept at -80°C until use. The steps in the extraction assay were as follows: 
1. The RBCs were first homogenised in approximately 10 ml of acetone using a TissueLyser 
machine (QIAGEN). 
2. The homogenate was centrifuged and the supernatant was discarded.  
3. Ethanol (approximately 6 ml) was added to the residue and shaken together to wash. The 
mixture was centrifuged and the supernatant discarded. 
At this point the remaining cell pellets were transported on ice packs from the Imperial College 
London laboratories to the Chemovation laboratories in Horsham. 
4. The pellets were re-suspended in ethanolic AgNO3 (0.25g AgNO3 first dissolved in a minimum 
of water and then added to 10 ml ethanol) 
5. The solution was acidified by the dropwise addition of ethanolic 5% trifluracetic acid to 
adjust the pH to approximately 4, and stirred at room temperature for 1 hour. 
6. 2.5 ml of 10% aqueous K2CO3 was added and mixed. 
7. The mixture was then vacuum filtered and the liquid rotary evaporated to a gum. 
8. The gum was re-dissolved in water and extracted x 3 with Et2O.  
9. The combined extracts were then dried with Na2SO4 and rotary evaporated.  
Any PDE present was detected using the TLC and LC-MS.  
6.3.1.7 Development of PDE-DMBA blood extraction assay 
Since all available blood from mice exposed to AL had been used in the development of the PDE 
extraction assay, more test material for the development of the PDE-DMBA extraction assay was 
made by first reacting screened whole human blood with DHM in an effort to recreate the sulphur 
conjugated bonds found in humans exposed to PAs. Blood was obtained with informed consent from 
a patient receiving phlebotomy therapy at the regular hemochromatosis clinic at St. Mary’s Hospital, 
London. DHM, prepared as described in steps 1-8 of section 6.3.1.1 above, was reacted with the 
blood following the method of Mattocks et al.259, outlined below: 
1. Freshly prepared DHM was dissolved in 1 ml of dimethoxyethane. 
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2. The solution was mixed with 20 ml of blood and shaken at room temperature for 10 minutes 
and frozen until use. 
The reacted blood samples (and an un-reacted sample used as a blank) were then subjected to the 
PDE-DMBA extraction process as described by Lin et al.146 The samples were homogenised and 
washed as described in steps 1-3 of section 6.3.1.6 above at Imperial College London, and the cells 
pellets then transported on ice packs to the Chemovation Laboratories for the remaining steps, 
detailed below: 
1. A blood cell pellet from both reacted blood and blank blood was reconstituted in 10ml of a 
2% ethanolic AgNO3 solution. One blood pellet was also reconstituted in 10 ml of absolute 
ethanol only (to control against any positive results being due to reaction with free DHM, 
rather than the action of the AgNO3 on the S-conjugated pyrrole bonds). 
2. The three reaction mixtures were acidified to pH 4 with ethanolic 5% trifluracetic acid and 
shaken for 30 mins at room temperature. 
3. The mixtures were centrifuged and the supernatant mixed 4:1 (v/v) with an ethanolic DMBA 
solution containing 1% percholic acid (made from 20 mg DMBA and 0.1 ml percholic acid in 
9.9 ml absolute ethanol). 
4. The reaction mixture was then stirred for 10 minutes at 55 °C. 
The mixture was then analysed for the presence of PDE-DMBA using LC-MS. 
6.3.2 UPLC-MS Urine Analysis 
6.3.2.1 Sample preparation 
Urine samples had been collected over two visits to Ethiopia and stored until use at -80 °C 
(Collections and patient diagnoses detailed in chapters 3 and 5). After defrosting, 100 µL of each 
sample was mixed with 100 µL of HPLC grade water (Romil, UK) and centrifuged at 13,000 rpm on a 
bench top centrifuge for 5 minutes. The supernatant was then transferred into the well of a 96-well 
plate. A quality control (QC) was prepared by mixing equal parts of the supernatant from all the 
diluted urine samples, and added to two wells of the well plate. 
Reference standards of AL were prepared from a racemic mixture of acetyl-lycopsamine and its 
isomer acetyl-intermedine, extracted from the plant Symphytum Officinale and supplied by Planta 
Analytica, USA. The acetyl-(lycopsamine/intermedine) extract  was dissolved in HPLC grade water or 
Molecular Biology grade methanol (Sigma, UK) to make 2 solutions of 1 mg/ml. These were then 
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serially diluted 20 times to give a final concentration of 50 µg/ml and were added to the same well-
plate as the urine samples.  
6.3.2.2 UPLC-MS conditions 
Instrument parameters were set-up following a standard urinary protocol266. Samples (5 µL) were 
injected onto a 2.1 × 100 mm (1.7 µm) HSS T3 Acquity column (Waters Corp., Milford, MA) and 
eluted using a 12 min gradient of 100% A to 100% B (A , HPLC grade water, 0.1% formic acid (Sigma, 
UK); B, acetonitrile (Sigma, UK), 0.1% formic acid), with the last 2 min as column re-equilibration. 
Samples were analyzed using a UPLC system (UPLC Acquity, Waters Ltd., Elstree, U.K.) coupled 
online to a LCT Premier mass spectrometer (Waters MS Technologies, Ltd., Manchester, U.K.) in both 
positive and negative electrospray modes with a scan range of 50-1000 m/z. Capillary voltage was 3 
kV, sample cone was 30 V, desolvation temperature 350 °C, source temperature 120 °C, and 
desolvation gas flow 800 L/h. Instrument set-up for accurate mass and calibration was carried out 
prior to analysis, according to the manufacturer guidelines. To stabilize retention times (RT), 10 
injections of the QC was ran at the beginning of the analysis to condition the system, and 
subsequently the QC sample was run every 10 samples to check measurement stability. 
6.3.2.3 Data Analysis 
Mass spectra and chromatograms were created using the MassLynx ver. 4.1 software (Waters, USA). 
Raw data files were imported into the XCMS package267 in the ‘R’ statistical software (ver. 2.11, 
http://www.r-project.org/). XCMS incorporates an algorithm for nonlinear RT alignment, matched 
filtration, peak detection, and peak matching in order to identify metabolite signals within the 
sample. Metabolite peaks are detected from extracted ion chromatograms using a signal to noise 
ratio cut-off of 10 and RTs are aligned across samples, to provide a matrix of RT-m/z pairs along with 
their relative metabolite ion intensities for each sample. The intensities for each peak were then 
normalised (to account for concentration differences) by dividing by the sum of all peak intensities 
for each sample and multiplying by 106. 
Statistical analysis of the normalised relative ion intensities for the RT-m/z peak corresponding to AL, 
was conducted using STATA ver. 10.1 (Stata Corp., USA). The Wilcoxon rank sum test was used when 
comparing samples from HLVD patients to one group of controls and an extension of the Kruskal-
Wallis test was used to compare the trend in intensities across all three samples classes. Controls 
were classified as asymptomatic individuals either sharing a household with a HVLD patient 
(household control) or living in a household free from the disease (village control). Regression 
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models were constructed using the logarithm of the ion intensity as the dependent variable, since it 
was normally distributed at this scale. 
6.3.2.4 Spike-in experiment 
To confirm that the RT-m/z peak corresponding to AL across samples was is in fact produced by AL 
(within the same analytical run), an experiment where the AL standard was spiked into a sample was 
performed. One sample was chosen with a high AL-associated RT-m/z peak intensity and rerun 
under the same conditions both before and after 1 µL of an aqueous 10 µg/ml AL solution was 
spiked into 1ml of the sample. 
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6.4 Results 
6.4.1 Pyrrole Adduct Extraction Assays 
6.4.1.1 PDE Reference Standard 
The identity of the PDE reference standard was confirmed by the fragmentation pattern on LC-MS 
and its 1H NMR spectra (Figure 6-5) corresponding to published data259. PDE produced a 
chromatographic peak at a RT of 3.76 minutes. The mass spectrum showed characteristic ion 
fragments at 120, 136, 164 and 204 m/z, although the intact PDE ion at 209 m/z was not produced in 
the LC-MS system used (Figure 6-4). The compound was chemically stable and showed little 
degradation after six weeks storage in CCl4 and kept at 4 °C in the dark.  
 
Figure 6-4: LC-MS analysis of PDE reference standard. Top: chromatogram using diode array detector, Middle: 
chromatogram using ion channel detector. PDE elutes at around 3.7 mins and CCl4 solvent elutes at around 5.4 mins. 
Bottom: Mass spectrum at 3.7 mins showing characteristic fragment pattern of PDE. 
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Figure 6-5: 1H NMR Spectra of PDE standard with characteristic peaks labelled with associated proton. 
6.4.1.2 PDE Standard Curve 
PDE was only weakly detectable using the diode array detector of the LC system, but when the ion 
channel of the mass spectrometer was used as detector, PDE could be measured at levels as low as 
6.25 µg/ml. A standards curve constructed from known concentrations of PDE (r2=0.99) showed 
good correlation to chromatographic peak area (Figure 6-6). TLC with staining by Ehrlich’s reagent 
could detect PDE at levels as low as 125 µg/ml, and was actually a more sensitive method than 
detection with LC using the diode array. 
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6.4.1.3 Detection of PDE in mouse blood samples 
The assay to release and detect S-conjugated pyrrole adducts as PDE from samples of mouse blood 
was performed on 9 separate blood samples, some of which were pooled together to increase the 
volume of material available for the assay development (Table 6-1).  The assays were performed 
each time alongside an equivalent volume of sample from a control mouse (that had not been dosed 
with AL) that served as a blank. No PDE could be detected by TLC (Figure 6-7). PDE could be detected 
by LC-MS in only trace quantities for one sample only, collected from a mouse that had been 
exposed to a single dose of 1500 mg/kg AL 24 hours earlier. The concentration of PDE present was 
below the measurable limit of 6.25 µg/ml but chromatograms produced following selective ion 
monitoring at 120, 164 and 204 m/z, the main fragment ions of PDE, showed a discernable peak at 
the expected RT of around 3.73 minutes. No discernable peaks could be detected at this retention 
time when ions not produced by PDE were selected (Figure 6-8).  
Figure 6-6: PDE standards curve. Left: Graph showing relationship of PDE concentration to chromatographic peak 
intensity. Right: Chromatograms of PDE standard starting at concentration of 200 µg/ml at bottom and halving in 
concentration for each subsequent chromatogram until 6.25 µg/ml is reached shown at top. 
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Table 6-1: Summary of blood samples collected from mice dosed with AL, and assayed for the presence of PDE. See 
chapter 7 for details of dosing. 
AL Dose details  Time of sampling Total 
volume 
blood 
collected 
(ml) 
Result of 
assay by 
TLC 
Result of 
Assay by 
LC-MS 
1 x 100 mg/kg 24 and 48 hour post dose 
samples (pooled together) 
0.75 Negative Negative 
1 x 250 mg/kg 48 hours post dose 0.75 Negative Negative 
1 x 500 mg/kg 24 and 48 hour post dose 
samples (pooled together) 
0.75 Negative Negative 
1 x 1000 mg/kg 24 and 96 hour post dose 
samples (pooled together) 
0.75 Negative Negative 
8 x 500 mg/kg 48 hours post last dose of 28 
day chronic dosing study 
0.50 Negative Negative 
8 x 500 mg/kg 48 hours post last dose of 28 
day chronic dosing study 
0.20 Negative Negative 
Pooled chronic samples (8 samples collected from the two 
chronic dosing studies at different time points) 
1.20 Negative Negative 
1 x 1500 mg/kg 24 hours post dose 0.60 Negative Positive 
Pooled samples collected 
from 6 mice, each  
receiving 1 x 1500 mg/kg 
24 hours post dose 3.00 Negative Negative 
 
 
Figure 6-7: TLC plate stained with Ehrlich's reagent. '+' spot shows extraction product from single mouse dosed with 1500 
mg/kg AL. Brown staining is oily residue not removed during clean-up. '-' shows extraction product of mouse not dosed 
with AL. 'Std' spot is PDE standard that produces a purple colour on staining with Ehrlich’s reagent. The highest purple spot 
is produced by PDE itself. 
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Figure 6-8: LC-MS analysis of blood extraction of PDE from mouse dosed with 1500 mg/kg AL. Top: 
Chromatogram with selective ion monitoring at 195 m/z (not a fragment ion of PDE) showing no discernible 
signal. Middle three: Chromatograms with selective ion monitoring at 164, 120 and 204 m/z (main fragment ions 
of PDE) showing weak signals at around 3.72 mins. Bottom: Chromatogram of assay product without selective 
ion monitoring. 
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6.4.1.4 PDE-DMBA reference standard 
The identity of the PDE-DMBA reference standard was confirmed by LC-MS (Figure 6-9). The 
compound eluted at 3.08 minutes and gave a strong signal using the diode array detector. The mass 
spectrum for this peak showed an ion at 341.2 m/z, corresponding to the expected monoisotopic 
mass. 
 
 
The compound was not stable chemically and after storage for 72 hours in the dark at -20°C, it could 
no longer be detected, with the LC chromatogram instead dominated by a the signal for free DMBA 
(Figure 6-10). 
Figure 6-9: LC-MS analysis of PDE-DMBA reference standard immediately after synthesis. Top: Chromatogram showed 
PDE-DMBA signal at 3.08 mins. Bottom: Mass spectrum at 3.08 mins showing PDE-DMBA ion at 341.2 
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Figure 6-10: Chromatogram of PDE-DMBA reference standard, after cold storage for 72 hours. Only a signal at 3.27 mins 
for free DMBA itself is visible. 
6.4.1.5 Development of PDE-DMBA blood extraction assay 
Efforts to develop the PDE-DMBA blood extraction assay were not successful. The assay procedure 
was performed on human blood reacted with DHM and control human blood (not reacted with 
DHM). A modified assay procedure that omitted the AgNO3 was also performed on a sample of 
human blood reacted with DHM.  The results of analysis by LC-MS were similar for all three 
reactions; no peak corresponding to PDE-DMBA could be detected and instead the main peak 
detected was free DMBA (Figure 6-11) 
 
Figure 6-11: Chromatogram of reaction mixture following attempted PDE-DMBA extraction of human blood reacted with 
DHM. 
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6.4.2 UPLC-MS Urinary Analysis 
6.4.2.1 AL Reference Standard 
Al eluted in positive mode at approximately 3.9 mins (Figure 6-12). The m/z spectrum at this RT 
shows a dominant ion at 342.19 m/z (Figure 6-13), which corresponds to the calculated 
monoisotopic mass of 341.18 for AL. Similar results were obtained when the compound was 
dissolved in methanol or water. 
 
Figure 6-12: Chromatogram of AL dissolved in water. Largest peak occurs at around 3.9 mins. Other peaks likely to 
correspond to impurities and polymerisation occurring during the analysis. 
 
Figure 6-13: m/z spectrum at 3.9 RT. Dominant peak at 342.19 corresponds to expected m/z of AL 
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6.4.2.2 Detection of AL signal in urine samples 
UPLC-MS data was acquired from 45 HVLD case samples, 25 household control samples and 18 
village control samples. A signal corresponding to the RT-m/z of AL was detected in the majority of 
urine samples (Figure 6-14). The median relative ion intensity for this RT-m/z peak was significantly 
greater among HVLD patients than village controls (p=0.006) or all controls combined (p=0.02). No 
significant difference was found between HVLD cases and household controls (p=0.33). There was 
good measurement stability for this peak since the standard measurement error calculated from 8 
runs of the QC sample over the course of the whole analytical run was 1.5% (Figure 6-15). A 
significant trend (p=0.007) was observed with the greatest median intensity among HLVD cases, 
which was higher than among household controls, which in turn were higher than among village 
controls (Figure 6-16).  
 
Figure 6-14: Extracted ion chromatograms with selective ion monitoring at m/z 341.18. Top four chromatograms are 
from patient urine samples, bottom two are from acetyl‐lycopsamine standards. Note peaks corresponding to AL at 3.9 
mins RT. 
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Figure 6-15: Comparison of distributions of ion intensity of RT-m/z peak (3.9 mins, 342.2 m/z) associated with AL in urine 
collected from cases and controls. Box shows interquartile range and line within box shows median value. Circles show 
outlier values. N of cases= 45, N of controls= 43, N of Quality Control (QC) replicates = 8. A.U. = arbitrary units. P value 
calculated from Wilcoxon rank test comparing cases and controls. 
 
Figure 6-16: Comparison of distributions of ion intensity of RT-m/z peak (3.9 mins, 342.2 m/z) associated with AL in urine 
across sample classes. Box shows interquartile range and line within box shows median value. Circles show outlier values. 
N of cases= 45, N of household controls= 25, N of village controls = 18. A.U. = arbitrary units. P value for trend calculated 
from Kruskal-Wallis test with samples ordered cases =1, household controls =2, village controls =3. 
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6.4.2.3 AL Spike-in experiment 
The spike-in experiment confirmed that the AL associated RT-m/z peak is produced by AL. The 
relative ion intensity at 342 m/z increased from 10% (of 340 m/z intensity) before the AL standard 
was spiked-in, to 49% after the spike-in (Figure 6-17).  
 
Figure 6-17: Spike-in experiment, showing m/z spectra at ca. 3.85 mins RT. Top: AL standard, Middle: Patient urine 
sample before AL spike in, Bottom: Same patient urine sample after AL spike-in. Note ion at 342 m/z in standard and its 
increase in relative intensity after spike-in 
6.4.2.4 Adjustment for potential confounding of AL signal 
A possible confounder of these results is the presence of an ion at 341 m/z of greater intensity than 
the ion at 342 m/z, and eluting at the same RT, in 66% of samples. This can be seen in the pre-spike-
in patient sample in Figure 6-17. This suggests that in some samples the RT-m/z ion that is produced 
by AL, may also be produced by a different compound which ionises at an m/z of 341 (or 340). This is 
because the m/z spectrum acquired under these conditions for a given compound, typically includes 
an ion at greatest intensity equivalent to its protonated molecular weight (divided by its charge of 
+1), plus ions at 1 or 2 m/z higher. These ions result from a proportion of the compound measured 
containing 1 or 2 low abundance 13C atoms, and therefore having a greater molecular weight. 
To explore this potential confounding effect, median intensities of ions at 341 m/z and 343 m/z (that 
had the same RT as AL) were compared between cases and controls. A 341 m/z ion is not produced 
STANDARDPAINH20
m/z
338 339 340 341 342 343 344 345 346 347
%
0
100
%
0
100
%
0
100
OJKR_290611_STANDARDPAINH20 534 (3.870) Cm (524:546) 1: TOF MS ES+ 
2.16e6342.19
341.27340.36339.69337.96 338.86
343.20
344.18 345.18 346.04 347.01
OJKR_290611_SAMPLE48_3 534 (3.845) Cm (519:543) 1: TOF MS ES+ 
7.79e4340.17
339.21338.19 338.70
341.17
342.16
346.20343.15 345.13344.15 345.67 347.17
OJKR_290611_sample48withfreshspikei 533 (3.839) Cm (520:555) 1: TOF MS ES+ 
1.03e5340.18
339.21338.18 338.69
342.19
341.18
341.69
343.18 346.20344.17 345.17
345.69
347.16
188 
 
at significant levels by the ionisation of AL, while the 343 m/z ion is produced by AL (that contains 1 
13C atom) but only a very small amount will be produced by the confounding compound. While there 
was no significant difference in the median intensity of the 341 m/z ion between cases and controls 
(p=0.33) a significant difference was detected at ion 343 m/z (p=0.04) (Figure 6-18). This suggests 
that the significant difference observed between cases and controls observed in the ion intensity at 
342 m/z, is driven by a difference is urinary AL concentration between cases and controls 
 
 
 
Any confounding by this other compound of the association observed between the AL-associated ion 
and HVLD was adjusted for statistically using a multiple regression model that incorporated the 
relative intensities of the RT-m/z ion at 3.9 mins-341 m/z. This ion would be expected to have 
correlation close to 1 with the potentially confounding daughter ion at 342 m/z and so could be used 
as an indicator of its intensity in the model. Three different models were built using the logarithm of 
the AL-associated relative ion intensity as the response variable. A significant association (p= 0.018) 
was observed in the first univariate model with only disease status (either HVLD case or not) 
included as an explanatory variable. The second model adjusted for the 341 m/z relative ion 
intensity by incorporating it as an additional explanatory variable and a significant association was 
still observed with HVLD status (p= 0.023). The final model tested for the trend for increasing AL 
concentration among HVLD cases compared to household controls and in turn compared to village 
controls. This model included three ordered categories of disease status (HVLD case, household 
control and village control) and also adjusted for the 341 m/z relative ion intensity. A significant 
trend for increasing AL-associated ion intensity could still be detected (p=0.010). The model results 
are summarised in Table 6-2. 
Figure 6-18: Comparison of ion 341 m/z and 343 m/z intensities (at 3.9 mins RT) between case and control urine 
samples. Box shows interquartile range and line within box shows median value. Circles show outlier values. N of cases= 
45, N of controls= 43, A.U. = arbitrary units. P value calculated from Wilcoxon rank test.  
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Table 6-2: Summary of regression models using the logarithm of the AL-associated relative ion intensity as the 
dependent variable. Units used are arbitrary. Number of samples = 89. 
 Explanatory Variable Coefficient 95% CI p value 
Model 1: 
 Disease status:  
(case=1, control=0) 
0.56 0.10-1.02 0.018 
Intercept 4.16 3.83-4.50 - 
Model 2: 
 Disease status:  
(case=1, control=0) 
0.53 0.09-0.99 0.028 
3.9mins-341m/z relative ion 
intensity 
0.00 0.00-0.00 0.106 
Intercept 3.97 3.56-4.38 - 
Model 3: 
 Disease status: 
(village control=1,  
household control=2,  case=3) 
0.35 0.09-0.61 0.010 
3.9mins-341m/z relative ion 
intensity 
0.00 0.00-0.00 0.120 
Intercept 3.46 2.80-4.13 - 
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6.5 Discussion 
6.5.1 UPLC-MS Urinary analysis 
The UPLC-MS analysis has provided good evidence that the urinary concentration of AL is greater 
among cases than controls, suggesting that HVLD cases are more heavily exposed to AL. An ion that 
is produced by AL, was found to have significantly greater intensity among cases than among 
controls. A greater intensity was also found among household controls, who share a food supply 
with cases, than among village controls. Although in many samples, an unknown compound may 
also produce this ion, the fact that a significant difference was also observed for the ‘daughter ion’ 
of AL, but not for the ‘parent’ ion of the co-eluting ion, suggest that the potential for confounding, 
the observed difference does in fact reflect an actual difference in AL concentration. This was 
confirmed by the significant difference still being observed after statistical adjustment for the 
confounding ion.  
The AL signal could be detected, albeit at lower levels, among household and village controls. This 
may be expected due to the widespread distribution of A. conyzoides and suggests that some of the 
participants enlisted as controls may also eventually develop HVLD, with sufficient cumulative 
exposure. It was interesting that household controls had generally lower levels of AL than cases 
(although not significantly so) despite sharing a contaminated food supply. This points to particular 
dietary habits, which differ within households, being protective against AL exposure. Some 
differences in the consumption of certain products such as sua (beer made from millet) and dairy 
were reported during the household interviews presented in chapter 4. It was also shown during the 
recent Afghan outbreak that cases consumed a significant greater proportion of bread in their diet 
than controls who shared the same household. 
The UPLC-MS urinary profiling presented here is a novel method of detecting PA exposure. It is most 
suitable for situations of suspected contamination of the staple food supply where cases are likely to 
have daily exposure to PAs and relies on prior identification of the candidate PAs. It also requires a 
high sensitivity analytical platform. This method may be less suitable for more lipophilic PAs since 
less unchanged parent PA would be present in the urine. Conversely these PAs are more easily 
detectable using pyrrole extraction methods260 since a greater portion is metabolised to reactive 
forms. One drawback of comparing levels of unchanged PA between case and control is that slow PA 
metabolizers who would be more resistant to its effects, would also have more unchanged PA 
present in the urine than a fast metabolizer with the same levels of exposure. This could potentially 
obscure the true exposure differences between cases and controls (and household controls in 
particular). 
191 
 
The ‘gold standard’ of compound identification would include a tandem mass spectrometry analysis, 
which would give additional fragmentation and therefore structural information that could be 
compared with the fragmentation pattern of the AL standard. Although this may be possible, with 
access to a quadrupole-equipped mass-spectrometer of sufficient sensitivity, the problem of the 
confounding compound in the majority of samples would remain. Ultimately the only way to confirm 
PA exposure among HVLD cases with absolute certainty may be to repeat the analysis using 
lycopsamine (that was also detected in grain supplies and may be a metabolic product of AL), 
assuming that it is not similarly confounded, or further develop a pyrrole-adduct assay.   
6.5.2 Pyrrolic Adduct Assay 
Although the development of the assay to free and detect S-conjugated pyrrole metabolites 
successfully detected PA exposure in one mouse exposed to a large dose of AL (1500 mg/kg) 24 
hours earlier, it was not considered reliable enough to perform on stored human whole blood 
samples. The assay was repeated on pooled blood samples (with a total volume closer to the volume 
of human samples) from a group of mice that received the same dose of AL, without success 
showing the inconsistent nature of the assay. There were some differences observed within the 
reaction process between these two attempts. In the first successful assay, a much greater quantity 
of trifluracetic acid was required to adjust its pH of the ethanolic AgNO3 solution to 4, than in any of 
the other attempts. This may have been due to a problem with the litmus paper used to check the 
pH or this reaction mixture being more basic initially. It is reported by Mattock et al.259 that a 
sufficiently acidified environment is required to catalyse the conversion of a pyrrolic mono-ether 
intermediary to the PDE, and therefore perhaps only this reaction mixture was sufficiently acidic. 
Another difference between the two assay attempts was that after the vacuum filtration step, the 
filtrate from the successful attempt still had some red colour, while the unsuccessful attempt did 
not. This may reflect different solubilities between the reaction mixtures and it is possible the PDE 
may have been removed (if present) at this step during the other attempts. In the methods reported 
by Mattocks and Jukes260, centrifugation was used instead of filtration at this step and may have 
been more suitable.  
Lin et al.146 successfully demonstrated PA exposure in Man using the approach of extracting and 
detecting S-conjugated pyrrole metabolites. Following their methods it was found that that the 
reference standard could be synthesised in relatively few steps (although it requires the use of the 
very toxic and corrosive BF3) and be more easily detected than PDE without the DMBA 
derivatization.  Attempts to develop my expertise in their methodology were hampered by a lack of 
blood from exposed animals to use as test material. Although I was unable to extract and detect 
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PDE-DMBA from blood samples reacted with DHM it was not clear whether the fault lay with the 
extraction method, the instrument sensitivity or the blood incubation with DHM. Since at this point 
in my research the UPLC-MS urinary analysis had proved successful, it was decided not to pursue this 
approach any further. 
It is apparent from both my research and the work of Lin et al. that at present analytical platforms of 
high specifications are required to detect PA exposure among humans through the analysis of 
biofluids. The approach of detecting pyrrole protein adducts does have great promise however since 
it does not require prior knowledge of the identity of the candidate PAs, is a measurement of 
metabolically activated (and toxified) PA and can show exposure many weeks previously. Mattocks 
and Jukes were able to show PA exposure in a rat 24 hours after it had received just 9 mg/kg of 
retrorsine and in a group of rats 17 days after receiving approximately 2.25 mg/kg/day 
monocrotaline over 25 days, through TLC detection of PDE extracted from the blood. Therefore 
improvements to the extraction process such as by improving the silver nitrate reagent or finding a 
better trapping agent than ethanol may allow human PA exposure to be detected with more readily 
available analytical platforms. This would be desirable since PA outbreaks could be confirmed within 
developing countries where the outbreaks more often occur.  
6.5.3 Strengths and limitations 
The research presented here has highlighted the need for analytical instruments of high sensitivity in 
order to detect PA exposure. The use of a quadrupole equipped UPLC-MS machine may have 
improved this study by allowing the detection of the pyrrole –protein adduct in HVLD blood samples 
and possibly provided additional fragmentation information regarding the AL associated ion 
detected in urine samples. 
However, through the novel use of a UPLC-LCT MS platform to detect unchanged PA in a large 
number of case and control urine samples, this study has provided good evidence that the urinary 
concentration of AL is significantly greater among HVLD cases than controls. 
6.5.4 Conclusion 
The urinary analysis supports the hypothesis that HVLD is caused primarily by exposure to AL (and 
other PAs detected in the food supply), at levels greater than received by controls. Although the 
detection of pyrrole-protein adducts was not reliable enough to apply to HVLD blood samples, the 
method does show some promise for further development. 
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7. Toxicology of Acetyllycopsamine 
7.1 Introduction 
hapter 2 has detailed the detection of PAs, mainly AL but also lycopsamine and its isomer 
intermedine, in the food stores of houses affected by HVLD. In the previous chapter, I 
showed that the concentration of a compound most likely to be AL, was significantly 
greater among urine samples from HLVD cases than controls. In chapter 3, the clinical presentation 
of HVLD was described, and while it showed many features of PA poisoning, the liver pathology 
observed was not typical of previous human cases.  
The effects of exposure to AL itself have never been previously tested in an animal model, while 
previous descriptions of the effects of lycopsamine and intermedine are inadequate. Exposure to 
lycopsamine and intermedine had no effects at the maximum tested doses of 60 and 120 mg/kg 
respectively in 14 day old rats188, while another isomer of these PAs, indicine, had no effect at doses 
of 1000 mg/kg in the adult rat116. A single oral dosage to rats with an alkaloidal fraction from 
Amsinckia intermedia, consisting mainly of lycopsamine and intermedine plus two other unidentified 
PAs, caused acute death at a dose rate of 1500 mg/kg, and chronic liver damage that is not 
described, at 500 mg/kg189. 
7.2 Aims and Objectives 
The overall aim of the work presented in this chapter is to determine whether exposure to AL is 
capable of causing liver injury in the mouse model that resembles HVLD. This will be judged using 
plasma liver function tests to measure liver inflammation, by characterization of the 
histopathological changes caused in the mouse liver and by describing the metabolic profile of mice 
following dosing. Specific objectives are as follows: 
1. Determine the dose levels required to cause liver injury (determined by plasma ALT level), 
through a pilot dose ranging study. 
2. Tests the effects of chronic dosing over 28 days. 
3. Test the effects of a single large dose. 
4. Describe the metabolic changes in the mouse urine, as measured by 1H NMR spectroscopy, 
following both chronic and acute dosing. 
 
C 
194 
 
7.3 Methods 
7.3.1 Animal Husbandry 
All work with mice was approved by the local ethics committee and was carried out under Home 
Office supervision in accordance with the Animal (Scientific Procedures) Act 1986 taking care to 
minimise any distress caused to the animal. Procedures were performed under the authority of 
licence 70/6943‘Mouse Models of Hepatic Fibrosis & Therapeutics’.  
Male inbred C57BL/6J strain mice, aged 6-10 weeks, were obtained from Harlan U.K. and were kept 
under controlled light (12 hour light/dark cycle), temperature (21±2°C) and humidity (55±10%) 
conditions in the Huggett CBS laboratories in St. Mary’s Hospital Campus, Imperial College.  They had 
free access to purified and sterilised water and were fed ad libitum on a standard commercial diet 
(‘RM1 diet’, SDS diets, UK).  
7.3.2 Dosing 
Mice were dosed with a mixture of acetyl-lycopsamine and its isomer acetyl-intermedine, extracted 
from the plant Symphytum officinale and supplied by Planta Analytica, USA. Henceforth this will be 
referred to as just AL. The identity of the compound was confirmed by NMR and LC-MS and was 
found to be approximately 99% pure (see appendix). The extract was dissolved in phosphate 
buffered saline prepared from sterilised water and administered by oral gavage. Doses were freshly 
prepared prior to dosing. Control mice received the same volume of phosphate buffered saline 
vehicle by oral gavage. Mice were weighed prior to dosing. 
7.3.3 Sampling 
Urine was collected at the same time of day (within 2 hours) either by free-catch or from extraction 
from the bladder after sacrifice and placed immediately on ice. 1% (weight/total volume) sodium 
azide was added and samples kept at -80°C until use. Mice were sacrificed by terminal 
exsanguination by cardiac puncture under general anaesthetic (Isoflurane-vet 100% w/w inhalation 
vapour).  Blood was collected into lithium-heparin tubes (Microvette CB300, Sarstedt, Germany), 
and the plasma was obtained by centrifuging at 5000 rpm for 10 minutes on a benchtop micro-
centrifuge and kept at -80°C until use. Livers were removed, weighed and the right lobe was 
preserved in formalin for histological analysis. The rest of the liver was snap frozen in liquid nitrogen 
and stored at -80°C for any future RNA/protein analysis. 
7.3.4 Clinical Chemistry Plasma Analysis 
Plasma samples were transported on dry ice to the Clinical Pathology Laboratory at the Medical 
Research Council centre in Harwell for analysis of ALP, AST and  ALT concentrations on an AU400 
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(Olympus Diagnostic Systems, UK) automated clinical chemistry analyser equipped with an ion 
selective electrode.  
7.3.5 Statistical analysis 
Statistical analysis was performed using the ‘R’ Software package (ver. 2.11, http://www.r-
project.org/).  Differences in continuous variables such as plasma enzyme concentration and weights 
were assessed using the Wilcoxon rank sum test. 
7.3.6 Liver histology 
Formalin fixed tissue was processed into paraffin wax and sections were stained with Haematoxylin 
& Eosin (H & E) by Ms. Hiromi Kudo. Some sections were also stained using the diastase periodic acid 
– Schiff reaction (d-PAS). The sections were jointly examined by light microscopy with 
histopathologist, Prof. Robert Goldin. 
7.3.7 1H NMR urinary analysis 
30 µL of urine sample was mixed with 30 µL of phosphate buffer solution (pH 7.35, prepared with 
100% D2O solvent (Cortecnet, France) and containing 3 mM NaN3 preservative and 1 mM TSP, 
(Sigma UK)) and centrifuged at 13,000 rpm for 10 minutes. 50 µL of supernatant was then 
transferred to 1.7 mm NMR capillary samples tubes (Cortecnet, France). The capillary tubes were 
then housed inside a microNMR 5mm adaptor tube (New Era, USA) for spectral acquisition on a 
Bruker Avance II NMR spectrometer (Bruker Biospin, Rheinstetten, Germany) operating at a 1H 
frequency of 600 MHz. Acquisition parameters were as follows:  Standard NOESY 1-dimensional 
pulse sequence, acquisition time of 2.73 s, t1 of 3 μs, mixing time of 0.1s, 128 scans and 8 dummy 
scans collected into 64k data-points, with spectral width of 12.2 ppm and exponential line 
broadening function of 0.3 Hz and water suppression was applied prior to FT. Metabonomic 
multivariate statistical analysis was used as described in Chapter 5 methods.  
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7.4 Results 
7.4.1 Pilot dosing study 
To determine the tolerable dose of AL, while minimizing the number of animals used, single mice 
were administered a single dose of AL and their liver function was assessed by blood test 24 hours 
later. If no significant liver damage was observed (as indicated by an ALT value above 180 U/l, which 
is 2 standard deviations above the mean value for male C57BL/6J mice268) then the effects of a larger 
dose was assessed in a different mouse, and so on. Table 7-1 summarizes the results of this dose-
ranging study. As can be seen no significant liver damage is observed following doses up to 500 
mg/kg. Following a 1000 mg/kg dose, ALT and AST values are significantly raised above normal, and 
there is widespread centrilobular necrosis of the hepatocytes across the lobe (Figure 7-1). Despite 
extensive necrosis in the zone 3 regions, the central veins remained patent and undamaged with 
some non-necrotic cells surrounding the vein. Changes in ALP values did not appear to relate to the 
severity of liver damage. The mouse receiving this dose was observed for four-days, since this is the 
longest period of time reported for acute toxicity to occur following PA administration, and 
appeared outwardly healthy. On sacrifice, ALT and AST values for this mouse were ≥1000 (above 
range of assay) and 1268 respectively, which was greater than the values measured 24 hours post-
dose, illustrating the progressive nature of the liver injury. 
Table 7-1: Effects of single doses of acetyl-(lycopsamine/intermedine) in individual mice. 
Dose 
mg/kg 
Plasma Liver function test, 
24 hours post-dose 
Observation 
period 
Liver Histology (H&E Staining)  Gross Liver 
appearance 
ALP  
(U/l) 
ALT 
(U/l) 
AST 
(U/l) 
100 127 34.7 51.9 2 days Normal Normal 
250 73 45.7 86.5 2 days No obvious apoptosis or necrosis. 
Single mitosis and more prominent 
macrophage.  
Normal 
500 109 56.1 89.5 2 days Small collection of inflammatory 
cells, variation of nuclear size 
Normal 
1000 106 442 558.7 4 days extensive bridging  zone 3 necrosis Pale with red 
blood spots 
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7.4.2 Chronic dosing study 
Following the pilot dose-ranging study, a 28-day chronic dosing study was initiated with two groups 
of four mice: one control group and one dosed group planned to receive 750 mg/kg of AL, 3 times 
per week. However after 6 days of dosing, one mouse in the dosed group died and despite lowering 
the dose to 500 mg/kg, a second mouse in the dosed group died after 11 days and the study was 
therefore aborted (Figure 7-2). The liver of the mouse who died after 6 days was available for 
histological examination and showed widespread necrosis of the liver lobule, similar in extent to the 
mouse receiving the single 1000 mg/kg dose in the pilot study. The livers of the two mice surviving 
to the end of this study showed some non-specific inflammatory changes including some apoptosis 
and in one mouse occasional scattered necrosis. 
Figure 7-1: Histology of mouse liver 4 days after 1000 mg/kg  AL dose. A:. Extensive necrosis. Cells in peri-portal region 
and immediately around central vein remain unaffected. X200. B: Same liver as in A, showing zonal pattern of necrosis. 
X100. 
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Figure 7-2: Graphical summary of aborted chronic dosing study. Red tubes show survival of individual mice in dosing 
group while blue tube shows control group. Doses administered are shown on bottom arrow and correspond to time point 
shown at top. Histological descriptions of liver pathology are annotated where available. 
A second 28-day dosing trial was then conducted with the dosed group of 4 mice receiving 500 
mg/kg AL, 2 times per week and the control group of 4 mice receiving the PBS vehicle at the same 
time. The control group had a mean weight gain of 2.75g over the course of the trial which was 
significantly greater (p = 0.002) than the mean weight gain of the dosed group of 0.55g. 
Interestingly, the greatest drop in mean weight of the dosed group occurred after the first dose 
(days 0-3), with following weight fluctuations being less dramatic (Figure 7-3).  Liver weight as a 
percentage of body weight was significantly lower (p=0.04) among dosed mice (mean 4.5%, standard 
error, S.E. = 0. 4%) than control (mean 5.3%, S.E. =0.2%) mice  
Day 0 Day 6 Day 11
Control Mice (4) – PBS only gavage
Mouse 1
Mouse 2
Mouse 3
Mouse 4
750 
mg/kg
750 
mg/kg
750 
mg/kg
500 
mg/kg
Cull All
Minimal/mild 
liver inflammation
Mild inflammation,
mild apoptosis
Apoptosis, Inflammation,
Scattered necrosis
Confluent necrosis
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Figure 7-3: Mean weight of dosed and control groups over course of experiment (2 x 500 mg/kg per week). Errors bars 
show standard error. 
Plasma liver function tests were performed at days 14 and 28 of the trial (Figure 7-4). After 28 days, 
dosed mice had a mean plasma ALT value of 109 U/l (S.E. = 45.2) and a mean AST value of 132 U/l 
(S.E. = 55.5). ALT values among dosed mice were significantly higher (p= 0.04) than among control 
mice (mean= 43 U/l, S.E. = 6.4). The mean ALT and AST values of the dosed group of 122 (S.E= 52.7) 
and 166.3 (S.E. = 54.5) U/l respectively, measured at the half-way stage of 14 days were actually 
slightly higher than the final  28 day measurements, and both measurements were significantly 
greater than respective control measurement (p=0.02 for both tests). 
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Figure 7-4: Liver functions tests of plasma collected at 14 and 28 days following dosing of 2 x 500 mg/kg per week. Blue 
bars show mean ALT values and red bars show mean AST. Error bars show standard error. P values calculated from 
Wilcoxin rank sum tests. 
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Upon removal, the gross appearance of all but two livers was normal. One liver from a dosed mouse 
with the highest plasma transaminase values was pale and mottled, while another dosed mouse liver 
showed a slight loss of colour around its edge. The histological picture of livers from the dosed group 
is one of varying states of non-specific inflammation. There is mild anisonucleosis and some 
neutrophilic inflammation with one liver showing prominent Kupffer cells. The changes are most 
marked in the liver from the mouse with the highest transaminase values (ALT= 244 U/l, AST= 297 
U/l) where lobular lymphocytic inflammation near the central vein can be observed and there are 
apoptotic cells. D-PAS staining also indicated that there was marked macrophage activity in this liver 
(Figure 7-5). However inflammation could also be observed in some of the control group livers with 
two having small foci of neutrophilic inflammation and one liver showing some mild anisonucleosis. 
This was reflected in the slightly raised aminotransferase values among two of these mice after 28 
days. 
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Figure 7-5: Histology of livers from mice dosed 8 x 500 mg/kg AL over 28 days and their controls. A: Lymphocytic 
inflammation near the central vein in dosed mouse. X400. B: Kupffer cells apparent in dosed mouse. X400. C: Normal 
liver from control x200. D: Small foci of neutrophilic inflammation in control liver. X400. E: Macrophage activity 
indicated by d-PAS staining in dosed mouse x 400.F: d-PAS stain of liver from control mouse. 
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7.4.3 Acute Dosing Study 
A group of 8 mice were each administered a single dose of 1500 mg/kg AL. 24 hours following the 
dose, mice 7 and 8 appeared moribund, while the remaining mice showed normal behaviour. The 
mice were sacrificed and samples collected for analysis. Liver function tests indicated substantial 
liver injury in the majority of mice, with many values exceeding the upper limit of the assay. Two 
mice had far lower plasma aminotransferase concentrations than the other mice, although still 
significantly greater than normal values (Table 7-2). The main histopathological damage observed 
was varying degrees of necrosis of the zone 3 region of the liver lobule (Figure 7-6). This ranged from 
mild hepatocyte damage and focal necrosis in two livers, through to more wide spread zone 3 
necrosis with sparing of the perivencular hepatocytes in another liver. The other 5 livers had 
extensive zone 3 necrosis which bridged across to adjacent lobules. The central veins were patent in 
all these livers. 
Table 7-2: Plasma aminotransferase values and histopathological descriptions of liver specimens for each mouse, 24 
hours after receiving a dose of 1500 mg/kg acetyl-(lycopsamine/intermedine). *These values may be inaccurate due to 
haemolysis of plasma sample. Aminotransferase values are given as ≥ the upper limit of dynamic range of assay if they 
exceed this limit and further dilutions were not possible. 
Mouse ID ALT 
(U/l) 
AST (U/l) Histology Gross liver 
appearance 
1 ≥1000 6442* zone3 necrosis with focal perivenular 
sparing 
Dark with red blood 
spots 
2 ≥1000 ≥500* extensive bridging necrosis Dark with red blood 
spots 
3 211 214 extensive bridging necrosis Pale 
4 ≥1000 972 mild zone3 hepatocyte damage and 
apoptosis 
Normal 
5 ≥1000 5607 extensive bridging necrosis Dark, marbled with 
blood 
6 265 410 focal, non circumferential necrosis Pale 
7 ≥1000 4208* extensive bridging necrosis Dark 
8 ≥1000 5499* extensive bridging necrosis Dark 
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Figure 7-6: Histology of mouse liver 24 hour after 1500 mg/kg  AL dose showing extensive Zone 3 necrosis bridging into 
neighbouring lobules Left: x 100. Right: x200. H& E Staining 
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7.4.4 Metabonomic Urinary Analysis 
7.4.4.1 Acute dosing trial  
Metabolites of AL were detectable in the urine of mice 24 hours after a 1500 mg/kg dose (Figure 
7-8). Although the metabolites could not be conclusively identified, STOCSY analysis and 2D NMR 
(see appendix for details) was used to determine the interconnectivity of the AL metabolite signals 
and was able to separate them into four different groups, each arising from a different molecule. 
The molecules, AL-1 to AL-4, are annotated on figure 7-8 and their chemical shifts are shown in Table 
7-3. Metabolite AL-3 was identified as an AL-glucuronide conjugate, as confirmed by the J-coupling 
of the doublet signal at 5.24 ppm arising from the anomeric protons of the glucuronide moiety 
(Figure 7-7).  
Table 7-3: Chemical shifts of the four acetyl-lycopsamine metabolites detected in mouse urine 24 hours after a 1500 
mg/kg dose, determined by STOCSY analysis. Multiplicity of signal is annotated if identifiable (s=singlet, d=doublet, 
m=multiplet). 
Metabolite  Chemical shifts (ppm)  
AL-1  0.88m, 1.615m, 1.875, 2.298, 3.68, 4.125, 5.074, 7.058  
AL-2  0.99, 1.15, 1.1d, 1.38d, 3.96  
AL-3  1.003, 1.33d, 1.494, 2.14, 3.23, 3.75, 4.134, 5.24d  
AL-4  0.89, 2.238, 4.26, 4.439, 4.912, 5.805, 5.983, 8.558  
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3.76 Hz 
Figure 7-7: Post dose spectra showing doublet signal at 5.24 ppm from glucuronide moiety of metabolite AL-3, 
annotated with J-coupling. Inset shows STOCSY diagram with peaks structurally correlated (r=1) to this region showed in 
red. 
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Figure 7-8: Mean Urinary 1H NMR Spectra of mice dosed with 1500 mg/kg  of acetyl-(lycopsamine/intermedine). The blue spectrum is the mean of pre-dose spectra and the red spectrum is the 
mean of spectra from samples collected 24 hours post dose. Discriminatory metabolites (from PLS-DA analysis) are annotated 
AL1 
AL1 
AL1 
AL2 
AL3 
AL4 
TMA 
Creatinine 
Taurine 
AL3 
AL4 
AL3 
AL4 
Unknown 8 
Tyrosine 
P cresol glucuronide 
Phenylacetylglycine 
Hippurate 
207 
 
The signals from these metabolites strongly contributed to multivariate analysis of the spectra, 
which showed a clear separation between pre- and post- dose samples (Figure 7-9). PCA, which 
explained 33% and 16% of variance on the first and second components respectively,  grouped the 
available spectra into distinct groupings; the 6 pre-dose spectra, 4 post-dose spectra from the 
“susceptible” mice (Plasma ALT ≥1000 U/l) and 1 post- dose spectra from a “resistant” mouse 
(Plasma ALT =265 U/l). However, the spectrum from this resistant mouse was considerable noisier 
than the other spectra, which greatly contributed to the observed separation. A PLS-DA model 
(permutation validation: p < 0.01) comparing pre- and post- dose spectra was strongly predictive 
(Q2Y= 0.78) and well-fitted (R2Y =0.90). 
 
Figure 7-9: PCA and PLS-DA models comparing of pre- and post- dose spectra. Mice dosed with 1500 mg/kg AL and urine 
sampled 24 hours later. Top left: PCA scores scatterplot. • = Postdose, • = Predose. Top right and bottom: Back-scaled 
covariance loadings plot from PLS-DA model (Q2Y: 0.78, R2Y: 0.90, R2X: 0.28). Class permutation validation p = 0.01. 
Annotated metabolites have spectral permutation p < 0.005.   
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To determine whether pre- and post-dose spectra could be separated only on the basis of changes 
to endogenous metabolic processes, AL metabolites signals were cut out from the NMR spectra and 
normalisation and multivariate modelling was then conducted using these edited spectra. Again 
there was clear separation between pre- and post- dose samples by PCA, which explained 38% of the 
variance on the first component and 14% on the second component (Figure 7-10). PLS-DA was also 
predictive (Q2Y= 0.61) and well fitted (R2Y =0.75).  
 
Figure 7-10: PCA and PLS-DA models comparing of pre- and post- dose spectra, with AL metabolites cut out. Mice dosed 
with 1500 mg/kg AL and urine sampled 24 hours later. Top left: PCA scores scatterplot. • = Postdose, • = Predose. Top right 
and bottom: Back-scaled covariance loadings plot from PLS-DA model (Q2Y: 0.61, R2Y: 0.75, R2X: 0.30). Class permutation 
validation p = 0.01. Annotated metabolites have spectral permutation p < 0.005.   
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Endogenenous metabolites that were identified as strongly contributing (p < 0.005) to the 
discriminatory variable in the PLS-DA model are shown in Table 7-4. Amino acids creatine and 
taurine, known biomarkers of hepatotoxicity, and tyrosine, identified as elevated among human 
HVLD patients, were raised post dose. The mamalian-microbial co-metabolites hippurate and 
trimethylamine were decreased, while phenyacetylglycine and p-cresol-glucuronide were elevated 
post dose. 
Table 7-4: Metabolites contributing to separation of pre and post-dose spectra. Multiplicity of signal is annotated by 
chemical shift if identifiable (s=singlet, d=doublet, m=multiplet). r shows correlation coefficient to latent discriminatory 
variable in PLS-DA using AL metabolite excised spectra. All metabolites have spectral permutation p < 0.005.   
Metabolite Chemical shifts Change 
post-dose 
r 
Unknown 7 2.48s, 2.84t, 5.11d, 6.5, 6.67, 6.71, 6.76 ↓ -0.89 
Trimethylamine 2.88s ↓ -0.69 
Creatine 3.04s, 3.94s ↑ 0.93 
Taurine 3.28t, 3.43t ↑ 0.84 
Phenylacetylglycine 3.68s, 7.36m ,7.42m ↑ 0.79 
Unknown 8 6.72, 6.74, 7.48, 7.49, 7.66, 7.67 ↓ -0.75 
Tyrosine 6.90d,7.2d ↑ 0.72 
Hippurate 3.97d, 7.55t, 7.64t, 7.84d ↓ -0.80 
p-cresol glucuronide 2.30s, 5.09d, 7.05m, 7.23m ↑ 0.79 
 
The integrated values of peaks from these identified metabolites were then subjected to a further 
univariate analysis shown in Figure 7-11. All were found to show statistically significant 
perturbations following dosing, although tyrosine was only borderline significant (p=0.052). 
Interestingly, the ‘resistant’ mouse (with less severe ALT score and liver pathology) had the most 
perturbed levels of many of these identified metabolites, suggesting that they do not correlate very 
well with the extent of liver injury. 
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Figure 7-11: Relative concentrations of identified metabolites following acute dosing. Intensities calculated from spectra 
with AL metabolites removed before normalization. Titles show region integrated in brackets. P values calculated from 
Wilcoxon rank sum test comparing pre- and post-dose spectra. Each point represent individual urine sample. Horizontal 
bar show median value. Post –dose sample from ‘resistant mouse’ represented as triangle.   
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7.4.4.2 Chronic dosing trial 
3 dosed spectra and 4 control spectra were available from urine samples collected after 28 days of 
dosing (8x500 mg/kg doses). Again multivariate analysis, using complete NMR spectra since AL 
metabolite concentrations were not detectable, showed a clear separation between the samples 
(Figure 7-12). PCA, which explained 37% and 18% of variance on the first and second components 
respectively, grouped control samples away from dosed samples, which showed a great deal of 
variance. A PLS-DA model comparing the groups again was predictive (Q2Y= 0.71) and well-fitted (R2Y 
=0.90). Endogenenous metabolites that were identified as strongly contributing (p < 0.005) to the 
discriminatory variable in this PLS-DA model are shown in Table 7-5. 
 
Figure 7-12: PCA and PLS-DA models comparing dosed and control spectra from chronic dosing (8x500 mg/kg) trial. Top 
left: PCA scores scatterplot. • = Dosed, • = Control. Top right and bottom: Back-scaled covariance loadings plot from PLS-
DA model (Q2Y: 0.71, R2Y: 0.90, R2X: 0.34). Class permutation validation p = 0.01. Annotated metabolites have spectral 
permutation p < 0.005.   
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Table 7-5: Metabolites contributing to separation of case and control spectra following chronic dosing. Multiplicity of 
signal is annotated by chemical shift if identifiable (s=singlet, d=doublet, m=multiplet). r shows correlation coefficient to 
latent discriminatory variable in PLS-DA. All metabolites have spectral permutation p < 0.005.   
Metabolite Chemical shifts, ppm (multiplicity) Change among 
dosed mice 
r 
2-Oxoglutarate 2.45t, 3.01t ↑ 0.79 
Citrate 2.55d, 2.66d ↑ 0.85 
Trimethylamine 2.88s ↓ -0.82 
Unknown 9 (Malonate?) 3.12s ↓ 0.88 
Taurine 3.27t, 3.43t ↑ 0.91 
Guanidinoacetate 3.80s ↑ 0.82 
Betaine 3.90s, 3.25s ↑ 0.96 
Fumarate 6.52s ↑ 0.85 
Unknown 10(4-hppa?) 6.9d, 7.15d ↑ 0.79 
Unknown 11 7.31s ↑ 0.86 
Phenylacetylglycine 3.68s, 7.35,7.36,7.41,7.43 ↑ 0.84 
 
Again, taurine, phenyacetylglycine and trimethylamine was perturbed among dosed mice. However 
other perturbed metabolites following chronic dosing showed clear evidence of alteration to the TCA 
cycle. Intermediaries citrate, 2-oxoglutarate and fumarate were elevated among dosed mice 
suggesting reduced energy metabolism. Guanidinoacetate, a precursor in the production of creatine, 
and betaine, a methyl-donor, were also elevated among dosed mouse samples. 
 Figure 7-13 shows the relative concentration of these metabolites among case and control samples 
and the results of a univariate analysis. Despite large concentration differences between the groups, 
the small sample sizes meant that none of the comparisons could achieve statistical significance at 
the 5% confidence level, illustrating the power of the multivariate approach to identifying 
discriminatory metabolites. Of the discriminatory metabolites, the most perturbed concentrations 
were found in the most susceptible mouse (with the greatest ALT scores and degree of pathological 
changes in the liver). Interestingly the only exception to this was for the microbial co-metabolites, 
trimethylamine and phenylacetylglycine, suggesting that the gut microbial changes are separate 
from the toxic effects on the liver. 
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Figure 7-13: Relative concentrations of identified metabolites, following chronic dosing. Titles show region integrated in 
brackets. P values calculated from Wilcoxon rank sum test comparing dosed and control spectra. Each point represent 
individual urine sample. Horizontal bar show median value. Sample from ‘susceptible dosed mouse’ represented as square. 
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7.5 Discussion 
7.5.1 Pathological effects of Acetyllycopsamine 
These experiments have demonstrated in the mouse model, the potential of exposure to AL to 
induce Hirmi Valley Liver disease. Single doses of 1500 mg/kg induced specific liver pathology, 
necrosis of hepatocytes in the zone 3 region of the liver lobule, that is similar in character to the liver 
injury observed in biopsies from patients with recent onset (less than a year) symptoms.  Recovery 
processes from sustained injury of this nature would also lead to the fibrotic disposition observed in 
most of the HVLD patient biopsies9. 
Furthermore like the HVLD patient biopsies, there was no histological evidence of venous outflow 
obstruction. VOD, blockage of the hepatic veins by fibrin accompanied by massive centrilobular 
congestion, is considered the characteristic pathology of PA poisoning in humans and has been 
reproduced in rats following administration of high doses of macrocyclic diester PAs such as 
monocrotaline269 and fulvine257.  In this study mice receiving a 1500 mg/kg dose were sacrificed after 
24 hours and the mouse receiving the 1000 mg/kg dose was sacrificed after four days. Previous 
accounts of rodent models of VOD describe the histologically distinctive occlusion of the central 
veins as arising 7 days after a single dose of PA, so it is possible that this lesion would occur following 
AL administration if allowed time to develop. However, in these models early signs of VOD occur 
within 2 days after administration including haemorrhage of the centrilobular areas257, 269, which is 
absent at this time point following the 1000 mg/kg dose. In DeLeve et al.’s269 detailed account of 
VOD in the rat following monocrotaline exposure, the initial pathological effects occurring at 24 
hours post-dose are sinusoidal haemorrhage and damage to the central vein endothelial lining, with 
zonal necrosis not occurring until three days post dose. Conversely following AL exposure the 
primary pathological effect appears to be necrotic injury to the hepatocytes rather than any vascular 
lesion. The failure of AL to induce VOD-like pathology in this study suggests that this PA may be less 
capable of causing this injury in humans than other PAs. It has been reported that other ‘open’ (i.e. 
non-cyclic) PAs such as heliotrine and laisocarpine induce VOD-like pathology in rats far less 
frequently than monocrotaline and fulvine34 
Chronic dosing of 500 mg/kg twice weekly over four weeks was also found to have hepatotoxic 
effects as judged by the significantly higher plasma ALT and AST concentrations among dosed rats 
compared to control rats. The lower liver weights recorded for dosed mice also indicate a degree of 
liver atrophy. Histological analysis of dosed group livers revealed a picture of chronic hepatitis 
without the distinctive pathological features of enlarged hepatocytes (megalocytosis) and bile 
ductular cell proliferation that was observed in the HVLD patient biopsies and has been reported 
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following chronic dosing with a number of different PAs34, 110, 139, 270 and Indonesian specimens of 
Ageratum conyzoides186 in rats.  It is possible that these features would have been observed if the 
experiments were continued over a longer period. Bull and Dick carried out a number of chronic 
dosing experiments with 10 different PAs110, 139, using doses of 0.1 LD50, two or three times weekly, 
and continuing until all rats tested had died, which was generally well over 100 days from 
commencing dosing. Megalocytosis was observed following dosing with all PAs and bile ductular 
proliferation was observed following exposure to six of these PAs.  However the feeding trial of 10% 
Indonesian A. conyzoides to rats took place over only six weeks186, comparable to this trial. 
Histopathological changes could be observed after one week, including anisonucleosis and 
mononuclear cell infiltration as observed here, but also bile ductular proliferation which developed 
in extent as the trial continued. Megalocytosis appeared after the third week and focal necrosis by 
the fourth week. The researchers found the A. conyzoides plant specimens to contain only 0.014% 
PA-like substances271 which would equate to a lower PA dose (approximately 2 mg/kg daily) than 
used in this trial, suggesting that exposure to the plant itself may be more toxic than exposure to its 
extracted PAs only, despite inducing pathology characteristic of chronic PA poisoning. This 
phenomenon has been previously reported for the plant Heliotropium indicum and its isolated PA, 
indicine (a stereoisomer of lycopsamine)116.  
Assuming that AL is capable of inducing bile ductular proliferation, a further explanation for its 
absence here, is that this feature is not easily induced in the male ‘black 6’ strain mice used.  
Following a 13-week trial of the PA riddelliine in both rats and black 6 strain mice, bile ductular 
proliferation was observed in the majority of both male and female rats at the highest dose used (10 
mg/kg, 5x per week), but not in mice at the highest dose used (25 mg/kg, 5x per week). Bile ductular 
proliferation was observed only in female mice and only following 7 week and 14 week recovery 
periods after stopping dosing 270. Megalocytosis was induced in both the rats and mice, suggesting 
that insufficient total dosing of AL was the reason for the absence of this lesion in this trial.  
The chronic dosing trial also indicated that mice become less susceptible to subsequent doses of AL 
after initial dosing. Mean AST and ALT values were slightly lower among dosed mice after 28 days 
than after 14 days suggesting little development of further liver damage in the second half of the 
trial. Furthermore the greatest drop in bodyweight among dosed mice occurred after the first dose, 
with only slight weight changes following subsequent doses. It has been shown that liver 
microsomes from rats pre-dosed with the PA retrosine, show lower metabolic conversion of 
retrosine in vivo to its toxic pyrrolic metabolites272, suggesting inhibition of cytochrome p450 
activity. This may be a specific effect such as with toxins such as CCl4 where the activated 
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metabolites destroys the P450 heme or a result of general reduction in liver function resulting from 
the initial liver injury15. This development of resistance, combined with the progressive nature of the 
liver injury observed following single doses, complicates efforts to develop a reproducible model of 
chronic liver injury using this PA.  
7.5.2 Variability of Acetyllycopsamine toxicity 
Another interesting feature of the toxic effects of AL noted in this study was the wide variability in 
susceptibility. One attempted chronic dosing trial had to be abandoned before completion due to 
the early deaths of two mice in the dosed group, one of which was found to suffer extensive hepatic 
necrosis. The two surviving mice (who had received additional dosing) were found to be suffering 
only mild liver damage. In the completed chronic dosing trial, final plasma AST scores among the 
dosed group ranged from 66 - 297 U/l.  Similarly among the acutely dosed mice, AST scores 24 hours 
post-dose ranged from 214 to over 5000 U/l.  The consistently variable susceptibility of mice across 
all these trials indicate that this is not due to some technical error such as inaccurate dosing, but 
rather a genuine aspect of the toxicity of AL. Since inbred mice of the same strain and sex were used, 
genetic factors such as variation in drug-metabolizing enzymes cannot be responsible in this study. A 
possible explanation may be variable levels of bacterial endotoxin or lipopolysaccharide (LPS) in the 
mice. LPS exposure occurs normally due to its release by gram-negative bacterial flora in the 
gastrointestinal tract, and translocation into the portal venous circulation273 and has been shown to 
synergistically increase the hepatotoxicity of the PA monocrotaline274 at dosage levels that were 
non-injurious when administered separately. It was shown that LPS did not increase the production 
of reactive pyrrolic metabolites, but instead must have acted indirectly possibly through 
inflammatory events274. The slight inflammation observed in two of the control mice, indicates that 
endotoxin-producing bacteria may be prevalent in the animal facility or among mice from the 
supplier used.  Variations in gut microfloral composition may be investigated though urinary 
metabonomics94 with pre-dose levels of certain bacteria-associated metabolites affecting 
hepatotoxin metabolism275. Therefore, attempts were made to construct multivariate models of 1H 
NMR spectra of pre-dose urine samples, comparing susceptible to resistant mice to identify any 
predictive metabolites. However no validated models could be constructed with the number of 
samples available, suggesting only small metabolic differences beyond the power of this study to 
detect. 
7.5.3 Toxicity of Acetyllycopsamine 
The alkaloids used in this study, a racemic mixture of acetyl-lycopsamine and acetyl-intermedine 
extracted from S. Officinale, are similar to the mixture of alkaloids, mainly acetyl-lycopsamine but 
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also lycopsamine and intermedine, detected in grain supplies from affected households and are 
therefore well representative of their toxicity. No deaths were observed in the 24 hour period 
following administration of the highest dose in this study indicating a relatively low acute toxicity 
with an LD50 above 1500 mg/kg. This is higher than the LD50 values reported in mice for the PAs 
retrosine85 (65 mg/kg), senecionine276 (64 mg/kg), laisocarpine276 (85 mg/kg276), heliotrine276 (257 
mg/kg) and monocrotaline277 (261 mg/kg), that have been responsible for previous outbreaks of 
human poisoning.  
A WHO Task force on PAs102 compared 11 cases and outbreaks of human poisoning where PA intake 
has been estimated. Using rat LD50 data they converted the different PA intakes to their heliotrine 
equivalent (i.e. the quantity needed to cause equivalent toxicity if caused by heliotrine). The lowest 
total dose causing VOD was a case reported by Ridker142 where a total of 1 heliotrine equivalent 
mg/kg was ingested, while the highest total dose was in the Indian outbreak at 120 heliotrine 
equivalent mg/kg, which caused VOD and deaths. This suggests that humans are markedly more 
sensitive to the acute and chronic effects of PAs than rodents. The Task force thought it prudent it to 
use the case reported by Ridker (despite suspicions the patient may have had more exposures than 
admitted) to suggest that the estimated daily dose from that case of 0.01 heliotrine equivalent 
mg/kg may cause disease in humans. The UK Committee On Toxicity (COT) Statement on 
Pyrrolizidine Alkaloids in Food154 give a lower estimate that intake above 0.1 µg/kg/day of the PA 
riddelliine (0.03 µg/kg/day heliotrine equivalent) may cause non-cancer effects in humans, based on 
a two year study of riddelliine in rodents140 that reported a no observable effect level of 0.01 mg/kg 
b.w./day and applying uncertainty factors of 10 for interspecies variation and 10 again for 
intraspecies variation.  
The highest detected level of PA detected in Hirmi Valley was 0.477 µg/g of millet found in a vacated 
house in Tseada Amba previously belonging to an affected household. If one estimates that a 50 kg 
person may consume 100g of grain from this store per day, the daily intake of PA would be 1 µg/kg. 
Using a LD50 of 1500 mg/kg for these PAs, the daily intake would equate to 0.2 µg/kg of heliotrine 
equivalent PA. According to the UK COT estimate, but not the WHO estimate, intake at this level 
could cause human illness. However the extensive centrilobular necrosis observed in two of the 
patient biopsies and occurring in mice in this study following only the highest doses used, would 
suggest an AL intake higher than could be achieved by daily consumption of this contaminated grain 
store. Other un-sampled routes of exposure such as milk and honey may contribute additional PA, 
while these patients may also have higher levels of PA in their grain stores than in the grain stores 
we sampled. Additional plant toxins contained in the Ageratum seeds (for instance coumarins and 
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perocenes) may contribute to the toxicity of AL. Furthermore, other factors such as alcohol (millet is 
generally used to brew the local beer) and the pesticide DDT may potentiate the toxic effects of AL 
(this effect is investigated in Chapter 8). 
7.5.4 Metabolism of Acetyllycopsamine 
Metabolites of AL were detectable by 1H NMR in the urine 24 hours after receiving a 1500 mg/kg 
dose, but not at 72 hours after the final 500 mg/kg dose in the chronic dosing trial. Using STOCSY 
analysis and 2D NMR experiments it was possible to group these signals into four different groups or 
molecules, labelled AL-1 to AL-4. Further AL metabolites (or further signals from the identified 
groups) may have also been present but below the detection limit or obscured by overlapping 
signals. While metabolite standards were not available to conclusively confirm the identity of the 
metabolites, the NMR data and previous studies on the metabolism of other PAs can provide 
information regarding their identity. Mattocks showed that in the first 3.5 hours following an 
intraperitoneal 60 mg/kg dose of retrosine in the rat, 8.6% of the dose is recovered as unchanged 
alkaloid, 10.8% as N-oxide, and 4.1% as pyrrole278. After 24 hours, 0.1% is recovered as alkaloid, 0.2% 
as N-oxide and 1.8% as pyrrole. Some differences in metabolism are to be expected with acetyl-
lycopsamine, since ‘open’ diesters such as this are metabolized more slowly and a greater 
proportion is converted to N-oxide than with macrocyclic diesters such as retrosine279. Figure 7-14 
proposes of scheme of metabolism for AL following what is known about general PA metabolism112, 
117. Published data for the NMR spectra of dehydroretronecine (pyrrolic metabolite)280 and the two 
known glutathione conjugates281 in the same solvent are available and neither of these metabolites 
share the same spectral profile as the detected AL metabolites. GSH pyrrole conjugates, if produced, 
are known to be excreted in the bile282 so one may not expect to detect them in the urine. 
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Figure 7-14: Postulated metabolism of acetyllycopsamine. 
The 1H NMR spectrum of AL itself (see appendix) includes methyl multiplet signals at 0.9 and 1.2 
ppm (from protons at 20 and 21 numbered in Figure 7-15), a large acetyl singlet at 2.15 ppm (proton 
at 11), a flat multiplet at 2.35 ppm (proton at 19), a multiplet signal at 4.2 ppm (proton at 13) and a 
signal at 5.6 ppm (proton at 7) characteristic of the pyrrolizidine base ring.  
  
Figure 7-15: Structure of acetyl-lycopsamine with carbon atoms numbered. 
Metabolite AL-1 has the methyl signals at 0.88 and 1.3 ppm and the multiplet signal at 2.34 ppm but 
not any of the pyrrolizidine signals, suggesting it may be the necic acid moiety of AL, viridofloric acid. 
This conclusion is further supported by its first methyl signal occurring at a lower ppm than the 
signals from AL or the other AL metabolites, which would be expected due to an absence of shielding 
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from the pyrrolizidine ring. Metabolite AL-2 is characterised by two prominent doublet signals at 
1.10 and 1.38 ppm, with a methyl signal also present at 0.99 ppm. This metabolite could be an N-
oxidised metabolite as it appears quite different from AL. While pyrrolizidine signals are not 
detected for these molecules it is possible they may be obscured by other signals. 
AL-3 can be confidently identified as an AL-glucuronide conjugate from the J-coupling of its 5.24 
doublet signal and the structurally associated peaks matching published data for glucuronic acid228 
and since it also contains AL-like methyl signals. Glucuronidation has only recently been identified as 
a metabolic pathway in PAs124. Intact senecionine, and three other macrocyclic PAs, were shown to 
be conjugated with glucuronosyl on its nitrogen atom in liver microsomes from a number of species 
including mice and humans, although activity was almost absent in the mouse. AL may be 
conjugated differently to senecionine, since it is already more water soluble and its acid moieties will 
cause less steric hindrance than the macrocycle of senecionine, making glucuronidation at sites 
other than the N atom easier. It is not possible to determine in this study whether AL-3 is also an N-
glucuronide or instead an O-glucuronide, conjugating at other sites such as the carboxylic acid or 
hydroxyl groups of AL, possibly after phase I activation. This is however the first evidence of PA 
glucuronidation in vivo. 
Finally, AL-4 contains both characteristic pyrrolizidine signals and methyl signals. However it does 
not match the AL spectra exactly and lacks a large acetyl-signal suggesting that the acetyl group of 
AL has been hydrolyzed and that AL-4 is most likely to be lycopsamine. If retronecine is also present 
its signal may be obscured by that of AL-4. AL itself may also be present at quantities below 
detection at 24 hours post-dose. 
7.5.5 Metabolic effects of Acetyllycopsamine 
24 hours following an acute dose of 1500 mg/kg AL the urinary concentrations of amino acids 
creatine, taurine and tyrosine and microbe-mammalian co-metabolites, trimethylamine (TMA), 
hippurate, p-cresol glucuronide and phenyacetylglycine (PAG) were perturbed. The metabolic 
changes following 28 days of chronic dosing was slightly different: Taurine was the only amino acid 
with altered concentration, although TMA and PAG were also perturbed. Changes were also 
observed to one-carbon metabolism and TCA cycle intermediaries. 
Creatine and taurine are well established urinary markers of liver injury having been observed to 
increase in rodents following exposure to a range of different hepatotoxins210, 230, 283 and following 
partial hepatectomy247, and are reported to co-rise following exposure to toxins that cause 
hepatocellular necrosis. This is the first time they have been reported to change following PA 
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exposure. These metabolites are freely present in the cytosol and are likely to be raised following 
acute dosing, at least in part, due to leakage from necrotic cells284. However specific mechanisms 
may also be responsible. Taurine is an end-product of sulphur metabolism so its excretion may be 
associated with increased availability of cysteine. Increased glutathione synthesis, in response to 
depletion following oxidative attack from pyrrolic metabolites, would require increased production 
of its precursor cysteine, which is produced from methionine in the diet. In the course of this 
metabolic pathway, S-adenosylmethionine (SAM) must donate a methyl group to a methyl acceptor, 
a role principally played by guanidinoacetate, which is converted to creatine on addition of this 
methyl group. Excess creatine would be expected to be excreted quickly so as not to prevent further 
methyl donation by SAM, so increased production of cysteine would be matched by increased 
creatine production, observable as elevations in the urine284. Taurine production would require 
cysteine at the expense of GSH production so it appears that taurine is being actively up regulated. It 
has been shown that taurine, like GSH, has cytoprotective properties itself285 and is actively 
synthesized following carbon tetrachloride administration286. Therefore the liver may be actively 
synthesizing taurine for circulation to other tissues in the body following the toxic insult by AL and 
the excess is excreted in the urine, with creatine production also elevated in order to satisfy the 
cysteine requirements. 
However the picture following chronic dosing of AL is rather different. One-carbon metabolism 
intermediaries guanidinoacetate and betaine are both elevated and are both involved in the cycling 
between SAM and homocysteine in the production of cysteine. An excess of these metabolites might 
suggest a reduction in this process. Creatine is not found to be elevated among chronically dosed 
mice as would be expected with the excess of guanidinoacetate, but taurine is still elevated. One 
explanation stems from DNA and protein attacking properties of PAs, which may lead to an overall 
drop in protein synthesis. This would reduce the cysteine requirement, reducing the conversion of 
guanidinoacetate to creatine, and leading to a ‘passive’ increase in taurine produced from the excess 
cysteine. It has been suggested that due to the role of the liver in the production of creatine and the 
liver specificity of the enzyme betaine-homocysteine methyltransferase (which metabolises betaine) 
means that compounds involved in one-carbon metabolism may be useful probes of liver-specific 
processes247. Betaine was found to be elevated in the rat following galactosamine230, 
thioacetamide212 and 1-naphthylamine238, while guanidinoacetate was raised in the mouse, but not 
the rat, following hydrazine administration283 and so appears a more mouse specific marker. Both 
were raised in the rat following partial hepatectomy so could be indicators of regeneration247. 
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A striking aspect of the metabolic profile of chronically dosed mice was the elevations in TCA cycle 
intermediaries citrate, 2-oxoglutarate and fumarate. Perturbation to the TCA cycle is a standard 
response following single doses of many different hepatotoxins and are generally considered non-
specific marker of energy metabolism, although usually a reduction in TCA intermediaries26, 212, 230, 238, 
283 is observed. It is has been shown that the levels of these metabolites closely follow dietary intake 
and are reduced on a restricted diet283. Examination of the body weight changes of the dosed group 
over the last days of the trial shows they are gaining weight while the control animals are 
maintaining a steady body weight. It may be that as the dosed animals have become desensitized to 
the effects of AL, they are starting to recover and increasing their food, and energy, intake. 
TMA was reduced and PAG was elevated following both acute and chronic dosing, indicating that AL 
also effects the composition of the gut microbiota. TMA-oxide is reduced in the rat following 
exposure to bromobenzene26 and hydrazine211, while in the mouse, where apparently less TMA is 
oxidized than in the rat, a reduction in TMA itself is reported following hydrazine exposure283. TMA is 
produced by the breakdown of dietary choline by intestinal microorganisms287, so it is possible that 
the pool of choline for TMA production is diverted into betaine production, giving the excess amount 
observed following chronic dosing, but this seems unlikely since betaine is unchanged following 
acute dosing. Rather, considering the changes observed to other mammalian-microbe co-
metabolites, there may be a direct effect on the microbial population, which does not necessarily 
follow the systemic effects of liver injury, such as through the production of toxic AL metabolites in 
the mucosal lining or transport of toxic metabolites to the gut intestinal tract through enterohepatic 
circulation. PAG, produced by microbial conversion of phenylalanine to phenylacetate by the gut 
microflora251 and then glycine conjugated in the liver, may be increased due to resistance to the 
toxic effects of AL by phenylacetate producing species, and an increase in their population at the 
expense of other microbial species, such as those that produce TMA for instance.  
There were many similarities observed between the metabolic changes following exposure to AL in 
the mouse and among human HVLD patients. Broadly in both situations changes associated with 
liver injury and the composition of the gut microflora were observed. Tyrosine was found to be 
elevated and hippurate lowered among patients with HVLD, demonstrating that specific metabolic 
changes among HVLD patients can be reproduced following dosing with AL in the mouse model. 
Furthermore, tyrosine was only found to be elevated among HVLD patient in the early acute stages 
of the disease and similarly was only raised in mice following an acute dose of AL. The significance of 
these changes has been discussed in chapter 5. Other metabolic changes observed in HVLD patients 
are also linked to metabolic pathways perturbed in the mouse model. Formate and N-
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methylnicotinamide, raised among HVLD patients, are both involved in one-carbon metabolism that 
was perturbed in the mouse as shown by the changes to betaine, creatine and guanidinoacetate. 
Formate is the end product of metabolism of 5,10-methenyl-tetrahydrofolate, used in the 
conversion of homocysteine to methionine, while N-methylnicotinamide is a methyl-acceptor 
involved in the metabolism of SAM. Some differences in metabolism are to be expected between 
animal species283, 288 and the elevation of taurine was not noted in HVLD patients. However excess 
taurine may have been excreted by increasing the proportion of taurine-conjugated bile acids while 
excess cysteine may have been metabolized to pyruvate (raised in HLVD patients) rather than 
taurine. 
P-cresol glucuronide was elevated following acute dosing. This metabolite has been reported to co-
rise with PAG in some studies101 232, and it has a similar origin, being produced from tyrosine by the 
gut microflora and then conjugated with glucuronide in the liver. Therefore the increased levels of 
tyrosine observed may contribute to its elevation, although the suite of microbial metabolic changes 
suggests that the microbial ecology has been altered. A rise in p-cresol glucuronide and PAG was 
reported following arginine-induced pancreatic toxicity232, so these ‘extra-genomic’ markers may not 
be specific to a particular organ toxicity in the host. Conversely, p-cresol sulfate (the major 
conjugated form of p-cresol in humans) was lower among HVLD cases than controls, and this 
difference may reflect differences in response between the different conjugated forms or species 
differences. Alternatively, p-cresol glucuronide is elevated in the urine of ‘non-responder’ (i.e. no 
toxic effects detected) rats following galactosamine exposure97 compared to controls and is 
suggested to reflect a different metabolic route of the toxin (via the gut microflora) in resistant rats. 
It may be if greater mouse numbers were used a similar effect could be seen following AL exposure 
and it should be noted that the highest levels of p-cresol glucuronide were observed in mice 4 and 6 
that had the mildest liver pathology. Therefore the lower levels of p-cresol sulphate observed among 
human HVLD cases compared to controls may be due in part to the ability of asymptomatic 
individuals to metabolize AL though an alternative detoxifying route. 
7.5.6 Strengths and Limitations 
In any study there are further experiments that may be performed to more completely characterize 
the area of interest. For sound ethical reasons, only the minimum of mice were used to initially 
determine the tolerable doses of AL, especially considering there was so little prior knowledge as to 
its toxicity. However considering the wide variability in the effects of AL subsequently discovered, 
the use of more mice would have given a better picture of levels at which AL starts to exert 
hepatotoxic effects. Chronic dosing over a longer period of time, possibly using lower doses and 
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including recovery periods, may have better reproduced the chronic form of HVLD. It would also be 
useful to carry out similar work, dosing with actual Ageratum conyzoides samples instead.  
There were also some difficulties with sampling. In the acute dosing study, most of the blood 
samples taken for each were used to develop the pyrrole ether extraction assay presented in 
chapter 6, leaving only a small amount for liver function testing by measurement of ALT/AST. This 
meant further dilution of extra sample by the automated analyzer was not always possible and many 
LFT scores were presented as a minimum value. Precise ALT scores would have been useful to 
anchor the metabonomic analyses of urine samples. There was also great difficulty in taking urine 
samples from mice using the free-catch method, reducing the number of samples available for 
analysis. Efforts were made to take urine throughout the chronic dosing trial but there were not a 
sufficient number of samples for comparison. The urinary analysis following acute dosing would also 
have been improved if further time points were captured.  Although 24 hours post-dose is a 
commonly used time point in metabonomic studies, giving sufficient time for changes to develop, it 
is useful to capture early and later changes, providing a ‘metabolic trajectory’. Similarly further 
metabolites of AL may have been missed, since the majority of AL may be excreted before 24 hours 
has passed. 
The main strengths of the study were the use multiple outcomes measures that provided many 
points of comparison between the mouse model and HVLD in man. While not completely 
exhaustive, the experiments conducted have been sufficient to demonstrate the hepatotoxicity of 
AL, describe its effects and determine its potency. 
7.5.7 Concluding remarks 
The work presented in this chapter has shown that single doses of acetyllycopsamine (and its isomer 
acetylintemedine), at relatively high doses, are capable of causing liver injury in the mouse that is 
similar to HVLD in man, as judged by levels of plasma aminotransferase concentrations, specific 
histopathological changes in the liver such as centrilobular necrosis, and metabolic changes detected 
in the urine by 1H NMR. Smaller doses administered repeatedly over 28 days were shown to induce a 
chronic hepatitis, with some similarities to the chronic form of HVLD, although specific pathology 
such as megalocytosis and bile ductular proliferation were not induced. It is thought that a dosing 
regimen over a longer period of time or with greater total dose may induce these features, if 
inducible in the mouse strain and gender used. The work has also shown that even after controlling 
for genetic factors, environmental factors such as food and housing, and dose level used there is still 
a great deal of variation in pathological outcome following AL exposure. Overall this work supports 
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the hypothesis that AL, along with similar PAs detected in the Hirmi Valley food stores, are the 
principal aetiological agents of HVLD. 
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8. DDT as a Modulator of PA Toxicity 
8.1 Introduction 
8.1.1 DDT identity and use 
DDT (dichlorodiphenyltrichloroethane) was first synthesised in 1874 and its insecticidal properties 
shown in 1949289. ‘Technical grade’ DDT that is produced commercially, contains the active 
ingredient, p,p´-DDT, smaller amounts of isomeric by-products such as o,p´-DDT and its major 
breakdown product DDE (dichlorodiphenyldichloroethylene). DDT and DDE persist in the 
environment, are highly lipophilic, and bioaccumulate in humans because of their long half-lives (6 
years and possibly up to 10 years, respectively)290. DDT is metabolised to the less toxic DDE by 
dehydrochlorination, where it is stored for an indefinite period of time in the adipose tissue. The 
major detoxification pathway of DDT is dechlorination to DDD (dichlorodiphenyldichloroethane), 
which readily degrades to DDA (2,2-bis(4-chlorophenyl)-acetic acid) which is water solulable and 
rapidly excreted290 (Figure 8-1).  
 
 
Its tremendous utility as pesticide was first demonstrated during the Second World War, where it 
was used to protect troops from vector-borne diseases such as malaria and typhus. Its use in the 
USA was rapidly expanded to include military installations and transport hubs contributing to the 
eradication of malaria in the country by 1953289. It use in agriculture had also been growing since the 
end of the war, reaching a peak in production in USA in 1959 of 35 771 tonnes291. The Global Malaria 
ClCl
Cl
Cl Cl
Cl Cl
Cl Cl
Cl Cl
Cl Cl
Cl
Cl
Cl Cl
Cl
O
Cl Cl
OH
Figure 8-1: DDT and related compounds. Top left: p,p´-DDT. Top right: o,p´-DDT. Bottom left: p,p’-DDD. Bottom middle: 
p,p’-DDE. Bottom right: p,p’-DDA. 
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Eradication Campaign initiated in 1955, was based on widespread indoor and outdoor spraying of 
DDT targeted at mosquitoes and led to the eradication of the disease in developed countries and 
many subtropical Asian and Latin American countries by 1967. The campaign was ended two years 
later as it was realised the infrastructure for eradication around the world was inadequate and some 
mosquitoes were becoming resistant292.  
Following evidence of bioaccumulation in the environment and its harmful effects to pelagic birds293, 
the use of DDT was banned for agricultural use in several countries during the 1970s and 80s291. 
Increased awareness of the potential adverse human health effects of chemicals such as DDT led to 
the ratification of the Stockholm Convention on Persistent Organic Pollutants in 2004, which enacted 
a global ban of DDT and 11 other persistent organic pollutants. However over 20, mainly Sub-
Saharan African, countries requested an exemption for the use of DDT in malaria control arguing 
that alternatives were far less cost-effective.  Therefore Annex B of the convention permits the use 
of DDT only for disease vector control for 15 countries, including Ethiopia, currently listed on the 
DDT Register for an indefinite period294. The WHO position statement on the use of DDT states that: 
“DDT is still needed and used for disease vector control simply because there is no alternative of both 
equivalent efficacy and operational feasibility, especially for high-transmission areas”.
295 
8.1.2 DDT use in Ethiopia 
Malaria is endemic in all but the central highlands of Ethiopia, with 1.75 million confirmed cases in 
2009. This is a decrease from an average of 3 million cases in the period 2000-2005 when the most 
recent epidemic occurred. Tigray is a high transmission region with 50 – 100 cases per 1000 
people296. Over the last 10 years, vector control has relied principally on seasonal indoor residual 
spraying (IRS) with DDT. The National Strategic Plan for Malaria Control 2005-2010, set the target of 
increasing household coverage by IRS in endemic areas from the 22% level set in 2005 to a 60% level 
2010. Since 2001, Sprayable (“wet powder”) DDT has been produced within Ethiopia by a state-
owned company, with capacity to process up to 700 tonnes per year294. Annual use over the period 
2006-2009 was approximately 360 tonnes with use peaking at 1445 tonnes in 2008294.  According to 
the Tigray Health Bureau Profile for 2006, there was 96-98% coverage of households by IRS with DDT 
in the woredas affected by HVLD163. In 2009 this had dropped to 46-70% coverage. However in 2010, 
the Ethiopian Ministry of Health decided to switch from DDT to deltametrin as the primary 
insecticide used in IRS297, 298, citing evidence of mosquito resistance299 and the detection of trace 
amounts of DDT on exportable goods, including the country’s biggest export coffee300. 
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Despite the use of DDT for purposes other than disease vector control being prohibited by national 
and international law, the abuse of DDT in Ethiopia has been reported. DDT has been found to be 
freely and openly available at rural markets throughout Ethiopia repacked into 500g packs that are 
far more affordable than alternative pesticides sourced from government regulated agro-dealers300, 
301. A recent study of 422 farmers in the Rift Valley region by the NGO, Pesticide Action Network, 
found that around 29% of farmers were using DDT on their crops with only 33 % believing that 
pesticide use could be harmful to human health302. A smaller study of farmers in the southern Dire 
Dawa region in 2003 reports that DDT is mixed with stores of staple crops, maize and sorghum to 
prevent storage pests301. My own research (chapter 4) found a similar practice by farmers in the 
HVLD affected areas of Tigray. The DDT supplies are believed to arise from “leakage” from Ministry 
of Health sprayers and factory personnel300, while it is also reported that stores of DDT have been 
broken into and looted301.  
8.1.3 Effects of DDT on Health 
The toxic effects of DDT are well studied in animals. It is primarily a central nervous system stimulant 
acting on the cerebellum and motor cortex. Its effects at high doses include hyper-excitability, 
tremor and muscular weakness and occasionally convulsions and increased myocardial sensitivity. 
The toxicity of a single dose is affected by the solvent vehicle and administration route. LD50 values 
for the mouse are 100-800 mg/kg and 300 – 1600 mg/kg for oral administration in oil and water 
suspension/powder respectively303. Liver changes are also observed at lower doses including focal 
necrosis of hepatocytes, and hepatomegaly and enlargement of the endoplasmic reticulum in rodent 
species, thought to reflect stimulation of the microsomal enzymes290 
The compound is considered relatively safe in people with an estimated adult lethal dose of 30g304 
and only a small number of cases of poisoning have been reported. Smith comments that the “the 
safety record for humans in the use of DDT is phenomenally good considering the huge quantities 
distributed”289. Its subclinical and subtle effects have not been seriously probed until the last few 
decades. Recent studies have associated exposure to the chemical with a number of adverse health 
outcomes  although the evidence is still ambiguous289, 305, 306. Of major concern is the link to 
reproductive outcomes, with links to spontaneous abortion, preterm delivery and earlier weaning of 
particular relevance to Sub-Saharan Africa. A study of 1,717 American women associated high serum 
DDE levels (45-59 ppb) with an elevated risk of fetal loss in previous pregnancy307 supporting the 
findings of earlier smaller studies308. However a Japanese study of habitual aborters, found no 
association with serum DDE although mean levels were much lower (cases, 1.2 ppb)309. Another 
study on the American cohort mentioned above, showed increased odds of preterm delivery among 
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women with serum DDE above 60 ppb310. Later studies, with lower DDE concentrations among 
participants have had mixed results with some showing an association311 and others not312.  Three 
studies have linked DDT exposure to early weaning313-315, however a study of Mexican woman only 
found an association in women who had previously breastfed. The reason suggested in that lactation 
can reduce a woman’s DDE body burden and those that breastfeed for a long time with previous 
babies tend to do so with current babies316. Therefore previous associations found may be spurious, 
warranting further research. 
DDT exposure has been linked to diabetes in a number of different populations317-319 although 
exposure was also correlated with exposure to a number of different organochlorines in these 
studies. The link to diabetes has been postulated to play a role in the causal link between DDT and 
pancreatic cancer which has been suggested by a number of epidemiological320, 321 and 
mechanistic322 studies, although others found no association323. Breast cancer has also been linked 
to DDT exposure by some studies but the age of exposure is thought to be crucial, with one recent 
study finding that high DDT concentration in archived serum samples was associated with elevated 
breast cancer risk, but only in those women younger than 14 when DDT was introduced for general 
use in 1945324. 
 Of most relevance to HVLD is the links found between DDT exposure and liver cancer. An ecological 
study showed that standardized mortality rates from HCC were raised among whites Americans (but 
not African Americans) who lived in states with high population level DDE adipose tissue levels325. A 
case control study by McGlynn et al.326 of 553 Chinese men found those with DDT blood levels in the 
highest quintile had a higher risk of developing HCC (OR = 3.8, 95% CI = 1.7–8.0) compared to men in 
the lowest quintile. Interestingly no association was found with DDE levels perhaps reflecting the 
importance of recent exposure to DDT. Zhao et al.51 recently reported associations between both 
DDT and DDE with HCC from a case control study of 1306 Chinese in a region of high DDT exposure 
(median case serum DDT= 39 ppb). Those with serum DDT levels in the highest quartile had an 
elevated risk of HCC (OR = 4.1, 95% CI= 2.7-6.7) compared to those in the lowest. For equivalent DDE 
quartiles there was a lower but still elevated risk (OR= 2.0, 95% CI = 1.4-2.8). Interestingly, there was 
an interactive effect with serum levels of aflatoxin B1 –albumin adducts, an established risk-factor for 
HCC. The relative excess risk of interaction between DDT and aflatoxin B1 –albumin adducts was 2.55 
(p=0.005), which may be of relevance since the cytotoxicity and genotoxicity of aflatoxin, like PAs, 
are mediated through the cytochrome P450 enzymes15. 
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8.1.4 DDT as a hepatic enzyme inducer 
Experiments in the 1960s first demonstrated that DDT is a phenobarbital-type inducer of hepatic 
microsomal monooxygeneases327, 328 and more recent studies have shown that DDT is an inducer of 
the cytochrome P450 enzymes in the rat329, 330, including the CYP3A subfamily67, 331-333. Hoffman et 
al.327 showed a dose dependent increase in hepatic enzyme activity (p-nitroanisole O-demethylation) 
in rats according to levels of DDT in their diet. This effect began at doses of 2 ppm in food and 
increased until doses of 750 ppm at which point central nervous system effects were observed. 
Ronald et al.330 demonstrated that DDT and its metabolites DDE and DDD all have similar intrinsic 
CYP2B induction potencies (measured by benzyloxyresorufin O-dealkylation), with a significant 
effects observable at dietary levels from 8.5 ppm. Immunochemical detection showed induction of 
CYP2B1, and to a lesser extent CYP3A1 and CYP3A2, by both DDT and DDE. The pleiotropic response 
to DDT in the diet at levels from 5-500 ppm was shown by Lubet et al.332 who measured increases in 
liver microsomal activity of enzymes CYP1A, CYP2B, CYP3A, epoxide hydroxlase, aldehyde 
dehydrogenase, quinone oxidoreductase and glucuronyltransferase. The greatest changes were to 
CYP2B with a 35-fold induction and then CYP3A with a 3-fold induction relative to controls. A sex 
difference in rats in response to single doses of DDT, ranging from 0.1-100 mg/kg, was observed by 
Sierra-Santoyo331. Among male rats significant increases of levels of CYP enzyme activity were 
observed following a 1 mg/kg dose while among female rats doses greater than 5 mg/kg were 
needed. However at the highest dose, far greater relative induction of immunoreactive CYP3A2 
protein (which is not normally expressed in females) was observed among females (18.1) than males 
(2.1). DDE has been shown to induce CYP2B and CYP3A expression through activation of the nuclear 
receptors, CAR and PXR334. 
Studies of occupationally exposed populations have provided evidence of hepatic enzyme induction 
by DDT in humans, through measurement of the clearance of model drugs or steroid metabolites335. 
Factory workers with mean serum levels 573 and 506 ppb for DDT and DDE showed a 57% mean 
increase in 6β-hydroxycorticosterol urinary excretion (an indicator of CYP3A induction) compared to 
controls336. A serum DDT concentration of around 300 ppb (a dosage of around 0.25 mg/kg/day) was 
required to demonstrate an increase. The enzyme induction properties of DDT have also been 
exploited in the clinical setting. Doses from 0.3 to 3 mg/kg/day were administered to selected 
patients with jaundice to decrease serum bilirubin levels337. While no improvement was observed in 
patients with jaundice resulting from cirrhosis with no evidence of liver enzyme deficiency, a boy 
with familial, unconjugated jaundice arising from a deficiency of glucuronyltransferase, showed 
rapid reduction of bilirubin and an alleviation of symptoms. Rappolt338 used a single dose of DDT to 
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promote the metabolism of phenobarbital in three overdose patients, who all made recoveries.  A 
rise in serum GGT activity (a non-specific marker of hepatobiliary disease and microsomal enzyme 
induction) has also been associated with DDT exposure by a number of studies335, 339, 340. Mild 
symptoms of liver damage have been reported in a few case studies of DDT exposure48, 303, while one 
study of specimens of body fat from human autopsies found total DDT levels (DDT and its 
metabolites) to be 2 to 2.5 times higher in 70 specimens from subjects with a history of various liver 
disorders than from 42 subjects that died an accidental death341. This suggests a role for DDT 
exposure in liver disease. 
8.1.5 Enzyme induction and PA toxicity 
The CYP3A and, to a lesser extent, CYP2B enzymes are responsible for catalysing retronecine-based 
PAs to their highly reactive pyrrolic metabolites119, 342, 343 that bind to nucleophilic tissues and cause 
the adverse effects of PAs. However the effect of pre-treatment with enzyme inducers such as DDT 
is not straight forward. The toxicity of PAs is determined by a complex balance of toxification and de-
toxification enzymatic activity, all of which may be induced.  
Pretreating rats with an intraperitoneal dose of DDT (75 mg/kg) led to a four-fold increase in the 
liver microsomal conversion of the PA retrosine to its pyrrolic metabolites in vitro, but also a two 
fold increase in PA N-oxides, their major detoxification products272. For comparison a similar 
treatment with phenobarbitone (3 x 100 mg/kg), the prototypical enzyme inducer, led to a three-
fold increase in pyrrolic metabolites and a 2.3 fold increase in N-oxides. The effects of pre-treatment 
by phenobarbitone on PA toxicity in vivo appear to depend on the speed at which the particular PA 
used is normally metabolized by the animal tested112. Pretreatment with phenobarbitone increased 
the toxicity of monocrotaline and heliotrine in male and females rats but decreased the toxicity of 
lasiocarpine115. Similar pre-treatment protected male rats from retrosine toxicity but enhanced its 
toxicity in females. The susceptibility of guinea pigs to retrosine (who are normally relatively 
resistant) is greatly enhanced by phenobarbitone pre-treatment, while the susceptibility of mice is 
decreased85. Long term treatment with phenobarbitone was suggested as a factor contributing to 
two cases of veno-occlusive disease (VOD) following consumption of the PA-containing medicinal 
herb Heliotropium eichwaldii in India344. Autopsy of one of these cases showed extensive 
centrilobular necrosis of the liver. Conversely, centrilobular necrosis was not reported in the autopsy 
of another VOD case that had not had phenobarbitone treatment. 
Pretreatment with DDT significantly increased the hepatotoxicity of CCl4
25, a hepatotoxin with a 
similar toxic route to PAs, as shown by a decrease in the LD50 value and increases in isocitrate-
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dehydrogenase and bilirubin plasma concentrations. However one study reports that DDT pre-
treatment (100 ppm in diet over 14 days) protects against the toxicity of the PA-containing plant 
Senecio jacobaea in rats345. This conclusion is supported by an increased weight gain over 31 days in 
rats fed DDT in addition to S. jacobaea, and an enhanced survival time among male rats. However 
neither of these differences are reported as statistically significant. 
8.2 Aims and objectives 
The overall aim of this chapter is to test the hypothesis that chronic exposure to DDT increases the 
susceptibility of Hirmi Valley residents to the toxic effects of PA exposure. Specific objectives are 
therefore as follows: 
1. Measure levels of DDT and its metabolites in biofluids of residents of the affected villages. 
2. Determine whether there is a difference in concentration of DDT and its metabolites in 
biofluids from HVLD cases and controls. 
3. Determine the effects of DDT exposure on hepatic enzyme induction in the mouse model, 
through measurement of cyp3A11 expression. 
4. Test whether DDT exposure increases susceptibility to the PA, acetyllycopsamine, in the 
mouse model though biochemical measurements and characterisation of histopathological 
changes. 
5. Characterise the effects of DDT exposure on PA metabolism and associated endogenous 
metabolic changes, through 1H NMR analysis of mouse urine. 
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8.3 Methods 
8.3.1 DDT/DDE ELISA of patient biofluids 
8.3.1.1 Sample Collection 
Biofluid samples were collected from patients and controls, as detailed previously, over two visits to 
the region in November 2008 (serum and urine collected) and December 2009 (only urine collected). 
Samples were stored at -80 °C until use. 
8.3.1.2 ELISA assay 
A commercially available Enzyme Linked Immunosorbent Assay (ELISA) kit supplied by Abraxis, USA, 
was used to measure total levels of DDT and its metabolites DDE and DDD in urine and serum 
samples, according to the manufacturer’s protocol.  Prior to analysis, serum samples were first 
filtered through 0.2 µm filters and diluted 1:5 with 10% methanol in DDT/DDE-free distilled water. 
Urine samples were assayed undiluted. Standards were prepared from a p-p’-DDE stock solution and 
the 10% methanol solution and made up to 0, 0.625, 1.25, 2.5, 5, 10, 25 (and 75 for second urine 
assay) ppb of p-p’-DDE. 100 ml of wash buffer was diluted with 400 ml of distilled water. All reagents 
were supplied with the kit. 
25 µL of the standards solutions and biofluid samples were added to different wells of a 96 well 
microtitre plate coated with goat anti-mouse antibody. Two technical replicates were performed for 
each standard and sample. 50 µL of monoclonal mouse anti-DDT/DDE antibody solution was then 
added to each well using a multi-channel pipette and the plate covered with film, mixed by a careful 
and gentle swirling motion and allowed to incubate for 30 minutes.  50 µL of DDE/DDT- horseradish 
peroxidase enzyme conjugate was then added, which initiates a competitive reaction between the 
enzyme conjugate and the DDE/DDT present in the sample for the antibody binding sites. The wells 
were covered, mixed by gentle swirling and incubated for 30 minutes. The contents of the wells 
were then emptied into a waste container by vigorous shaking, 250 µL of wash buffer was added and 
then emptied by further shaking. Any remaining buffer was removed by patting onto paper towels. 
This wash step was repeated two more times. 150 µL of colour solution (containing hydrogen 
peroxide and the chromogen 3,3’,5,5’ tetramethylbenzidine ) was then added, which is catalyzed by 
the antibody-bound enzyme conjugate to produce a yellow colour, inversely proportional to the 
concentration of DDE/DDT originally in the sample. The reaction was left for 20 minutes and then 
stopped by the addition of 100 µL of stopping solution (dilute sulphuric acid). The plate was then 
immediately loaded onto a SpectraMax 340PC384 Absorbance Microplate Reader (Molecular 
Devices Inc., USA) and the absorbance read at 450 nm. 
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DDT concentration was calculated by first calculating the %B/B0 (standard mean absorbance divided 
by the zero standard mean absorbance) for each standard and then constructing a 4-parameter 
standard curve in Microsoft Excel. DDT/DDE concentrations for each sample were then calculated by 
interpolation to the curve. Statistical analysis was performed using the STATA software package. 
Wilcoxon rank sum tests were used to compare absorbance data (in lieu of total DDT concentration) 
between groups, expressed as the %B/B0 (sample technical replicate mean absorbance divided by 
the zero standard mean absorbance). 
8.3.2 Mouse dosing study design 
Animal husbandry, acetyl-(lycopsamine/intermedine) (AL) dosing, sampling, clinical chemistry and 
histological analysis, were as described in the chapter 7 methods section. 
p-p’- DDT (98%, Sigma-Aldrich, U.K.) was prepared by dissolving in olive oil (Tesco, U.K.) to make a 15 
mg/ml solution, which was administered by oral gavage. Mice in groups not receiving DDT, received 
the same volume of pure olive oil at the same dosing time. Mice were divided into four groups of 10 
mice and received the following dosing regimen (Table 8-1): 
Table 8-1: Dosing study design 
Group N Predosing over 1 week Postdose (Start of second 
week) 
Cull (24 hrs 
later) 
1: Control 10 3 x Oil only 1 x PBS only 
2: DDT only 10 3 x 75mg/kg DDT in Oil  1 x PBS only 
3: AL only 10 3 x Oil only 1 x 750 mg/kg AL  in PBS 
4: DDT & AL 10 3 x 75mg/kg DDT in Oil 1 x 750 mg/kg AL in PBS 
 
The experiment was conducted first with groups 1 (control) and 2 (DDT only). Their cyp3A11 
expression levels were then assessed before proceeding with dosing of groups 3 (AL only) and 4 
(DDT and AL). 
8.3.2.1 Histopathological severity scoring 
In consultation with pathologist Prof. Goldin, each mouse liver was given a score to rank them in 
order of histopathological severity. The liver pathology score was a follows: 1=normal, 2=mild 
vacuolation / congestion, 3= hepatocyte swelling, 4 = zone 3 necrosis, 5 = zone 2 and 3 necrosis. 
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8.3.3 Measurement of cyp3A11 expression in mouse liver 
8.3.3.1 RNA extraction 
RNA was extracted from snap frozen liver tissue using an RNeasy Mini kit (Qiagen, USA) following the 
manufacturers protocol. Prior to the start of the extraction, 10 µL of β-Mercaptoethanol (2-
mercaptoethanol 98+%, Sigma, UK) was added to 1 ml of Buffer RLT (proprietary buffer from kit). 1 
part of buffer RPE (proprietary buffer from kit) concentrate was diluted with four parts absolute 
ethanol (98%, molecular biology grade, Sigma, UK).  
Approximately 30 mg of liver tissue was used for each extraction. The tissue was quickly transferred 
to 1.5 ml Eppendorf tube containing 650µL of the β-Mercaptoethanol/ RLT buffer solution, without 
letting the tissue thaw, where it was lysed with a plastic grinding pestle. The RLT buffer contains 
guanidine isothiocyanate, which ensures any RNases present are rapidly inactivated. The lysate was 
transferred into a QIAShredder column (Qiagen, USA), which was then centrifuged at 12,000 rpm for 
2 minutes to homogenate the sample and left at room temperature until the next stage. The flow-
through from the column was collected and 650 µL of a 50% ethanol solution (prepared from 98% 
molecular biology grade ethanol and RNase free water, Sigma, UK) was added and thoroughly mixed 
by pipette aspiration, to promote binding to the membrane of the RNeasy spin column (from kit). 
650 µL of this mixture was transferred into the column which was centrifuged at 10,000rpm for 15 
seconds and the flow-through then discarded. This step was repeated with the remaining 650 µL of 
sample.  
350 µL of the first wash buffer RW1 (proprietary buffer from kit) was then added and the column 
centrifuged for 15 seconds at 10,000 rpm, and the flow-through discarded. To ensure no genomic 
DNA confounded subsequent rtPCR analysis, 80 µL of a solution containing 10 µL DNase I stock 
solution and 70 µL of buffer RDD (both proprietary reagents from the RNase-free DNase Set, Qiagen, 
USA) was added directly to the RNeasy spin column membrane and then incubated at room 
temperature for 15 minutes. A second wash with 350 µL of RW1 buffer was then performed as 
above. 500 µL of wash buffer RPE was then added and the column centrifuged for 15 seconds at 
10,000 rpm and the flow-through discarded. A second wash with 500 µL of wash buffer RPE was 
again performed but centrifuged for 2 minutes at 10,000rpm to dry the column membrane, and the 
flow-through discarded. The column was then carefully transferred into a new 2 ml collection tube 
(supplied with kit) and centrifuged at 10,000 rpm for 1 minute to avoid any contamination with the 
wash buffers. The column was finally transferred into a new 1.5 ml collection tube (supplied with kit) 
and 50 µL of RNase free water (from kit) was added, allowed to soak into the column membrane for 
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1 minute and then centrifuged for 1 minute at 10,000 rpm to elute the RNA. Appropriate measures 
were taken at all times to avoid contamination. RNA samples were stored at -80°C until use. 
8.3.3.2 RNA gel electrophoresis 
To determine whether the RNA extraction had been successful, an RNA gel electrophoresis was 
performed. A 1 % agarose gel was prepared by adding 0.5 g of agarose to 50 ml of 1 x TBE buffer 
(dilution of 10x tris-borate ethylenediaminetetraacetic acid buffer, Sigma, UK) and heating in a 
microwave until dissolved. The cooled solution was added to a gel tank (cleaned with RNase zap, 
Ambion) with well combs already inserted and allowed to set. 1x TBE running buffer was added to 
cover the gel. Eight representative RNA samples were chosen for testing and 5 µL of each sample 
was mixed with 2 µL of RNA sample loading buffer, pre-prepared with 50 μg/mL of ethidium 
bromide (Sigma, UK) for UV visualization. The samples were heated to 65 °C for 10 minutes to 
denature the RNA and then pulse centrifuged before loading onto the gel. A current of 80 volts was 
applied for 50 minutes before being examined under UV lights.  
8.3.3.3 Complimentary DNA (cDNA) synthesis 
cDNA was synthesised from the extracted RNA, using the RETROscript kit (Ambion, USA), following 
the manufacturer’s protocol. The RNA samples were allowed to thaw on ice while reaction mixes 1 
and 2 were prepared. Reaction mix 1 was made up of 44 µL of oligo(dT) primers (a short sequence of 
deoxy-thymine nucleotides) and 165 µL of nuclease-free water. Reaction mix 2 contained 44 µL of RT 
buffer, 88 µL of dNTP mix (a mix of the four deoxyribonucleotides), 22 µL of RNase inhibitor and 22 
µL of MMVL-RT (the reverse transcriptase). All reagents were included in the kit.  
9.5 µL of reaction mix 1 was mixed with 2.5 µL of each RNA sample in a polymerase chain reaction 
(PCR) tube. The tubes were then pulse-centrifuged prior to heating for 3 minutes at 80 °C in a 
GeneAmp PCR system 9700 (Applied Biosystems, USA), to denature the RNA and initiate binding at 
the poly-adenine tail of mRNA. The tubes were then removed onto ice and briefly centrifuged before 
8 µL of reaction mix 2 was added to each tube and gently mixed by pipette aspiration. The tubes 
were briefly centrifuged before incubation at 43 °C for 1 hour and then a final heating to 92 °C for 10 
minutes to inactivate the reverse transcriptase. The sample tubes were then stored at -20 °C until 
further use.  
8.3.3.4 Standard PCR 
To confirm the quality of cDNA, a PCR reaction was performed on a subset of  five cDNA samples 
using custom primers for the housekeeping gene Glyceraldehyde 3-phosphate dehydrogenase 
238 
 
(gapdh, Invitrogen , USA) (Table 8-2). A reaction mix was first made up containing 60 µL premade 2 x 
PCR Master Mix (Promega, USA), 4.8 µL of 10µM forward primer, 4.8 µL of 10µM backward primer, 
and 44.4 µL of nuclease-free water. 19µL of the reaction mix was mixed with 1 µL of each cDNA 
sample (or 1 µL of nuclease-free water for the negative control) in a PCR tube and the tubes pulse 
centrifuged before loading onto a GeneAmp PCR system 9700. The thermocycling conditions are 
shown in Table 8-3. 
Table 8-2: Primers used in standard PCR 
Primer name Sequence 
Mouse GAPDH forward A A C T T T G G C A T T G T G G A A G G 
Mouse GAPDH backward A C A C A T T G G G G G T A G G A A C A 
  
Table 8-3: Thermocycling conditions for standard PCR of GAPDH 
Reaction Step Temperature °C Time 
Initial Activation  95 3 minutes 
Cycle x 35 Denature 94 30 seconds 
Anneal 54 30 seconds 
Extend 72 30 seconds 
Final Extension step  72 5 minutes 
Hold  4 Indefinite 
 
Gel electrophoresis was performed on the PCR products using a 2 % agarose gel (made from 1 g 
agarose and 5µL of ethidium bromide in 50 ml of 1 x TBE buffer) in a 1x TBE buffer solution. 5 µL of 
xylene orange loading dye was mixed with 20 µL of each PCR sample and loaded onto the gel. 5 µL of 
100-1000 bp DNA ladder (Hyperladder IV, Bioline, UK) was also added to adjacent wells. An 85 volt 
current was applied for 35 minutes before UV visualisation. 
8.3.3.5 rtPCR 
To determine the relative gene expression of cyp3a11 in the mouse livers, a quantitative PCR 
analysis was performed using TaqMan Gene Expression Assays (Applied Biosystems, USA). FAM-
labelled assays specific for cyp3aA11 (catalogue number: Mm00731567_m1) and gapdh 
(endogenous control) were used in separate simplex reactions, following the manufacturer’s 
protocol. A reaction mix was made up separately for both of the TaqMan assays, containing 70 µL of 
the 20 x Taqman Assay being used, 700 µL of 2 x TaqMan Gene Expression Master Mix (Applied 
Biosystems, USA) and 560 µL of RT-PCR Grade Water (Ambion, USA). 19 µL of the appropriate 
reaction mix was added to each well of an optical 96-well plate (Applied Biosystems, USA) that was 
being used for a reaction. After gently tapping down the plates, 1µL of cDNA sample was added 
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directly to the reaction mix within the well, and mixed by pipette aspiration. The plates were sealed 
with film and briefly centrifuged before loading onto an Applied Biosystems 7500 Fast Real-time PCR 
System. A standard speed thermal cycling condition set up was used (Table 8-4). Three technical 
replicates were performed for each sample and 6 negative (no cDNA template) controls were run for 
each assay: 
Table 8-4: TaqMan rtPCR Cycling Conditions 
Reaction Step Temperature °C Time 
Amperase UNG Activation  50 2 minutes 
Initial Activation Step  95 10 minutes 
Cycle x 45  Denature 95 15 seconds 
 Anneal/ Extend 60 1 minute 
 
cyp3a11 expression data were normalised to gapdh expression using the Comparative ΔΔCT 
method346 to determine the difference in expression between the DDT treated group relative to 
control animals. 
8.3.4 Metabonomic Analysis of mouse urine 
1H NMR of mouse urine and analysis was as described in the previous chapter. 
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8.4 Results 
8.4.1 Measurement of DDT in patient serum 
To confirm exposure to DDT among HVLD patients, an ELISA assay was conducted on serum samples 
from cases and controls, which measures levels of total DDT (DDT and its metabolites DDE and DDD).  
The standard curve constructed from standards of known DDE concentration run on the same ELISA 
plate as the serum samples, was well-fitted (R2=0.99) to the absorbance data of the standards 
(Figure 8-2). 
 
Figure 8-2: Standards curve for serum ELISA, constructed from standards of known DDE concentration. %B/B0 shows the 
mean absorbance of technical replicates of standard, divided by mean absorbance of zero standards (containing no 
DDT/DDE). 
Serum samples were analysed from 40 HVLD patients and controls, whose demographic information 
is shown in Table 8-5. 31 out these samples (78%) had serum total DDT concentrations above 125 
ppb, the upper limit of the ELISA assay, indicating high levels of DDT exposure in the majority of 
participants. To determine whether there was any difference in DDT concentrations between cases 
and controls, a Wilcoxon Rank Sum test was performed using the plate absorbance data (%B/B0, 
which is directly proportional to total DDT concentration). No significant difference could be 
detected (p=0.81). 
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Table 8-5: Demographic information and total DDT serum concentration results of participants, stratified by disease 
status. 
  Cases Controls 
Number 26 14 
Mean Age (Standard Deviation) 24.2 (19.5) 30.9 (19.6) 
Number males  22 (85%) 5 (36%) 
Number from Kelakil 9 (35%) 5 (39%) 
Number from Kiburto 9 (35%) 1 (7%) 
Number from Mekeyho 8 (31%) 8 (57%) 
Number with total DDT serum 
concentration > 125 ppb 
21 (81%) 10 (71%) 
Minimum total DDT concentration  50 ppb 40 ppb 
 
Interestingly, comparison of absorbance data revealed total DDT serum concentrations to be 
significantly higher (p=0.04) among residents of Kelakil (the temporary village camp of residents 
from Tseada Amba, the originally affected village) than among residents from Kiburto and Mekeyho 
(Figure 8-3).  
 
Figure 8-3: Distribution of serum total DDT concentrations (optical density from plate reader) in samples collected from 
Kelakil and from Mekeyho or Kiburto. Total DDT concentrations are inversely related to the optical density of the sample 
and therefore the optical density is expressed as 1-%B/B0. P value calculated from Wilcoxon rank sum tests comparing 
%B/B0 between serum samples collected from Kelakil residents and from other villages. 
No relationship between age of participant and total DDT concentration could be detected (Figure 
8-4). This suggests that it is DDT (a measure of recent DDT exposure) rather than DDE (a cumulative 
measure of life-time DDT exposure347, 348) that is contributing most to measurements in this assay. 
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Figure 8-4: Relationship between age and serum total DDT concentration (shown as optical density). 
8.4.2 Measurement of DDT in patient urine 
Figure 8-5 displays the standard curve constructed for the second assay performed on urine 
samples, which again was well-fitted (R2=1.00). Since I had collected a large number of urine samples 
combined with information specifically regarding the prevalence of HVLD in the households of 
controls providing these samples, it was possible to age and gender match cases with “village 
controls”, who did not share a food supply with HVLD cases. This may have indicated whether DDT 
exposure was greater among cases than village controls from unaffected households. Again total 
DDT concentrations were found to be high with 21/40 samples (53%) having urine concentrations 
above 75 ppb, the upper limit of the assay (Table 8-6). The minimum concentration was found to be 
5 ppb.  There was no significant difference between total DDT concentration (plate absorbance data) 
between cases and village controls (p=0.97).  
 
Figure 8-5: Standards curve for urine ELISA, constructed from standards of known DDE concentration. %B/B0 shows the 
mean absorbance of technical replicates of standard, divided by mean absorbance of zero standards (containing no 
DDT/DDE). 
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Table 8-6: Demographic information and total DDT urine concentration results of participants, stratified by disease 
status. 
  Case Village control 
Number 20 20 
Number male 11 (55%) 9 (45%) 
Mean Age (Standard Deviation) 26.8 (19.4) 26.7 (19.6) 
Number collected in Kelakil 2009 14 (70%) 15 (75%) 
Number collected in Kiburto 2008 6 (30%) 5 (5%) 
Number with total DDT urine  
concentration >  75 PPB 
11 (55%) 9 (45%) 
Minimum total DDT urine 
concentration  
4.93 ppb 5.23 ppb 
 
There was a large difference (p = 0.0002) in total DDT concentration between samples collected 
from residents of Kiburto in 2008 and Kelakil in 2009 (Figure 8-6).  While the higher levels among the 
Kelakil residents may reflect greater DDT use as observed in the serum samples, the difference in 
urinary concentrations between collections was much greater and is likely to reflect sample 
degradation following an extra year of storage. 
 
Figure 8-6: Distribution of urine total DDT concentrations (optical density from plate reader) in samples collected from 
Kiburto in 2008 and from Kelakil in 2009. Total DDT concentrations are inversely related to the optical density of the 
sample and therefore the optical density is expressed as 1-%B/B0. P value calculated from Wilcoxon rank sum tests 
comparing %B/B0 between serum samples collected from Kelakil residents and from other villages. 
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8.4.3 Induction of CYP3A in mice dosed with DDT 
Successful RNA extraction from mouse liver samples and subsequent cDNA synthesis were both 
confirmed by gel electrophoresis (Figure 8-7), as indicated by the characteristic double rRNA bands 
and the expected gapdh PCR product at around 200 bp. 
 
Figure 8-7: Photographs under ultraviolet light of RNA (left) and cDNA (right) gel electrophoresis. 
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Real time-PCR analysis demonstrated a mean 2.34 fold increase in cyp3a11 expression among DDT 
treated mice compared to control mice (p= 0.0002) (Figure 8-8).  
 
Figure 8-8: Changes in cyp3a11 expression (relative to gadph expression) following DDT treatment. Top: cyp3a11 
expression (relative to gadph expression) for each mouse in control group (on left of graph, labelled with numerical ID 
beginning in ‘C’) and DDT treated group (right of graph, labelled with numerical ID beginning with ‘T’). Errors bars indicate 
standard deviation within technical replicates. NTC indicates the non-template controls. Bottom: Mean fold change in 
cyp3a11 expression in DDT treated group compared to control group. Errors bars indicate standard error within group. 
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8.4.4 Hepatotoxicity of co-exposure to DDT and PA 
Pre-dosing mice with DDT significantly increased the hepatotoxicity of AL, as indicated by plasma 
aminotransferase values (Figure 8-9). Mice exposed to a week of pre-dosing with DDT (3 x 75 mg/kg) 
followed by a single 750 mg/kg dose of AL, showed a significant increase (p= 0.0065) in plasma ALT 
concentrations (Mean = 469.8 U/l, S.E. = 205.2) compared to mice who received the same dose of 
AL, without being pre-dosed with DDT (Mean = 84.7 U/l, S.E. = 15.9).  
 
Figure 8-9: Comparison of mean ALT and AST plasma concentration between groups of mice receiving various 
combinations of DDT and AL. Errors bars indicate standard error. P values show result of Wilcoxon rank sum test on ALT 
values. In the case of 1 mouse in group 4, which had aminotransferase concentrations above upper limit of assay, the 
upper limit was used to calculate statistics. 6 plasma samples also showed slight haemolysis, which may make some AST 
values inaccurate. 
The AL-only dosed group had significantly higher (p= 0.0002) ALT plasma concentrations compared 
to the control group (Mean = 32.5 U/l, S.E. = 2.7), while the DDT–only dosed group ALT 
concentrations (Mean = 48.7 U/l, S.E. = 16.9) were not significantly different from the control group, 
despite one mouse in the DDT- only dosed group having raised aminotransferase values. This mouse 
also had the highest levels of cyp3A11 expression, suggesting that the hepatotoxic properties of DDT 
are related to its enzyme induction capabilities (Figure 8-10). 
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Figure 8-10: Relationship between plasma aminotransferase concentration and cyp3A11expression, among mice dosed 
with DDT only. 
Liver weight (as a percentage of body weight) was significantly higher (p = 0.008) among mice in the 
DDT and AL dosed group (mean = 5.2%, S.E.= 0.5%) compared to the AL- only dosed group (mean = 
4.5%, S.E.= 0.7%). There was no statistically significant difference in liver weight between mice in the 
DDT –only dosed group (Mean = 5.0 %, S.E. = 0.7%) and the control group (mean = 4.6%, S.E. =0.4%). 
Histological analysis of liver samples also revealed greater liver injury among mice in the DDT and AL 
treated group, compared to all other groups (Figure 8-11). In the DDT and AL treated group, there 
were varying states of liver injury: This ranged from no observable injury in one liver, to mild 
vacuolation in the zone 1 region in two livers, through to congestion in the zone 3 region in one liver; 
and swollen hepatocytes apparent in three other livers, principally in the zone 3 region. In three 
other livers (from mice with the greatest plasma ALT/AST scores) there was extensive zone 3 
necrosis, which extended into the zone 2 region in two of these liver specimens. The extent of 
observed liver pathology was well correlated with ALT score (r=0.79, Figure 8-12). 
No significant liver damage could be observed in livers from the control group and from all but two 
livers in the DDT–only treated group. In two of the DDT-only treated livers there was focal lobular 
inflammation, with focal necrosis in one of these livers and granuloma observable in the other. All 
livers in the AL-only treated group appeared normal, except for one liver where swollen hepatocytes 
could be observed in the zone 1 region.  
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B 
Figure 8-11: Histology of mouse livers. Stained by H & E. A: Normal liver from DDT-only dosed group. x100. B: Normal Liver 
from AL-only dosed group. x100. C: Small foci of necrosis observed in one liver in DDT-only dosed group x400. D: Swollen 
hepatocytes (arrowed) in DDT and AL treated mouse. x 200. E: Zone 2 and 3 bridiging necrosis in DDT and AL treated mouse. 
X100. F: Same as E. x200. G: Zone 3 necrosis in DDT and AL treated mouse. X100. H: Same as G. x200 
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Figure 8-12: Relationship between plasma ALT score and histopathological severity among mice treated with DDT (3x 75 
mg/kg) and AL (750 mg/kg). r shows Spearman rank correlation. See methods for details of histopathology score. One 
mouse with ALT score above upper limit of assay (and most severe liver pathology score of 5) was excluded from analysis. 
8.4.5 Effect of DDT on PA metabolism 
Comparison of the concentration of the four AL metabolites identified in the 1H NMR spectra of 
urine samples, revealed only small changes between the AL only dosed group and the DDT and AL 
dosed group (Figure 8-13). Little difference could be observed for metabolites AL-2 and AL-4, while 
there was a borderline significant increase in the concentration of AL-1 among the DDT and AL 
treated group (p= 0.049). The concentration of AL-3 (a glucuronide of AL) was greatly increased 
among 3 mice in the AL only treated group, although there was little difference among the rest of 
the mice and the overall difference was non-significant. 
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Figure 8-13: Comparison of urinary concentration of the four AL metabolites identified between the AL only and the DDT 
and AL treated groups.  Titles indicate the region of the spectrum integrated to derive metabolite peak intensities. Points 
represent values for individual mouse samples. Horizontal bars show median values. P values calculated from Wilcox Rank 
Sum test comparing groups. 
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Since within each group there was a wide variation in the liver injury caused, PA metabolism was 
compared after mice were divided into further susceptible and resistant groups based on their ALT 
scores (Figure 8-14). Mice in the AL only treated group were divided into two equal sized groups of 
high and low scores while mice in the DDT and AL dosed group were divided into two groups based 
on having an ALT score above or below the highest value among mice in the AL only dosed group 
(217 U/l). Metabolite AL-1 was not significantly different between resistant and susceptible mice in 
either dosing group, although counter-intuitively the median AL-1 concentration was slightly lower 
in susceptible mice than in resistant mice in the AL only dosed group and slightly higher in 
susceptible mice in the DDT and AL dosed group. This suggests that this metabolite is neither a 
toxification or detoxification product. Metabolites AL-2 and AL-4 were both decreased among 
susceptible mice in both dosing groups, and significantly so in the DDT and AL dosed group (p= 0.038 
and p=0.001 respectively), indicating that these are both detoxification products. AL-3, the 
glucuronide conjugate, was elevated among susceptible mice in the AL only dosed group and this 
increase was borderline significant (p=0.056) compared to the resistant mice. Interestingly, there 
was no difference in AL-3 levels between resistant and susceptible mice in the DDT and AL dosed 
group and this metabolite was not greatly elevated among any of the mice in this group, despite 
many of the resistant mice having similar ALT scores to the susceptible mice in the AL-only dosed 
group. 
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Figure 8-14: Comparison of AL metabolite concentrations among susceptible and resistant mice within each dosing 
group.. Points represent values for individual mouse samples. Horizontal bars show median values. P values calculated 
from Wilcox Rank Sum test comparing groups. 
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8.4.6 Effect of DDT and AL on endogenous metabolism 
The relative urinary concentrations of endogenous metabolites identified in the previous chapter as 
being perturbed following acute AL dosing, were compared between mice in the AL-only and DDT 
and AL dosed groups (Figure 8-15). No significant differences were observed between the groups, 
although the differences in median concentrations were greater for metabolites associated with the 
gut microflora than for metabolites associated with liver injury. The largest difference was observed 
for hippurate, which had a lower median concentration among DDT and AL treated mice, but this 
was not significant at the 5% confidence level (p = 0.075).  
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Figure 8-15: Comparison of urinary concentration of selected endogenous metabolites between the AL only and the DDT 
and AL treated groups.  Titles indicate the region of the spectrum integrated to derive metabolite peak intensities. Points 
represent values for individual mouse samples. Horizontal bars show median values. P values calculated from Wilcox Rank 
Sum test comparing groups. Triangles indicate susceptible mice and squares indicate resistant mice with each group. 
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Only tyrosine was correlated with the extent of liver injury (Figure 8-16) in both the AL only dosed 
group (r=0.72, p=0.02, with ALT score) and the DDT and AL dosed group (r= 0.70, p= 0.03, with 
histopathology score). Interestingly, p cresol was positively correlated with liver injury in the AL only 
dosed group (r=0.58, p=0.09, with ALT score) but negatively correlated in the DDT and AL dosed 
group (r= -0.57, p= 0.09, with histopathology score) although these were not significant at the 5% 
confidence level.  
 
Figure 8-16: Associations between tyrosine (top row) and p-cresol glucuronide (bottom row) and extent of liver injury, in 
each dosing group. r shows Spearman rank correlation.  
Tyrosine was also found to be well correlated with levels AL-3, the glucuronide of AL, following both 
a single 750 mg/kg dose of AL (r= 0.90, p = 0.001) and a single 1500 mg/kg dose (r=1.0, p=0.017, 
from work presented in last chapter) (Figure 8-17). 
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Figure 8-17: Association between tyrosine and AL-3 concentration, 24 hours after a 750 mg/kg dose (left) and a 1500 
mg/kg dose of AL (right). r shows Spearman rank correlation. Note that datasets for each graph were normalised 
separately so metabolite concentrations may not be directly comparable between dosing. 
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8.5 Discussion 
8.5.1 DDT exposure among Hirmi Valley residents 
The majority of serum samples tested (78%) had high levels of total DDT, above 125 ppb which was 
the upper limit of detection with the assay used. This confirms that the chemical the villagers report 
adding to their harvest prior to storage was in fact DDT (and not a mistranslation or locally available 
variant). Unfortunately because of the dynamic nature of the colourmetric reaction of the assay up 
to its upper limit, it is not possible to reliably extrapolate the standard curve to estimate the total 
DDT concentrations above this limit. However from comparison to existing studies that report total 
DDT serum concentrations among different populations it is clear that residents of the Hirmi Valley 
are heavily exposed to DDT. A mean of 13 ppb (range: 5-38 ppb) was reported among 44 healthy 
English adults in the 1960’s304 and a mean of 77 ppb (SD = 26 ppb) was reported among 96 
occupationally exposed Ugandan IRS sprayers of DDT340. The mean total DDT serum level among the 
Hirmi Valley residents is also likely to be above levels reported for 499 people living downstream 
from a DDT factory304 (mean = 159 ppb) and above the highest level ever reported for dwellers of 
houses sprayed with DDT, where a mean of 175 ppb (SD= 120 ppb) was reported for 66 South 
African residents, 10 days after DDT was applied to their houses349. No spraying of DDT to homes in 
the months prior to serum sampling was reported by the Hirmi Valley interviewees. 
Furthermore this measurement is likely to be an underestimate of actual serum concentrations due 
to degradation of samples in the 28 months since sample collection. The manufacturers of the ELISA 
assay recommend that samples are immediately extracted with 10% methanol in glass vials with 
Teflon lined caps to prevent any absorptive losses into the collection tubes. Serum and urine 
samples were not collected specifically for this assay and so were stored normally in plastic 
containers. Analysis of urine samples collected a year apart showed a significant reduction in DDT 
levels, and while there may be real differences between exposures between the years, this is likely 
to reflect a degree of sample degradation. 
No significant difference could be detected in the total DDT concentrations between cases and 
controls in serum samples and also in urine samples where cases had been age, collection and 
gender matched with controls from unaffected households. This may be expected since the addition 
of DDT to food stores is reported to be a common practice among residents of the affected villages. 
The work to detect AL in urine samples, presented in chapter 6, has indicated that the concentration 
of AL itself differs significantly between case and control, and is therefore likely to be the necessary 
(if not sufficient) factor in determining disease outcome. Significantly greater total DDT 
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concentrations were found in both serum and urine samples collected from residents originally from 
Tseada Amba. This suggests different levels of DDT exposure among villages within the region and 
may be a contributory factor to the greater prevalence of HVLD in Tseada Amba. 
8.5.2 DDT synergistically increases the hepatotoxicity of Acetyllycopsamine 
These experiments have shown that prior exposure to DDT dramatically increases the hepatoxic 
effects of AL, as demonstrated by both biochemical and histopathological assessment. The mean 
plasma ALT scores of mice pre-treated with DDT, following a single dose of AL was more than 4 times 
higher than in mice not pre-treated with DDT. While some liver inflammation was detected when 
these chemicals were administered independently, the plasma ALT increase when administered 
together was greater than the combined increases when administered separately, compared to 
controls. This indicates a synergistic, rather than additive, effect that is consistent with induction of 
cytochrome p450 enzymes and increased activation of AL toxicity. 
Histologically, there was observable liver injury in all but one of the mice treated with both DDT and 
AL, while only one of the AL only treated mice showed any liver injury. The most severely affected 
DDT and AL co-treated mice showed extensive centrilobular necrosis, reminiscent of the necrotic 
injury observed in acute HVLD patients. Furthermore an additional pathological feature of HVLD, 
swollen hepatocytes or megalocytosis, was observed in three other livers from DDT and AL co-
treated mice in a similar centrilobular distribution. While swollen hepatocytes were observed in one 
AL-only treated mouse, they occurred in a more periportal region. This demonstrates that following 
exposure to DDT; the pathological features of HVLD are more closely and readily induced, using 
lower doses of AL.  
Again, bile ductular proliferation was not induced and may not be expected as it appears to be 
associated with the chronic form of the disease in HLVD patients (and as discussed in the previous 
chapter, may not frequently occur in the male ‘black 6’ strain mice used). However this pathological 
feature is caused by an inappropriate regenerative response to liver injury and often occurs 
following PA exposure34, and may have been observed had mice been given a sufficient recovery 
period following dosing. Mild vacuolation was observed in the periportal region of two mouse livers 
following exposure to both DDT and AL and may be indicative of the initial injury to which the 
proliferation occurs as a response.  
The results are apparently in contrast to the only other paper I am aware of that reports the effects 
of DDT pre-treatment on PA toxicity. Cheeke and Garman345 report that between groups of 5 rats 
each fed a diet of 5% S. jacobaea until death, the group that was initially pre-treated with DDT (100 
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ppm in diet over 14 days) had a greater weight gain (by a factor of 1.53 in males and 1.82 in females) 
and male rats from the DDT treated group apparently survived for longest (76 days compared to 48 
days in equivalent group without DDT pre-treatment). However, it is not reported how the weight 
gains are measured and reported, what proportion of the groups survived to time reported and 
whether these differences are statistically significant. If their results do reflect a truly protective 
effect, the conflicting results may be explained by the type of PAs test since senecio PAs are far more 
toxic than AL and so may be metabolised differently. More pertinently to HVLD, the difference may 
also reflect a different effect of DDT on single acute dosing and chronic dosing over a long period of 
time. 
8.5.3 Cytochrome P450 induction following DDT exposure 
The increased liver weight observed following DDT treatment is likely to reflect induction of liver 
microsomal enzymes (and may be of additional significance since hepatomegaly is a common 
feature of HVLD). In this study, significant increases (mean 2.3 fold) in the expression of CYP3A11 
was observed following dosing of 3 x 75 mg/kg DDT over the week prior to measurement. This is in 
line with results reported in other studies, although comparison is difficult since most induction 
studies dose by ppm of DDT in the diet over 2 weeks of feeding. Assuming mice eat a quantity of 
food equal in weight to 15% of their body weight per day, the dosing in this study is approximately 
equivalent to a week of a diet containing 200 ppm DDT. Similar dosing over two weeks in rats led to 
approximately a 100% increase in p-nitroanisole metabolism327, an approximately 3-fold increase in 
testosterone 6β-hydroxylase activity (mediated by CYP3A)332 and a 20-fold increase in 
pentoxyresorufin O-dealkylation activity (mediated by CYP2B)330. A 2000 ppm DDT diet led to a 2.1 
fold increase in levels of measured immunoreactive CYP3A1 protein in rat liver microsomes330. Lower 
dosing than used in this study, a single 75 mg/kg intraperitoneal injection of DDT, led to an 
approximately 35% reduction in the LD50 of carbon tetrachloride in rats
25 and a 4-fold increase in rat 
liver microsomal conversion of the PA retrosine to its pyrrolic metabolites in vivo85. While CYP3A is 
known to be a very important enzyme in the activation of PA toxicity, the increase in its expression 
measured in this study is likely to reflect induction of a number of enzymes involved in the 
metabolism of AL, including CYP2B that in previous studies is induced at greater levels than CYP3A330, 
332. 
The level of enzyme induction was not measured in HVLD patients and it is possible that the DDT 
doses given to mice in this study (that induced enzyme expression) were greater than the levels 
ingested by Hirmi Valley residents. Only two studies, to the best of my knowledge, have attempted 
to associate enzyme induction with serum DDT measurements in humans. Poland et al.336 found that 
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among factory workers with serum DDT levels above 300 ppb, urinary levels of 6β-hydroxycortisol 
were significantly higher than controls while Morgan and Roan350 found no association between 
urinary glucaric acid and serum DDT concentration among agricultural workers (mean serum DDT of 
participants in highest concentration quartile = 52 ppb). 6β-hydroxycortisol is produced by CYP3A4 in 
humans from cortisol, and is considered a fairly good indicator of the activity of this enzyme, 
although it appears that due to circadian and inter-individual variation it is only a reliable indicator 
where subjects are used as their own controls and 6β-hydroxycortisol levels are expressed as a ratio 
to cortisol351. Glucaric acid concentration reflects the activity of the glucuronidation pathway352. 
Therefore of the two studies, the work by Poland is the most relevant since its outcome measure, if 
not completely validated, is directly related to the PA activation pathway. Ronald et al.330 related 
total DDT serum burden to DDT levels in the diet in experiments with rats. A serum concentration of 
92 ppb total DDT (lower than in 88% of Hirmi Valley serum samples) was measured following feeding 
of a diet containing 9.4 ppm DDT over 2 weeks, which induced a small but significant increase (30%) 
in hepatic O-dealkylation activities associated with CYP2B. This suggests that even the minimum 
possible DDT serum concentrations among the majority of Hirmi Valley resident samples reflect 
exposure levels that are capable of inducing hepatic enzymes. 
8.5.4 Effects of DDT on AL metabolism 
The relative urinary concentrations of AL metabolites, identified in the previous chapter, were 
measured by NMR spectroscopy. Since DDT appears to alter the metabolism of AL by increasing the 
proportion converted to toxic pyrrolic metabolites, one would expect to observe differences to 
levels of AL metabolites excreted in the urine, following DDT pre-treatment. Although these may not 
be directly related to the toxification pathway since the pyrrolic metabolites bind to macromolecules 
and may not be excreted in the urine, alteration to levels of metabolites involved in other metabolic 
pathways can indirectly indicate changes to the toxification pathways. Comparison of the mean 
levels of AL metabolites detected in urine of all mice in groups either pre-treated or not with DDT, 
showed only a significant increase in metabolite AL-1. Also of interest, was the fact that AL-3, a 
glucuronide of AL, was not greatly elevated in any of the DDT pre-treated mice, suggesting that DDT 
may prevent the glucuronidation of AL. Since this process is associated with the detoxification of 
xenobiotics, this may indicate an alternative mechanism by which DDT increases the toxicity of AL.  
A high variability in liver injury was observed among DDT pre-treated mice, which is likely in part to 
reflect variation in enzyme induction since CYP3A11 relative expression among DDT-only treated 
mice ranged from 1.36-3.40. Although variability was also observed among mice dosed with AL only, 
it was smaller than among mice pre-treated with DDT. Al metabolite relative concentrations were 
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compared between resistant and susceptible mice within each dosing group. The median 
concentrations of AL-2 and AL-4 were lower among susceptible mice in both dosing groups 
indicating that they are detoxification metabolites, potentially an N-oxide and lycopsamine 
respectively. The levels of these metabolites were significantly lower among the susceptible mice of 
the DDT pre-treated group. This is consistent with DDT-induced increased metabolism of AL to toxic 
intermediaries among these mice, reflected in the lower concentration of the metabolites of 
alternative detoxifying pathways.  
AL-1, thought to be viridofloric acid -the necic acid of acetyl-lycopsamine, showed no significant 
difference in median concentration between susceptible and resistant mice in either dosing group, 
and in fact was lower among susceptible mice not pre-treated with DDT but higher among 
susceptible mice that were DDT pre-treated. This suggests AL-1 is neither a toxification or 
detoxification metabolite, which would be expected of viridofloric acid because it is produced by 
either hydrolysis of acetyl-lycopsamine (a detoxification pathway), or by hydrolysis of the putative 
toxic pyrrolic ester metabolite(s), dehydro(acetyl)lycopsamine, to produce a secondary toxic 
metabolite, the pyrrolic alcohol dehydroretronecine, and viridofloric acid. The significantly higher 
levels of this metabolite among all DDT pre-treated mice may therefore reflect a greater overall AL 
metabolic activity. 
AL-3, a glucuronide of AL, was elevated among the susceptible mice of the group not pre-treated 
with DDT, suggesting it may be associated with the toxic effects of AL. Furthermore it was raised 
only in mice with the highest levels of tyrosine and also associated with urinary tyrosine levels 
among mice who received a 1500 mg/kg dose of AL. This seems likely to mainly result from the 
association tyrosine has with the levels of injury caused by AL. Since glucuronidation is considered a 
phase 2 detoxification reaction, AL-3 may be a glucuronide of a pyrrolic metabolite and the 
association with increased toxicity a reflection of greater availability of these pyrrolic metabolites. 
However it is not obvious why a similar level of glucuronidation was not observed among DDT 
treated mice, despite some of the resistant DDT-treated mice having similar ALT scores to the mice 
that had elevated levels of AL-3. DDT has been shown in one study to induce the activity of 
glucuronyltransferase to a similar extent to CYP3A332, although the assay used may not have been 
specific to the enzyme involved in AL glucuronidation. Alternatively the glucuronosyl group may be 
attached at the nitrogen atom of unchanged AL, as demonstrated for the PA senecionine in vitro124. 
The lower levels of AL-3 in DDT treated mice may then be explained by greater metabolism leaving 
less AL available for N-glucuronidation. Either way the lower levels of the glucuronidation pathway 
of AL following DDT treatment, is likely to contribute to the enhanced toxicity. 
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A further point of interest regarding the urinary levels of AL metabolites relates to a single mouse in 
the AL-only dosed group. This mouse had a very high outlying ALT score for the group of 217 U/l but 
none of the typical changes to AL metabolism observed among susceptible mice. Assuming that this 
is not the result of an experimental or labelling error (and it should be noted that there was no 
associated liver pathology observed), it suggests that the variation in AL toxicity observed in my 
research does not arise exclusively from differing levels of enzyme activity and toxic pyrrole 
production, and in some cases is more consistent with a role for endotoxin contamination increasing 
toxicity through mediation of the inflammatory response274. 
8.5.5 Interactions with endogenous metabolism 
No significant difference was found in the urinary concentrations of selected endogenous 
metabolites (that were found to be perturbed following a single 1500 mg/kg dose and detailed in 
previous chapter), when mice in the AL only and DDT and AL dosing groups were compared. This 
suggests that the concentration of these metabolites is for the most part, not directly associated 
with the severity of liver damage induced. There was greater difference observed (although still non-
significant) for the microflora associated metabolites than metabolites associated with liver damage. 
This supports the view that changes to the microbial ‘ecology’ are a separate effect and not 
secondary to effects on the liver and in turn host environment. The greatest difference between the 
groups was detected in hippurate levels which had a lower median concentration among mice 
receiving both DDT and AL. This could relate to induction of CYP3A enzymes that are present (but 
unevenly distributed) in the gastrointestinal tract353, increasing the ‘first-pass metabolism’ of AL to 
toxic pyrrolic metabolites, and reducing the prevalence of benzoic acid producing-bacteria, either 
directly or indirectly by damaging the gut mucosal lining. Interestingly the response of p-cresol 
glucuronide, similarly a mammalian-microbe co-metabolite, was rather different. Its concentration 
increased with liver damage within the AL only dosed group and its median concentration was 
higher among the DDT and AL dosed group samples. This may be explained in two ways. Firstly, the 
bacterial species that produce p-cresol may be less sensitive to AL than the benzoic acid producing 
species and expand in numbers at their expense or may reside in areas of the gastrointestinal tract 
where the CYP3A4 expression is much lower. Secondly, the greater pool of tyrosine available 
following AL exposure allows a greater production of p cresol. While no significant correlation could 
be detected between tyrosine and p-cresol glucuronide levels (r=0.41, p=0.25, AL-only dosed group) 
it may not be expected as tyrosine availability would increase p-cresol-production which in turn 
would reduce tyrosine levels. However within the DDT and AL dosing group, p-cresol glucuronide 
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levels decreased with increased liver severity, suggesting that past a certain level of pyrrole 
availability, p-cresol producing species become susceptible to its toxic effects. 
Tyrosine was unusual among the liver-related metabolites since it increased with the extent of liver 
injury in both dosing groups. This has been noted previously for plasma levels of tyrosine and 
histopathological severity induced by galactosamine, but not other liver toxins such as ethionine, 
thioacetamide and isoniazid239. It is likely to be related to impairment of protein synthesis stopping 
the production of TAT, a very short lived enzyme that catabolises tyrosine. However, tyrosine levels 
were broadly similar between the two dosing groups which appear at odds with its association with 
liver damage. One explanation is the enzyme induction properties of DDT, which may also up-
regulate TAT production and counter to some extent the impairment of protein synthesis by AL. A 
similar effect was demonstrated when DDT exposure in rats cancelled out the protective effects of a 
protein deficient diet (that presumably reduced cytochrome p450 production) on carbon 
tetrachloride toxicity25. Furthermore, phenobarbital which has similar properties to DDT, has been 
shown to induce TAT activity in cultured rat hepatocytes354.  
Urinary levels of AL-3 (AL- glucuronide) were more closely correlated with urinary levels of tyrosine 
(r= 0.90, p = 0.001) than with plasma ALT concentration (r=0.66, p= 0.04) among the AL only treated 
mice. Although the association of tyrosine and AL-3 is likely to be driven mainly by their respective 
associations with liver injury, the strength of the association does raise the possibility of further 
mechanistic link between them, independent of liver injury. Furthermore, the inhibition of both 
tyrosine excretion and AL glucuronidation following DDT pre-treatment may also be indicative of a 
common pathway. However, there were too few samples in this study to explore the relationship 
further through statistical adjustment for liver damage. 
8.5.6 Strengths and limitations of study 
Although this study has, for the most part, been able to achieve its aims there were some 
limitations. Unfortunately, the majority of human serum samples tested were above the upper limit 
of the ELISA assay used to measure total DDT concentration and so the precise concentrations could 
not be determined. This may had been avoided if samples had been further diluted. This information 
would have been useful as it could have been used to estimate DDT ingestion and mouse 
experiments could have been planned using an equivalent dose. The study only investigated the 
effects of one dose level of DDT on a single dose of AL and ideally a range of doses and combinations 
would have been used. Urinary samples were only taken 24 hours post-dose and may not have 
captured the complete range and relative concentration of AL metabolites produced. Repeated 
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sampling (or the use of metabolic cages), particularly in the first few hours post-dose when more 
metabolites may be excreted may have been more reflective of AL metabolism, than the ‘snap-shot’ 
approach taken here. Alternatively a targeted measurement of pyrrolic metabolites in the liver may 
have better shown a direct increase in pyrrole production resulting from CYP3A11 induction. 
The study has, however, been able to demonstrate high levels of DDT exposure in both HVLD 
patients and residents of the affected areas. It has achieved a balance between the power level 
required to demonstrate the effects of DDT pre-treatment and minimising animals used. The direct 
measurement of CYP3A11 expression has indicated the likely mechanistic route though which it 
enhances AL toxicity, while the use of both biochemical and histopathological markers of liver 
damage has further validated the results. The use of a global analysis of urine samples has allowed 
the simultaneous measurement of AL metabolites, identifying potentially novel metabolites and 
suggesting alternative mechanisms through which DDT may enhance AL toxicity.  
8.5.7 Conclusion 
The work presented here supports the hypothesis that chronic exposure to DDT increases the 
susceptibility of Hirmi Valley residents to the toxic effects of PA exposure. Hirmi Valley residents 
have been shown to be highly exposed to DDT, a chemical which significantly enhances the toxicity 
of AL in the mouse model and in combination induces specific pathology, necrosis and megalocytosis 
in the centrilobular regions, similar to that observed in HLVD patients. DDT has been shown to 
modulate the metabolism of AL, most likely through the induction of CYP3A, and possibly other, 
enzymes. 
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9. General Discussion 
9.1 General Conclusions 
he accumulated body of evidence supports the conclusion that HVLD is principally caused by 
PAs produced by the plant A. conyzoides contaminating the food supply. Early investigations 
by Ethiopian researchers identified A. conyzoides as a PA-producing plant that had potential 
to cause human disease. The subsequent analysis at the University of Bonn of grain samples 
collected opportunistically from abandoned houses in Tseada Amba showed that grain was 
contaminated by PAs, which importantly, were identified as acetyllycopsamine (AL, in the largest 
quantity), lycopsamine and intermedine. These PAs are of the type that may be produced by A. 
conyzoides and on closer examination, grain supplies were found to be contaminated by the seeds of 
the plant. Investigation efforts led by the CDC produced important new information such as the 
extent of the disease within Kiburto and potential lifestyle risk factors, such as the owning of sick 
animals. They were able to rule out many potential causes of HVLD such as aflatoxicosis, visceral 
leishmaniasis, malaria, HBC and HCV, heavy metal and water poisoning. Researchers for the SCI at 
Imperial College were able to exclude schistosomiasis as a causative factor. 
The work presented in this thesis has provided important further evidence regarding the disease 
aetiology. Clinical investigation revealed a unique combination of symptoms and signs, biochemical 
indicators and histopathology. Although histological evidence of VOD was not found, other 
pathological features of PA poisoning in Man were indentified such as zone 3 necrosis, bile ductular 
proliferation, brown pigmentation and rapidly developing fibrosis. Features that have not been 
previously reported in Man such as megalocytosis and copper accumulation have often been 
reported following animal exposure to PAs. Furthermore the distinctive features of bile ductular 
proliferation and megalocytosis were also reported in rats following exposure to Indonesian 
specimens of A. conyzoides.  
In-depth interviews revealed many important lifestyle factors that were consistent with PA 
poisoning. Millet, the grain found to be most contaminated with PAs, was the only grain grown by all 
affected households interviewed and was most likely (along with teff) to be contaminated by A. 
conyzoides, due to the height of these crops and the size of their seeds. Millet was reported to be 
mainly used for the brewing of beer and co-exposure to alcohol could potentiate the effects of PAs. 
The beer was reported to be widely drunk even by children. Furthermore the use of dairy products, 
T 
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from animals that consume A. conyzoides and suffer from a similar disease to human HVLD, is a 
further possible exposure pathway. These products were also consumed more during the summer 
months, which may contribute to the reported seasonal pattern of the disease. The widespread 
addition of DDT, a potent hepatic enzyme inducer, directly to food stores was also revealed.   
Chemical analysis of patient urine samples also provided important evidence. Although the 1H NMR 
metabonomic analysis was unable to identify any toxin metabolites, it was shown that cases, 
household and village controls could be distinguished upon the basis of their metabolic profile and 
the metabolic features of HVLD were characterized. The UPLC-MS analysis revealed the first 
statistically significant evidence of PA association with HVLD, since it showed that the median 
intensity of an ion that is produced by AL, was significantly higher among case samples than controls. 
The toxic effects of AL were then tested in the mouse. The PA was found to be hepatotoxic, although 
less potent that PAs involved in other cases of human PA poisoning, and could induce at  high doses 
the same zone 3 distribution of necrosis as observed in acute HVLD patients, without obstruction to 
the hepatic veins. The metabolic changes induced in the mouse by AL exposure was also similar to 
the changes observed among HVLD cases, including elevated tyrosine levels, perturbed levels of 
microbe-associated metabolites and changes in the levels of the products of one-carbon 
metabolism. 
Finally, the work presented here has indentified DDT use as an additional risk factor for HVLD. Hirmi 
Valley residents were found to be heavily exposed to DDT with the highest serum concentrations 
found among residents of Tseada Amba, the originally affected kushet that is still considered the 
‘epicentre’ of the disease. DDT was shown to greatly increase the hepatotoxicity of AL in the mouse, 
through the induction of hepatic enzymes including CYP3A11, which increases the proportion of AL 
that is metabolized to toxic intermediaries. The pathological features of HVLD such as megalocytosis 
and zone 3 necrosis were more readily induced in mice when DDT was administered prior to AL 
exposure.  
Co-exposure to DDT provides a plausible explanation of the aspects HVLD that are unusual among 
previously reported outbreaks of PA poisoning.  The atypical pathology of HVLD may result from the 
alteration of PA metabolism by DDT, favouring the necrotic rather than vascular effects of PAs. The 
restricted geographical distribution of HVLD may be related to the practice of adding DDT directly to 
harvested grain being restricted to the affected villages. The PA levels required to cause disease are 
likely to be lower for residents of the Hirmi Valley since they are exposed to DDT, and may account 
for the relatively low levels of PA detected in grain supplies 
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9.2 Public health recommendations 
While further research may strengthen these conclusions the evidence is strong enough that specific 
public health recommendations should be made: 
 The population in the Hirmi Valley regions should be educated about the dangers of A. 
conyzoides and DDT.  
 Farmers should be encouraged to remove A. conyzoides from areas where they grow crops, 
thresh the harvest or graze animals. 
 Weeding of the Ageratum should take place prior to maturation of the grain crops. 
 Efforts should be made to remove its seeds when sowing grain from the previous harvest. 
 A. conyzoides material should be removed from the stalks and chaff from the harvest that 
will be used for animal fodder. 
 DDT should not be added directly to food stores, and reserved solely for the purposes of 
vector control. 
 Surveillance systems should be strengthened and adherence to these measures should be 
monitored. 
 An ‘early warning’ system should be developed. 
Public education regarding the dangers of Ageratum is crucial, especially since Hirmi Valley residents 
generally disregarded this plant and were at first sceptical of a food-borne origin for the disease. 
Diagrammatical posters in prominent places such as the local churches, markets and health posts 
may be effective in addition to spreading the message through important local figures such as 
priests and health workers. Once aware and convinced of the dangers, it is possible that farmers will 
be able to incorporate control measures of their own devising that are most appropriate to their 
present agricultural practices and conditions. Public education measures have already been 
introduced by the local authorities and some weeding has taken place upon grazing lands. Soviet 
Uzbekistan authorities introduced control measures of Heliotropium plants which included some of 
the measures outlined above and were generally effective in preventing further outbreaks102. 
However additional Soviet measures such as state standards for grain quality, monitoring by a State 
Seed Inspectorate and the use of mechanical grain cleaning may not be appropriate in the Ethiopian 
context. 
It may be possible to introduce sieving techniques that are capable of removing the fine Ageratum 
seeds from the harvested grain. However even if all seeds were removed from grain it is possible 
that leaf and stem fragments of the plant may electrostatically adhere to the grain, as was 
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demonstrated following an episode of Heliotropium contamination in the 1990’s: after removal of all 
of the plant seeds from a grain sample involved in the poisoning, PAs could still be detected and the 
‘cleaned’ grain was still poisonous to pigs167. Therefore it may be more important to preemptively 
keep the plant infestation under control to prevent PA exposure than to clean grain intended for 
consumption (although it is vital that Ageratum seeds are removed from crop seed intended for 
sowing). Selective pesticides or bio-control measures could also eventually be considered and 
viruses specific to Ageratum species have already been identified355. 
However Ageratum is widely distributed across the region and so its elimination would be very 
difficult. The control of DDT use therefore provides a more practical public health measure. It is 
fortunate that the Ethiopian government has already stopped producing and using the pesticide for 
vector control since 2010. It is not known however if this has translated into a reduction in the 
availability of DDT on the black market, but one would expect the supply to be reduced eventually 
once production has stopped. It may be instructive that only two new deaths attributed to HVLD 
have been reported since 2010. Education efforts should also be directed at discouraging DDT use on 
food stores, although convincing farmers of its dangers may be more difficult since they may have 
used the pesticide for many years without any prior observable ill effect.  
The actual success of measures to reduce Ageratum prevalence and DDT use should be monitored as 
this information could provide additional longitudinal evidence regarding the disease aetiology when 
combined with continued surveillance of changes to HVLD incidence. An early warning system in the 
area to detect future large outbreaks may be feasible and could prevent future large human 
exposures to PAs. A system such as this is already in place in the Gulran district of Afghanistan where 
sporadic cases and large outbreaks of PA poisoning has occurred for over 50 years. The monitoring 
of the disease in animals has also been suggested as a potential method of surveillance since cases 
may occur earlier in animals and observation of their grazing and browsing preferences may also 
indicate which plants in the area are likely to be poisonous167.  
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9.3 Further work regarding HVLD 
Further research into HVLD should be conducted to strengthen the conclusions made above and to 
help direct effective public health interventions. There are several areas where the current evidence 
base is lacking, which include: 
 The routes of exposure through which Hirmi Valley residents are exposed to PAs: At 
present, the relative importance of dietary items such as injera, beer and dairy products, as 
exposure pathways has not been determined. 
 Behavioural risk factors for HVLD: To most effectively reduce PA exposure, it very important 
to identify ‘best practice’ behaviours such as certain agricultural techniques which reduce 
the possibility of grain contamination. 
 Epidemiological evidence for an interaction between DDT and PAs in the aetiology of 
HVLD: Although there is evidence of high DDT exposure from ethnographic study and body 
burden measurements, at present there is little human data to indicate that the interaction 
observed in the mouse experiments is replicated in HVLD patients. 
 The ‘chemotype’ of specimens of A. conyzoides in the region, and the potential role of 
other poisonous plants: The PA levels of A. conyzoides specimens both within and outside 
the affected areas in the region have not yet been measured. Furthermore, other as yet 
unidentified plants may contribute to the PA contamination of grain. 
 The link between the parallel disease in livestock and HVLD: It has not yet been shown that 
the liver disease in animals has the same origin as the disease in people. 
In the following sections, I outline further work to address some of these areas of uncertainty. 
Although the conditions in the region make research of this nature challenging, the studies 
suggested are feasible with sufficient financial and political support. 
9.3.1 Case control study 
While some progress has been made in identifying potential dietary and behavioural risk factors, a 
case-control study of sufficient size with well-defined cases and controls should identify these risk 
factors.  The study by Kakar et al.107 in Gulran, Afghanistan provides an excellent model of the type 
of study that could be achieved in the Hirmi Valley.  As many cases as possible should be recruited 
using a specific case definition. The previously developed ‘probable case definition’ incorporating 
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elevated serum GGT could be used although a looser definition may be more pragmatic. Controls 
should be age and gender matched and stratified as household and village controls to identify within 
house differences in dietary practice. Adjustment for socio-economic status could be made using 
information such as the number of animals and area of land owned. Questions regarding diet should 
quantify the levels of consumption and for staple items such as injera, a question should be asked 
regarding how frequently the food is consumed alone at meal times. Questions should be asked 
regarding farming practices including DDT use, weeding methods and the prevalence of Ageratum in 
fields. 
Serum and urine samples should be collected from cases and controls for LFTs and measurement of 
DDT and AL levels. Levels of pyrrole adducts in serum could also be measured using the method of 
Lin et al.146. Measurements of DDT and PA levels should be correlated with dietary and farming 
information gathered in the case-control questionnaire. 
9.3.2 Further grain and food analysis 
Systematic PA analysis of a large number of grain samples and food items such as honey, tej, tella 
and milk would help identify pathways of exposure, potentially provide further evidence of 
differential exposure between affected and unaffected households and also give better estimates of 
PA contamination levels. The grain samples should also be analyzed for levels of contamination with 
the seeds of Ageratum (and other weeds) and DDT/DDE and ideally linked to the case-control study 
above  
Analysis for PA levels and identity could be made at the University of Bonn, where they have a 
validated analytical platform for PA detection. However it may be possible to set up an initial rapid 
assessment facility within Ethiopia. Local laboratories in Tigray would be sufficiently equipped to 
perform TLC analysis of samples using Ehrlich’s reagent356, enabling the quick confirmation of PA 
contamination (albeit at lower sensitivity) without the problems and delay involved with shipping to 
another countries. A subset of samples identified as contaminated through this rapid assessment 
could then be further analysed in more sophisticated laboratories.   
9.3.3 DDT analysis 
The measurement of DDT exposure through the analysis of serum samples should be repeated to 
determine actual serum concentrations of DDT and its metabolite DDE separately using a different 
analytical platform than used in this thesis, such as LC-MS. If sufficient samples are available, analysis 
of PA and/or pyrrole adduct levels in the same sample could determine whether there is any 
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statistical interaction with the different contaminants associated with HVLD. Samples could be 
collected specifically as part of a case-control study or previously collected stored samples could be 
used. It would also be helpful to measure levels in a reference population outside the Hirmi Valley, 
to assess the contribution of DDT to the geographical localization of HVLD. Levels of CYP3A4 activity 
could also be assessed though either urinary measurement of 6β-hydroxycortisol /cortisol levels351 
or a breath test based on the N-demethylation of erythromycin357. These measures could then be 
compared with DDT exposure measurements, although the analysis should also consider the 
potential inhibitory effects of PAs themselves. 
9.3.4 A. conyzoides and plant survey 
A. conyzoides specimens from Kenya and Hawaii have been previously analysed and found to 
produce slightly different profiles of lycopsamine-type PAs. Therefore, the profile and total content 
of PAs produced by Hirmi Valley specimens should be measured and compared with the PA profile 
detected in grain samples. Differences in the chemical make-up of Ageratum may exist in specimens 
present at different locations in Tigray, due to certain ecological factors, and contribute to the 
localisation of HVLD. A powerful way to test this would be to perform a 1H NMR metabonomic 
analysis of Ageratum specimens collected from both inside and outside the Hirmi Valley and linked 
to GPS data. A protocol describing this sort of analysis with plants is available358 and would be 
particularly suitable as PAs are easily identifiable due to the H2 proton occurring in a region of the 
spectrum (around 5.8 δ ppm) with few overlapping signals. Furthermore, toxins other than PAs may 
be present in Ageratum and identifiable in this manner.    
The possibility remains of another plant that has not yet been identified, contributing to the PA 
contamination of grains. Although a botanical survey of the area was conducted by ENHRI, it is not 
clear how extensive it was and several PA producing species are known to grow in Ethiopia. 
Therefore a systematic survey of potential poisonous plants within the Hirmi Valley should be 
conducted, relying on the rapid assessment of PA content of surveyed plants within Ethiopia. 
9.3.5 Livestock research 
Although the parallel liver disease in animals is outside the remit of this thesis, it appears to be an 
important component of HVLD since it has been found to be significantly associated with the disease 
in Man and shares many common features. Grazing experiments using livestock exposed to 
Ageratum (and possibly other plants) could provide important new evidence. Pyrrole analysis of 
livestock blood and liver samples should clarify the disease origins, while PA analysis of milk samples 
would clarify whether animals have a causal role in HVLD  
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9.4 Future directions in PA research 
I believe there are two general areas of research regarding human exposure to PAs that should be 
pursued. Firstly, research should be continued into the development of non-invasive biomarkers of 
PA exposure and secondly the reasons why epidemics of acute PA poisoning sporadically occur 
should be considered. 
9.4.1 Biomarkers of PA exposure 
The investigations into the cause of HVLD were initially hindered by a lack of available biomarkers of 
PA exposure. Potential methods had been developed that could detect S-conjugated pyrrole adducts 
and DNA pyrrole adducts in blood from animals exposed to PAs, but neither method was sufficiently 
sensitive to apply to human blood samples collected from Ethiopia. However, since then, the 
method to detect unchanged AL in urine by UPLC-MS was applied in this thesis and Lin et al.146 
presented their UPLC-MS method that successfully detected S-conjugated pyrrole adducts in a VOD 
patient. These methodologies present an important breakthrough in the diagnosis of acute PA 
poisoning and further validation studies should be conducted using both these approaches. 
The situation regarding human disease and PAs is very similar to the circumstances surrounding 
aflatoxins, which are now highly regulated both domestically and in international trade167. Both 
classes of toxins have caused sporadic large outbreaks of acute liver failure in countries where 
subsistence farming is the main occupation and the agricultural systems are less developed and in 
some cases food scarcity has contributed to the relaxation of control methods allowing high levels of 
contamination to occur31, 108. Low level exposure to both these toxin classes have long been 
suspected of contributing to a variety of human diseases but estimating exposure through the 
sampling of food stuffs has been difficult due to the heterogeneity of contamination. However, the 
development and validation of both DNA and protein adduct biomarkers of aflatoxin over the past 
25 years has revealed its contribution to more chronic disease. Aflatoxin exposure has now been 
identified as a risk factor for HCC in a number of studies33 and shown to have an interactive effect 
with both hepatitis viruses359, 360 and environmental pollutants51.  
In many regions of the world humans are exposed to levels of PA361 that have the potential to cause 
chronic disease. PAs are well-established carcinogens in animal models and considered likely to also 
be human carcinogens102, 140. HCC may be considered an eventual result among those surviving acute 
hepatic injury, although follow-up of previous incidences of acute PA exposure has not been 
conducted. The primary toxic metabolites of PAs, the pyrrolic esters, would be constrained to the 
liver due to their instability, and tumours are most often induced in the liver following experimental 
273 
 
PA exposure. Therefore to determine the contribution of PAs to the development of human HCC, an 
estimate of PA exposure should be incorporated into future epidemiological studies of HCC and, as 
shown for both aflatoxin and HBV33, the development of a validated and sensitive biomarker is the 
most robust way to do so. At present, a biomarker of sufficient sensitivity for this kind of study is not 
available but it is certainly possible to develop an appropriate biomarker with current technology. 
Improvements to the detection of the exogenous DNA-pyrrole adducts identified by Yan et al.258 
seems an appropriate avenue of research, especially as the levels of these adducts are directly 
related to PA-induced DNA damage. 
PA exposure may also be associated with other cancers that are induced, with less frequency than 
HCC, in other tissues of experimental animals, including the lungs, pancreas and intestines135. These 
are likely to be caused by the more stable circulating secondary metabolite, the pyrrolic alcohol, 
which is formed by hydrolysis of the pyrrolic ester or through release from the internal ‘reservoir’ of 
tissue bound pyrrole. The pyrrolic alcohol, dehydroretronecine has induced rhabdomyosarcomas in 
the rat362 and Daughton has suggested that an unexplained cluster of Leukaemia cases in Nevada, 
USA may be attributable to PAs363. Diseases such as Indian childhood cirrhosis (ICC) and idiopathic 
pulmonary arterial hypertension have also been suspected of being associated with PA exposure364. 
Animal models of these diseases have been produced following PA administration365, 366. ICC shares 
some similarities to HVLD, while a recent case of pulmonary hypertension with minimal associated 
liver pathology was reported in a Swiss woman who had regularly consumed a comfrey tea367. The 
use of pyrrole-adduct based biomarkers should also be incorporated into both the research and the 
clinical diagnosis of these diseases. 
9.4.2 The risk factors of an epidemic 
During the 2000’s there were large outbreaks of acute PA poisoning in Gulran, Afghanistan and in 
the Hirmi Valley. Before that a pair of outbreaks occurred in Northern India and Gulran again at the 
beginning of the 1970s. There is no record of any other large outbreaks due to contaminated grain 
before that until an outbreak in the USSR in 1946. In some cases the epidemics can be attributed to 
external factors such as drought during the 1970 Gulran outbreak or war during the outbreak in 
Tajikistan in 1992. In other cases such as the most recent outbreaks, no adverse weather conditions 
or war-related factors were reported. Although one cannot discount a purely stochastic explanation, 
it may be that other underlying ecological ‘risk factors’ have contributed to these epidemics and are 
common to both. 
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Greater use of DDT in Hirmi Valley since the 2000’s, resulting from greater availability of the 
pesticide due to increased production following the WHO ‘Roll Back Malaria’ campaign, is a rational 
explanation for the HVLD epidemic. However this is yet to be confirmed and it is likely that changes 
to Ageratum type and density have also contributed. Changes to Heliotropium type and density may 
have also occurred during the Gulran epidemic. Systematic comparison of the two outbreaks may 
reveal common reasons for these changes. The fact that pairs of outbreaks occur at similar times in 
different regions of the world could suggest that a global reason for the outbreaks and examination 
of available longitudinal environmental records may provide some preliminary information. An 
understanding of the reasons for these epidemics could allow the prediction of future outbreaks and 
the introduction of preventative measures.  
9.5 The DDT debate  
The use of DDT has been a much debated subject305, 306 that has gained wider interest outside 
scientific circles. On one hand, DDT is regarded as having prevented millions of deaths due to 
malaria and contributed to its elimination in many regions of the world289, 305. Furthermore in the 
Hirmi Valley, where food is already scarce, it may protect stored grain from infestation. On the other 
hand, besides its damaging effects on the environment, there is growing evidence linking long term 
exposure to a number of adverse health outcomes including breast and liver cancer, diabetes, 
reproductive health and impaired neurological development in children306. However, as with most 
epidemiological study providing unequivocal evidence is difficult and a quick scan of the internet 
reveals that DDT has become a cause-célèbre among anti-environmentalists who promote the view 
that its prohibition is a form of ‘eco-imperialism’ imposed upon developing countries368. Therefore 
care should be taken when making conclusions regarding the role of DDT exposure in disease. 
The work presented here has shown two things. Firstly it has provided evidence that the pesticide, in 
combination with PAs, contributes to the development of an acute disease with a high fatality rate. 
This is a further addition to the ‘risks’ column of any risk-benefit ledger regarding DDT use, 
particularly in countries such as Ethiopia where people may be exposed to relatively high levels of 
PAs. It has recently been shown that the presumed benefits within Ethiopia are less than previously 
thought due to increased mosquito resistance299 and thankfully, the government has ceased DDT 
production and use. This may already be translating into a reduction in HVLD incidence. Its role in 
potentiating the effects of naturally occurring liver toxins, including possibly aflatoxin, should be 
considered during future renewals of the Stockholm Convention of Persistent Organic Pollutants. 
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Secondly, Hirmi valley residents were found to be exposed to higher levels of DDT than has been 
measured among populations taking part in previous epidemiological studies. Even the recent study 
by Zhao et al.51 of HCC in a region of China where DDT use has traditionally been high, revealed a 
lower median serum total DDT level among HCC cases (50 ppb).  The Chinese study has illustrated 
the importance of using a high exposure population in order to identify any disease associations and 
it may be that many previous studies are inappropriate for the levels of DDT exposure in developing 
countries. Future studies of adverse outcomes such as with regards to reproductive health, should 
take place in regions, like Ethiopia, where DDT exposure is high, particularly where there is a 
concerted programme of IRS. 
9.6 Final Remarks 
In this thesis I have presented a form of liver disease that has never previously been described which 
has a unique combination of symptoms, signs and histopathology. Using a multi-disciplinary 
approach involving clinical research, ethnography, biochemical and metabonomic analysis and 
toxicology, I have accumulated a body of evidence supporting the role of co-exposure to DDT and 
PAs, including AL, in the aetiology of the disease. 
The work has highlighted the role of the ‘xenosensors’ of the liver such as PXR and CAR in increasing 
hepatocyte susceptibility to toxin exposure. The rising levels of diseases such as HCC within 
developed countries360, and also outbreaks such as HVLD, may in part be due to a heightened 
hepatic metabolism resulting from overstimulation of these xenosensors due to daily exposure to 
the ‘chemical jungle’. 
Although less resources are allocated to PA-associated disease than the ‘big three’ of malaria, TB and 
HIV, and even the ‘neglected tropical diseases’ by hard-pressed ministries of health and funding 
bodies, the impact of such an outbreak such as in the Hirmi Valley can be devastating. Not only does 
HVLD have a high incidence rate within the most affected villages, it also carries a high mortality rate 
particularly among children. As well as affecting whole families with disease or the fear of impending 
disease, it has destroyed livelihoods with its associated affects on livestock and crop value. 
Concerted action is required to prevent future outbreaks. Rising food prices, changes to the local 
ecology due to global warming and a lack of agricultural development in many countries make the 
safety of food an increasingly important issue. Without proper safeguards in food production among 
the rural poor who may rely on subsistence farming and the use of dangerous chemicals, mass 
poisoning incidents such as this may become more common. 
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11.1 Lifestyle Questionnaires used during December 2008 Census of 
Kiburto 
 
296 
 
 
  
297 
 
11.2 Spectral analysis of Acetyl (lycopsamine/intermedine) extract. 
11.2.1 LC-MS 
 
 
11-1: LC-MS analysis of acetyl(lycopsamine/intermedine) extract obtained from Planta Analytica. Top: chromatogram 
showing with peak areas displayed, indicating sample has high purity. Bottom: Extracted mass spectra from 
acetyl(lycopsamine/intermedine) peak at 2.32 minutes. For LC-MS conditions see section 6.3.1.3.  
11.2.2 NMR analysis 
Following advice from the supplier (Planta Analytica, USA), 1 mg of the acetyl-
(lycopsamine/intermedine) plant extract used in this thesis, was dissolved in 600 µL of deuterated 
methanol.  3 µg of TSP (3-trimethylsilyl-(2,2,3,3,-2H4)-1-propionate) was added as an internal 
chemical reference standard. One dimensional 1H (zgpr pulse programme) and two-dimensional 
(COSY, TOCSY, HSQC, HSBC and J-resolved) spectra were obtained on an 800 MHz Bruker Advance 
spectrometer. 
The predicted 1H NMR spectrum for 7-acetyllycopsamine (Figure 11-3.) was calculated using 
ChemSketch freeware (ACD labs). The obtained 1 dimensional 1H spectrum (Figure 11-4) is similar to 
the predicted spectrum albeit with many overlapping peaks due to the additional resonance of 7-
acetyintermedine and possible hydrolysis products.  
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Figure 11-2: Structure of 7-acetyllycopsamine (numbered for following NMR assignment) 
 
Figure 11-3: Predicted 1H NMR spectra for 7-acetyllycopsamine . 
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Figure 11-4: 1H NMR overview spectrum of plant extract, acquired at 800 MHz. Largest single peak at 3.25 ppm is the 
resonance of the solvent methanol. 
 
Figure 11-5: Overview of whole spectrum.  
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Figure 11-6: Expansion of 1H NMR 0.5-2.6 ppm region for plant extract. 
The J-resolved spectra (Figure 11-7) indicate several methyl doublet signals in 0.8-1.0 ppm region. 
The largest pair of peaks at 0.91 ppm appears to be composed of more than one overlapping 
doublet signals. The J-resolved plot (Figure 11-8) indicates that the two peaks at 2.1 ppm are in fact 
two singlets (most likely from methyl group 12 in both acetyl- lycopsamine and intermedine).
 
Figure 11-7: J-resolved 2D spectra 0.8-1 ppm region 
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Figure 11-8: J-resolved 2D spectra 1.7-2.5 ppm region 
 The 2D COSY experiment (Figure 11-9) plot shows the coupling of methyl signals at 0.91ppm (methyl 
groups 20 and 21) to a quartet signal at around 2.0 ppm (proton 19). 
 
Figure 11-9: 2D COSY contour plot of 1H NMR region 0.7-2.2 ppm. 
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Figure 11-10: 2D COSY contour plot of 1H NMR region 0.8-4.5 ppm. 
One can also observe the coupling (Figure 11-10) between the methyl signal at 1.2ppm (methyl 
group 23) with the quartet at 4.95 ppm (proton 22). 
 
Figure 11-11: 1d 1H NMR spectra. Blue spectrum was acquired 72hr before the red spectrum. 
1D 1H NMR spectra obtained 72 hrs apart from the same plant extract (Figure 11-11), indicate that 
the extract is stable at room temperature in methanol since no chemical changes can be observed. 
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11.3 Identification of AL metabolites groups 
STOCSY  analysis and 2D NMR experiments (see section 5.3.6 for details) were used to identify NMR 
signals present in dosed mouse urine that corresponded to metabolites of AL, as being produced by 
four different metabolites, termed AL1- AL4 (chapter 7): 
 
 
 
Figure 11-12: STOCSY figures identifying metabolite AL-1. δ ppm value at top of each figure shows STOCSY driver peak. 
STOCSY used five 1H NMR spectra from mouse urine obtained 24 hrs post 1500 mg/kg dose. 
Figure 11-13: STOCSY figures identifying metabolite AL-2. δ ppm value at top of each figure shows STOCSY driver peak. 
STOCSY used five 1H NMR spectra from mouse urine obtained 24 hrs post 1500 mg/kg dose. 
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Figure 11-14: STOCSY figures identifying metabolite AL-3. δ ppm value at top of each figure shows STOCSY driver peak. 
STOCSY used five 1H NMR spectra from mouse urine obtained 24 hrs post 1500 mg/kg dose.  
 
Figure 11-15: STOCSY figures identifying metabolite AL-4. δ ppm value at top of each figure shows STOCSY driver peak. 
STOCSY used five 1H NMR spectra from mouse urine obtained 24 hrs post 1500 mg/kg dose.  
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Figure 11-16: HSQC NMR spectrum obtained from urine sample collected 24 hours after 750 mg/kg following a week of 
DDT dosing (3 x 75 mg/kg) 
 
 
Figure 11-17: J-resolved NMR spectrum obtained from urine sample collected 24 hours after 750 mg/kg following a week 
of DDT dosing (3 x 75 mg/kg) 
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Figure 11-18: COSY NMR spectrum obtained from urine sample collected 24 hours after 750 mg/kg following a week of 
DDT dosing (3 x 75 mg/kg) 
 
Figure 11-19: COSY NMR spectrum obtained from urine sample collected 24 hours after 750 mg/kg following a week of 
DDT dosing (3 x 75 mg/kg) 
